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Thesis Abstract 
 Alzheimer’s Disease (AD) affects over 30 million people worldwide, however no 
disease modifying therapies have been approved to date. The majority of failed therapeutic 
intervention targeted the accumulation of beta-amyloid (Aβ) species. While these 
interventions were effective in preclinical mouse models of early stage amyloid pathology 
they failed to translate into the clinic. While several explanations may underlie this 
apparent lack of translation, one commonly held view is that first generation mouse models 
possess artefacts that contribute to brain and cognitive phenotypes.  Another factor that has 
not received detailed consideration is the extent to which reduction of endogenous amyloid 
production influences cognition and synaptic processes in cognitively normal mice. This 
thesis aimed to elucidate the role of Aβ in cognitive function in both wild-type (WT) mice 
and a novel single knock-in mouse APP-NL-F mouse model of pre-symptomatic amyloid 
pathology.  
Selective inhibition of Aβ production was achieved by using the 2B3 antibody, 
which binds to the β-cleavage site of the amyloid precursor protein (APP), sterically 
inhibiting metabolism. 2B3 administration significantly reduced Aβ and altered glutamate 
receptor dynamics in the hippocampus of 5-month old WT mice following icv 
(intracerebroventricular) infusion. These mice failed to detect changes in object-in-place 
(OiP) associations, confirming that hippocampal Aβ was required for this cognitive task. 
 APPNL-F knock-in mice express a humanised Aβ sequence with the Swedish 
(KM670/671NL) and Iberian (I716F) mutations within the endogenous murine APP gene. 
These mice underwent behavioural characterisation at 8 and 17 months of age and this 
revealed a pattern of selective memory deficits that were age-dependent. This included an 
age-dependent deficit in a foraging-based spatial working memory task and deficits in both 
associative OiP and temporal order recognition memory. 2B3 infusion in aged WT and 
APPNL-F mice reduced Aβ production but resulted in dissociable effects on memory. A 
deficit in OiP performance was rescued by 2B3 administration in APPNL-F mice but 
performance was impaired in healthy WT controls. These data provide novel evidence for 
the importance and dynamic role of Aβ in both normal and early stage AD pathology. One 
implication of these findings is that, should anti-amyloid therapies gain traction in the 
treatment of pre-symptomatic AD, the benefits must be weighed against the potential 
adverse effect of disrupting normal amyloid function. 
[vi] 
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Chapter 1 – 
General Introduction 
 
  
[2] 
1.1 Chapter Overview 
 This introductory chapter will initially describe the physiology of APP, detailing its 
major metabolic pathways and the enzymes involved within them. The evidence 
underpinning the current understanding of how the protein influences neuronal function 
will be presented as well as the roles of individual APP fragments with a particular focus 
on the beta-amyloid (Aβ) peptide. Section 1.3 describes some pathological features of APP 
fragments and introduces the argument detailing how the accumulation of Aβ triggers 
pathogenesis leading to neurodegeneration, “The Amyloid Cascade Hypothesis”. This has 
become the principal hypothesis guiding the understanding of mechanisms of Alzheimer’s 
Disease alongside research aiming to produce therapeutic treatments. Section 1.4 will 
outline the aetiology and clinicopathology of the disease and present examples of current 
treatments as well as the therapeutic strategies employed by anti-amyloid drugs currently 
in clinical development. Despite copious treatments demonstrating promising results in 
preclinical models of AD, none have successfully progressed through clinical trials, 
bringing the design of the models into disrepute. Section 1.5 will summarise how the use 
of first generation, transgenic mouse models has guided our understanding of the 
pathogenic mechanisms of Aβ, before presenting how potential artefactual influences of 
APP overexpression has necessitated more physiological models. Knock-in models do not 
overexpress APP and thus represent a more faithful recapitulation of the human disease. 
The design and development of these models is introduced, with a detailed description of 
the APPNL-F mouse, which will be the focus of much of this thesis. Finally, the aims and 
hypotheses of this thesis will be presented in section 1.6. 
 
1.2 Amyloid Precursor Protein 
Amyloid precursor protein (APP) is a highly conserved transmembrane protein that is 
expressed both in neuronal and non-neuronal tissue (Tharp and Sarkar 2013). It undergoes 
a complex metabolism producing various proteolytic fragments and so has been implicated 
in copious cellular functions including neuronal development, cell signalling and synaptic 
function. The gene encoding App is located on chromosome 21 in humans and alternative 
splicing produces 8 isoforms ranging from 639 to 770 amino acid residues in length, with 
APP695 identified as the major isoform expressed in the central nervous system (CNS) 
[3] 
(Sisodia et al. 1993). Two other isoforms, APP751 and APP770 are also common but are 
predominantly expressed in non-neuronal tissue. APP belongs to a family of homologous 
proteins related by structure and function. The amyloid precursor-like proteins 1 and 2 
(APLP1 & APLP2) are both also expressed in mammals and they, like APP, have a single 
transmembrane region and large extracellular N-terminal domains (Bayer et al. 1999). 
While APP and APLP2 are ubiquitously expressed, APLP1 mRNA is exclusively detected 
in the CNS (Lorent et al. 1995). Phylogenetic analysis reveals that the genes encoding APP-
like proteins emerged in insects such as the fruit fly (Drosophila melanogaster) and 
roundworm (Caenorhabditis elegans), organisms with simple nervous systems and 
functional synapses (Shariati and De Strooper 2013). The APP family genes seems to have 
undergone multiple duplication and contraction events throughout evolution, for example 
while insects have one gene encoding an APP protein, fish and amphibians have four, birds 
have two and mammals have three (Zheng and Koo 2011). The complex trajectory and 
highly conserved sequences of these genes indicates that they have been consistently 
subjected to stringent evolutionary forces, suggesting that they serve important cellular 
functions. However, despite evidence implicating APP involvement in many different 
signalling pathways, thorough understanding of its physiological function remains limited.  
Genetic deletion of the APP gene results in viable offspring displaying a mild 
phenotype involving reduced grip strength and age-dependent cognitive deficits, 
suggesting it plays a subtle role in neuronal function (Dawson et al. 1999, Senechal et al. 
2007). However, duplication of genes affords genetic robustness, increased gene dosage 
and the possibility of redundancy, potentially precipitating compensatory activity of the 
APLP proteins. In fact, double knock-out of both APP and APLP2 results in a lethal 
phenotype, as mice die shortly after birth (von Koch et al. 1997). Whether this severe 
phenotype is produced due to abolition of redundant function or interruption of various 
independent pathways is unclear. The expression of 181 genes is affected in both APP and 
APLP2 single knock-out mice compared to the total of 1061 that are altered following 
combined deletion (Aydin et al. 2011). However, the severity induced following loss of 
both genes further indicates that together they may play important roles in physiology. 
▪ 1.2.1 – APP Metabolism 
APP, APLP1 and APLP2 are all metabolised in a similar way, producing large N-
terminal ectodomains as well as intracellular regions. They have all been found aggregated 
[4] 
in the neuritic plaques that are a hallmark of brain pathology in Alzheimer Disease (AD) 
patients (Bayer et al. 1997). However, only the metabolism of APP generates an 
amyloidogenic fragment, due to a divergent sequence around the beta-amyloid section 
(O’Brien and Wong 2011). APP is heavily expressed in the CNS and is rapidly 
metabolised, undergoing sequential cleavage along two (amyloidogenic versus non-
amyloidogenic) pathways, (Lee et al. 2008) as depicted in figure 1.1. In reality, metabolism 
of this protein is far more complex and many more secretase enzymes and proteolytic 
fragments have recently been identified. These non-canonical pathways include δ- and η-
secretases which cleave the ectodomain of APP and have been reported to increase 
amyloidogenic processing of APP. Gene deletion of δ-secretase resulted in less Aβ 
generation in vitro and ameliorated biochemical, synaptic and cognitive pathology in 
transgenic APP mouse models (Zhang, Song, et al. 2015). η-secretase generates alternative 
proteolytic fragments linked to synaptic dysfunction (Willem et al. 2015, Baranger et al. 
2016). The existence of these alternative APP processing pathways is of particular 
relevance when considering BACE1 inhibition as a therapeutic mechanism, as modulating 
its activity may lead to accumulation of other, potentially neurotoxic fragments. For a full 
review, see Andrew et al (2016) and Nhan et al (2015). 
Figure 1.1: Alternative pathways of APP metabolism. 
APP can be processed via amyloidogenic or non-amyloidogenic pathways. The former 
involves β-secretase cleavage followed by γ-secretase, which permits variation in the 
exact cleavage of the Aβ C terminus due to different composition of the enzyme 
complex. Therefore, different lengths of Aβ are possible, predominantly 40 or 42 amino 
acids long. In the non-amyloidogenic pathway, APP is cleaved by α-secretase, 
preventing Aβ formation. 
[5] 
Following translation in the endoplasmic reticulum, APP is delivered down the 
axon to synaptic terminals and inserted into either cell surface or cell body endosomal 
compartments (Koo et al. 1990). The direction of metabolism depends on the cellular 
location and the enzyme complexes involved. The “non-amyloidogenic pathway” 
comprises cleavage by α- and γ-secretases at the cell surface (Parvathy et al. 1999), while 
the “amyloidogenic pathway” occurs in cell body endosomal compartments containing β- 
and γ-secretase (Zhang et al. 2011). Following proteolysis, the metabolic products of the 
latter pathway are secreted during cell surface endosome recycling. 
The “non-amyloidogenic pathway is the predominant pathway for APP processing 
(~90%) (Zhang et al. 2011).  α-secretase cleavage is mediated by the membrane bound 
ADAM (a disintegrin and metalloproteinase) family of enzymes, of which three have been 
proposed as the putative enzyme, ADAM9, ADAM10 and AMAM17 (Asai et al. 2003). 
This enzyme cleaves at a point on the APP sequence between the β- and γ-secretase 
cleavage sites, therefore preventing release of the amyloidogenic peptide. Instead, the 
large, soluble, N-terminal ectodomain sAPPα is produced along with the membrane bound 
C-terminal fragment CTF83 (CTFα). While the ectodomain is released into the 
extracellular space, γ-secretase cleavage of the CTF83 fragment generates two more 
peptides: P3 and the APP intracellular domain (AICD) (Haass et al. 1993, Kojro and 
Fahrenholz 2005). γ-secretase is a large complex of enzymes including presenillin-1 or 2 
(PS1, PS2), nicastrin, anterior phalanx defective and presenillin enhancer 2 (Francis et al. 
2002, Haass and Steiner 2002). Although the individual roles of these constitutive proteins 
are not yet fully elucidated, selective deletion of two transmembrane aspartate residues in 
PS1 prevented APP cleavage by γ-secretase and significantly decreased production of Aβ, 
while βCTF levels increased (Wolfe et al. 1999). γ-secretase has numerous alternative 
substrates which are involved in vital signalling functions, for example the Notch family 
of proteins which are crucial during stem cell differentiation and nervous system 
development (Louvi and Artavanis-Tsakonas 2006). 
The alternative mechanism for APP processing is the amyloidogenic pathway, in 
which the protein is first cleaved by beta-site APP cleaving enzyme (BACE, or β-
secretase). BACE is a membrane-associated aspartic protease-2 (memapsin 2) and has 
attracted considerable attention as a potential therapeutic target. It was reported by five 
independent groups in 1999 who all agreed on a consistent sequence of 501 amino acids 
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(Sinha et al. 1999, Vassar et al. 1999, Yan et al. 1999, Hussain et al. 1999, Lin et al. 2000). 
Secretion of Aβ was abolished in BACE1-null neuronal cultures, confirming BACE1 over 
BACE2 as the neuronal β-secretase and the rate limiting enzyme for production of the 
peptide (Cai et al. 2001). Although most cell types produce Aβ, implying that both APP 
and BACE1 are widely expressed (Haass, Schlossmacher, et al. 1992); β-secretase activity 
seems to be greatest in neurons than other cells (Zhao et al. 1996). BACE1 exhibits optimal 
enzymatic activity in acidic environments such as endosomes in which Aβ is thought to 
occur (Huse et al. 2000). Indeed, immunofluorescence experiments showed BACE1 
naturally colocalising with APP in endosomes, and blocking surface endocytosis was 
shown to inhibit Aβ secretion by 80% while impairing direct trafficking of APP to the cell 
surface increased it (Kinoshita et al. 2003, Haass, Koo, et al. 1992). In contrast, increased 
trafficking to the cell surface significantly reduced Aβ production (Cataldo et al. 1997). γ-
secretase may be localised to both the cell surface and endosomal compartments, enabling 
it to complement both α- and β-secretase processing of APP (Fukumori et al. 2006). 
BACE1 cleavage of APP releases sAPPβ, and a 99 residue long C terminal 
fragment (β-CTF) containing Aβ which remains attached to the membrane until γ-secretase 
cuts APP at multiple sites (Sinha et al. 1999). AICD is released into the cytosol from the 
ε-site before cleavage at the γ-site releases the Aβ peptide (Glenner and Wong 1984, Zhao, 
Tan, et al. 2007). This is a short, ~4.2 kDa peptide of 38-43 amino acids (predominantly 
40 or 42), depending on the exact position at which it is cleaved. The 40-residue peptide is 
most common, particularly in healthy people. Approximately 10% of human Aβ is the 42 
residue species, which is more prone to aggregation and associated with neurotoxicity and 
plaque formation (Jarrett, Berger, and Lansbury 1993, Walsh and Selkoe 2007). 
▪ 1.2.2 – Physiological Role of APP  
Evidence concerning the function of APP is controversial, in part due to the many 
metabolites of the protein and the vast range of different signalling pathways and protein 
interactions with which they have been associated. The protein interacts with over 200 
molecules and is able to act as both a receptor or a ligand to influence both intra- and 
extracellular signalling (Müller, Deller, and Korte 2017). The evolutionary emergence of 
APP family genes in the first organisms with functional central nervous systems and 
synapses immediately hints that the proteins may play a role in synapse formation and/or 
function. Furthermore, the maximal expression of the protein occurs during post-natal 
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development, during which a high rate of synaptogenesis occurs (Wang et al. 2009). 
Beyond this circumstantial evidence, APP-KO mice show subtle phenotypes including 
reduced brain and body weight, locomotor activity and grip strength (Zheng et al. 1995, 
Ring et al. 2007). They also exhibited hypersensitivity to seizures and brain injury as well 
as impairments in neuronal morphology, synaptic function and cognition that developed 
from 10 months of age (Steinbach et al. 1998, Corrigan et al. 2012, Dawson et al. 1999, 
Seabrook et al. 1999).  
APP exhibits characteristics of cell adhesion molecules which are critical for the 
development of the synaptic junction in early metazoan eukaryotes (Emes and Grant 2012, 
Soba et al. 2005). APP has also been implicated in the guidance and growth of neurites in 
hippocampal cell cultures (Qiu et al. 1995). Germline APP deletion resulted in 
neuromuscular junction deficits, and this was replicated following conditional KO of APP 
in either the pre-synaptic motor neuron or post-synaptic muscle tissue, indicating the 
protein is necessary in both synaptic compartments (Wang et al. 2009). The same paper 
also reported that, when overexpressed in HEK cells, APP induced synaptogenesis in 
cocultured primary hippocampal neurons. Furthermore, overexpression of APP increased 
spine density in hippocampal neurons and genetic deletion reduced it in both the 
aforementioned cultures and transgenic mice (Lee et al. 2010, Tyan et al. 2012, Weyer et 
al. 2014). Another study reported that while overall spine density was not significantly 
reduced in APP-KO mice, spine turnover (both formation and pruning) was decreased, 
indicating a role of the protein in spine dynamics (Zou et al. 2016). The mechanism for 
synapse formation and stabilisation may involve dimerization across the synapse where 
two APP molecules interact via the heparin binding domains in their extracellular N termini 
to produce cross-linked dimers (Soba et al. 2005, Coburger, Hoefgen, and Than 2014). 
Immunofluorescence and live cell-imaging experiments revealed that APP localises to 
lamellipodia (motile, actin-rich protrusions in cellular growth cones) both in vitro and in 
vivo and influences actin-based membrane motility (Sabo et al. 2003, Cheung et al. 2014). 
Together this evidence promotes APP as a putative mediator of both axonal outgrowth and 
synapse formation. 
Further to its role in synapse formation, APP has been extensively implicated in 
neuronal function. The metabolism of APP by α- and β-secretases is dependent on neuronal 
activity, suggesting that it occurs with a specific purpose (Nitsch et al. 1993, Fazeli et al. 
1994, Kamenetz et al. 2003). However, studies concerning the role of APP often generate 
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conflicting results, for example: overexpression of APP in neuronal cultures was shown to 
depress synaptic activity in one study, yet enhance synaptic plasticity and memory in 
another (Kamenetz et al. 2003, Ma et al. 2007). Interactome analysis revealed that APP 
associates with vesicle release machinery at hippocampal synapses, is involved in vesicle 
turnover and facilitates neurotransmitter release (Fanutza et al. 2015, Kohli et al. 2012). 
Meanwhile, APP deletion in mice decreased the expression of the synaptic vesicle proteins 
synaptophysin and synaptotagmin-1 at the pre-synaptic membrane (Lassek et al. 2014, 
Dawson et al. 1999). Unsurprisingly, these mice exhibited decreased frequency of 
miniature excitatory post synaptic potentials (mEPSPs), which are an indicator of vesicle 
release probability. These results suggest a presynaptic function for APP. Furthermore, 
conditional APP-KO mice lacking expression of the protein in excitatory forebrain neurons 
exhibited impairment of paired-pulse facilitation and post-tetanic potentiation (Hick et al. 
2015). These processes represent short term plasticity which is dependent on pre-synaptic 
release mechanisms such as vesicle release probability, recycling rate and neurotransmitter 
content (Regehr 2012). These studies therefore validate the protein as a potential mediator 
of presynaptic plasticity mechanisms. However, as previously mentioned, APP is also 
localised to post-synaptic compartments, where there is also evidence of its impact on 
synaptic function. 
The contribution of APP to pre- or post- synaptic mechanisms may depend on 
individual synapse function. The post-synaptic role may involve interaction with N-methyl 
D-aspartate (NMDA) glutamate receptors, which are ligand-gated cation channels. 
Immunoprecipitation experiments demonstrated that APP, as well as APLP1 and APLP2, 
associate with the GluN1 subunit of NMDA receptors and enhance their expression at the 
postsynaptic membrane (Cousins, Dai, and Stephenson 2015). Together, the described 
putative roles of APP at both the pre- and post-synaptic terminals would result in enhanced 
transmission and plasticity due to the augmented release of neurotransmitters and increased 
availability of NMDA receptors. Indeed, APP-KO mice do exhibit deficits in transmission 
and LTP induction (Ring et al. 2007, Dawson et al. 1999, Seabrook et al. 1999), while 
conditional KO of APP in the forebrain of young adult mice induced pronounced 
impairment of LTP induction and maintenance (Hick et al. 2015). As plasticity of neuronal 
communication is thought to underpin memory processes, it is unsurprising that APP-KO 
mice also exhibit deficits in tests of cognitive performance. While young (3-4 months old) 
mice were cognitively normal, 10 month old APP-KO mice demonstrated deficits in spatial 
learning in the Morris water maze (Phinney et al. 1999, Dawson et al. 1999, Ring et al. 
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2007), passive avoidance memory (Senechal et al. 2007) and fear conditioning (Dawson et 
al. 1999). The interaction of the observed synaptic and cognitive deficits with age is 
particularly interesting in the context of APP involvement in AD, another age-related 
pathology. Together this suggests that the function of the protein becomes more important 
in aged neurons. 
 Current understanding of APP function mainly stems from genetic deletion in 
addition to overexpression studies. However, conclusions from these studies must be 
tempered by the understanding that these mice lack APP from conception and therefore 
any phenotype is potentially the result of loss of its function during development. APP is 
expressed as early as embryonic day 7.5 and so its deletion is likely to have a wide-ranging 
impact. Alternatively, compensatory activity of other genes, particularly by APLP1 and 
APLP2, may mask the effect of APP deletion on the resulting phenotype. Indeed, 
constitutive deletion of multiple APP family proteins results in more severe abnormalities 
in brain development (Herms et al. 2004, Weyer et al. 2014). The fact that cognitive 
phenotypes of APP-KO mice become apparent in aged mice suggests that these 
compensatory mechanisms may fail with age. Another major issue with investigating the 
function of APP is the difficulty in independently manipulating different fragments as 
inhibition techniques such as knock-out or siRNA cannot discriminate specific loss of 
function effects of each peptide. Understanding of individual functions has mainly come 
from isolation of the peptides and administering them into neuronal cultures or mouse 
models. Further discussion concerning the physiological function of APP will be divided 
into separate reviews of individual fragments. 
 
β-Amyloid 
 The Aβ peptide sequence is conserved throughout vertebrates with over 90% 
homology between humans, birds, reptiles and amphibians, suggesting it conveys an 
evolutionary advantage (Tharp and Sarkar 2013). Ever since its identification in the neuritic 
plaques of AD patients by Glenner and Wong (1984), the main focus of research into Aβ 
has been its neurotoxic properties. However, hints at possible neurotrophic functions were 
suggested after the peptide was first described. While high concentrations of Aβ led to 
dendritic retraction and neuronal death in differentiated neurons, low concentrations were 
neurotrophic to undifferentiated cells and a recombinant peptide corresponding to the first 
28 residues of the Aβ sequence enhanced survival of hippocampal pyramidal neuronal 
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cultures (Yankner, Duffy, and Kirschner 1990, Whitson, Selkoe, and Cotman 1989). 
Despite this indication of beneficial activity at physiological concentrations, the field has 
focused on the toxic effects of high (>nanomolar) Aβ. More recently, attention has returned 
to the physiological role of the peptide, and the concentration dependent reversal of activity 
has gained traction as an hormetic effect (Puzzo et al. 2008). Hormesis is a pharmacological 
phenomenon whereby a substance can be beneficial at low concentrations but toxic when 
increased and seems to be a consistent rule for memory enhancers, first described by Karl 
Lashley in 1917 while documenting the effects of strychnine and caffeine (Lashley 1917). 
The hypothesis that physiological Aβ facilitates synaptic function and memory has 
gained support through experiments showing that addition of picomolar concentrations to 
hippocampal slices enhanced synaptic plasticity, while nanomolar concentrations impaired 
it (Puzzo et al. 2008, Garcia-Osta and Alberini 2009, Morley et al. 2010). The 
electrophysiology results were supported evidence that injection of low concentrations of 
the peptide into the hippocampus augmented memory performance. Furthermore, anti-Aβ 
antibodies injected in the same manner inhibited memory, as well as LTP induction in 
hippocampal slices (Puzzo et al. 2011). The facilitatory effect of Aβ may only require the 
N-terminal domain which is shared with sAPPα. Concurrent α- and β-secretase cleavage 
of APP releases a short, 15 residue peptide which exhibited similar enhancement of LTP 
synaptic plasticity, similar to that induced by full length Aβ and sAPPα (Lawrence et al. 
2014, Portelius et al. 2011). Meanwhile, another group reported that the Tg5469 mouse 
model, which overexpresses human APP at ~6 times greater than the endogenous protein, 
exhibit enhanced spatial memory which is blocked by BACE1 inhibition, indicating it was 
mediated by Aβ and not sAPPα (Ma et al. 2007).  
Further to the evidence that the synaptic role of Aβ activity is concentration 
dependent, (Koppensteiner et al. 2016) reported that increased duration of incubation also 
switched its impact from facilitatory to dysfunctional. Neurons incubated with picomolar 
Aβ42 for minutes exhibited increased plasticity, while incubation for hours reduced it. 
These findings were replicated in vivo. This change in effect of the peptide may be due to 
an increasing aggregation state, whereby the three-dimensional structure of the peptide is 
altered sufficiently until it is not recognised by receptors (Puzzo et al. 2015). For example, 
picomolar Aβ modulates presynaptic vesicle release via activation and potentiation of α7 
nicotinic acetylcholine receptors (α7-NAChR), while higher concentrations antagonise 
[11] 
them (Mura et al. 2012). In fact, a specific tyrosine residue within the agonist binding 
pocket of α7-NAChR receptors was critical to permit Aβ-mediated potentiation, although 
this study did not investigate multiple concentrations of the peptide (Tong et al. 2011). 
Activation of α7-NAChR can modulate NMDA receptor internalisation, which may 
represent a mechanism for Aβ-mediated enhancement of LTP (Snyder et al. 2005). 
Furthermore, application of the peptide also enhanced LTD in the dentate gyrus of rat 
hippocampal slices and this was mediated through metabotropic glutamate receptors (Chen 
et al. 2013).  However, it is often difficult to evaluate the impact of the peptide as many 
studies do not specify the concentration of Aβ used in their experiments. 
While a physiological effect of Aβ on synaptic activity is now widely accepted, its 
overall role in neuronal activity remains poorly understood. Production of the peptide is 
sensitive to excitatory synaptic activity, raising the possibility of it being involved in a 
regulatory feedback mechanism (Cirrito et al. 2005, Kamenetz et al. 2003, Lesné et al. 
2005). This hypothesis was supported by experiments in which β- and γ-secretase inhibitors 
were incubated with neuronal cell cultures for 24 hours, leading to increased cell death 
(Plant et al. 2003). The same group later reported that this effect was dependent upon 
increased excitotoxicity following the loss of regulation of potassium Kv4 subunit 
expression by Aβ (Plant et al. 2006). The loss of this protective action may explain why 
APP and BACE1 knock out mice exhibit a hypersensitivity to seizure (Steinbach et al. 
1998, Hitt et al. 2010). Aβ has also been implicated in various other protective 
physiological mechanisms including antimicrobial activity, tumour suppression, blood 
brain barrier (BBB) integrity and brain injury recovery (Brothers, Gosztyla, and Robinson 
2018). The intriguing proposal of the peptide as protective against infection and cancer is 
the beyond the scope of this thesis. However, Aβ interacts with multiple species involved 
in vascular function, including endothelial cells, microglia, red blood cells and 
haemoglobin and metal ions (Fe and Cu), allowing it to act as an anti-coagulant and mediate 
the sealing of damaged blood vessels (Ravi et al. 2004). In fact, cerebrovascular insults 
such as TBI have been shown to trigger Aβ production and localisation to the site of injury 
within minutes (Roberts et al. 1991). Aβ also accumulates around cerebral blood vessels 
following hypertension, ischemia or haemorrhages caused by needle stick lesions 
(Carnevale et al. 2016, Hung et al. 2015, Purushothuman et al. 2013). Two studies reported 
that a greater concentration of the peptide in brain interstitial fluid following acute brain 
injury corresponded to better neurological outcome in patients (Brody et al. 2008, Magnoni 
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et al. 2012). Meanwhile, controlled cortical impact and stroke induced greater severity of 
outcome in mice with deletion of APP or BACE1, further indicating that Aβ exerts a 
protective function (Mannix et al. 2011, Koike et al. 2012). Although plaques have been 
identified in children following head injury, the brains of long-term survivors do not show 
greater plaque deposition than age matched controls despite Aβ deposits remaining in 
injured axons (Graham et al. 1995, Chen et al. 2009). Collectively this suggests that the 
recruitment of Aβ following injury is an immediate, protective and transient effect. 
Breakdown of the BBB is a well-characterised effect of aging and is highly 
associated with AD (Montagne et al. 2015).  Amyloid plaques contain vascular and 
inflammatory proteins and are associated with microhaemorrhages (Cullen, Kocsi, and 
Stone 2006). Therefore, it is tempting to suggest that plaque accumulation is initiated by 
the recruitment of Aβ to disruption of BBB integrity. Amyloid involvement in the 
development of AD will be discussed in detail in the upcoming section. However, the 
interaction of Aβ and the BBB is especially relevant in the context of its physiological 
functions following recent evidence from multiple clinical trials of anti-amyloid therapies 
have reported adverse side-effects including brain oedema and/or microhaemorrhages 
(Sperling et al. 2012, Sevigny et al. 2016). These effects are termed Amyloid related 
imaging abnormalities (ARIA) because they are identified following brain magnetic 
resonance imaging (MRI) analysis. Collectively, this evidence indicates that Aβ plays a 
role in protecting BBB integrity which may become more important during the age-related 
increase in permeability. It therefore hints at a physiological role for the development of 
amyloid plaques independent of their cardinal role in signalling of AD pathology. 
 
sAPPα 
sAPPα is widely considered to have a neuroprotective function and enhances 
synaptic plasticity and memory (Turner et al. 2003, Meziane et al. 1998). This evidence 
mainly comes from studies reporting that the presence of the sAPPα ectodomain rescued 
the morphological abnormalities in dendrites, synaptic plasticity deficits and cognitive 
impairments observed in mice and cell cultures following deletion of the APP gene (Ring 
et al. 2007, Tyan et al. 2012, Hick et al. 2015). The soluble ectodomain may directly 
associate with BACE1 to modulate APP metabolism, promoting the non-amyloidogenic 
pathway (Obregon et al. 2012). Expression of sAPPα naturally declines in aged WT rats 
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but addition of recombinant sAPPα facilitated LTP in hippocampal slices and enhanced 
memory in an object location test (Anderson et al. 1999, Moreno et al. 2015, Xiong et al. 
2017). Furthermore, infusion of sAPPα enhanced LTP during in vivo recording of the 
perforant path in anaesthetised rats (Taylor et al. 2008). The Taylor group also 
demonstrated that both infusion of antibodies targeted to sAPPα and pharmacological 
inhibition of α-secretase impaired LTP and spatial memory, while both effects were 
prevented by co-administration of the peptide (Taylor et al. 2008). Importantly, despite 
being only 16 residues shorter than sAPPα, addition of sAPPβ did not reproduce the 
plasticity enhancing properties either in vitro or in vivo, indicating that those effects were 
specific to the α-secretase cleavage product (Hick et al. 2015, Taylor et al. 2008, Tyan et 
al. 2012). The synaptic mechanism for the action of  sAPPα is not fully elucidated, but it 
appears to facilitate postsynaptic NMDA mediated currents, activate signalling cascades 
and upregulate protein synthesis in the synaptosome, leading to neurotrophic and 
excitoprotective effects (Claasen et al. 2009, Taylor et al. 2008, Cheng et al. 2002, Mattson 
et al. 1993). sAPPα may exert its excitoprotective effect by activation of potassium ion 
channels leading to hyperpolarisation of the neuron and reduction of intracellular calcium 
levels (Furukawa et al. 1996). The loss of this excitoprotective function may have been a 
major factor in the epileptic phenotype exhibited by mice with conditional KO of the major 
α-secretase ADAM10 (Prox et al. 2013). However, it must be noted that inhibition of α-
secretase cleavage of APP increases β-secretase activity and therefore the effects may be 
mediated by a toxic gain of function of amyloidogenic pathway fragments (Wang et al. 
2012). While the overall role of sAPPα at the synapse is becoming clearer, the specific 
receptor activating the effect of the peptide at the postsynaptic membrane has yet to be 
elucidated. 
 
AICD 
Evidence concerning the function of the APP C-terminal Intracellular Domain 
(ACID) is less defined than that of the sAPPα ectodomain. However, studies have shown 
that this region may convey some features of APP function, particularly through a highly 
conserved YENPTY sequence located within the final 15 amino acid residues of the C 
terminus. APP knock-in mice have been generated which lack these final 15 residues, bred 
onto an APLP2-null background to circumventing compensatory activity by the APLP2. 
These mice displayed morphological defects at the neuromuscular junction and 
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impairments of synaptic plasticity, spatial learning and memory (Klevanski et al. 2015). 
To more specifically determine the role of this domain, the tyrosine residue in the 
conserved sequence was selectively mutated to glycine (Matrone et al. 2012). These mice 
exhibited age-dependent cognitive decline and reduction in both dendritic spine density 
and neuromuscular function, while combining the mutation with deletion of APLP2 led to 
postnatal lethality. These loss of function experiments along with the nature of 
evolutionarily conserved sequences, suggest that AICD performs a physiological function. 
This may involve regulation of transcription, as the fragment translocates to the nucleus 
and forms a complex with the nuclear adapter protein FE65 and the histone 
acetyltransferase Tip60 following liberation by γ-secretase cleavage (Cao and Sudhof 
2001, Schettini et al. 2010). This influence on gene transcription may be responsible for 
the implicated role of AICD in cellular functions, such as calcium signalling, cytoskeletal 
dynamics of dendritic spines and apoptosis (Chang and Suh 2010, Muller et al. 2008). The 
association of AICD with the FE65 adaptor protein in the endoplasmic reticulum is also 
significant because it was shown to promote translocation of APP to the cell surface, as 
well as both sAPPα and Aβ secretion (Sabo et al. 2003) Deletion of the conserved 
YENPTY region also strongly decreased amyloidogenic processing of APP (Klevanski et 
al. 2015). However despite this, the impact of overexpression of the AICD on amyloid 
pathology is controversial, as demonstrated by one study reporting increased hippocampal 
degeneration, tau pathology and working memory deficits and another showing no such 
effects (Ghosal et al. 2009, Giliberto et al. 2010). This difference may have arisen due to 
the methodology used. The former study co-expressed AICD with FE65 resulting in 1.5 to 
2-fold increased AICD levels and the amyloidosis-like pathology. However, the latter 
paper overexpressed AICD in mice with human tau protein without manipulating FE65, 
indicating the interaction of these two species is critical for increasing amyloid pathology. 
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1.3  Pathological Role of APP in AD 
This section evaluates the involvement of APP cleavage products in neuronal 
disfunction and in particular how, according to the amyloid cascade hypothesis (Hardy and 
Higgins 1992), the accumulation of Aβ leads to AD.  
β-CTF 
 In contrast to the AICD, the C-terminal fragment produced by β-secretase, is 
regarded as neurotoxic and detrimental to synaptic function. Overexpression of this 
fragment leads to age-dependent deficits in spatial and reversal learning measured in the 
Morris water maze, as well as in the maintenance of LTP (Nalbantoglu et al. 1997). 
Overexpression of β-CTF increased reactive gliosis and hippocampal neurodegeneration - 
two hallmarks of amyloid pathology (Berger-Sweeney et al. 1999). Whether these effects 
are specifically caused by β-CTF or following its metabolism to Aβ is unclear. γ-secretase 
is membrane-bound, meaning that the C-terminus construct would need to be translocated 
to the membrane in these transgenic mice in a similar manner to APP for this cleavage to 
take place. Recombinant β-CTF injected into the brain is unlikely to localise onto cell 
membranes, so any effects would be mediated by the full 99 residue sequence. In fact, 
intracerebroventricular (icv) injection of β-CTF did indeed induce similar effects as the 
overexpression models, with increased gliosis in both the hippocampus and neocortex and 
neurodegeneration identified in the latter region (Song et al. 1998). BACE1 expression is 
increased in the brains of AD patients, meaning that this fragment is also upregulated 
(Zhao, Fu, et al. 2007). Meanwhile, transgenic APP mice overexpress this fragment 
compared to WT controls, meaning the observed pathology cannot be specifically 
attributed to the accumulation of Aβ (Sasaguri et al. 2017). Therefore, the detrimental effect 
of β-CTF must be considered as a potential contributor to pathology in both AD patients 
and transgenic mouse models. Reducing Aβ may not impact β-CTF, allowing it to continue 
to impair neuronal function, and this effect may be partly responsible for the failure of anti-
Aβ therapies to improve cognition in clinical trials. 
 
β-Amyloid 
The plethora of studies describing the neurotoxic functions of Aβ generally describe 
impaired synaptic plasticity and/or memory performance following application of high 
(>nanomolar) concentrations or oligomeric forms of the peptide (Flood et al. 1994, Lesne 
et al. 2006, Townsend et al. 2006). However, the specific mechanisms by which this occurs 
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are not yet fully understood. Considering the involvement of Aβ in the synaptic 
mechanisms described above, any deregulation of these functions may contribute to 
neuronal dysfunction. Increased aggregation of the peptide can influence its interaction 
with receptors such as the α7-NAChR, leading to internalisation of NMDA receptors and 
impaired LTP (Mura et al. 2012, Snyder et al. 2005, Dewachter et al. 2009). Chronic Aβ 
exposure is generally associated with synaptic depression, through NMDA or metabotropic 
glutamate receptor (mGluR1) dependent mechanisms, resulting in the internalisation of α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors (Hsieh et al. 
2006, Chang et al. 2006). However, the biochemical dysfunction induced by Aβ 
accumulation extends beyond synaptic impairment and includes mitochondrial dysfunction 
leading to oxidative stress, excitotoxicity and neurodegeneration (Devi et al. 2006).  
 
Mitochondrial Dysfunction 
Despite the aforementioned potential of Aβ as a key part of a protective, negative 
feedback loop in neuronal excitation, the ability of pathological levels of Aβ to induce 
excitotoxicity has been proposed to involve blocking the reuptake of glutamate by 
astrocytes (Harkany et al. 2000). Increased extracellular accumulation of glutamate will 
cause greater NMDA receptor activation and calcium overload that ultimately induces cell 
death. Aβ accumulation and disrupted calcium homeostasis is also associated with 
mitochondrial dysfunction, which is an early event in AD pathogenesis (Swerdlow and 
Khan 2004, Reddy 2009). Post-mortem analysis of patients revealed an accumulation of 
APP in the protein import channels of mitochondria, particularly within AD-vulnerable 
brain regions, that was not present in age-matched control brains (Devi et al. 2006). Aβ 
itself displays the ability to cross mitochondrial membranes by binding to the translocase 
of the outer mitochondria membrane homolog (TOMM40) (Tillement et al. 2006). Altered 
expression of this transport protein has been reported in AD patients, while polymorphisms 
in the gene have been reported as risk factors for AD by genome-wide association studies, 
strengthening the evidence that this protein is involved in Aβ-mediated mitochondrial 
dysfunction (Goh et al. 2015, Roses et al. 2010). Accumulation of the peptide inhibits the 
function of TOMM40 and other components within the organelle, limiting mitochondrial 
function resulting in decreased ATP production and generation of oxidative stress that has 
been associated with hyperphosphorylation of tau and neuronal damage (Reddy 2011, 
Melov et al. 2007). Importantly, these mechanisms generate a positive feedback loop 
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whereby the increased oxidative stress induces greater Aβ production (Leuner et al. 2012). 
A mitochondria-targeted anti-oxidant drug treatment arrested progression of oxidative 
stress, neuroinflammation and synapse loss in an APP transgenic mouse model and 
inhibited development of spatial memory deficits (McManus, Murphy, and Franklin 2011). 
Accordingly, this evidence adds further support to the hypothesis that AD pathogenesis 
involves a cascade of mitochondrial dysfunction (Swerdlow and Khan 2004). 
 
Inflammation 
While mitochondrial dysfunction can stimulate neuroinflammation due to the 
release of ROS (Kaur et al. 2015), amyloid accumulation alone can induce activation of 
the immune system in both humans and animal models (Heneka et al. 2010). In fact, Trem2 
and complement receptor type 1 (CR1) are two immune-associated risk genes for AD, 
further suggesting a pathogenic involvement of the inflammation pathway (Carmona et al. 
2018). Microglia cells are the resident innate immune cells of the brain, and they are 
activated by Aβ accumulation due to their role in phagocytosis and degradation of 
aggregated proteins (Liu et al. 2012, Simard et al. 2006). Inflammatory cytokines such as 
IL-1β, IL-6 and TNF-α have been shown to ameliorate amyloid pathology (Shaftel et al. 
2007). However, similar to other mechanisms of Aβ-mediated neuronal dysfunction, 
neuroinflammation forms part of a positive feedback loop, generating more peptide and 
exacerbating biochemical dysfunction (Goldgaber et al. 1989). Chronic inflammation and 
prolonged activation of microglia disrupt their ability to clear Aβ, possibly due to the 
downregulation of Aβ-binding scavenger receptors, leading to further immune activation 
and neurotoxicity (Hickman, Allison, and El Khoury 2008, Meda et al. 1995). Chronic 
neuroinflammation has also been proposed as the putative link between increased amyloid 
deposition and tau pathology, following reports that administration of lipopolysaccharide, 
an inducer of neuroinflammation, significantly induced tau hyperphosphorylation in young 
3xTg-AD mice (Kitazawa, Yamasaki, and LaFerla 2004). Furthermore, co-culture of 
astrocytes with cortical neurons exacerbated Aβ-mediated tau phosphorylation, caspase-3 
activation and neuronal damage (Garwood et al. 2011). Epidemiological studies have 
hinted that anti-inflammatory drugs may exhibit a protective role in AD (Breitner et al. 
1994), this has been replicated in mouse models supporting the hypothesis that Aβ-
mediated neuroinflammation plays a malicious role in the pathogenesis of the disease 
(McGeer, Schulzer, and McGeer 1996, Olmos-Alonso et al. 2016). 
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▪ 1.3.1 – The Amyloid Cascade Hypothesis 
Amyloid metabolism and accumulation have been a cornerstone of AD research for 
over 25 years. Some of the initial findings related to APP came from studies of patients 
with genetic abnormalities. Individuals with Down Syndrome who possess an extra copy 
of chromosome 21, which encodes APP (Delabar et al. 1987, Goldgaber et al. 1987) and 
miss-sense mutations in families with an increased incidence of AD (Goate et al. 1991, 
Mullan et al. 1992, Sherrington et al. 1996, Chartier-Harlin et al. 1991, Murrell et al. 1991) 
provided considerable support for the cardinal role of amyloid in AD onset. Biochemical 
studies connected amyloid pathology to the other hallmarks of the diseases including 
neurofibrillary tangles (NFT) and neurodegeneration (Pike et al. 1991, Koh, Yang, and 
Cotman 1990, Mattson et al. 1992, Baudier and Cole 1987). Collectively, this evidence led 
to the formation of the “Amyloid Cascade Hypothesis” which presented accumulation of 
the peptide as the central event in the pathogenesis of AD (Hardy and Higgins 1992). The 
hypothesis stated: “that deposition of amyloid β protein, the main component of the 
plaques, is the causative agent of Alzheimer's pathology and that the neurofibrillary 
tangles, cell loss, vascular damage, and dementia follow as a direct result of this 
deposition”. The recent discovery of an APP mutation that reduces β cleavage and lowers 
the incidence of AD further strengthens the hypothesis (Jonsson et al. 2012). However, 
despite the Amyloid cascade hypothesis guiding research for 25 years, numerous therapies 
reducing Aβ burden have failed in clinical trials (Cummings, Morstorf, and Zhong 2014). 
The ensuing challenges to the hypothesis have resulted in recent updates published by the 
original authors (Selkoe and Hardy 2016). 
The development of MRI and positron emission topography (PET) scanning of 
patients has permitted detailed assessment of amyloid plaques alongside neuronal damage 
and cognitive performance. Multiple studies have reported that the severity of NFT 
pathology, not plaque deposition correlates with clinical measurements of disease 
progression (Braak and Braak 1991, Arriagada et al. 1992). In further challenges to the 
amyloid cascade hypothesis, prominent plaque deposition has been identified in brains of 
non-demented individuals, meanwhile up to 30% of the elderly population are positive for 
amyloid imaging signals, despite appearing cognitively normal (Jellinger 1995, Jack et al. 
2009). However, recent evidence suggests that these individuals may exhibit subtle deficits 
in the AD cooperative Study-Preclinical Alzheimer Cognitive Composite (ADCS-PACC, 
a comprehensive assessment of multiple cognitive domains) as well as accelerated cortical 
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atrophy. This could be considered a pre-symptomatic or prodromal stage of AD with more 
severe cognitive decline yet to develop (Donohue et al. 2014, Chételat et al. 2012). Despite 
these challenges to the amyloid cascade hypothesis, it still remains the prevailing viewpoint 
for the pathogenesis of AD and has been updated to reflect the more recent findings (figure 
1.2) (Selkoe and Hardy 2016). Analysis of the timepoints of pathophysiological processes 
in AD reveals that measurement of rising Aβ levels in the CSF and in amyloid-PET scans 
precedes detectable changes in tau, while cognitive deficits occur much later (Jack et al. 
2013), supporting the theory that amyloid pathology is the initiating mechanism. 
Furthermore, a recent study of 300 cognitively normal individuals reported that while Aβ 
pathology and hippocampal atrophy were both related to memory capability, there was no 
association between the two variables (Svenningsson et al. 2019). Furthermore, Aβ 
pathology was associated with memory only in relatively younger individuals (65 to 73 
years of age); meanwhile hippocampal volume exhibited the opposite effect and was 
associated with memory function in participants of an older age range (73 to 88). Therefore, 
this study further suggests that the influence of Aβ on cognition occurs during early aging. 
 In the last two decades, research into the aggregation mechanisms of Aβ has 
revealed a more specific understanding of its neurotoxicity. While the peptide is relatively 
benign in its monomeric and insoluble plaque states, the intermediary oligomeric or 
protofibril state is proving to be the neurotoxic species (Martins et al. 2008, Haass and 
Selkoe 2007, Hefti et al. 2013, Shankar et al. 2008). For example, Aβ dimers extracted 
from the cortices of AD patients induced tau hyperphosphorylation and degradation of 
neurites in hippocampal neurons, and this effect was inhibited by co-administration of anti-
Aβ immunotherapy (Jin et al. 2011). Shankar et al  (2007) observed that application of a 
picomolar concentration of oligomers to rat organotypic slices led to a degeneration of 
synapses through an NMDA receptor dependent mechanism (Shankar et al. 2007). 
Oligomers also inhibit the induction of LTP as well as memory performance when infused 
into the brain of live rats (Townsend et al. 2006, Lesne et al. 2006, Reed et al. 2011). 
Concentration of oligomeric Aβ also correlates more effectively than that of plaques with 
the severity of clinical symptoms (Bao et al. 2012). Furthermore, while many clinically 
normal individuals exhibit prominent plaque pathology, Esparza and colleagues used 
oligomer-specific ELISAs to demonstrate that these individuals had a very low oligomer-
to-plaque ratio compared to AD brains with a comparable plaque density (Esparza et al. 
2013). In this way, presenting oligomeric Aβ as the neurotoxic species sustains the central 
arguments supporting the amyloid cascade hypothesis while counteracting its most salient 
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criticisms. It also relegates amyloid plaques, the classical hallmark of AD pathology, to an 
undetermined role in the disease. Recent hypotheses involve plaques acting as inert “sinks” 
that are able to sequester soluble Aβ in an equilibrium up to a physical saturation point, at 
which the oligomers diffuse onto the surrounding synapses (Hong et al. 2014, Benilova, 
Karran, and De Strooper 2012). In fact, observations of plaques in transgenic APP mice 
revealed a penumbra of soluble oligomers surrounded each plaque correlating with 
decreased synaptic density in that area which ameliorated with distance from the plaque 
core (Koffie et al. 2009). Meanwhile, Martins et al (2008) described the formation of 
amyloid protofibrils (oligomers) into fibrils (plaques) as reversible and that once formed, 
plaques may act as sources of the neurotoxic Aβ species. Multiple clinical trials of anti-
amyloid therapies have reported clearance of plaques in absence of cognitive benefit for 
patients. Perhaps this clearance represents the recycling of plaques back into oligomers 
which would not alleviate neuronal impairment. Furthermore, if the accumulation of 
plaques is considered a downstream symptom of augmented soluble Aβ, patients 
presenting with extensive plaque pathology may represent a late stage of AD that is beyond 
the therapeutic window for remedial treatment. Having acknowledged these factors, 
current clinical trials now aim to reduce oligomeric or protofibril Aβ species in early-stage 
AD patients. 
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Figure 1.2: The original and revised amyloid cascade hypotheses. 
The original amyloid cascade hypothesis, proposed by Higgins and Hardy in 1992, 
focused on amyloid deposition directly leading to the other forms of neuropathology 
associated with AD. However, in the decades since, the hypothesis has been 
embellished with additional details that have been elucidated by studies into amyloid, 
for example how plaque deposition is no longer considered as part of the pathogenic 
process. This diagram highlights the fact that Aβ performs a physiological, synaptic 
function. However, as the peptide accumulates, it exerts a detrimental effect on synaptic 
function, causes mitochondrial damage, activates the immune system and induces tau 
pathology. These processes culminate in the synaptic dysfunction and neuronal cell 
death that are hallmarks of AD. 
Original Modern Amyloid Cascade Hypothesis 
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1.4 Alzheimer Disease 
▪ 1.4.1 – AD Introduction 
First described in 1906 by Alois Alzheimer, Alzheimer’s Disease (AD) is an age-
related neurodegenerative condition and the leading form of dementia, responsible for 
around two-thirds of the over 50 million cases of dementia worldwide (World Alzheimer’s 
Disease Report 2018). In the US the percentage of the population living with Alzheimer’s 
dementia is 3% of 65-74-year olds and this statistic increases with age as it affects 17% of 
people aged 75-84 and 32% of people over 85 (Alzheimer’s Association Facts and Figures, 
2019). Due to the globally aging population, the number of people living with dementia 
will increase by 204% from 50 million in 2019 to 152 million in 2050 (Dementia fact sheet 
2017, World Health Organisation). Therefore, while the cost of healthcare for dementia 
patients in the UK was £26.3 billion in 2014 (Alzheimer’s Society: Dementia UK update, 
2014) and $290 billion in the US in 2019 (Alzheimer’s Association: Facts and Figures, 
2019), this is expected to more than double by 2040. Meanwhile, over 18.5 billion hours 
of informal (unpaid) care was provided to US AD patients in 2018 at an estimated value of 
$234 billion, showing that the actual cost of dementia care far exceeds the original value. 
Moreover, the physical and emotional impact suffered by dementia care-givers leads to 
increased development of stress, anxiety and depression and resulted in an estimated 
further $11.8 billion in health care costs in the US (Ferrara et al. 2008). The financial and 
personal care burden will particularly affect the developing world, whose population is set 
for the steepest increase in age due to improved life expectancy (World Alzheimer’s 
Disease Report 2015). There are currently no therapies able to prevent AD progression, 
and while symptomatic treatments are able to enhance cognition, they do not impede the 
rate of decline. Therefore, considering the expected increase in its impact, it is imperative 
that further research is undertaken in order that the mechanisms leading to AD pathogenesis 
are better understood. 
▪ 1.4.2 – Aetiology of Alzheimer’s Disease 
Over 95% of AD cases are classified as sporadic, or late onset AD, in which 
pathogenesis is likely initiated by a combination of genetic and environmental factors 
(Bettens, Sleegers, and Van Broeckhoven 2013). In contrast, familial AD (FAD) represents 
the other 1-5% of cases and is an autosomal dominant inherited form involving mutations 
in three genes and resulting in augmented production of the Aβ peptide. Importantly, the 
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neuropathological cascade leading to clinical onset is common between the two classes of 
AD, resulting in the amyloid cascade hypothesis (Lippa et al. 1996), further detail on which 
is discussed in section 1.3.1. While sporadic AD does not have a discrete genetic cause, its 
heritability has been estimated to reach 79% by studies involving the Swedish Twin 
registry, indicating genetics still play a meaningful role (Gatz et al. 2006). The rapid 
development in sequencing techniques has led to genome-wide association studies that 
analyse genetic variants within a population and give a readout of any genes in which 
variants associate with a particular trait such as AD. These studies have revealed genes in 
which single nucleotide polymorphisms (SNP) increase the risk of developing AD. The 
gene with the greatest known effect on sporadic AD development is APOE, which has three 
genetic isoforms. The APOE ε3 allele is the most common, and the risk of developing AD 
increases by 3 or 15 times in individuals that are hetero- or homozygous for the APOE ε4 
allele, respectively (Farrer et al. 1997). Meanwhile, the APOE ε2 variant reduces risk of 
developing the disease, but it is less common than the APOE ε4 (Corder et al. 1994). The 
APOE gene encodes the apolipoprotein E protein, and two decades of interest has 
implicated it in many pathways such as vascular function, neuroinflammation, glucose 
metabolism, synaptic plasticity and transcriptional regulation (Liao, Yoon, and Kim 2017). 
However, the prevailing view is that APOE function is involved in Aβ metabolism and 
clearance and that efficiency of this is reduced due to expression of the APOE ε4, leading 
to the increased deposition observed in these individuals (Kok et al. 2009). Other risk loci 
implicated by recent GWAS studies include PICLAM, CLU, BIN1, (Harold et al. 2009). 
Importantly, these risk genes appear to converge on amyloidogenic processing of APP as 
they have been implicated in clathrin-mediated endocytosis, giving further weight to the 
amyloid cascade hypothesis (Liu and Niu 2009, Thomas et al. 2016). Recently, CR1 and 
TREM2 have been reported as risk genes and their involvement in inflammatory pathways 
has galvanised investigation into how this process interacts with AD (Guerreiro et al. 2013, 
Carmona et al. 2018). While further identification and analysis of functional risk loci will 
enhance our understanding of sporadic AD pathogenesis, current GWAS data can be 
applied to individual genomes to generate polygenic risk scores, which can predict whether 
that individual will develop AD with a success rate over 80% (Chaudhury et al. 2019). 
Furthermore, the ability to predict the age-specific genetic risk of AD development would 
be invaluable for recruiting patients to clinical trials at an earlier stage of the disease, 
potentially opening access to the elusive therapeutic window for clinical efficacy of 
disease-modifying treatments. 
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▪ 1.4.3 – Symptoms & Diagnosis 
AD is characterised by progressive decline in cognitive ability, such as memory 
loss and problem solving due to functional impairments in the brain regions underpinning 
cognition. Amyloid neuropathology initiates in the medial temporal lobe (MTL), which 
encompasses the entorhinal cortex and hippocampus, and progresses to the parietal and 
frontal lobes (Braak and Braak 1991). In terms of its clinical progression, the earliest 
symptoms involve a decline in MTL-dependent episodic and semantic memory, which can 
be detected during a “preclinical” stage of the disease (Hodges, Salmon, and Butters 1990, 
Bondi et al. 2008). Worsening cognitive condition may lead to the diagnosis of mild 
cognitive impairment (MCI), a transitional stage from typical cognitive function for a given 
age to AD (Petersen et al. 1999). However, whether patients are diagnosed with AD 
depends on both clinical and biomarker criteria (McKhann et al. 2011). More severe stages 
of the disease involve alterations in personality, difficulty with speech and the loss of 
everyday function, alongside a pronounced impairment of recent memory and the inability 
to form new memories (Forstl and Kurz 1999). The two biochemical hallmarks of the 
disease, first described by Alzheimer himself, are extracellular amyloid plaques and 
intracellular neurofibrillary tangles (NFT) of hyperphosphorylated tau. 
The clinical criteria for diagnosis of different stages of Alzheimer’s dementia were 
revised in 2011 from the initial guidelines set out in 1984 by the National Institute on 
Aging-Alzheimer’s Association (NIA-AA) (Albert et al. 2011, Sperling et al. 2011, 
McKhann et al. 2011). The original criteria for definitive diagnosis required both clinical 
and histopathological assessment, meaning that it was not possible until post mortem 
examination of the patient (McKhann et al. 1984). The revision included the use of 
biomarker evidence (including imaging, serum and CSF analysis) alongside cognitive tests 
to distinguish patients with even the earliest stages of AD from those with other forms of 
dementia and MCI (McKhann et al. 2011). The ability to monitor cognitive and 
biochemical symptoms concurrently is proving to be particularly useful to the 
pharmaceutical industry. Current trials utilise biomarkers for both inclusion criteria and an 
outcome measurement (Sevigny et al. 2016). In fact, recent analysis estimated that up to 
25% of patients enrolled in AD clinical trials did not exhibit amyloid pathology (Selkoe 
and Hardy 2016). This information is particularly important within the context of this 
thesis, as anti-amyloid therapies may have exacerbated cognitive decline in these patients. 
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In terms of cognitive assessment of potential AD patients, two of the most commonly 
used tests are the Mini-Mental Status Examination (MMSE) and the Cambridge 
Neuropsychological Tests Automated Battery (CANTAB) (Cockrell and Folstein 1988, 
Fray, Robbins, and Sahakian 1996). The MMSE (or Folstein test) is a 30-point 
questionnaire able to assess episodic and semantic memory, working memory, attention, 
language and spatiotemporal orientation within 10 minutes (Folstein, Folstein, and 
McHugh 1975). In contrast, the CANTAB is a non-verbal, computer-based examination of 
learning, working memory, semantic memory, executive function, attention and reaction 
time (Fray, Robbins, and Sahakian 1996). Similar frequently used cognitive assessments 
for AD patients include the General Practitioner Assessment of Cognition (GPAC) and the 
Montreal Cognitive Assessment (MCA) (Brodaty et al. 2002). In order to measure the 
impact of a drug on a patient’s daily functions during a clinical trial, the Alzheimer Disease 
Cooperative Study – Activities of Daily Living (ADCS-ADL) records observations of their 
competence when performing basic tasks such as eating, walking and dressing (Fish 2019). 
The criteria of AD diagnosis now require both a clinical deficit in episodic memory 
measured on one of the tests above as well as at least one abnormal AD relevant biomarker. 
This includes analysis of Aβ42, hyperphosphorylated tau and total tau in the cerebral spinal 
fluid (CSF), which delivers diagnostic accuracy of 85-90% (Palmqvist et al. 2015). 
However, CSF biopsy necessitates lumbar puncture, an invasive and sometimes 
inconvenient procedure, while results may take weeks to obtain (Zetterberg et al. 2010). 
Meanwhile, the development of amyloid specific PET ligands such as florbetapir, 
florbetaben and flutemetamol has permitted non-invasive, diagnostic imaging analysis 
(Yeo et al. 2015). For example, florbetapir PET scans accurately diagnosed AD in 59 
patients with up to 92% sensitivity and 100% specificity, as proven by post mortem 
neuropathological analysis (Clark et al. 2012). However, the patients were in a late-stage 
of AD and therefore the sensitivity for detecting prodromal AD was not assessed. When 
examining prodromal patients, the same method measured significantly increased cortical 
uptake in patients versus age-matched controls, while global cortical amyloid load 
correlated with cognitive performance (Saint-Aubert et al. 2013). However due to the high 
expense, amyloid-PET imaging is mainly limited to analysis of patients within clinical 
trials. Development of less invasive diagnostic tests are under way and recently there have 
been promising results in blood biomarker assays that measure BACE1 activity or the 
Aβ42/Aβ40 ratio and are able to predict amyloid pathology with up to 94% success rate 
(Nakamura et al. 2018, Shen et al. 2018).  
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▪ 1.4.4 – Current Treatments  
Despite a plethora of AD modifying therapies entering clinical trials with promising 
preclinical results, no new treatments have been approved for the disease since 2003. The 
five treatments currently available for patients are merely symptomatic: although they 
enhance cognition, they do not impede the rate of cognitive decline. Of these five, three 
are anticholinesterase inhibitors, one is an NMDA antagonist and one is a combinatorial 
therapy of two of these compounds. The anticholinesterase inhibitors donepezil (Aricept; 
Pfizer), rivastigmine (Exelon; Novartis) and galantamine (Reminyl; Janssen), are 
prescribed for mild to moderate stage AD and augment acetyl choline (Ach) activity by 
inhibiting the enzyme responsible for its breakdown, acetyl cholinesterase (Birks 2006). 
Cholinergic transmission has been shown to be decreased during AD pathology and ACh 
is an important neurotransmitter within learning and memory mechanisms (Davies and 
Maloney 1976). Therefore, enhancing the activity of ACh may compensate for the 
impairments in neuronal communication present in AD brains and partially restore efficient 
memory processing. Meanwhile, the NMDA receptor inhibitor memantine (Ebixa; Eli 
Lilly), is prescribed for moderate-to-severe stage AD patients (Tariot et al. 2004). Its 
method of action is to impede the NMDA-dependent excitotoxicity caused by surplus 
extracellular glutamate and disrupted calcium homeostasis (Danysz and Parsons 2003). 
Furthermore, combinatorial administration of memantine with donepezil resulted in 
significantly greater improvement of symptoms than donepezil alone (Tariot et al. 2004). 
However, although these treatments relieve some of the cognitive decline associated with 
AD, they do not halt the progression of the disease because they do not target the underlying 
pathology. Therefore, there has been significant investment to explore both the pathogenic 
mechanisms of the disease, and how these might be impeded. Disease modifying therapies 
aimed at manipulating the deposition/clearance of amyloid and/or ameliorating tau 
pathology have been extensively tested in preclinical models, but have consistently failed 
in human clinical trials. 
▪ 1.4.5 – Developing Treatments  
Putative therapeutic treatments for AD have mainly focused on two amyloid-related 
strategies: small molecule inhibitors of the enzymes responsible for APP metabolism and 
immunotherapies that target Aβ to augment its clearance by the immune system. Despite 
promising results in preclinical studies, these strategies have consistently failed in clinical 
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trials. While an overview of the proposed strategies and their outcomes will be highlighted 
in this section, a thorough review of clinical trial outcomes will be presented in chapter 7. 
Although this section focuses on anti-amyloid strategies due to the themes of the 
thesis, a summary of the current state of tau-based therapy development provides context 
of the current clinical environment around AD. As tau pathology in AD involves aberrant 
phosphorylation, kinase and phosphatase enzymes have been proposed as therapeutic 
targets despite selectivity complications and potential off-target effects. Glycogen synthase 
kinase 3β (GSK-3β) has been proposed as one of the key enzymes responsible for the 
abnormal tau phosphorylation associated with AD (Lovestone et al. 1994). Tideglusib 
(Zeltia Group) is an orally available molecule that irreversibly inhibits GSK-3β and 
demonstrated the potential to reverse tau pathology, rescue neuronal death and alleviate 
memory deficits in a transgenic mouse model expressing mutated APP and tau (Sereno et 
al. 2009). However, a phase II trial did not demonstrate clinical benefit (Lovestone et al. 
2015). Another strategy involves inhibition of tau aggregation with drug molecules such 
as LMTM (TauRx), however this also failed to achieve primary endpoints in phase II trials 
(Gauthier et al. 2016). As tau is a microtubule associated protein, its primary role in AD 
pathogenesis is widely considered to be loss of its microtubule-stabilising function, and so 
pharmacological stabilisation is a potential avenue for AD treatment (Ramser et al. 2013). 
However, despite demonstrating promising memory protective effects in tau transgenic 
mice, no drugs of this class have progressed beyond phase I clinical trials for AD 
(Matsuoka et al. 2008). The final anti-tau treatment described here involves using 
antibodies raised against abnormally phosphorylated tau to promote its clearance by the 
immune system, a concept which is detailed below within the context of anti-amyloid 
strategies. Some anti-tau immunotherapies have shown promising preclinical results and 
are currently in early stage clinical trials (Theunis et al. 2013, West et al. 2017). In 
summary, while tau-based strategies for the treatment of AD have demonstrated some 
potential, they are at an earlier stage of development compared to anti-amyloid therapies. 
Small Molecule Inhibitors 
 One therapeutic strategy to relieve amyloid pathology is to inhibit the β– and γ–
secretase enzymes responsible for amyloidogenic APP metabolism. Evidence supporting 
this strategy is available from genetic studies. For example, genetic deletion of the enzyme 
in KO mouse lines eradicated production of Aβ and βCTF (Luo et al. 2001, Kobayashi et 
al. 2008, McConlogue et al. 2007). BACE1 KO also rescued cognitive deficits exhibited 
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by transgenic APP mouse lines, e.g., Tg2576, PDAPP and 3xTg mice (Ohno et al. 2004, 
Ohno et al. 2007). First generation BACE1 inhibitor molecules were peptidomimetic 
analogues of the APP cleavage site and significantly reduced soluble Aβ in vitro and in 
vivo. Nevertheless, they suffered from poor oral bioavailability, poor BBB penetrability 
and a long serum half-life (Asai et al. 2006, Kimura et al. 2005, Ghosh, Brindisi, and Tang 
2012, Yan and Vassar 2014). More recent iterations of inhibitor molecules have 
demonstrated improved pharmacokinetics leading to robust effects on Aβ clearance and 
rescued cognitive deficits in transgenic models (Hussain et al. 2007, Fukumoto et al. 2010). 
Several drugs such as LY2811376 (Eli Lilly) and MK-3931 (Verubecestat, Merck) have 
demonstrated the potential to reduce CSF Aβ levels in both animals and humans (May et 
al. 2011, Kennedy et al. 2016). However, these molecules have all been withdrawn from 
trials at varying stages due to either off-target effects (possibly due to the influence of 
BACE1 within other pathways) or a lack of effect on cognitive symptoms (see section 7.2). 
 A similar pattern has been observed during the development of γ-secretase 
inhibitors. Modulation of γ-secretase function is known to impact AD pathogenesis because 
mutations in PS1 cause FAD (Sherrington et al. 1995). γ-secretase inhibitors were able to 
reduce Aβ levels in vitro and in the brains of PDAPP transgenic mice (Dovey et al. 2001). 
However, similar to the BACE1 inhibitors, promising preclinical results have not translated 
to clinical trial success. Both avagacestat (Bristol-Myers Squibb) and semagacestat (Eli 
Lilly) were discontinued from their respective phase II and III trials due to lack of cognitive 
benefit as well as increased risk of adverse effects including skin cancer (Doody et al. 2013, 
Coric et al. 2012). Moreover, patients receiving the highest doses of both drugs were 
associated with a trend for worse cognitive decline compared to placebo-treated control 
patients, despite semagacestat having previously demonstrated a dose-dependent decrease 
in human plasma and CNS Aβ (Bateman et al. 2009, Fleisher et al. 2008). The detrimental 
effects of γ-secretase inhibition may be due to the impact on non-APP substrates (Haass 
2004). For example, PS1 deficiency reduced the γ-secretase cleavage of both APP and 
Notch, which has been linked to oncogenesis (De Strooper et al. 1999). This potential for 
off-target effects has led to the development of γ-secretase modulators that have 
demonstrated selective inhibition of APP cleavage; reducing the amyloid plaque burden in 
the cortex and hippocampus while attenuating the spatial memory deficit of a transgenic 
AD mouse model, with no effect on Notch signalling in HEK239Swe cells (Imbimbo et al. 
2009). Other groups have reported similar effects in Tg2576 mice using alternative novel 
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compounds, further indicating the preclinical efficacy of this mechanism (Rogers et al. 
2012, Kounnas et al. 2010, Wagner et al. 2017). These modulator compounds were 
originally derived from non-steroidal anti-inflammatory drugs, which have been 
epidemiologically associated with a reduced risk of AD development (Breitner et al. 1994, 
Crump, Johnson, and Li 2013). Whether this more selective inhibition of γ-secretase 
cleavage successfully translates to clinical trials remains to be seen. 
Anti-Amyloid Immunotherapies 
Immunotherapy - the recruitment of immune molecules to perform a therapeutic 
effect – is a popular pharmacological approach due to the specificity granted by high 
affinity antibodies. Active immunotherapy exploits the patient’s immune response, while 
passive immunotherapy involves injection of exogenous antibodies raised against the target 
protein. Aβ peptides and plaques were the most logical target, especially considering AD 
patients were found to have fewer endogenous anti-Aβ antibodies in their serum and CSF 
(Du et al. 2001). The Solomon group reported in 1996 that monoclonal antibodies (mAb) 
raised against Aβ inhibited aggregation of the peptide when incubated in vitro, suggesting 
mAbs as a potential therapeutic approach (Solomon et al. 1996). There are several 
mechanisms by which anti-Aβ antibodies might promote clearance of the peptide. Firstly, 
immunoglobulin molecules contain an Fc domain, which specifically interacts with the Fc 
receptors on microglia and stimulates phagocytosis of both the antibody and the Aβ peptide 
it is bound to (Bard et al. 2000). However, this may not be the exclusive mechanism as the 
effect of Aβ immunisation was maintained following deletion of the Fc receptor (Das et al. 
2003, Bacskai et al. 2002). Anti-Aβ antibodies may sequester the peptides circulating in 
the serum thereby shifting the concentration gradient across the BBB and encouraging 
increased efflux from the brain parenchyma (Lemere et al. 2003). Indeed, anti-Aβ 
immunotherapy studies have reported increased serum concentrations of the peptide 
(DeMattos et al. 2001). Meanwhile the sequestering of monomers and oligomers in the 
CNS may both inhibit aggregation and neutralise the mechanisms required to induce 
synaptic dysfunction (Walsh et al. 2002). Reduction of the soluble Aβ concentration may 
promote the disaggregation of plaques, as the various species of Aβ are thought to exist in 
equilibrium (Benilova, Karran, and De Strooper 2012). However, despite a plethora of 
studies demonstrating the potential of anti-Aβ immunotherapies to reduce the amyloid 
burden and rescue the cognitive impairment of aged transgenic mouse models, as well as 
evidence of plaque clearance in human trials, no significant beneficial effect on human 
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cognitive decline has been reported. A thorough review of both active and passive 
immunotherapies in clinical trials of AD patients is presented in chapter 7. 
Conclusion 
The consistent failure of anti-amyloid therapies in clinical trials for AD patients has 
resulted in challenges to the amyloid hypothesis. As mentioned above, an updated 
hypothesis has modified the approach of clinicians, switching the focus from plaques to 
soluble oligomeric Aβ species while also recruiting patients at an earlier stage of the 
disease. The existence of mutations within the APP gene that significantly elevate or reduce 
the likelihood of developing AD is ostensibly impervious evidence supporting the protein’s 
role in AD pathogenesis. However, explanations for the failure of anti-amyloid therapies 
must be promptly illuminated if the hypothesis is going to deliver a treatment. One 
explanation is that detectable pathology may already represent a stage beyond the remedial 
potential of anti-amyloid drugs; particularly considering current animal models (in which 
the treatments have shown success) reproduce preclinical stages of AD. However, in 
addition to medication being delayed beyond the therapeutic window, it is possible that 
premature administration of anti-amyloid treatment may also be detrimental. This major 
theme of this thesis is originally derived from the intriguing observation that BACE1 KO 
mice which exhibit deficits in spatial memory (Ohno et al. 2004, Laird et al. 2005, 
Kobayashi et al. 2008). Furthermore, pharmacological evidence also suggests that BACE1 
inhibition is detrimental to cognition, as two separate inhibitors administered to WT mice 
both resulted in Y-maze alternation impairments (Filser et al. 2015). Therefore, while 
reducing the levels of Aβ has resulted in cognitive benefits in many studies involving 
transgenic APP models of AD, the detrimental effects in WT mice raises concerns for the 
welfare of patients; particularly with clinical trials aiming to recruit patients in earlier 
stages of the disease who may not have developed widespread amyloid deposition. In fact, 
during a clinical trial of 1454 patients diagnosed with prodromal AD, administration of the 
BACE inhibitor Verubecestat was actually associated with significantly worse cognitive 
decline and greater progression to AD than placebo treatment (Egan et al. 2019). This 
further suggests that amyloid inhibition as a therapeutic strategy may carry risks especially 
in those whose cognitive function is not severely compromised. One question that remains 
to be addressed is whether the detrimental effect of BACE inhibitors is caused by Aβ 
reduction or off-target effects. This issue will be addressed in Chapter 3 by using an 
antibody that binds to the β-cleavage site of APP and sterically inhibits cleavage, resulting 
in knock-down of Aβ (Thomas, Liddell, and Kidd 2011).  
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1.5 Modelling AD 
One goal of this thesis was to investigate how the physiological role of Aβ changes 
during its accumulation leading to the toxic effect we see in AD. The failure of so many 
clinical trials of treatments had been supported by promising preclinical studies has led to 
the questioning the validity of genetically modified FAD models. In particular, the 
transgenic nature and hyperexpression of APP is under scrutiny. Recent evidence suggests 
that overexpression mechanisms may lead to artefactual effects in transgenic mice, 
particularly with APP as all of its fragments are overexpressed, meaning that the resulting 
phenotype is not specifically related to augmented Aβ levels. In order to elucidate these 
artefacts and assess the impact of increased Aβ expression in a more physiological manner, 
Takaomi Saido (RIKEN Centre for Brain Science, Japan) generated three novel “knock in” 
mouse models that express murine APP with a humanised Aβ sequence, under the control 
of the endogenous promoter. Therefore, APP is not overexpressed but Aβ production is 
upregulated due to the presence of FAD mutations, generating a more reliable in vivo 
system of the human disease. The focus of the current section will be to provide an 
overview of how first generation, transgenic models have shaped our understanding of 
amyloid pathology. It is important to comprehend the criticism concerning the relevance 
of these models, particularly within the context of the failure of promising therapies to 
deliver beneficial effects in clinical trials. Finally, this section will present current evidence 
of the phenotype observed in the second-generation, knock-in mice. 
▪ 1.5.1 - First Generation Transgenic Models 
Genetically modified mouse models have been used to model amyloid pathology 
and AD for two decades (Hsiao et al. 1996). These models exploit the discovery and 
sequencing of autosomal dominant, FAD-associated mutations in the genes encoding APP, 
PS1 and PS2 (Webster et al. 2014). Genetic constructs containing these human FAD 
mutations are expressed under the control of artificial promoters, which results in 
upregulated protein production above endogenous levels (Kobayashi and Chen 2005, 
Sasaguri et al. 2017). All the mutations linked to early onset AD result in increased 
amyloidogenic processing of APP, with the majority altering γ-secretase activity to 
increase the Aβ42/Aβ40 ratio, releasing peptides that are more likely to aggregate (Citron 
et al. 1997). Therefore, expression of these mutations in mice generates in vivo models of 
amyloidosis, which have permitted detailed investigations into the mechanisms of Aβ-
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related pathogenesis. Common neuropathology observed in these mouse models are 
cerebral Aβ deposition and reactive gliosis: (activation and proliferation of microglia and 
astroglia that indicates neuroinflammation) (Irizarry et al. 1997, Games et al. 1995). Some 
models also exhibit the synaptic impairment, dendritic spine degeneration and hippocampal 
cell loss associated with high levels of Aβ (Redwine et al. 2003, Reilly et al. 2003, Jacobsen 
et al. 2006). Crucially, transgenic models also exhibit cognitive deficits, the major clinical 
hallmark of human AD. A comprehensive review of cognitive investigations using 
longitudinal designs in 10 distinct transgenic AD models revealed a common pattern: that 
spatial working memory (SWM) impairment manifests prior to the decline of other aspects 
of memory, such as object recognition (Webster et al. 2014). Inconsistencies in the reported 
age points of cognitive changes reflects the distinct background strains and specific nature 
of the transgene overexpression, as well as the precise protocols performed by each 
research group. As spatial memory tasks are well-characterised to depend on intact 
hippocampal activity, cross-sectional analysis suggests that this brain region is particularly 
susceptible to Aβ-related dysfunction (Morris, Hagan, and Rawlins 1986, Olton and Werz 
1978, Aggleton, Hunt, and Rawlins 1986). Importantly, this recapitulates the clinical 
progression of cognitive impairment in human AD, of which a decline in MTL-dependent 
episodic memory is an early marker (Bateman et al. 2012). 
The first mouse models of AD transgenically expressed mutant human APP 
(hAPP). The PDAPP mouse expressed hAPP containing the Indiana (V717F) mutation at 
over 10-fold higher levels than endogenous murine APP (Games et al. 1995). The PDAPP 
mouse exhibits plaques from 4-6 months of age, as well as dendritic spine loss and reactive 
gliosis. SWM deficits have been observed at 3 and 4 months of age in the radial arm maze 
(RAM) and Morris Water Maze (MWM), prior to plaque pathology (Dodart, Meziane, et 
al. 1999, Hartman et al. 2005). Another well-characterised human APP transgenic (hAPP-
Tg) mouse model is the Tg2576, which expresses the Swedish (KM670/671NL) mutation 
located at the BACE1 cleavage site of APP (Hsiao et al. 1996). The Swedish mutation 
increases the affinity for the BACE1-APP interaction, resulting in a bias for β-, over α-
secretase metabolism demonstrated by 5- and 14-fold increases in Aβ40 and Aβ42(43), 
respectively (Hsiao et al. 1996). The Tg2576 mouse develops plaques at 11-13 months of 
age, while synaptic impairment and degeneration was detected in the hippocampus at 4-5 
months (Jacobsen et al. 2006). Deficits in spatial reference memory and alternation have 
been observed at 9-10 months of age, while visuospatial object recognition memory deficits 
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appeared in 14 month old mice (Hale and Good 2005). No single AD animal model 
recapitulates all the pathological features of the human disease, and multiple mutations are 
often combined to produce a more comprehensive set of pathological features. 
Overexpression or knock-in of pathogenic mutant PS1 alone induced neurodegeneration 
but not amyloid pathology, possibly due to insufficient quantity of Aβ (Chui et al. 1999). 
Alternatively, the three amino acid residues that distinguish murine Aβ from the human 
version may impede amyloidogenesis (Xu, Ran, et al. 2015). Crossing transgenic strains to 
combine human APP over-expression with mutations in PS1 accelerates AD-related 
neuropathology (Borchelt et al. 1997). These double transgenic mice include the APP/PS1 
mouse, which develops plaques in the cortex from six weeks and in the hippocampus at 3-
4 months of age (Radde et al. 2006). Cognitive deficits have been reported in spatial 
learning and memory at 7 months (Serneels et al. 2009) and reversal learning at 8 months 
(Radde et al. 2006). The APPswe/PS1dE9 strain developed detectable plaques at 4 months 
of age, while cognitive deficits were reported in the object-in-place task in 5 month old 
mice (Bonardi, Pardon, and Armstrong 2016, Garcia-Alloza et al. 2006). 
The interest in mouse models expressing multiple mutations resulted in the 
generation of 5XFAD and 3xTg-AD mice, both of which develop cognitive deficits at a 
young age (<4 months). The 5XFAD model was developed by Oakley et al (2006) and 
combines three APP mutations with two in PS1, all driven by the Thy-1 promoter. The 
rapid onset of pathology includes Aβ accumulation and reactive gliosis from <2 months of 
age, while synaptic loss and cognitive deficits were detectable at 4-5 months of age (Oakley 
et al. 2006). However, rapid and severe amyloidosis in the 5XFAD model did not progress 
to NFT pathology in the absence of mutant tau. In order to concurrently observe both 
amyloid and tau pathogenesis, Oddo and colleagues (2003) developed the 3xTg-AD 
mouse, which overexpresses APPSWE and TauP301L on a PS1M146V knock-in background. 
This model recapitulates both the Aβ plaque and NFT pathology exhibited by human AD 
patients, as well as the other hallmarks of synaptic and cognitive impairment (Billings et 
al. 2005, Oddo et al. 2003). However, it must be noted that the tau mutant expressed in 
these mice is not associated with AD but frontotemporal dementia with parkinsonism 
linked to chromosome 17 (Lewis et al. 2000). While some unknown aspect of murine 
physiology prevents NFT formation following expression of FAD mutations, KO of MAPT 
(microtubule associated protein tau: the gene encoding tau) conferred neuroprotection and 
ameliorated memory deficits in APP-Tg mice (Roberson et al. 2007, Ittner et al. 2010), 
suggesting that there is still some connection between amyloid and tau in these animals.  
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Class of 
Model 
Strain(s) 
Genetic 
Background 
Promoter Mutation(s) 
General 
Phenotype 
Specific 
Disadvantages 
Single 
Transgenic 
APP-Tg 
PDAPP 
 
J20 
 
 
 
APP23 
 
 
Tg2576 
 
C57/Bl6 
 
C57/Bl6 
 
 
 
C57/Bl6 
 
 
Bl6,SJL 
mixed 
 
PDGF-β 
 
PDGF-β 
 
 
Mouse 
Thy1 
 
Hamster 
prion 
protein 
APPV717F 
 
APPKM670/671NL 
APPV717F 
 
APPKM670/671NL 
 
 
APPKM670/671NL 
Amyloid 
deposition 
from ~6 
months 
 
Moderate 
behavioural 
phenotype 
 
Neuronal loss 
in some 
models 
 
No NFTs 
 
Cognitive 
impairment 
preceding Aβ 
accumulation 
 
Mixed 
background in 
some cases 
 
Double 
transgenic 
APP-Tg x 
PS1-Tg 
(or KI) 
 
APP/PS1 
 
 
5xFAD 
 
C57/Bl6 
 
 
(C57Bl/6 x 
SJL)F1 
& 
C57Bl/6 
 
Mouse 
Thy1 
 
Mouse 
Thy1.2 
 
APPKM670/671NL 
PS1I166P 
 
APPKM670/671NL 
APPI716V 
APPV717I 
PS1I166P 
PS1l286V 
Aβ 
accumulation 
from early age 
 
Moderate 
behavioural 
phenotype 
 
Neuronal loss 
in some 
models 
Potential 
interaction of 
multiple 
mutations 
 
Mixed 
background in 
some cases 
 
Complicated 
cross-breeding 
 
Triple 
Transgenic 
 
3xTg-
AD 
 
C57Bl/6 
 
Mouse 
Thy1.2 
(APP, Tau) 
Endogenous 
(PS1) 
 
APPKM670/671NL 
MAPTP301L 
 
PS1M146V 
 
 
Moderate to 
severe 
behavioural 
phenotype 
 
NFT 
formation 
 
Neuronal loss 
Potential 
interaction of 
multiple 
mutations 
 
MAPT mutation 
not associated 
with AD 
 
Complicated 
cross-breeding 
 
Cognitive 
impairment 
preceding Aβ 
accumulation 
 
Single 
APP 
Knock-In 
 
APPNLF 
 
 
APPNLGF 
 
 
C57Bl/6 
 
Endogenous 
APP 
 
APPKM670/671NL 
APPI716F 
 
APPKM670/671NL 
APPI716F 
APPE693G 
Minor 
behavioural 
phenotypes 
 
Aβ 
accumulation 
from an early 
age, alongside 
endogenous 
APP 
expression 
Potential 
interaction of 
multiple 
mutations 
 
Lack of 
behavioural 
phenotypes 
 
Slow breeding 
due to genomic 
homozygosity 
Table 1.1: Comparison of current APP mouse models of AD. This table summarises 
multiple classes of AD mouse model, to highlight their specific disadvantages, adapted 
from Sasaguri et al (2017). There are individual strains within each class that express 
various mutations. Transgenic mice have general disadvantages applicable to all of 
them, including random transgene insertion into the genome, APP overexpression-
related artefacts, artificial promoters and the lack of relevant control mice. 
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Transgenic AD mouse models have been invaluable for researchers aiming to 
elucidate the mechanisms of amyloid accumulation and subsequent pathology. For 
example, while the lack of correlation between plaque burden and memory deficits initially 
confounded researchers, it triggered the shift in the understanding that soluble oligomeric 
species of Aβ delivered the neurotoxic activity of the peptide, rather than plaques (Chen et 
al. 2000). Evidence that gene knock-out of BACE1 abolishes cerebral amyloid deposition 
and the downstream neuropathology of synapse loss and cognitive impairment in all 
transgenic models tested to date strongly indicates a causative effect of Aβ accumulation’ 
although the potential impact of βCTF overexpression cannot be excluded (Ohno et al. 
2004, Ohno et al. 2007, Laird et al. 2005, McConlogue et al. 2007). The beneficial effect 
of genetic BACE1 depletion led to the screening of BACE1 inhibitors in these models. 
Small molecule inhibitors reduced cerebral amyloid load by up to 90% which accompanied 
rescue of learning and memory impairments (Kennedy et al. 2016, May et al. 2015, 
Neumann et al. 2015). Similarly, these models have been useful in the development of anti-
amyloid immunotherapies such as aducanumab, which induced a dose-dependent reduction 
in the Aβ levels of Tg2576 mice (Sevigny et al. 2016). Furthermore, in vivo studies 
investigating the influence of γ-secretase on notch signalling predicted the adverse effects 
of inhibitor molecules observed in clinical trials (De Strooper et al. 1999).  
▪ 1.5.2 – Criticism of 1st gen models 
While the studies described in the previous section established the proof of principle 
of secretase inhibitors or anti-Aβ antibodies as putative therapeutic mechanisms to relieve 
amyloid pathology and memory deficits in first generation, transgenic mice; the failure of 
any treatments to show clinical benefit in trials of AD patients has brought their relevance 
as models into disrepute. The mutations expressed in these genetic models are associated 
with familial, not sporadic AD. Estimates for the proportion of AD cases that are familial 
range from 5% to less than 1% (Campion et al. 1999, Reitz and Mayeux 2014), and this 
percentage will decrease due to the aging global population. Almost all clinical trials for 
AD have recruited patients with sporadic AD, in which pathogenesis occurs by alternative 
genetic and environmental mechanisms to FAD (Bettens, Sleegers, and Van Broeckhoven 
2013). Although amyloid deposition is hypothesised to be the central initiating factor in 
both forms of the disease, the use of FAD models to screen therapeutic treatments may not 
be relevant for the vast majority of patients (Hardy and Higgins 1992). For example, 
transgenic overexpression of mutated human APP may result in the generation of APP 
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fragments and Aβ species that are not present in the brains of sporadic AD patients 
(Sasaguri et al. 2017). Furthermore, many models involve multiple, combined mutations 
which do not naturally occur and are therefore not representative of any human form of the 
disease. Combinatorial models involve the cross-breeding of inbred mouse lines which 
further delineates the genetics and physiology from the original, natural state, generating 
artificial phenotypes (Saito et al. 2014). Meanwhile, although mice expressing mutant APP 
and/or PS1 exhibit the age-related plaque formation and cognitive deficits associated with 
AD, a complete recapitulation of the human condition seems impossible (LaFerla and 
Green 2012). Pathology does not always progress to the NFTs and neurodegeneration 
observed in late stage AD patients (Webster et al. 2014). In fact, mutations in the gene 
encoding the tau protein are required to produce tangle pathology (Lewis et al. 2001). These 
mutations are not associated with AD and therefore introduce further unphysiological 
alterations from both the human condition and wild-type mice (Lewis et al. 2000). 
The most salient critique of transgenic models focuses on the overexpression 
mechanism utilised to generate the Aβ accumulation. Protein hyperexpression inherently 
confers potential cellular effects that are independent of the specific amplified protein. For 
example, insertion of the transgene into the mouse genome is random and potentially 
occurs within endogenous gene loci, impeding its expression (Kuro-o et al. 1997, Verret et 
al. 2012). Furthermore, the artificial promoter may result in non-specific tissue expression 
of the protein while also competing with endogenous promoters for transcription factors; 
both of which may influence cellular and network function in a spontaneous and 
uncontrolled manner (Matthaei 2007). Importantly, the inherent issues concerning the 
random insertion of transgenes, not least the variable copy number, diminish the reliability 
of wild-type negative control animals to reveal specific effects of the protein of interest 
(Sasaguri et al. 2017). Meanwhile, the variable combination of different artificial 
promoters, transgene constructs and background strains render comparisons between 
models difficult and restrict the presentation of a standardised phenotype (Webster et al. 
2014). The nature of APP itself exacerbates the inherent variability of transgenic models, 
due to the multiple fragments produced from its metabolism, all of which are upregulated 
in mice overexpressing the protein. Therefore, the phenotypes observed in these hAPP 
transgenic mice may not be specifically caused by increased Aβ accumulation, but instead 
the unphysiological interaction of non-Aβ fragments with cellular proteins (Chang and Suh 
2005, Mitani et al. 2012, Nhan, Chiang, and Koo 2015, Willem et al. 2015). For example, 
the Swedish mutation in the Tg2576 mouse confers increased production of βCTF, a 
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fragment that has demonstrated neurotoxic and memory impairing effects following its 
augmented expression (Nalbantoglu et al. 1997, Berger-Sweeney et al. 1999). Moreover, 
overexpression of full-length APP may disrupt its endogenous interactions with cellular 
proteins including JIP-1 (Chiba et al. 2014). 
The confounds of APP overexpression manifest in artefactual, age-independent 
effects detectable prior to amyloid pathology. For example, the Dodart group observed 
anatomical and physiological abnormalities in PDAPP mice from as young as three months 
of age. They reported significant atrophy in the hippocampus, reduced cerebral glucose 
metabolism and mild learning deficits, suggesting that these results may represent effects 
of APP overexpression, rather than amyloid accumulation (Dodart, Meziane, et al. 1999, 
Dodart, Mathis, et al. 1999). Chen et al (2000) assessed SWM performance at both 6-9 and 
13-15 months of age in the MWM. Transgenic mice performed significantly worse at the 
early time point, and this difference exacerbated with age. Further investigation elucidated 
an age-independent difference in training behaviour which was dissociated from age-
dependent components that manifested at 13-15 months of age (Chen et al. 2000). In a 
separate study, Evans observed age-independent differences in navigational foraging 
strategy from 6-8 months old. The task involved searching for a liquid reward in a circular 
arrangement of six pots, and the experimenters reported that transgenic mice were more 
likely to visit neighbouring rather than distal pots and also to adopt a chaining response 
(consecutive visits to three or more adjacent pots) (Evans et al. 2018). They also revealed 
a separate age-dependent phenotype, as 14-16-month-old PDAPP mice performed 
significantly worse than WT littermates. However, it must be noted that in the absence of 
data from earlier time-points, one cannot exclude the possibility that 6 months simply 
represented the point at which the described phenotypes manifested in both studies. 
Another group observed age-independent deficits in spatial strategies used by PDAPP mice 
in the circular maze alongside significantly lower body temperature in both young (3-5) 
and aged (20-26 month old) transgenic mice compared to WT littermates (Huitron-
Resendiz et al. 2002). Furthermore, young PDAPP mice exhibited significantly lower 
locomotor activity during the dark period and also a reduction in the generation of rapid-
eye-movement sleep versus WT mice. This evidence of age-independent effects supports 
the notion that APP overexpression induces artefactual results which are particularly 
relevant in behavioural tests involving navigation. A more physiological method of 
generating AD models would generate more reliable data.  
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▪ 1.5.3 – Second Generation, Knock-In Models 
In order to overcome the inherent unreliability of hAPP transgenic models and 
eliminate potential artefactual effects, a more elegant, “knock-in” method has been 
proposed. Specific gene-targeting techniques permit selective FAD mutations to be 
introduced within the endogenous murine APP gene. Therefore, mutant APP is expressed 
without transgene insertion, under the control of the endogenous promoter, avoiding 
potential artificial phenotypes. Reaume et al (1996) generated one such knock-in model 
which expressed APP at normal levels, however the incorporation of the Swedish double 
mutation resulted in 9-fold greater Aβ production. However, as further analysis revealed 
that these mice did not develop amyloid pathology up to 22 months of age, these mice were 
cross-bred with a mutant PS1 knock-in mouse to generate a double knock-in (Flood et al. 
2002). These double gene targeted mice exhibited elevated Aβ42 resulting in amyloid 
deposition that began at 6 months of age and progressed linearly with age, in contrast to 
Tg2576 / PS1 knock-in mice in which deposition increased exponentially. The 
APPSWE/PS1 double knock-in mice did not exhibit differences in locomotor or anxiety-
related behaviours, however they did develop cognitive dysfunction with age observed in 
object recognition and the radial arm water maze from 11 and 15 months of age respectively 
(Webster, Bachstetter, and Van Eldik 2013). Despite the extensive amyloidosis, 
neuropathology did not progress to NFT formation and neurodegeneration, even in mice 
aged up to 27 months (Malthankar-Phatak et al. 2012). Another knock-in model was 
developed by Li et al (2014) which carried the Dutch (E693Q) and London (V717I) 
mutations alongside the Swedish. The Dutch mutation is not associated with FAD but 
causes cerebral amyloid angiopathy (CAA) leading to brain haemorrhage and early 
mortality in humans (Van Broeckhoven et al. 1990). Similar to the knock-in strain 
generated by Reaume, these mice did not develop significant Aβ deposits until they were 
crossed with PS1 mutants. The double knock-in mice exhibited deposition in both the 
cerebral parenchyma and vasculature, symptomatic of expression of the Dutch mutation. 
For that reason, this model has become more relevant for studying CAA. Meanwhile, the 
APPSWE/PS1 double knock-in mice have also not been widely used by the AD community, 
potentially due to their double homozygous nature and late development of pathology, 
which leads to inefficient breeding and a long delay before observing significant effects. 
Takaomi Saido and colleagues at the RIKEN Brain Science Institute, in Japan, have 
also generated knock-in models of FAD (Saito et al. 2014). They first humanised the Aβ 
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sequence by changing three residues within the endogenous mouse APP gene (G676R, 
F681Y and H684R), and subsequent expression of either one, two or three FAD mutations 
leads to three different knock-in strains. The APP-NL model includes the Swedish double 
mutation (KM670/671NL), which augments the interaction of BACE1 with APP, resulting 
in increased cleavage and Aβ generation (Citron et al. 1992). The APP-NL-F mouse also 
incorporates the I716F Iberian mutation, which promotes γ-secretase cleavage at the 42 site 
and augments the Aβ42:Aβ40 ratio by a factor of 30 in vitro (Lichtenthaler et al. 1999). 
Finally, the APP-NL-G-F mouse expresses both aforementioned alterations as well as the 
E694G Arctic mutation which occurs in the central domain of the Aβ sequence and renders 
the peptide more prone to oligomerisation (Cheng et al. 2004, Nilsberth et al. 2001). 
Importantly, homozygous models of these mice expressed APP and non-amyloidogenic 
fragments at the same level as WT littermates. βCTF increases with Aβ in all models in a 
gene dose-dependent manner, thereby promoting the APP-NL mouse as the ideal negative 
control for assessment of the specific effects of the augmented amyloid pathology exhibited 
in the APP-NL-F and APP-NL-G-F mice. However, it must be noted that using this strain in this 
way would introduce greater genetic heterogeneity between the test (APP-NL-F) and 
negative control mice (APP-NL), due to loss of littermate comparisons. Independent 
characterisation of 24-month-old APP-NL mice revealed no development of plaque 
pathology, reactive gliosis or cognitive deficits compared to age and sex matched C57Bl/6 
mice (Salas et al. 2018). It is notable that this was consistent with the phenotype of the 
knock-in mice developed by Reaume et al, which shares the same mutant APP sequence 
(Reaume et al. 1996). This suggests that any pathogenic phenotypes demonstrated by APP-
NL-F and APP-NL-G-F mice are linked to the effects of the further mutations incorporated into 
their genomes on Aβ pathology and are not associated with differences in βCTF levels. 
Investigations using these knock-in models have already demonstrated results that 
suggest some pathological effects reported in transgenic animals were artefacts of APP 
overexpression. For example, the Saido group previously reported that Aβ plaque 
deposition was associated with a calcium-activated cysteine protease, calpain, in both 
APP23 transgenic mice and AD patients (Higuchi et al. 2012). Genetic deficiency of 
calpastatin, a protein that specifically inhibits calpain, exacerbated amyloidosis and 
downstream neuropathology pathology in the transgenic mice while the mortality rate 
increased to 50% by 10 weeks of age. However, when APP-NL-F mice were crossed with 
calpastatin KO animals, although amyloidosis was augmented, the early death phenotype 
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was eradicated (Saito et al. 2016). Furthermore, while studies in transgenic mice have 
proposed that one mechanism of amyloid pathogenesis involves Aβ initiating the 
conversion of p35 to p25 (a CDK5 activator), increased p25 generation was not observed 
in APP-NL-F mice, even following hyperactivation by calpastatin depletion (Seo et al. 2014, 
Saito et al. 2016). A third effect observed in multiple first generation models that has not 
been replicated in knock-in mice is the downregulation of Nav1.1 sodium channels present 
in parvalbumin-positive interneurons (Verret et al. 2012, Saito et al. 2016, Kim et al. 2011). 
The decreased expression of this voltage gated sodium channel had been linked to the 
network hypersynchrony and memory deficits exhibited by hAPP transgenic mice after 
restoration of the channel to normal levels rescued deficits in the mice; however, the role 
of Nav1.1 channels in AD pathogenesis will have to be re-examined. The Saido group have 
estimated that as many as 60% of the phenotypes reported in APP transgenic models may 
have been influenced by artefactual effects of overexpression. 
While the second-generation AD models are theoretically more reliable systems in 
which to investigate mechanisms of amyloid pathology, they are not without limitations. 
They do not recapitulate progression to late-stage AD neuropathology, as NFT formation 
and neurodegeneration are absent. Therefore, these mice may be considered models of 
preclinical AD, a stage at which underlying amyloid pathology is developing and cognitive 
decline is beginning to manifest. It is possible that the progression of AD-associated 
pathology is limited by the life-span of the mice, as these processes occur over decades in 
humans while the mice do not outlive three years (Bateman et al. 2012). Furthermore, the 
combination of FAD mutations in the APP-NL-F and APP-NL-F-G mice does not represent a 
natural form of the disease, and multiple mutations may interact in an unforeseen manner, 
reducing the reliability of the APP-NL-G-F model to investigate mechanisms of Aβ 
oligomerisation and deposition (Sasaguri et al. 2017). Furthermore, although the chimeric 
APP expressed in these strains is a necessary confound to limit changes from control mice, 
it may result in different Aβ deposition mechanisms compared to the endogenous protein. 
These knock-in models represent more reliable models than first generation transgenic 
mice in which to screen potential AD treatments, however the Swedish mutation may result 
in the APP sequence exhibiting altered sensitivity to BACE1 inhibitors and this must be 
taken into account in preclinical studies. However, the fact that APP is expressed under the 
endogenous promoter in these mice constitutes a major advantage over first generation 
models because it ensures that results are not impacted by unphysiological APP expression. 
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▪ 1.5.4 – The APP-NL-F Knock-In Model 
The augmented production of Aβ4 due to the presence of the Iberian mutation in 
APP-NL-F mice results in progressive deposition of the peptide in the cerebral cortex and 
hippocampus detectable from 12 months of age (Saito et al. 2014). The plaques observed 
in these mice consisted mainly of a particular pathogenic species of Aβ (Aβ1/3pE-42), thereby 
more faithfully resembling plaques found in human AD brains in comparison to those of 
other transgenic APP models, which are unphysiologically large and predominantly 
composed of Aβ40 (Saido et al. 1995, Sasaguri et al. 2017). Heterozygous (APP-NL-F/WT) 
mice did not exhibit cortical amyloidosis until they were over 24 months of age. 
Amyloidosis in APP-NL-F mice was accompanied by the neuropathology commonly 
associated with brains of AD patients or mouse models: activated microglia and astroglia 
cells were observed around Aβ plaques, while reduced immunoreactivity of synaptophysin 
and PSD95 suggested reduction of synaptic density. However, Sato and colleagues did not 
observe evidence of somatodendritic atrophy or hyperphosphorylated tau, indicating that 
these knock-in mice represent a model of preclinical AD. The Arctic mutation present in 
the Aβ sequence of APP-NL-G-F mice resulted in earlier, more aggressive accumulation of 
pathology compared to the APP-NL-F mice. Cortical amyloid deposition was detectable from 
2 months and had approached saturation point by 7 months of age (Saito et al. 2014). These 
mice also exhibited significantly greater microglia and astrocyte activation in the cortex 
from 12 months of age (Masuda et al. 2016). Interestingly, there was a significant effect of 
sex in these mice, with 18-month-old females demonstrating more amyloid pathology and 
astrocytosis in both the cortex and hippocampus than their male counterparts. Meanwhile, 
the APP-NL mice did not develop detectable amyloid deposition when tested up to 18 
months; although increased microgliosis was observed in the hippocampus when tested 
against WT mice at this age point. 
The knock-in mice developed by the Saido group also develop cognitive 
impairment. The initial paper by Saito et al (2014) analysed spontaneous alternation 
behaviour in a Y-maze, reporting that while APP-NL-G-F mice showed a deficit at 6 months 
of age, APP-NL-F performance matched WT and NL levels. The APP-NL-F animals were aged 
up to 18 months before they demonstrated decreased alternation behaviour and the APP-NL 
mice never developed this impairment. A follow up study aimed to characterise APP-NL-F 
behaviour at 8-12 and 13-17 months of age using an IntelliCage system which permitted 
analysis of multiple cognitive domains (Masuda et al. 2016). Mice were housed in the 
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IntelliCages in mixed genotype groups of 10-12 and each received a subcutaneously 
implanted radio transponder in order to simultaneously assess individual behaviours. The 
four corners of the cage contained chambers from which water was available. Access to 
the chambers was controlled by doors, which could be opened by a nose poke at specific 
times during the training and testing schedules. The different paradigms available for 
assessment by the Intellicages revealed a deficit in place avoidance learning alongside, 
intriguingly, a significant enhancement of place preference reversal learning in the APP-NL-
F mice at the younger age point. At the second age-point the APP-NL-F group had developed 
a deficit in place preference reversal learning; however, analysis of the place avoidance 
task was not accessible because none of the groups demonstrated retention. A compulsive 
phenotype was evident at both age points, measured via a delay discounting task in which 
the waiting time for a liquid reward to become available following a nose poke was 
increased each day. Premature licks during the delay period were counted as measures of 
compulsivity. Meanwhile, the APP-NL-G-F mice demonstrated similar behavioural 
phenotypes, exhibiting compulsivity and deficits in place avoidance and place preference 
avoidance learning at both age points (Masuda et al. 2016). 
Since the initial publications by the Saido group, the cognitive impairment reported 
in APP-NL-G-F mice has not been consistently replicated and the number of studies that have 
aged the APP-NL-F mice up to 18 months is limited (figure 1.3). As these knock-in mice are 
a more accurate representation of age-related amyloid pathology than the first-generation 
transgenic mice, it is imperative that the effect of Aβ accumulation without APP 
overexpression on both cognitive and biochemical phenotypes is elucidated. This will also 
enable better understanding of the effects reported in transgenic mice that may be artefacts 
of the genetic mechanism of transgenic overexpression. The APP-NL-F model is the more 
appropriate to investigate these aims than the APP-NL-G-F because AD is associated with 
senescence, and so mice that develop pathology in early adulthood do not replicate this 
critical feature. Furthermore, the combination of three FAD mutations in the APP-NL-G-F 
mice may produce unphysiological interactions, thus rendering this model a less accurate 
representation of AD. Moreover, considering the APP-NL-F model exhibits a slow 
accumulation of Aβ, it presents the opportunity to investigate how the role of the peptide 
switches from performing the physiological functions described in section 1.2, to its 
putative involvement in the pathogenesis of AD detailed in section 1.3.  
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Figure 1.3: Summary of the current published data concerning the behavioural 
phenotype of APP-NL-F mice. (Sakakibara et al 2019) 
The type of behaviour tested and the specific task used are shown in the left column. 
Age in months is presented on the top line and increases horizontally. Blue and red 
colours demonstrate whether APP-NL-F behaved the same (blue) or differently (red) than 
control mice. The “sex” column designates the sex of mice (M = male, F = female, M 
+ F = both combined). The “vs control” column denotes the strain of mice used in 
comparison (B6J = C57Bl/6J). 
 
(Shah et al. 2018, Pervolaraki et al. 2019) 
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1.6 Aims and Hypotheses 
This chapter has described the physiological functions of APP and how increased 
concentration and aggregation of Aβ is involved in the pathogenesis of AD. However, 
despite this research into the mechanisms of amyloid pathology, no disease modifying 
therapies have been developed for the condition. Among the potential reasons for this lack 
of success is that the role of Aβ in normal neuronal function has been widely disregarded, 
resulting in the development of anti-amyloid therapies such as BACE1 inhibitors that have 
demonstrated detrimental effects in the absence of amyloid accumulation (Filser et al. 
2015). However, it is unclear whether this effect manifested due to the impact on Aβ 
production or the reduced metabolism of alternative substrates. Therefore, the first aim of 
this thesis was to investigate whether specific inhibition of BACE1 dependent APP 
cleavage disrupted memory processes. Chapter 3 describes the administration of the anti-
APP β-secretase cleavage site antibody 2B3 in young WT mice, with the hypothesis that it 
would disrupt object-place associative memory due to the reduced function of Aβ. 
Another explanation for the failure of AD therapies is that model AD systems do 
not reliably recapitulate the mechanisms of the disease due to the presence of artefactual 
effects of APP overexpression. A more faithful genetic model, the APP-NL-F, has been 
developed by using a knock-in strategy; although behavioural and biochemical phenotypes 
have yet to be elucidated. A major aim of this thesis was to breed a cohort of APP-NL-F mice 
and WT littermates and perform behavioural assessments at multiple age-points, as it was 
hypothesised that the mutations would manifest in an age-related accumulation of Aβ 
alongside a decline in visuo-spatial memory. In order to ensure any cognitive impairments 
were specifically within tasks involving spatial components, chapter 4 assesses the mice 
within object recognition paradigms while chapter 5 presents a foraging based working 
memory task. These tests were utilised as they provided the opportunity to dissociate 
assessment of spatial and non-spatial components. Chapter 6 involved ex vivo analysis of 
brain samples from aged APP-NL-F and WT mice in order to elucidate potential biochemical 
correlates underpinning the difference in cognitive performance. 
Finally, chapter 7 sought to combine aspects of the two themes of this thesis and 
investigated whether selective inhibition of BACE1-dependent APP cleavage would result 
in opposite effects on cognition depending on the presence of amyloid pathology in aged 
APP-NL-F or WT mice. 
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Chapter 2 – 
General Methods 
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2.1 Introduction 
This chapter describes the methods that will be used through multiple experiments in this 
thesis. This includes the breeding, maintenance and cognitive testing of mouse colonies. 
The current chapter also describes the biochemical protocols used to quantify protein levels 
in brain tissue.  Specific experimental designs, as well as any variations in techniques are 
detailed in the relevant chapters. All reagents were purchased from Sigma Aldrich (UK) or 
Fisher (UK) unless otherwise stated. 
 
2.2 Breeding and Maintenance of NL-F Colony 
▪ 2.2.1 – Housing Conditions and Breeding 
 Mice were housed in standard cages (48 x 15 x 13 cm) in holding rooms of stable 
temperature (21+2°C) and humidity (60+10%) on a 12-hour light/dark cycle, with ad 
libitum access to food and water. Animal were maintained according to the Animals in 
Scientific Procedures Act (1986), as well as UK Home Office and EU regulations. 
 APP-NL-F mice were obtained from the Wiseman group at UCL (3 males, 3 females, 
all heterozygous) and a colony was produced from pairings of these animals. All further 
breeding involved heterozygous pairs of APP-NL-F mice. Pups were weaned at 21 days with 
males and females housed separately up to a maximum of 5 per cage. Ear-biopsies were 
taken from each mouse for identification and genotyping. Male APP-NL-F and wildtype 
(WT) mice were age and/or littermate paired and grouped with another matched pair in 
cages of 4 wherever possible. 
▪ 2.2.2 – Genotyping Using PCR and XbaI Digest 
In order to identify homozygous, heterozygous and WT mice, a polymerase chain 
reaction (PCR) was used to amplify the mutated region within the amyloid precursor 
protein (APP) gene. The APP-NL-F knock-in allele includes an XbaI restriction site inserted 
as part of the Swedish mutation, which was exploited in an XbaI restriction digest 
following PCR to distinguish genotypes, as the wildtype APP allele will not be cut. 
Therefore, a separate region containing an XbaI restriction site was also amplified in the 
PCR to act as a digest control. 
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A tissue sample (ear clip) was collected from each mouse at 3-7 weeks of age and 
frozen on dry ice. Tissue was digested and DNA extracted as follows: 75 µL NaOH 
extraction solution (25 mM NaOH, 0.2 mM EDTA) was added to the ear biopsy. This was 
incubated for 1 hour at 95°C before 100 µL neutralisation buffer (40 mM Tris-HCl, pH 
5.5) was added. This was mixed and centrifuged at 17000 g for 5 minutes before either 
being used for PCR or stored at -20°C. 
The PCR reaction mixture consisted of 5 µL Megamix Gold (Cat# 2MMG Microzone 
Ltd, West Sussex, UK), 3 µL nuclease free water, 1 µL of extracted DNA sample and 1 µL 
primer mix (2 µM concentration of each primer)}. Therefore, each reaction contained 10 
µL and 0.2 µM of each primer. Two primer sets were used in the reaction: NLF-fw (5’-
ACCAGTTTTTGATGGCGGAC-3’) & NLF-rv (5’-TTTGGCCACACAGGCATTACA-
3’) amplified ~330 base pairs of the APP region containing the NL and F mutations, whilst 
primers Wdr26set1 (5’-TCCAGTTTGGCAAGGAAGGG-3’) and Wdr26set2 (5’-
CAGTGTGGCTATTGCTCTGG-3’) amplified a ~700 base pair control region 
surrounding another XbaI restriction site. 
Reaction mixtures were immediately transferred from ice to a thermocycler (MJ 
Research, Massachusetts, USA). The PCR program used the following conditions: 95 °C 
for 3 minutes, then 31 cycles of 3 minutes at 94°C (denature DNA), 30 seconds at 57.2°C 
(primer annealing) and 45 seconds at 72°C (strand extension), followed by a final extension 
period of 10 minutes at 72°C. Following the PCR reaction, the products were subjected to 
XbaI restriction digest.  The reaction mixture consisted of the 10 µL PCR product, with the 
addition of 17 µL nuclease free H2O, 3 µL 10x Fastdigest green loading buffer and 1 µL 
Fast digest XbaI enzyme (Cat# FD0684, ThermoFisher). The reaction tubes were replaced 
in the thermocycler at 37°C for 1 hour. 
Products from the reactions were separated by gel electrophoresis, using a 1.5% agarose 
gel in TAE buffer on an ethidium bromide-free docking system (Bio-Rad, Hertfordshire, 
UK). DNA products were loaded with “Novel Juice” loading dye (GeneDirex, Newmarket, 
UK) at 1:5 Novel Juice:sample. Samples were run at 100 V for 65 minutes alongside a 
100bp DNA ladder (GeneDirex), an H2O (no DNA) control, a “no-cut” (no XbaI control) 
plus positive controls of known homozygous, heterozygous and wildtype APP-NL-F mice. 
Gels were visualised using a Syngene GBOX Chemi-XX6 gel doc system with associated 
software (Syngene, Cambridge, UK). 
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As shown in figure 2.1, the XbaI control region DNA product appears at ~600bp (700bp 
in the no-cut control). The amplified APP region appears at ~340bp if wildtype (the same 
as in no-cut control samples), but ~280 if homozygous due to the XbaI digestion. Samples 
from heterozygous mice have multiple bands from ~360bp to ~280bp. 
2.3 Behaviour Testing 
 This section describes the apparatus and protocols used throughout this thesis to 
assess object-novelty (ON) and object-in-place (OiP) memory in mice. The method for 
measuring locomotive activity is described as part of the habituation protocol. Individual 
chapters will describe specific experimental designs.  
▪ 2.3.1 – Apparatus 
A square arena (60 x 60 cm wooden floor, with 40 cm high clear Perspex walls) was 
used throughout the experiments. The floor was painted white and the walls internally 
covered with an opaque, white film. The arena was positioned under the ceiling light to 
ensure even lighting in all corners. It was placed on a 50 cm tall table to elevate it off the 
floor of the quiet test room. The walls surrounding the arena were decorated with salient 
extra-maze cues to be visible from inside, including a striped curtain on one side and a 
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Figure 2.1: Representative image of DNA bands following PCR and 
electrophoresis of APP-NL-F and WT mice. The XbaI restriction digest control region 
produces a band at 700 base pairs naturally, or 600 bp if cleaved. The diagnostic band 
for APP is at 340 bp if uncut, revealing a WT (-/-) genotype. Homozygous APP-NL-F 
(+/+) mice show a cleaved band at 280 bp. Heterozygous (+/-) mice show both the 280 
& 340 bp bands and an extra band at 400 bp. 
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black curtain on another side that hid the experimenter. Another wall was covered in black 
spots ~15 cm in diameter. The position of these cues, as well as the arena and experimenter, 
were consistent throughout all testing, unless otherwise stated. Every test was recorded 
using a varifocal USB camera (ELP-USBFHD04H-BFV-U, Ailipu Technology Co Ltd, 
China) positioned above the centre of the arena and connected to a laptop, and saved onto 
a hard drive. Mice were tracked live using EthoVision XT 13 software (Noldus, UK) and 
interaction with objects was manually scored in addition to the EthoVision data. 
▪ 2.3.2 – Open Field Test & Arena Habituation 
Animals were always transported within the cardboard tubes from their home cage and 
placed in the centre of the arena facing the same wall throughout all procedures. 
Locomotive activity was assessed by Open Field test, whereby the animal was placed into 
the empty arena and allowed to freely explore for 10 minutes. Total distance moved was 
recorded by EthoVision tracking software. The central 30x30 cm square of the arena was 
described as the “Inner Zone” on the software, while the boundary between that and the 
walls of the arena was the “Outer Zone”. The software recorded the amount of time spent 
within both zones by each mouse. 
The Open Field test represented day 1 of habituation. On days 2 and 3, four different 
objects were placed in the arena and mice had 3 sessions of 5 minutes exploring the objects, 
with a 5-minute delay separating each session. Four new objects were used for day 3. Up 
to 20 mice were habituated together, before being split into 2 counterbalanced groups of 
10 which began testing on either day 4 or 5. The order of different test and object sets were 
counterbalanced and no mouse saw the same object set more than once. Any differences in 
the testing protocol are specified in relevant chapters. 
▪ 2.3.3 – Objects and Scoring 
 The objects used were made of a variety of materials, usually plastic and glass, and 
around 20 cm tall (figure 2.2). They were chosen with the aim of limiting mice climbing 
on them while being heavy enough to remain still while being investigated. They were 
grouped into object sets of various colours and shapes including shampoo bottles, etched 
champagne glass and Duplo towers. Objects were placed near the corners of the arena, 25-
30 cm apart and ~15 cm from the walls. The arena and objects were cleaned with 70% 
alcohol prior to every session, in order to remove any odour cues which could affect 
discrimination. 
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 Object exploration was scored according to the protocol defined by Ennaceur & 
Delacour (1998): when the animal’s head was within 2cm and interacting with the object. 
For test sessions, object exploration was translated into a “Discrimination Ratio” (DR), 
which was obtained with the calculation below. Random object exploration equates to a 
ratio of 0.5, i.e. equal exploration of both novel and familiar objects, therefore scores 
greater than this value indicates a preference to explore novelty. 
Total time spent exploring “Novel” object 
Total time spent exploring all (Novel + Familiar) objects 
EthoVision tracking software was utilised in order to automatically score object 
interaction and provide an objective comparison to manual scoring. A photo was taken of 
each object arrangement and a zone was drawn around each object (e.g. Object A), using 
the arena settings feature of the software. A second zone drawn by enlarging the original 
zone by 4 cm in both diameters, providing a 2 cm radius (Object A+2). Object interaction 
was scored when the animal’s head was pointed towards Object A whilst also inside the 
“Object A+2” zone. Only experimenter scored data is presented due to the greater level of 
stringency it provides. For example: if the mouse was on top of the object, using it to 
explore around the room, or was sat within 2cm but facing away, it was not scored as 
exploration by the experimenter but may have been scored by the software. Statistical 
analysis of DRs calculated from the EthoVision-tracked object exploration resulted in 
identical conclusions to that of experimenter-tracked exploration in all experiments, and 
this tracking data is available on request  
Figure 2.2: Examples of objects used throughout object recognition tasks. 
= DR 
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▪ 2.3.4 – Object Novelty 
 Object novelty recognition (ON) was tested with either a 2 or 4 object array in 
different experiments of this thesis and is therefore individually described. However, the 
protocol was consistent: the mouse was presented with an object array and allowed to 
explore for a 10-minute sample phase 1 (figure 2.3 A). The mouse was removed back into 
the home cage for a 5-minute rest period, during which the arena and objects were cleaned 
with 70% ethanol wipes. This exploration and rest cycle were repeated in sample phases 2 
& 3 with the same objects. However, in the 5-minute delay following sample phase 3, either 
1 or 2 objects were removed (depending on the 2 or 4 object array), and replaced with novel 
ones. The mouse was replaced in the arena to explore the objects for a 10 minute “test 
phase”. Exploration of objects was scored as described above. The identity and location of 
the novel objects within each object set was counterbalanced. 
▪ 2.3.5 – Object-in-Place 
 The Object-in-Place (OiP) protocol consistently used four objects placed 15 cm in 
from the corners and ~30 cm apart throughout this thesis (figure 2.3 B). The task used the 
same sample phase protocol of the ON task: three 10-minute sessions each separated by a 
5-minute rest in the home cage. However, during the 5-minute delay prior to the test phase, 
the location of 2 diagonally opposite objects was switched. These were described as the 
novel objects for the analysis and exploration was scored as described above. The pair of 
objects switched and the novel location was counterbalanced within each object set, as well 
as the order of object sets if more than one was observed by each mouse. 
Sample Phase 1 Sample Phase 2 Sample Phase 3 Test Phase 
A 
B 
Figure 2.3: Diagrams of the object recognition protocols used in this thesis. All 
sample and test phases lasted 10 minutes and arrows represent a 5-minute delay. (A) 
Object novelty. (B) Object-in-Place. Red circles highlight the objects that are novel or 
have switched spatial locations. 
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▪ 2.3.6 – Data & Statistical Analysis 
 All object interaction data was collected with the EthoVision XT 13 software and 
exported to Excel for calculation of mean scores for each mouse and each group along with 
the associated standard error of the mean. All statistical analyses were performed using 
IBM SPSS statistics. Significance was determined using an α-level of 0.05 for all tests. 
Null hypothesis significance testing was performed throughout this thesis, using the tests 
detailed below. However, the limitations of such tests must be acknowledged, particularly 
concerning null results (p>0.05); as these tests lack the capacity to distinguish the true 
absence of an effect from a failure of an effect to reach significance. 
The Shapiro-Wilke test was used to test for violations of normality in all data, while 
Levene’s test checked for violations of equal variance. Where violation occurred, the data 
were transformed by the appropriate calculation in order to satisfy these assumptions, prior 
to analysis of variance (ANOVA), mixed measures ANOVAs and Student’s t-test 
(independent samples, paired sampled or one sample were all employed where 
appropriate). Bonferroni adjustment was used on all significant interactions and main 
effects, adjusting for multiple post-hoc comparisons. Wherever transformation was not 
possible or did not eradicate violations of normal distribution, data were analysed by the 
equivalent non-parametric statistical test. For example, the Mann-Whitney U test was used 
as an equivalent of the independent samples t-test, Wilcoxon-Signed Rank for the Paired-
Samples t-test, Kruskal-Wallis H Test for the One-Way ANOVA, Friedman Test for the 
Repeat Measures ANOVA. 
 
2.4 Intra-Cerebral Ventricular Infusion of 2B3 
 The anti-APP antibody, 2B3, was developed by Thomas et al by methods 
previously described (Thomas et al. 2006). Their original hybridoma was sent to ProMab 
(California, USA), for larger scale production by ascites. Following purification and 
sterilisation, 2B3 was administered by intracerebroventricular (ICV) infusion via osmotic 
minipumps. The pumps released the antibody at a constant flow rate of 0.25 μL/hour over 
14 days. 
▪ 2.4.1 – Antibody Purification and Sterilisation 
Concentrated ascites product from ProMab (California, USA), was thawed before 
being centrifuged at 1000 g and aliquoted after removing the top lipid layer. It was then 
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purified and concentrated with the MAb TrapTM affinity chromatography kit (GE 
Healthcare, Buckinghamshire, UK) according to the manufacturer’s instructions. The 
concentrated 2B3 IgG solution was diluted 1:1 in the prepared binding buffer. The column 
was first washed through with dH2O, then equilibrated with 3 mL binding buffer, at a 
consistent flow rate of 1 drop per second. The IgG solution was passed through the column, 
maximum 4.5 mL at a time, before 8 mL binding buffer was added to elute any non-2B3 
material. The 2B3 antibody was released by passing 5 mL elution buffer through the 
column and collected in Eppendorf tubes with 60 μL neutralising buffer to maintain 
affinity. The column was then re-equilibrated with binding buffer for further purifications. 
The protein contents of the collection tubes were quantified by BCA assay (described in 
section 2.5.3) and the fractions containing 2B3 pooled. 
The purified 2B3 antibody solution was then dialysed to replace the buffers from the 
MAb Trap kit with phosphate buffered saline (PBS; 137mM NaCl, 2.5mM KCl, 8mM 
Na2HPO4, 1.5mM KH2PO4, pH 7.2). The solution was injected into a Slide-A Lyzer 
Dialysis Casstte (3-12 mL volume, 10 kDa molecular weight cut off, Pierce), which was 
rotated in 2 L of PBS overnight at 4°C. Following dialysis, 2B3 was sterilised through a 
0.22 μm filter, aliquoted and stored at -20°C. The final concentration was measured on a 
NanoVue spectrophotometer (GE Healthcare Ltd, Buckinghamshire, UK). 
▪ 2.4.2 – Surgical Implantation of Minipump & Cannulae 
 Osmotic minipumps (model 1002, Alzet, UK), were filled with 200 μL of either 
purified 2B3 or control IgG1κ (mab201, Millipore, UK) and connected to a brain infusion 
kit (0004760, Alzet). This consisted of a 2 cm catheter, backfilled with the appropriate 
antibody and attached to a 28G cannula (0004760, Alzet). Mice were anaesthetised by 
isoflurane carried by O2 and fitted into a stereotaxic frame. Metacam was injected 
subcutaneously at 30 mg/kg as analgesia prior to the surgery. Minipumps were 
subcutaneously implanted between the scapulae of the mice. The cannula was inserted at 
the following coordinates 3.0 mm ventral to the skull surface, 0.5 mm posterior and 1.2 
mm lateral to bregma. Two screws were implanted alongside the cannula, enabling it to be 
fixed in place with dental cement. The skin was sutured around the cannula and the mouse 
was rehydrated with subcutaneous injection of mL gluco-saline into each flank. The mouse 
was allowed to recover in an incubator maintained at 30°C before being individually 
housed, (in order to limit damage to the sutures or the implants). 
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2.5 Ex Vivo Protocols 
 This section describes how mouse brains were prepared for biochemical analysis, 
and the methods used thereafter. Mice were culled by cervical dislocation and the brain 
was immediately removed. The hippocampus was dissected, and the cortex was divided 
into frontal and posterior regions, snap frozen in liquid nitrogen and stored at -80 °C. 
Proteins were extracted from the brain samples via two methods: the left hemisphere by 
homogenate extraction, while the right hemisphere underwent a protocol to isolate 
synaptosomes, allowing more efficient analysis of synaptic receptor expression. Extracted 
samples underwent protein analysis by either ELISA or Western Blot. 
▪ 2.5.1 – Homogenate Extraction 
Brain samples were homogenised in 2% sodium dodecyl sulphate at 75 mg/mL wet 
tissue/buffer. Protease inhibitor cocktail III (539134, Millipore) and phosphatase inhibitor 
cocktail V (524629, Millipore) were added to the homogenisation buffer at 1/100 and 1/50 
dilution, respectively. Samples were homogenised in a Precellys 24 Dual (Bertin 
Technologies, Montigny le Bretonneux, France) at 5500 rpm for 2 x 30 seconds with a 30 
second delay between before being rotated at 4°C overnight. The homogenate was 
centrifuged at 100,000 g (137,300 g) for 1 hour at 4°C before the supernatant was carefully 
removed, mixed and diluted 1/5 in EC Sodium Buffer (20mM Na2HPO4, 0.2mM EDTA, 
0.4 M NaCl, 0.2% bovine serum albumin). All samples were stored at 20°C. 
The insoluble pellet underwent further extraction by resuspension in 70% formic 
acid (Sigma Aldrich) at 150 mg/mL original tissue weight. The centrifugation was repeated 
at 100,000 g (137,300 g) for 1 hour at 4°C. The supernatant was diluted 1/20 in neutralising 
buffer (1M Tris, 0.5M Na2HPO4, pH 11) and stored at -20°C. 
▪ 2.5.2 – Synaptosomal Extraction 
Brain regions dissected from the right hemisphere were extracted using Syn-PerTM 
Synaptic Protein Extraction Reagent. Protease and phosphatase inhibitors were added to 
the Syn-Per just prior to the procedure in the same concentrations as above. The Syn-Per 
reagent was added at 10 mg/mL of the wet tissue weight, and homogenised manually with 
a microcentrifuge pestle. Samples were centrifuged at 1,200 g for 10 minutes at 4 °C. The 
supernatant was collected and 15 uL was taken as the homogenate fraction, while the pellet 
was discarded. The rest of the homogenate fraction was centrifuged at 13,000 g for 30 
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minutes (4 °C). The supernatant was taken as the cytosolic fraction and the synaptosomal 
pellet was resuspended in Syn-Per reagent at a final volume of 1.5 mg/mL of the initial 
tissue weight. All fractions were quantified by BCA assay and stored at -20°C. 
▪ 2.5.3 – Bicinchoninic Acid Protein Assay 
Protein concentrations of samples from both extraction protocols were quantified 
with a bicinchoninic acid (BCA) protein assay kit (ThermoScientific, UK). Bovine Serum 
Albumin (BSA) was serially diluted to prepare standards ranging from 2 – 0.003 mg/mL. 
20 µL of these standards plus a blank (dH2O) were analysed on a 96 well plate alongside 1 
µL of each sample and 4 µL EC buffer. All standards and samples were analysed in 
duplicate. The assay was performed by first making up the BCA Working Reagent (50:1 
Reagent A : Reagent B), 200 µL of which was added to each well. The plate was mixed for 
30 seconds and incubated for 30 minutes at 37 °C. Absorbance at 540 nm was measured 
across the plate using a spectrophotometer. A standard curve was produced from the BSA 
standards, which was used to calculate the protein concentration of each sample. 
▪ 2.5.4 – ELISA (Enzyme-Linked Immunosorbent Assay) 
All ELISA kits quantifying human or murine Aβ were produced by Invitrogen 
(California, USA), unless otherwise stated, and the protocols were carried out according to 
the manufacturer’s instructions. The provided Aβ standard was dissolved in filter sterilised 
reconstitution buffer (55 mM NaHCO3, pH 9) for all kits, and this was serially diluted in 
the Standard Diluent Buffer to generate the range of standard concentrations as described 
by the instructions. Variations in protocol between the kits are detailed below. A mouse 
Aβ42 kit (#KMB3441) was trialled however the concentration in WT mice was below 
detectable levels and so no data is shown. 
Mouse Amyloid Beta 40 (Aβ) (#KMB3481) 
Following dilution of standards and samples, 100 µL was added to each well and 
left for 2 hours at room temperature (RT). The plate was washed 4 times with the diluted 
Wash Buffer, before 100 µL detection antibody was added to each well for 1 hour at RT. 
The horseradish peroxidase (HRP)-conjugated anti-rabbit secondary antibody was diluted 
1/1000 in the provided buffer and 100 µL was added to each well after 4 more washes and 
incubated for 30 minutes at RT. Finally, after another 4 washes, 100 µL stabilised 
chromogen was added to each well and left in the dark for 30 minutes at RT before 100 µL 
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stop solution was added, turning each well from blue to yellow. Absorbance at 450 nm was 
measured on a spectrophotometer and a standard curve was produced from the absorbance 
levels of the known standard concentrations. Concentrations of Aβ-40 were calculated 
from this standard curve, using Graph Pad Prism 4.0 and Microsoft Excel, normalised to 
the amount of protein in each sample. 
Human Amyloid Beta (Aβ) 
The protein standard for human Aβ40 (KHB3481) and Aβ42 (KHB3441) was 
reconstituted as above and the range of standard concentrations was produced according to 
the manufacturer’s instructions. The protocol was identical to that of the mouse Aβ40 kit 
above, with one exception. Standards and samples were loaded onto the ELISA plate at a 
volume of 50 μL. 50 μL of the detection antibody was loaded on top of the samples and 
together this was left at RT for 3 hours, with shaking.  
▪ 2.5.5 – Western Blot 
Prior to Western blot (WB) analysis, extracted samples were diluted 2:1 in 3X sample 
buffer (6.3mM TrisBase, 0.8% SDS (w/v), 20% glycerol (v/v), 10% β-mercaptoethanol 
(v/v), 2% bromophenol blue (v/v)), and heated at 90°C for 45 minutes to reduce the 
proteins. Samples were stored at -20°C and, following the initial reduction, they were 
heated at 70°C for 5 minutes prior to loading in all other experiments. Cassettes (NC2010, 
LifeTechologies, USA) were filled with 10% polyacrylamide “separating” gels (3.3% 
(w/v) acrylamide, 375 mM TrisHCl, 0.1% SDS (w/v), 0.05% APS (w/v), 0.05% TEMED 
(v/v), all v/v) and topped with 5% polyacrylamide “stacking” gel. Samples were loaded 
onto these gels and separated by SDS-PAGE (Sodium Dodecyl Sulphate-PolyAcrylamide 
Gel Electrophoresis) in running buffer (25 mM Tris base, 190 mM glycine, 0.05% SDS, 
pH 8.3). Separated proteins were transferred from the gel onto 0.2μm nitrocellulose 
membrane (Amersham Biosciences, Little Chalfont, UK) in semi-dry blotting buffer (42.9 
mM Tris base, 38.9 mM glycine, 0.038% SDS (w/v), 20% methanol (v/v). 
The membrane containing the separated proteins was washed with Tris-buffered saline 
with Tween 20 (TBSt, 2 mM Tris, 15 mM NaCl, 0.1% Tween-20, pH 7.5) and then 
incubated at RT in 5% w/v BLOTTO (non-fat milk powder; Tesco, dissolved in TBSt) for 
1 hour. Membranes were then incubated in primary antibody diluted in 1% BLOTTO 
overnight on a roller at 4°C (dilutions described in table 2.1). The next day, membranes 
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were washed in TBSt 3 times for 5 minutes each, before secondary antibody incubation in 
1% BLOTTO at RT for 2 hours. The secondary antibodies were conjugated to horseradish 
peroxidase (HRP) and were selected depending on the host species of the primary 
antibodies (table 2.2). Membranes were washed as described above, before being incubated 
with PierceTM Enhanced Chemiluminescence Western Blotting Substrate (ECL, Pierce 
Biotechnology, IL, USA) and visualised in a Syngene GBOX Chemi-XX6 gel doc system 
with associated software (Syngene, Cambridge, UK). Images were saved and the densities 
of the bands were quantified using ImageJ software. 
 
 
  
Primary Antibody Species Dilution Source, Catalogue # 
APP (22C11) Mouse 1:1000 Millipore, #mab348 
BACE1 Rabbit 1:1000 Cell Signalling, #D10E5 
PSD95 Rabbit 1:1000 AbCam, #ab18258 
NMDA R1 Mouse 1:1000 BD Biosciences, #556308 
NMDA NR2B 
NR2B p-Y1472 
Rabbit 
1:500 
1:750 
Millipore, #AB1557P 
Millipore, #AB5403 
AMPA GluA1 
GluA1-pS845 
Rabbit 1:2500 
Abcam, #ab31232 
Abcam, #ab3901 
α7-NAChR Rabbit 1:500 Abcam, #ab10096 
Tau 
p-Tau  PHF-1 
p-Tau  CP13 
Rabbit 
Mouse 
Mouse 
1:500 
1:250 
1:250 
Dako, A0024 
Generous gift from P. Davies 
(Albert Einstein University, NY). 
βActin (Pre-
Conjugated to HRP) 
Mouse 
 
1:15,000 Sigma, A3854 
Secondary Antibody Species Dilution Source 
Anti-Mouse Horse 1:15,000 Vector, #PI-2000 
Anti-Rabbit Goat 1:15,000 Vector, #PI-1000 
Table 2.1: Primary antibodies used throughout this thesis in western blots. 
Table 2.2: Secondary antibodies used throughout this thesis in Western blots. 
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Chapter 3 –  
Inhibiting Aβ in Young                
Wild-Type Mice 
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3.1 Chapter Overview 
Chapter 3 describes experiments that investigated the normal physiological role of 
Aβ in cognition by selectively reducing its concentration in WT mice. The experiments 
utilised an antibody, 2B3, which binds to the β-secretase cleavage site of APP and sterically 
hinders cleavage. Experiment 1 involved infusing 2B3 directly into the hippocampus due 
to the region’s association with Aβ activity and the ability to specifically assess function 
with spatial-based memory tests. Immunofluorescence and biochemical analysis revealed 
the presence and activity of the antibody did not persist beyond 5 days, which was not 
sufficient for cognitive testing. 
Experiment 2 tested how chronic infusion of 2B3 affected Aβ production over a 
14-day period. The 2B3 antibody was infused into the lateral ventricle via an osmotic 
minipump, resulting in a significant drop in hippocampal Aβ levels. The impact on novel 
object and object-in-place recognition memory in WT mice was also assessed. The results 
demonstrated that WT mice infused with 2B3 successfully performed an object recognition 
task at the same level as controls, but failed to detect novel object-place associations. To 
my knowledge, this is the first assessment of these cognitive tests following chronic anti-
amyloid therapy in healthy WT mice. 
 
3.2 Chapter Introduction 
Following the identification of Aβ and the proposal of the amyloid cascade 
hypothesis (Hardy and Higgins 1992), the vast majority of research into AD has focused 
on the toxic effect of the peptide. It is now established that administration of high 
concentrations of Aβ to neuronal tissue culture induces apoptosis (Yankner, Duffy, and 
Kirschner 1990), while injection into the hippocampi of mice causes amnesia (Flood et al. 
1994, Cleary et al. 2005). However, one aspect of Aβ that is not regularly discussed is that 
at low concentrations it can be neurotrophic (Whitson, Selkoe, and Cotman 1989, Yankner, 
Duffy, and Kirschner 1990). Moreover, application of anti-Aβ antibodies to neuronal 
cultures reduced cell viability, further suggesting that the peptide plays an important 
normal physiological role (Plant et al. 2003). Due to the amyloid cascade hypothesis 
driving the field for nearly three decades, the majority of therapies in clinical development 
for Alzheimer’s disease patients are aimed at reducing Aβ levels. Given that amyloid 
[60] 
production has been the focus of therapies, it is critical to understand its normal function 
and role in memory processes. Knowledge of its normal physiological functions will 
further aid understanding of the potential effects of its reduction in pre-symptomatic 
individuals. 
Previous research has suggested that APP, and particularly the Aβ peptide, may be 
required for normal function. Mice with genetic knock-out of the APP gene develop age-
dependent deficits in neuronal morphology, synaptic plasticity, passive avoidance memory 
and spatial learning in the Morris water maze (Dawson et al. 1999, Ring et al. 2007, 
Seabrook et al. 1999, Phinney et al. 1999, Senechal et al. 2007). However, due to the 
multiple cleavage products produced by APP metabolism, results using genetic knockout 
cannot specify the consequences of aberrant Aβ production. For example, multiple studies 
have now shown that the phenotype of APP-KO mice can be rescued by the expression of 
sAPPα (Ring et al. 2007, Tyan et al. 2012). There is also evidence that manipulating the 
cleavage of Aβ from APP also exerts detrimental effects on neuronal function. BACE1 
knock-out mice show changes in axon guidance, myelination, exploration and anxiety in 
the open field and elevated plus maze, as well as impaired pre-pulse inhibition of startle 
and hypersensitivity to seizures (Hitt et al. 2010, Hu et al. 2006, Willem et al. 2006, 
Dominguez et al. 2005, Harrison et al. 2003, Savonenko et al. 2008). Importantly within 
the context of the current study, BACE1-KO mutants also exhibit impairment in synaptic 
plasticity and deficits in spatial learning and fear conditioning (Laird et al. 2005, Ohno et 
al. 2004, Ohno et al. 2007, Kobayashi et al. 2008). It is also worth noting that reduction of 
β-cleavage upregulates sAPPα expression up to 250% in BACE-null mutants. Therefore, 
unlike APP-KO mice, the cognitive deficit cannot be attributed to a loss of this domain 
(Luo et al. 2001). However, similarly to APP manipulation, effects of BACE1 inhibition 
cannot be exclusively Aβ-dependent. 
Many of the effects measured in BACE1-null mice may actually be due to the loss 
of cleavage of one of over 40 other substrates of the enzyme, including neureglin-1 and β-
subunits of voltage-gated sodium channels (Zhu et al. 2018, Hitt et al. 2012, Hu et al. 2013, 
Savonenko et al. 2008, Kim et al. 2011, Wong et al. 2005). Another drawback of knock-
out models is that, as the genetic manipulation is present from conception, any phenotype 
may manifest either due to loss of the function of the protein during development or 
compensatory mechanisms. In fact, conditional knock-out of BACE1 in adult mice resulted 
in a less severe phenotype resulting in no myelination, epileptiform and cognitive effects 
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(Ou-Yang et al. 2018). The mice did still demonstrate alterations in axonal organisation, 
indicating that BACE1-mediated cleavage of the cell adhesion protein close homologue of 
L1 (CHL1) remains a critical process in axonal guidance through to adulthood. 
A more elegant method to measure the effect of reducing Aβ may be to use small 
molecule β-secretase inhibitors, particularly because of their clinical relevance. While 
multiple groups have published the effects of BACE inhibitors in preclinical models of 
Alzheimer’s disease (Kennedy et al. 2016, May et al. 2015), data concerning their impact 
in WT mice are limited. A study by Filser et al (2012) reported that chronic (15 day) 
administration of a BACE inhibitor in 2-month-old WT mice induced a 75% drop in Aβ 
alongside a loss of dendritic spine density, synaptic plasticity impairments and deficits in 
spontaneous alternation and novel object recognition. A follow up study with a different 
inhibitor confirmed the effect on dendritic spines, however, it concluded that this effect 
was transient, contingent upon withdrawal of the treatment (Blume et al. 2018). 
Experiments aimed at further increasing the specificity of Aβ inhibition have utilised 
antibodies binding to regions of the APP protein. The first example of such an approach 
involved intracerebroventricular (icv) infusion of anti-APP antibodies into rats which 
significantly reduced memory performance in a passive avoidance test (Huber et al. 1993). 
More recent experiments with antibodies binding specifically to the Aβ peptide itself 
resulted in memory deficits in the water maze, contextual fear conditioning and a T-maze 
passive avoidance test (Garcia-Osta and Alberini 2009, Morley and Farr 2012, Puzzo et al. 
2011). Moreover, these studies also demonstrated that these antibodies caused dysfunction 
of synaptic plasticity mechanisms in hippocampal slices, indicating that the peptide may 
be important in induction of LTP. All of the impairments described following antibody 
treatment were rescued by concurrent administration of Aβ. Intriguingly, these groups also 
demonstrated that picomolar concentrations of Aβ alone actually enhanced memory and 
facilitated synaptic plasticity in WT mice (Puzzo et al. 2008, Morley et al. 2010).  
The experiments in this chapter aimed to investigate the impact of specific 
inhibition of APP cleavage by BACE. To overcome the challenges associated with the 
multiple substrates of BACE, an antibody directed towards the β-cleavage site on APP was 
infused into the CNS (Thomas et al. 2006). Thomas et al designed 2B12, a mAb raised 
against a 15-residue peptide sequence representing the β-cleavage site of APP (Thomas et 
al. 2006). Thomas et al (ibid.) showed that 2B12 inhibited BACE cleavage of APP and 
reduce the concentration of Aβ40 in human astrocytoma and neuroblastoma cell lines 
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expressing endogenous APP. Thomas and colleagues later showed that another antibody, 
2B3, exhibited greater affinity for APP and a more potent effect on Aβ40, Aβ42 and βCTF 
compared to 2B12, while levels of sAPPα remained unchanged (Thomas, Liddell, and Kidd 
2011). 2B3 remained bound to its antigen even following an hour-long incubation at pH4, 
equivalent to the acidic environments present in the endocytic compartments, where 
BACE1 interacts with APP (Vassar et al. 1999). The group later replicated the effect of 
2B3 on Aβ40 in primary cortical neurons derived from a transgenic AD mouse model 
expressing the hAPP London mutation (Thomas et al. 2013). Most recently, Evans et al 
(2019) administered 2B3 to aged PDAPP transgenic mice, expressing the V717F Indiana 
mutation, over 14 days, via intracerebroventricular (icv) infusion. The group reported a 
significant reduction of soluble Aβ40 and βCTF in the hippocampus and rescue of a 
visuospatial associative recognition memory deficit. 
The mechanism of 2B3 avoids the issues associated with manipulation of 
alternative BACE substrates or APP metabolites described above. However, one drawback 
of immunotherapies is their availability in the brain. Penetration of any peripherally 
administered drugs into the brain, particularly macromolecules such as antibodies, is 
severely limited by the blood brain barrier (BBB), a layer of endothelial cells that 
selectively blocks molecules entering the brain parenchyma from capillaries. In fact, the 
BBB may block up to 98% of small molecules while quantification of antibody penetration 
is estimated at 0.1% (Pardridge 2005, Banks et al. 2002). Therefore direct, intracerebral 
injection ensured the maximum concentration entered the desired area, especially when 
localised to a specific brain region. The hippocampus is one of the most vulnerable brain 
regions to amyloid pathology, and dysfunction within it leads to the memory loss observed 
in early stage Alzheimer disease patients (Braak and Braak 1991). The substantial evidence 
concerning the pathological effect of Aβ in this region, as well as the numerous cognitive 
tests developed to specifically measure its function, highlight the hippocampus as a critical 
region to analyse the physiological role of the peptide. Therefore, the experiments 
presented in this Chapter involved infusion of 2B3 into the hippocampus of WT mice in 
order to investigate the biochemical and cognitive effects.  
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3.3 Experiment 1: Acute Inhibition of hippocampal Aβ 
▪ 3.3.1 – Introduction 
The aim of this experiment was to investigate whether a measurable reduction of 
Aβ concentration could be induced following direct infusion of an anti-APP antibody, 2B3, 
throughout the hippocampus. It further aimed to ascertain the duration of this effect, in 
order to confirm the possibility of investigating the impact of Aβ inhibition on cognitive 
performance. 
▪ 3.3.2 – Experiment 1 Methods 
Subjects, Design 
Young C57Bl/6 mice (3-4 months old) underwent bilateral hippocampus injections. All 
mice had 2B3 infused into one hemisphere and a control antibody into the other. The mice 
were culled after either 1- or 5-days following surgery (n=8 for both timepoints), and 
hippocampi were immediately dissected and flash frozen on liquid nitrogen. One mouse 
had to be removed from the within-subjects comparison after 1 day of treatment due to an 
error in the extraction of the 2B3-treated sample. This meant that for the comparison of 
treatment versus duration, there was n=8 in the 5-day group and n=7 in the 1-day group. A 
further group of 8 mice did not undergo surgery and were compared alongside the others. 
The control antibody was the same isotype as 2B3 (IgG1κ) and was raised against rabbit 
IgG light chain (1.3 mg/mL, mab201, Millipore, UK). The origin and purification of the 
2B3 antibody was described in section 2.4 and the concentration was 2.31 mg/mL. The 
extraction protocol for the soluble fraction is described in section 2.5, and the concentration 
of Aβ was quantified using a mouse Aβ40 ELISA kit (KMB3481, Invitrogen, California, 
USA). Aβ42, measured by ELISA, was not detectable in WT mice (data not shown). This 
was consistent with a previous study measuring Aβ42 changes in WT mice (Iaccarino et 
al. 2016) 
Surgery 
Mice were anaesthetised with Isoflurane [2-chloro-2-(difluoromethoxy)-1,1,1-
triflouro-(ethane)] carried by oxygen throughout the surgery. They were fixed into a 
stereotaxic frame and the scalp incised and retracted to expose the skull. A bone flap was 
removed over both hippocampi spanning the range of the injection coordinates in table 3.1. 
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Mab201 control IgG or 2B3 was delivered through a 25G microinjection 2 μL Hamilton 
Syringe (#20751, Hamilton Company, Reno, USA) at 0.3 μL per minute into each 
coordinate up to the volume described. Volumes were based on previous studies using 
intrahippocampal infusions. The needle remained in place for 2 minutes following the end 
of each infusion, before being slowly withdrawn. Following all infusions, the scalp was 
sutured and the mouse was rehydrated with 1 mL gluco-saline injected subcutaneously into 
each flank. Mice were placed in a recovery chamber with temperature maintained at ~30 
°C until they were fully alert and responsive, before being placed in a clean home cage 
with tissue paper on the floor. They were provided with sweetened porridge (ReadyBrek) 
to encourage eating, alongside the usual ad libitum access to chow and water. Mice were 
treated with 30 mg/kg Metacam analgesia immediately before, and each day following the 
surgery until they were sacrificed. 
Site 
Stereotaxic Coordinates 
Anterior / 
Posterior 
Lateral         
(+/-) 
Ventral Volume (μL) 
1 -1.7 1.3 -2.5 0.75 
2 -2.3 2.5 -2.5 1.0 
3 -2.9 3.1 -2.8, -3.6 0.8 
4 -3.4 3.1 -3.2, -4.2 0.7 
Fluorescent Labelling of 2B3 
Purification of 2B3 was performed as described in section 2.4. A fluorescent tag was 
conjugated to the antibody using the Alexa FluorTM 647 Protein Labelling Kit (A10239, 
Invitrogen, California, USA) according to the protocol outlined in the manufacturer’s 
guidelines. The labelling reaction was performed by adding 50 μL of 1 M sodium 
bicarbonate to 0.5 mL of the 2B3 solution. This was mixed with the provided vial of 
reactive dye and stirred for 1 hour at room temperature. Purification resin was pipetted into 
the column and the dye/2B3 reaction product was loaded on top. The elution buffer was 
diluted and slowly added on top of the column and as it ran, the first coloured band was 
Table 3.1: Stereotaxic co-ordinates used for direct infusions of 2B3 or control IgG 
into the hippocampus. Co-ordinates are labelled as distance (mm) posterior and lateral 
from bregma, and ventral from the dura. 
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collected because it contained the labelled antibody. The concentration of labelled antibody 
was calculated using the equation in the protocol and a NanoVue spectrophotometer (GE 
Healthcare Ltd, Buckinghamshire, UK). 
Immunofluorescence 
Fluorescently labelled 2B3 (2.15 mg/mL) was injected into the hippocampus of one 
hemisphere according to the surgery protocol above. Mice were euthanised after 1 or 5 
days and brains were immersed in Optical Cutting Temperature compound and flash-frozen 
in liquid nitrogen. The brains were sectioned at 20 μm on a cryostat. As the brain was 
sectioned, photographs of coronal sections were taken throughout, recording the extent of 
the coloured dye. Sections were mounted onto slides and coverslips were fixed on top with 
Vectashield mounting medium with DAPI stain (H-1500, Vector Laboratories, 
Peterborough, UK). Fluorescence imaging was performed using a Leica DM5000B 
fluorescence microscope. 
▪ 3.3.3 – Experiment 1 Results 
Imaging Fluorescently Labelled 2B3 
 Fluorophore tagged 2B3 solution was injected into the hippocampus of one 
hemisphere of a 5-month old C57Bl/6 mouse. Figure 3.1 presents photographs depicting 
the frozen brain 1-day post-injection as it was being sectioned. The blue dye of the 2B3 
solution can be observed throughout one hippocampus around the injection sites (panel A). 
Panel B demonstrates the immunofluorescence images taken of sections of the same brain. 
The fluorescently labelled 2B3 can be seen in red throughout the hippocampus, in which 
the cell nuclei are identified by the blue DAPI counterstain. The fluorescent signal was not 
observable in the opposite hemisphere. In the brain collected 5 days post injection, neither 
blue dye nor immunofluorescence were detectable in the hippocampus (Figure 3.1C). 
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2B3 Reduction of β-Amyloid 
 In order to measure the effect of 2B3 on amyloid concentrations in the 
hippocampus, mice underwent contralateral infusions of 2B3 and IgG into either 
hemisphere, permitting a within-subjects comparison of Aβ40 concentrations between each 
hippocampus. Mice were culled after either 1- or 5-days post-surgery, in order to compare 
the duration of any effect. ELISA results for the four groups were checked for normality 
of distribution via the Shapiro-Wilke test, and all showed p>0.5. The results were then 
analysed by a mixed measures ANOVA using treatment (2B3 or IgG) as a within-subjects’ 
factor, and duration (1 or 5 days) as the between-subjects factor. Levene’s test and Box’s 
test revealed no violations of homogeneity of variance or covariance. 
Figure 3.1: Detection of fluorescently labelled 2B3 in the hippocampus, 24 hours 
and 5 days post-injection. (A) Photographs of injection sites in a frozen mouse brain.  
fluorescently tagged Bb3 is visible due to the blue dye. (B) Immunofluorescence 
microscope images of the hippocampus 24 hours following injection of fluorescent 
tagged 2B3 (red) and DAPI counterstain (blue). (C) Representative image of the 
hippocampus 5 days following injection. 
A 
B 
C 
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 The ANOVA revealed a significant treatment*duration interaction F(1,13) = 6.4, 
p=0.025 (Figure 3.2). There was no significant main effect of treatment F(1,13) = 3.3, 
p=0.095; or duration F(1,13)=0.98, p=0.34. Simple main effects analysis on the interaction 
term revealed that 2B3 significantly reduced Aβ40 concentration compared to the IgG-
injected hippocampi when measured 1-day post-surgery (p=0.011) but not at 5-days 
(p=0.6). Furthermore, there was no difference in Aβ40 concentration between day 1 and 5 
for the IgG-treated hippocampi (p=0.444), but Aβ40 levels significantly increased in the 
2B3-treated hippocampi over the 5 days (p=0.027). 
 
Effect of Surgery on beta-Amyloid 
 A group of untreated 8 mice were culled alongside the mice which had undergone 
surgery. The Aβ40 concentration in their hippocampi were compared to the control IgG-
treated mice in order to assess any effect of surgery. There were three groups: no surgery, 
1-day post-surgery and 5 days post-surgery. None of the datasets violated the assumption 
of normality (Shapiro-Wilke p>0.05), and they were analysed by a one-way ANOVA. The 
ANOVA reported a significant difference between groups F(2,23) = 3.87, p=0.037 (Figure 
3.3). Post hoc analysis with Bonferroni correction revealed a significant increase in 
hippocampal Aβ40 1-day following surgery (p=0.044). However, this did not reach 
Figure 3.2: Aβ concentration following direct infusion of 2B3 in the hippocampus, 
measured at 1- or 5-days following surgery and compared to the contralateral 
hippocampus which had been infused with control IgG. n=7 at 1 day and 8 at 5 days.  
Error bars represent S.E.M. *=p<0.05, 2x2 mixed measures ANOVA. 
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significance when measured in animals culled 5-days following surgery (p=0.161). There 
was no difference between the two surgery groups (p=1.0). 
▪ 3.3.4 – Experiment 1 Discussion 
 The aim of this experiment was to assess whether direct injection of 2B3 into the 
hippocampus could induce a measurable reduction in Aβ compared to the contralateral 
hippocampus, which was treated with a control antibody that does not bind mouse protein. 
The results of the ELISA revealed a significant reduction in Aβ40 concentration in the 
hippocampi treated with 2B3 at 1-day post infusion. This effect was absent at 5 days, 
presumably due to diffusion of the antibody out of the hippocampus and recovery of 
peptide concentrations to normal levels. This theory is supported by the fluorescently 
labelled 2B3 being visible in the brain 1 day after infusion, but not detectable 4 days later. 
Measurement of Aβ42 was attempted, however, the concentration was below detectable 
levels in all groups (data not shown). The 2B3 antibody has previously demonstrated the 
capability to inhibit β-secretase cleavage of APP and thus reduce the concentration of Aβ40 
in mouse primary cortical neuronal cultures derived from a transgenic mouse model 
expressing the London mutation in APP (Thomas et al. 2013). Endogenous Aβ 
concentrations in WT mice are estimated to be in the picomolar range (Puzzo et al. 2011, 
Figure 3.3: Mean Aβ40 concentration in the hippocampus of mice following 
hippocampal infusions of a control IgG after 1 or 5 days compared to a group that 
had no surgery. Error bars represent standard error of the mean. N=8 for all groups,         
*p<0.05. 
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Cirrito et al. 2005). The low concentration makes it difficult to detect significant changes 
during manipulation of the peptide, particularly considering the high level of background 
noise identified in commercial ELISA kits (Teich, Patel, and Arancio 2013). 2B3 was 
compared to a control IgG with each infused into the contralateral hippocampus of the same 
mouse. This within-subjects design was hypothesised to reduce variation. This is the first 
time an antibody has been used as the control condition when testing the effect of 2B3 in 
vivo. The results confirm that the reduction of Aβ is linked to the specific activity of 2B3 
to inhibit β-secretase cleavage rather than simply the presence of an IgG. 
 There are two potential explanations for why the effect of 2B3 on Aβ40 did not 
persist over 5 days: there could be an antagonistic increase in β-secretase activity or APP 
expression, to counteract the inhibition of β-cleavage and return the Aβ level to normal. 
Alternatively, the 2B3 IgG may have been cleared from the hippocampal parenchyma to 
an extent that its activity is negligible after 5 days. The absence of the fluorescently labelled 
2B3 after 5 days indicates that the second possibility is more likely. As macromolecules, 
antibodies do not readily cross the BBB, however, they may be actively effluxed by the 
neonatal Fc receptor in rodents (Cooper et al. 2013, Deane et al. 2005). One group 
calculated the half-life of an IgG antibody following intracerebral injection as 48 minutes 
(Zhang and Pardridge 2001). Despite this experiment involving a different isotype (IgG2a) 
and species (rat), it is still relevant to support the theory that the infused 2B3 may have 
been cleared by the 5-day timepoint. One conclusion from this study is that the reduction 
in Aβ40 did not persist for long enough to permit an in-depth assessment of cognitive 
function without implantation of a cannula to permit acute infusions. 
 The level of Aβ40 in was found to be significantly higher in hippocampi harvested 
1-day following control IgG infusion compared to a non-surgery control group. Elevated 
Aβ concentrations have frequently been linked to isoflurane anaesthesia, both in humans 
and mice (Xie and Xu 2013). Furthermore, general anaesthesia has also been linked to an 
exacerbation of Alzheimer-like pathology in both species (Tang et al. 2011, Zhang et al. 
2013, Bianchi et al. 2008). One group has analysed the acute effect of isoflurane 
anaesthesia on APP metabolism over 24 hours in 5 month old WT mice (Xie et al. 2008). 
Mice, placed in an anaesthetising chamber, received 2 hours of 1.4% isoflurane in 100% 
oxygen. Control mice underwent the same procedure without the anaesthetic. They 
reported robust increases in BACE expression in the prefrontal cortex at 12- and 24-hours 
post-surgery and consequently, the concentration of Aβ was also increased at 24 hours. 
[70] 
Together, these results indicate the possibility that 2B3 may have blocked the isoflurane-
induced increase in Aβ production.  
 In conclusion, Experiment 1 revealed that 2B3 reduced Aβ40 levels in the 
hippocampus of WT mice 24 hours after direct injection. However, this effect did not 
persist over 5 days, likely due to clearance of the antibody. Therefore, a chronic delivery 
method was subsequently adopted in order to assess the impact of decreased Aβ on object 
recognition. 
 
3.4 Experiment 2: Chronic Inhibition of Aβ in WT Mice 
▪ 3.4.1 – Introduction 
The aim of this experiment was to measure the biochemical and cognitive impact 
of chronic 2B3 infusion into the lateral ventricle of WT mice over 14 days. Specifically, 
this experiment quantified the expression of proteins involved in APP metabolism. The 
hypothesis was that infusion of 2B3 would inhibit Aβ production in the hippocampus by 
steric hindrance of β-secretase cleavage of APP. The chronic (14-day) nature of the icv 
infusions permitted a detailed cognitive assessment of Aβ reduction. Two object 
recognition tasks were used to assess the nature of networks influenced by 2B3. Object 
novelty and object-in-place (OiP) tests were performed in this experiment in a 
counterbalanced order. The former task depends on function of the perirhinal cortex during 
short-term memory tests, while the latter task also requires intact hippocampal function 
(Barker and Warburton 2011). The combined use of both tasks permits analysis of any non-
specific effect of 2B3 on performance (for further detail see chapter 4). The short timeframe 
in which cognitive testing was possible mandated a test with minimal training requirements 
and object recognition tests rely on the spontaneous exploratory behaviour of mice and 
their natural reaction to novel stimuli. 
In summary, the aim of this experiment was to assess how manipulation of Aβ 
levels would impact cognitive performance during chronic infusion of 2B3. It was 
hypothesised that reduction of the A peptide in the hippocampus would lead to a deficit 
in memory processes. 
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▪ 3.4.2 – Experiment 2 Methods 
Subjects, Design 
Five-month-old male C57Bl/6 mice underwent chronic intracerebroventricular (icv) 
administration of either 2B3 or a control antibody of the same isotype raised against rabbit 
IgG light chain (IgG1κ, mab201, Millipore, UK). There were 8 mice in each group, 
however, one of the mice in the 2B3 group was removed from the analysis because the 
catheter came loose from the brain infusion cannula prior to the commencement of 
behaviour testing, leaving group numbers as following: 2B3 infusion n=7; control IgG 
infusion n=8. The implantation of osmotic minipumps and infusion cannulas in the lateral 
ventricle was performed as described in section 2.4. ELISA and Western blot protocols are 
described in section 2.5.  
The within-subjects design of this experiment is depicted in Figure 3.4. Mice were 
assessed on both object novelty and object-in-place recognition before and during chronic 
2B3 infusion. The task order was counterbalanced, as was the use of object sets between 
both timepoints. Each mouse started the 6-day protocol on the 9th day after having the 
surgery. Mice were sacrificed 14 days after surgery and hippocampus and cortex were 
dissected, flash frozen in liquid nitrogen and protein was extracted following the protocols 
on page 52. 
 
 
 
Figure 3.4: Experimental design assessing Object Novelty (ON) and Object-in-
Place (OiP) memory before and following icv infusion of 2B3. The cohort of mice 
was split into groups A and B in order to counterbalance the order of tests. Each vertical 
line represents a new day. Truncated lines are rest days.  
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Object Recognition Tests 
The ON and OiP protocols are described in section 2.3 of this thesis. This experiment 
utilised a 2-object array for the ON task. Two identical objects were placed in opposite 
corners of the arena for the 3 sample phases (each 10 minutes long). During the 5-minute 
delay, prior to the test phase, one of the objects was replaced with a novel item. The identity 
of the novel object within each set (two pairs of identical objects) was counterbalanced. 
The OiP protocol was run as previously described, with 4 different objects. During the test 
phase two of the objects had switched positions. Calculation of discrimination ratios and 
statistical analysis were performed as previously described in 2.3. 
▪ 3.4.3 – Experiment 2 Results 
APP Processing 
Following the chronic icv infusion of 2B3 or a control IgG over 14 days, the 
hippocampi and cortices were collected for the assessment of Aβ40 levels by ELISA. The 
concentration in each 2B3-treated sample was normalised to the average of the IgG-treated 
samples in order to express percentage reductions which are presented in figure 3.5. The 
two datasets for the normalised hippocampal concentration were normally distributed as 
assessed by the Shaprio-Wilke test (p>0.05) and they were analysed by an independent 
samples t-test. The test revealed a significant difference between the groups t(1,14)=2.046, 
p=0.029 (Figure 3.5A). 
The Aβ40 concentration in the cortices was also analysed in order to assess the 
penetration of 2B3 to the cortex and any potential effect in that region. After normalisation 
to the control concentration, Shapiro-Wilke test confirmed the results of both groups had 
normal distributions. They were analysed by an independent samples t-test, which revealed 
no difference between the groups t(1,13)=0.366, p=0.722 (Figure 3.5B). 
 
[73] 
 
 
 
 
 
 
 
Figure 3.5: Icv infusion of 2B3 reduced concentration of Aβ40 in the hippocampus 
but not the cortex. The concentration for each 2B3 treated mouse was normalised to 
the average result of mice infused with the control antibody to produce a percentage 
reduction in the hippocampus (A) and cortex (B). N=8 for the control group, n=7 for 
2B3. Error bars represent SEM. * p<0.05, independent t-test. 
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APP and BACE1 Expression 
Western blot analysis was performed to detect whether any changes in Aβ 
concentration were mediated by alterations of endogenous APP or BACE1 expression. 
Figure 3.6 depicts representative blots (A) and the quantitative comparisons (B). The 
quantified expression densities were compared by independent Student’s t-tests. There was 
no difference in the levels of APP t(1,13) = -0.77, p=0.458; or BACE1 t(1,13) = -0.26, 
p=0.797. 
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Figure 3.6: 2B3 infusion did not affect expression levels of APP and BACE1. 
(A) Representative Western blot images of APP and BACE1 expression in hippocampal 
homogenates following icv infusion of control (n=8) or 2B3 (n=7) antibodies. (B) No 
significant differences were detected after quantification of densities normalised to the 
control level (p>0.05, independent t-tests). Error bars show SEM. 
[75] 
Open Field 
 The protocol for recognition memory assessment involved free exploration of the 
empty arena as the first point of habituation. This provided the opportunity to investigate 
non-cognitive motor effects of both general surgery and 2B3 administration. The total 
distance travelled by both groups before and during antibody administration was recorded 
and is presented in Figure 3.7. Visual inspection suggested a decrease in general 
locomotive activity after surgery for both groups. The datasets were normally distributed 
as revealed by the Shapiro-Wilke test (p>0.05). They were analysed by a mixed measures 
ANOVA with surgery time point as the within subjects’ factor and treatment type as the 
between subjects’ factor. The results of the ANOVA indicated no significant main effect 
of surgery time point F(1,13) = 2.4, p=0.148; no main effect of antibody treatment F(1,13) 
= 0.23, p=0.639; and no surgery*treatment interaction, F(1,13) = 0.029, p=0.868. In 
summary, neither surgery nor 2B3 treatment exerted any effects on the general locomotive 
behaviour of the mice. 
  
0
500
1000
1500
2000
2500
3000
3500
4000
Pre Post
D
is
ta
n
ce
/ 
cm
Open Field Total Distance
Control IgG
2B3
Figure 3.7: Total distance moved in the open field test pre and post-infusion of 2B3 
or the control antibody. Control IgG n= 8; 2B3 n=7. Error bars represent SEM. 
[76] 
Open Field Inner Zone Exploration 
 The Open Field test permits assessment of anxiety-related exploratory behaviour. 
Figure 3.8 depicts the ratio of time spent in the exposed inner zone (central 30 x 30 cm 
square) of the 60 x 60 cm arena compared to the total duration of the trial. Results of each 
group both before and during treatment are shown. All four groups demonstrated normal 
distributions and they were compared by a mixed measured ANOVA using treatment as 
the between subjects’ factor and pre- vs post- surgery timepoint as the within subjects’ 
factor. The ANOVA reported a significant main effect of surgery timepoint F(1,13) = 9.6, 
p=0.008, as mice entered the zone less post-implantation of the minipump and cannula. 
There was no main effect of treatment F(1,13) = 0.49, p=0.498 and no surgery*treatment 
interaction F(1,13) = 0.72, p=0.413.  
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Figure 3.8: Exploration of the “inner zone” of the open field arena pre- and post-
infusion of 2B3 or IgG antibody. Control IgG n= 8; 2B3 n=7. Error bars represent SEM, 
* p<0.05, 2x2 mixed measures ANOVA. 
* 
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Object Novelty 
Sample Phase Contact Times 
 During the object novelty tasks before and during chronic infusion of 2B3 or control 
IgG, total contact with both objects was scored and the results are summarised in table 3.1. 
The data suggest a slight decrease in object contact following surgery. There was also a 
general decrease in exploration as the sample phases progressed. The datasets were 
normally distributed as assessed by the Shapiro-Wilke test (p>0.05). Levene’s & Box’s 
tests revealed there was equality of error variances and covariance matrices (p>0.05). The 
data were analysed by a 3-way mixed measures ANOVA, with pre- vs post- surgery 
timepoint and sample phase as within subjects’ factors and treatment as the between 
subjects’ factor. 
 The ANOVA demonstrated significant main effects of surgery timepoint (pre- vs 
post-) F(1,13) = 6.25, p=0.019 and sample phase F(2,26) = 4.6, p=0.004. There was no 
main effect of treatment F(1,13) = 0.01, p=0.983; no surgery timepoint*treatment 
interaction F(1,13) = 3.9, p=0.071; no sample phase*treatment interaction F(2,26) = 0.71, 
p=0.389; no sample phase*surgery interaction F(2,26) = 0.53, p=0.532 and no sample 
phase*surgery*treatment interaction F(2,26) = 1.33, p=0.242. Post hoc analysis of the main 
effect of sample phase showed that although mice exhibited lower object exploration 
between phases 1 & 3, this was not significant (p=0.066). The main effect of surgery 
demonstrated that in general, mice explored objects less after having surgery. 
  
ON Sample Phase Contact 
 Control IgG 2B3 
Pre Post Pre Post 
Sample 
Phase 1 
Mean 43 51 63 44 
SD 18 26 29 18 
Sample 
Phase 2 
Mean 43 42 45 34 
SD 22 30 14 15 
Sample 
Phase 3 
Mean 44 31 43 29 
SD 18 13 18 12 
Table 3.2: Mean contact times across the object novelty (ON) contact phases pre- 
and post-infusion of 2B3 or control antibody. Contact time was measured in seconds. 
Data represent both mean scores and standard deviation (SD). 
[78] 
Test Phase Contact Times 
 Figure 3.9 presents the average contact times for exploration of either the familiar 
or novel object in the test phase for both groups before and during antibody infusion. 
Inspection of the data suggests all groups preferentially explored the novel object. All 
datasets were normally distributed (Shapiro-Wilke test p>0.05). the data were analysed by 
a three-way mixed measures ANOVA with object type and pre-vs post- surgery timepoint 
as within subjects’ factors, and antibody treatment as the between subjects’ factor. The test 
revealed a significant main effect of object type F(1,13) = 52.6, p<0.0005. There were no 
significant effects of pre- vs post-surgery timepoint F(1,13) = 0.03,  p=0.865 or treatment 
F(1,13) = 0.29, p=0.600. There were no significant interactions: surgery*object*treatment 
interaction F(1,13) = 0.72, p=0.412; surgery*treatment F(1,13) = 0.25, p=0.628; 
object*treatment F(1,13) = 0.029, p=0.867; surgery*object F(1,13) = 0.001, p=0.982. 
  
Figure 3.9: Contact times for novel and familiar objects in the test phase of the object 
novelty (ON) task pre- and post-infusion of 2B3 or control antibody. Control IgG n= 8; 
2B3 n=7. Error bars represent SEM. 
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Discrimination Ratio 
 The contact time for the familiar and novel object in the ON task test phase were 
converted into discrimination ratios. These are presented in Figure 3.10 for both treatment 
groups. The Shapiro-Wilke test disclosed that not all groups exhibited normal distributions 
(p>0.05), so they were all transformed by the reflect and square root calculation. The 
transformed data were compared by a mixed measures ANOVA with surgery state as the 
within subjects’ factor and treatment antibody as the between subjects’ factor. The 
ANOVA revealed no significant main effect of treatment F(1,13) = 0.07, p=0.796 or 
surgery F(1,13) = 0.009, p=0.925. There was no significant surgery*treatment interaction 
F(1,13) = 0.79, p=0.389. 
 The DRs of the four groups were compared to the predicted score of chance (0.5, 
highlighted in the graph) by a one-sample t-test. The equivalent test statistic was calculated 
by performing the same transformation on an imaginary score of 0.5. The one-sample t-
tests revealed that all groups performed significantly better than chance: Control pre 
surgery t(7) = -6.3, p<0.0005; 2B3 pre surgery t(6) = -7.2, p<0.0005; Control post-surgery 
t(7) = -5.8, p=0.001; 2B3 post-surgery t(6) = -5.3, p=0.002. 
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Figure 3.10: 2B3-treated WT mice display intact object novelty recognition. Mean 
discrimination ratios (DR) pre- and post-infusion of 2B3 or control antibody. The 
predicted random chance score of 0.5 is highlighted. Control IgG n= 8; 2B3 n=7. Error 
bars represent SEM. 
[80] 
Object-in-Place 
Sample Phase Contact Times 
Table 3.2 shows the mean total contact time throughout the sample phases of the 
OiP task. Inspection of the data suggests a decrease in total contact after having surgery. 
The 2B3 group seemed to exhibit greater contact both pre- and post-surgery. Furthermore, 
sample phase 3 appeared to involve less exploration of objects than the other phases. 
Specific datasets were not normally distributed (Shapiro-Wilke test p>0.05), so were all 
transformed by square root. The sample phase contact times were analysed by a three-way 
mixed measures analysis of variance test (ANOVA) with sample phase and surgery 
timepoint (pre- vs post-) as within-subject factors and treatment group as the between 
subjects’ factor. 
 The ANOVA revealed a significant main effect of sample phase F(2,26) = 8.8, 
p<0.001. There was no main effect of surgery timepoint (pre- vs post-) F(1,13) = 3.22, 
p=0.106 or treatment F(1,13) = 2.6, p=0.134. There were no significant interactions: 
phase*surgery*treatment F(2,26) = 0.32, p=0.639; phase*surgery timepoint F(2,26) = 0.94, 
p=0.444; surgery*treatment F(1,13) = 0.02, p=0.878; phase*treatment F(2,26) = 2.2, 
p=0.229. Pairwise comparisons on the main effect of sample phase showed that while there 
was no difference in contact time between sample phases 1 and 2 (p=1.0), there was 
significantly reduced contact with objects in sample phase 3 compared to both phase 1 
(p=0.033) and phase 2 (p=0.007). These data illustrate that, across all groups, mice showed 
habituation of exploratory behaviour across the sample phases. 
OiP Sample Phase Contact 
  
Control IgG 2B3 
Pre Post Pre Post 
Sample 
Phase 1 
Mean 73 69 105 91 
SD 29 23 35 34 
Sample 
Phase 2 
Mean 94 72 104 80 
SD 34 22 33 19 
Sample 
Phase 3 
Mean 71 56 71 65 
SD 35 17 26 22 
 
Table 3.3: Mean contact times across the object-in-place (OiP) sample phases pre- 
and post-infusion of 2B3 or control antibody. Contact time was measured in seconds. 
Data are mean and standard deviation (SD). 
[81] 
Test Phase Contact Times 
 The contact times for objects in familiar or novel locations in the OiP test phase are 
presented in Figure 3.11. Visual inspection of the data suggests the control mice explored 
the objects in the novel location more, in contrast to the behaviour shown by mice infused 
with 2B3. The datasets were analysed by a three-way mixed measures ANOVA with Object 
location and Surgery state as within subjects’ factors, and Treatment group as the between 
subjects’ factor. 
 The ANOVA revealed a significant main effect of object location F(1,13) = 44, 
p<0.0005; showing that overall, mice spent more time exploring the objects in novel 
locations. There were no significant effects of surgery F(1,13) = 3.3,  p=0.093 or treatment 
F(1,13) = 0.14, p=0.714. There were no significant interactions. Three-way 
object*surgery*treatment interaction F(1,13) = 2.8, p=0.119, object*surgery interaction 
F(1,13) = 4.4, p=0.056, surgery*treatment interaction, F(1,13) = 3.2, p=0.098 and 
object*treatment F(1,13) = 2.7, p=0.122. 
  
Figure 3.11: Mean contact times of WT mice with objects in either familiar or 
novel locations in the test phase of the OiP task pre- and post-infusion of 2B3. Error 
bars represent standard error of the mean (SEM). Control IgG n= 8; 2B3 n=7. 
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Test Phase Discrimination Ratio 
 The test phase contact times were converted into discrimination ratios and these are 
presented in Figure 3.12. Visual inspection indicates the group treated with 2B3 had a lower 
DR that was not above chance level. The datasets were all normally distributed and were 
analysed by a 2x2 mixed measures ANOVA. Surgery state (timepoint: pre or post) was the 
within subjects’ factor, and treatment group was the between subjects’ factor. The ANOVA 
revealed no significant surgery*treatment interaction F(1,13) = 2.9, p=0.114. There was no 
main effect of surgery F(1,13) = 3.0, p=0.109 but a significant main effect of treatment 
F(1,13) = 8.8, p=0.011. Pairwise comparisons on this main effect demonstrated that overall, 
mice in the 2B3 group exhibited a lower DR compared to the control IgG-treated group. 
 The group DR scores were compared to the predicted random chance score of 0.5 
by one-sample t-tests. Both groups significantly discriminated at greater than chance level 
before surgery (IgG t(1,7) = 4.4, p=0.003; 2b3 t(1,6) = 3.8, p=0.009). However, when tested 
during chronic administration, only the performance of the control group was above chance 
t(1,7) = 3.6, p=0.009; while the 2B3-treated group failed to discriminate between objects 
t(1,6) = -0.49, p=0.640. Collectively these data demonstrate that, while the ability to 
discriminate objects in different locations was numerically reduced to chance in mice 
treated with 2B3, the lack of a surgery timepoint*treatment interaction limits the strength 
of this conclusion. 
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Figure 3.12: 2B3-treated WT mice fail to discriminate novel object-place 
associations above chance. Mean discrimination ratios in the object-in-place task pre- 
and post-infusion of 2B3. the score predicted by random performance, 0.5, is highlighted. 
Error bars represent SEM. Control IgG n= 8; 2B3 n=7. 
[83] 
 
Synaptic Receptor Expression 
` Following the results of the OiP test, synaptosome preparations were extracted from 
the right hippocampi of the mice in order to analyse synaptic markers and receptor 
dynamics by Western blot (figure 3.13). Glutamate receptor expression in the hippocampus 
was investigated because these have been shown to be required for associative recognition 
memory (Barker and Warburton 2015). The data were normalised to the control treated 
mice for all proteins and statistically compared by independent samples t-tests.  
There were no significant differences in the total expression of post synaptic density 
scaffolding protein (PSD95) t(13) = 0.059, p=0.602, indicating that any changes in receptor 
expression cannot be attributed to differences in total synaptic density. There was also no 
effect of 2B3 on α7-NAChR expression t(13) = 0.457, p=0.384 (figure 3.13 A). 
Figure 3.13 C shows that total NMDA receptor (NR1) expression was unchanged 
by 2B3 infusion t(13) = 1.35, p=0.326. An NMDA receptor subtype that has been shown 
to be critical to OiP performance, NR2B showed no significant difference in its total 
expression t(13) = -0.469, p=0.647. Expression of the phosphorylated receptor at the 
regulatory tyrosine residue Y1472 (pY1472) was not significantly affected by 2B3 infusion 
t(13) = 1.79, p=0.096. However, calculation of the ratio of pY1472 to total NR2B (pY1472 
: NR2B) showed a significant reduction in the amount of pY1472 relative to the total level 
of NR2B t(13) = 2.8, p=0.011. 
AMPA receptor dynamics were analysed by examining the total expression and 
phosphorylation of the GluA1 subunit. There was no effect of 2B3 infusion in the total 
level of GluA1 t(13) = 0.94, p=0.365 or pGluA1 t(13) = 0.072, p=0.944. However, there 
was a significant decrease in the relative phosphorylation (pGluA1 : GluA1), t(13) = 2.3, 
p=0.037. 
[84] 
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Figure 3.13: Western blot analysis of synaptic receptor expression in WT mice 
following 2B3 infusion. Hippocampal synaptosomes were prepared from mice that had 
been infused with either 2B3 or a control IgG. (A) western blot images were used to 
analyse expression of synaptic markers and receptors. (B) Quantification of PSD95 
(postsynaptic density scaffolding protein), total nicotinic acetylcholine α7 receptor (α7-
NAChR). C: Quantification of total NMDA receptor expression (NR1), total NR2B and 
both the total pY1472 expression and after normalisation to NR2B (p1472 : NR2B). (C) 
quantification of total GluA1 subunit expression of AMPA receptors, along with total 
pGluA1 and the relative phosphorylation. Error bars represent SEM. Control IgG n= 8; 
2B3 n=7. *p<0.05, independent samples t-test. 
[86] 
▪ 3.4.4 – Experiment 2 Discussion 
 This experiment revealed that chronic icv infusion of 2B3 over 14 days induced a 
significant reduction in the concentration of Aβ40 in the hippocampus, but not the cortex. 
The effect on hippocampal Aβ is consistent with Experiment 1 and the absence of 
measurable effect in the cortex may simply reflect the lack of penetration by 2B3 to that 
region over the period of infusion. Analysis of endogenous APP and BACE1 expression 
levels in the hippocampus revealed no changes between the 2B3 and IgG control-treated 
samples, further validating the conclusion that changes in Aβ were mediated by specific 
inhibition of APP cleavage by BACE rather than changes in expression.  
Cognitive tests demonstrated that, while infusion of 2B3 had no effect on object 
novelty recognition, mice receiving the antibody failed to discriminate novel object-place 
associations above chance. The lack of significant interactions in the test phase behavioural 
data does not strictly support the hypothesis that a reduction of A by administration of 
2B3 disrupted associative recognition memory. The experiment appeared to be 
underpowered for the conservative nature of the ANOVA test. A post hoc power analysis 
performed on the pre- vs post-surgery timepoint*treatment interaction for the OiP DR 
scores using SPSS calculated the observed power as 0.349. While this does suggest a lack 
of statistical power, it is important to note that increasing sample size may not necessarily 
produce a significant result. Averaging over multiple trials would reduce the variation in 
the DR scores for the 2B3-treated mice which performed at the level of random chance. 
However, the fact these mice were not able to discriminate between the objects above 
chance indicates that there was an impact on their processing of object-place associations. 
This ability is well evidenced to depend on hippocampal function (Barker and Warburton 
2011, Barker et al. 2007). 
 During the object novelty task, the mice demonstrated lower total object contact in 
the sample phases after having the surgery. However, there was no interaction with 
treatment group, meaning that this was probably a result of undergoing surgery or simply 
an artefact of repeated testing. This effect of pre- vs post- surgery timepoint was not present 
in the OiP data, meaning that it was not robust enough to be maintained across tasks. 2B3 
did not alter total contact times, therefore did not impact general exploration or motivation 
to contact objects. In fact, results from the Open Field test showed no effect on general 
locomotor behaviour, however, entry into the central zone was decreased in all mice after 
[87] 
surgery. While the significant decrease in central zone exploration (Figure 3.7) could be 
caused by surgery, it must be acknowledged that it is the second time mice experienced the 
apparatus after habituation and further object memory tests. 
Western blot analysis of synaptosomes revealed no effect of 2B3 on synaptic 
density or total NMDA receptor expression. However, the relative phosphorylation of the 
NMDA subunit NR2B was significantly reduced in the 2B3-treated animals. Previous 
studies by the Warburton group have demonstrated that NMDA and AMPA receptors in 
the hippocampus are involved in associative recognition memory (Barker and Warburton 
2015). In particular, the NMDA subunit NR2B is required for OiP memory, as shown by 
Evans et al (2019) who reported that administration of the selective NR2B inhibitor, RO25-
6981, resulted in a deficit in OiP discrimination performance. Activation of NMDA 
receptors leads to the induction of synaptic plasticity due to expression or internalisation 
of AMPA receptors from the synapse, which is regulated by phosphorylation of the GluA1 
subunit at serine residue 845 (Lu et al. 2001, Lee et al. 2003). Therefore, the decrease in 
relative GluA1 phosphorylation observed in the current experiment may represent a 
downstream effect of the reduced NR2B activation and propose a mechanism for the failure 
of the 2B3-treated mice to discriminate object-place associations above chance level. 
Further discussion of the putative role of Aβ is provided in sections 7.5 and 8.3. 
 
3.5 Chapter Discussion 
This Chapter presents the first experiments investigating the effect of specific 
inhibition of β-cleavage of APP on WT mice using antibody-mediated steric hindrance. 
Experiment 2 revealed that chronic icv infusion of 2B3 significantly reduced Aβ40 in the 
hippocampus. Mice administered 2B3 showed control levels of object novelty detection 
that were reliably above chance but failed to show the same level of performance when 
tested on the OiP associative recognition memory task. The latter observation is consistent 
with the view that Aβ is involved in normal learning and memory processes (Puzzo et al. 
2008, Puzzo et al. 2011, Morley et al. 2010) 
Although the two tasks differed in the complexity of the sample arrays (two objects 
versus four), the absence of a deficit in the object novelty is consistent with evidence that 
the effect of the 2B3 antibody did not extend to the cortex. There is a plethora of data 
[88] 
showing that the perirhinal cortex is required for visual object novelty detection (Barker 
and Warburton 2011, Good et al. 2007, Forwood, Winters, and Bussey 2005, Warburton 
and Brown 2015). Of course, the perirhinal cortex represents a small part of the tissue 
analysed in experiment 2 and so the specific effect of 2B3 within this region requires further 
investigation. Lesion studies by Barker and Warburton (2011) demonstrated that disrupted 
performance on short-term OiP associative recognition tasks alongside intact ON memory 
may be caused by disruption of the medial prefrontal cortex (mPFC)-hippocampus-
perirhinal cortex network, suggesting that communication between regions in the network 
is critical for associative memory.  
While this is the first example of specific inhibition of APP cleavage by BACE 
impacting on cognitive processes in WT mice, it is consistent with previous studies. 
Genetic studies have shown that knock-out of the APP or BACE genes leads to impairment 
of cognitive function, among other phenotypes (Zhu et al. 2018, Müller, Deller, and Korte 
2017), while chronic administration of a small molecule BACE inhibitor disrupted both 
synaptic plasticity and memory (Filser et al. 2015). However, these approaches were not 
specific to modulation of Aβ, due to the various other metabolites of APP and substrates 
of BACE1 as well as the influence of both proteins during development (Vassar et al. 1999, 
Willem et al. 2006). In more specific manipulations of Aβ, antibodies with high affinity 
for the peptide have been shown to impair memory in three separate studies. These groups 
validated their conclusion that the loss of Aβ activity was the causative factor in their 
reported memory deficits by showing that concurrent application of exogenous Aβ42 
rescued performance. Both icv and intra-hippocampal injection of such antibodies prior to 
training induced a deficit in a T-maze passive avoidance task, as mice required a 
significantly greater number of training trials to reach the criterion for learning (Morley et 
al. 2010, Garcia-Osta and Alberini 2009). Puzzo et al (2011) reported that injection of anti-
Aβ antibodies 15 minutes prior to training impaired spatial reference learning and memory 
in the MWM, as well as contextual (but not cue-related) fear conditioning. No effect on 
memory performance was observed if infusion occurred post-training, suggesting that the 
peptide may be involved in encoding processes. The chronic infusion of 2B3 ensured that 
the antibody was present from the beginning of the encoding phase. Therefore, the inability 
to discriminate novel object-place associations may have manifested due to a failure to 
encode the original spatial arrangement of objects. However, habituation of exploratory 
activity during the sample phase indicated that encoding of the objects themselves 
proceeded normally in mice administered 2B3 (as reflected by a decline in contact times). 
[89] 
Despite the considerable number of anti-amyloid drugs entering clinical trials as 
treatments for Alzheimer’s disease (39 were counted as of January 2018), none have been 
approved since 2003 (Cummings et al. 2018). Clinical trials for AD therapies involve 
cognitive assessment to determine to what extent the treatment has reduced the decline of 
patients (Vassar 2014). For that reason, identifying any physiological functions of Aβ in 
cognition is even more pertinent. If healthy levels of the peptide play an important role in 
neuronal function, then anti-amyloid mechanisms may exacerbate rather than improve 
whatever symptoms the patient is experiencing. In fact, multiple cognitive trials have 
reported that some potential treatments actually worsened the cognitive decline in patients 
compared to placebo (Coric et al. 2012, Doody et al. 2013, Schneeberger et al. 2009). It is 
possible that this was due to the loss of physiological Aβ function and that this is also 
responsible for the inability of anti-Aβ therapies to produce efficacious phase III results. 
Recent trials have attempted to recruit patients at earlier stages of the disease to try and 
match their pathology with that exhibited by the preclinical AD models in which the 
treatments have shown beneficial effects. However, the data in the chapter indicate that 
administering anti-amyloid therapies to patients without amyloid burden may be 
detrimental to cognition. 
In conclusion, the experiments in this chapter revealed that icv infusion of 2B3 over 
14 days significantly reduced Aβ40 in the hippocampus but not the cortex. In addition, 2B3 
disrupted OiP memory while leaving object novelty detection intact – this pattern is 
consistent with disruption of hippocampal function. These results indicate that Aβ is 
necessary for a physiological role in hippocampal neuronal function and this must be taken 
into account during the design of anti-amyloid therapeutics for AD patients. 
  
[90] 
 
 
Chapter 4 –  
Characterising Object Recognition 
Memory in APP-NL-F Mice 
  
[91] 
4.1 Chapter Overview 
Genetic mutations found in Familiar Alzheimer Disease (FAD) patients, who 
develop an early onset form of AD, have permitted the expression of these mutations to 
investigate how AD pathology influences rodent behaviour. Numerous transgenic models, 
which express the human gene at artificially high levels, have been developed over the last 
decade with many of them showing age-dependent and independent cognitive (e.g., 
memory) and non-cognitive  (motoric, emotion-related) deficits (Lalonde, Fukuchi, and 
Strazielle 2012).  
This chapter describes the longitudinal assessment of emotional and cognitive 
domains of the APP-NL-F mouse model, which uses a knock-in method and expresses 
mutated human APP at endogenous levels. The experiments were designed with the aim of 
assessing whether the knock-in mice show age-dependent changes in behaviour compared 
to wild-type cage mates. Open Field and Elevated Plus Maze tests were used to assess 
locomotor and anxiety related phenotypes. Cognitive deficits were investigated using a 
battery of object recognition tasks. Manipulating the parameters of each of these tasks 
dissociated aspects of memory and permitted mapping of the pattern of performance in 
separate tasks to the functional efficiency of different brain regions and networks (Barker 
et al. 2007, Barker and Warburton 2011). 
The data presented in this chapter describe deficits in associative recognition 
memory performance in APP-NL-F mice that starts at 16-17 months of age, while memory 
for object novelty remains intact. These results are discussed in the context of previous 
(transgenic) mouse models and our current understanding of the neural basis of associative 
recognition memory. 
  
4.2 Chapter Introduction 
Object recognition paradigms were first described by Ennaceur and Delacour in 
1988  as a spontaneous test of memory in rodents that utilised their innate tendency to 
explore objects with a bias towards those that were unfamiliar (Ennaceur and Delacour 
1988). The report highlighted the benefit of not requiring specific training and 
positive/negative reinforcement used in contemporary memory tests to encourage 
engagement (Barnes 1979, Aggleton 1985).  Furthermore, the increased stress associated 
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with these tests can impact memory performance, particularly in the Morris water maze, in 
which mice are forced to swim in cold water (Kim and Diamond 2002, Aguilar-Valles et 
al. 2005). The protocol described by Ennaceur and Delacour involved a rat exploring two 
identical objects in an arena for a 3 or 5 minute “sample trial”. After a “delay” interval up 
to 24 hours, the animal returned to the arena to find one object remaining from the sample 
trial alongside a “novel” object that it had never seen before. The authors measured 
exploration of each object by recording the time elapsed while rat’s nose was directed 
towards the object within a radius of 2 cm. They reported that rats exhibited an inherent 
proclivity to explore the novel object, and that this ability to discriminate was sensitive to 
the amount of exploration time allowed in the sample phase, and the length of the delay 
interval prior to the test phase. This basic observation has been replicated substantially in 
the literature in both rats and mice. 
 The versatility of the object recognition paradigm manifests in its ability to test 
multiple aspects of memory including encoding, retrieval and retention, by manipulating 
the parameters of the sample phase as well as different properties of objects. It has been 
employed in various applications of psychological, pharmacological and anatomical 
research (Lueptow 2017). Lesion studies have identified critical roles played by specific 
neural systems in memory for distinct spatial and temporal properties of objects 
(Warburton and Brown 2010). Indeed, recent research has informed a previously 
controversial literature regarding the role of the hippocampus (Barker and Warburton 
2011). While some studies reported significant deficits in object recognition following 
hippocampal lesions;  (Clark, Zola, and Squire 2000, Broadbent et al. 2010) there is greater 
evidence that performance is not affected (Good et al. 2007, Winters et al. 2004, Warburton 
and Brown 2015, Mumby et al. 2002, Forwood, Winters, and Bussey 2005, Langston and 
Wood 2010). In contrast, the discrimination of novel and familiar objects is severely 
impaired after lesions to the perirhinal cortex (Mumby and Pinel 1994, Bussey, Muir, and 
Aggleton 1999, Ennaceur, Neave, and Aggleton 1996). A 2013 review by Warburton et al 
indicated unpublished results revealing that involvement of the hippocampus in object 
novelty recognition depends on whether the objects in the acquisition phase are identical 
or distinct (Warburton, Barker, and Brown 2013). Furthermore, there is evidence that 
NMDA receptors in the hippocampus contribute to task performance when delays of >3 
hours are used: ie for long term memory retrieval (Baker and Kim 2002). 
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In contrast to novelty/familiarity discrimination, lesions of the hippocampus disrupt 
memory for spatial or location properties of objects. The object location (OL) task includes 
the same sample phase protocol as the object novelty (ON), however instead of swapping 
one object for a new object, one of the objects is moved to a novel spatial location (figure 
4.1). During the test phase, the rat is presented with the same two objects as the sample 
phase, but one is now in a location that was previously unoccupied. Control rodents will 
preferentially explore the object in a novel location but rats with hippocampal lesions fail 
to show this pattern of exploration of the hippocampus (HPC). In contrast rats with 
perirhinal cortex (PRC) show a normal pattern of preferentially exploring the object in a 
new location (Barker and Warburton 2011). There are also recognition tasks that require 
intact function of both the PRC & HPC. The object-in-place task (OiP) requires the ability 
to form an association of a specific object with a spatial location. As both object and spatial 
information is encoded, it is not surprising that the PRC & HPC and their interaction is 
vital (as illustrated by cross hemisphere lesions technique) (Barker and Warburton 2011, 
Hannesson et al. 2004). Another neuroanatomical region that has a role in memory of 
object-place associations is the medial prefrontal cortex (mPFC), lesions of which abolish 
object-in-place and temporal order memory performance (Barker et al. 2007, Barker et al. 
2017, Bachevalier and Nemanic 2008). 
The final variation of object recognition described here is the temporal order task 
(TO). Episodic memory involves representations of temporal information, and Alzheimer 
patients have a decreased ability to remember the sequential order of words, objects and 
places (Bellassen et al. 2012). Temporal order memory has also been shown to depend on 
hippocampal function in both rodents and humans (DeCoteau and Kesner 2000, Barker and 
Warburton 2011, Kumaran and Maguire 2006). During the task described in the current 
chapter, mice were exposed to two different pairs of identical objects, with a 1-hour 
separation. In order to ensure that the task was not confounded by the relative strengths of 
memory for different objects, a long (3-hour) delay was used between the second exposure 
(sample phase B) and the test phase, in which the animal was presented with one object 
from each sample phase. Healthy control animals preferentially explore the object 
encountered in the first sample phase (i.e. the object least recently presented). This task 
also requires intact function of the PRC, HPC & mPFC, as well as the network through 
which the regions communicate (Mitchell and Laiacona 1998, Chiba, Kesner, and 
Reynolds 1994, Fortin, Agster, and Eichenbaum 2002). 
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 Disconnection studies by Barker and colleagues (2007 & 2011) demonstrated that 
interaction between the mPFR, PRC and HPC is essential for the associative recognition 
tasks (OiP & TO). While single bilateral lesions of either the PRC or HPC disrupted ON 
and OL tasks respectively, recognition remained intact after ipsilateral lesions of both 
regions in one hemisphere, showing that subjects were capable of performing the tasks with 
one intact hemisphere. Performance in both ON & OL tasks was also unimpaired after 
bilateral mPFC lesions. However, bilateral lesions of any of the 3 brain regions disrupted 
discrimination in the OiP and TO tasks. Intriguingly, while ipsilateral lesions of any 
combination of two out of the 3 regions did not impair associative recognition, any 
unilateral lesions of 2 different regions in contralateral hemispheres disrupted them. For 
example, lesions of the PRC in one hemisphere and the HPC in the other. The effect of 
different lesions and their combinations is summarised in table 4.1. The data from the two 
studies demonstrates that associative recognition memory is underpinned by a PRC-HPC-
mPFC circuit, so that intact connections between each region are vital for encoding of a 
multi-dimensional stimulus of what-where or what-when. This information is particularly 
relevant to mouse models of Alzheimer’s Disease, which often don’t exhibit 
neurodegeneration, because any pattern of deficits observed in object recognition 
paradigms may be due to a subtle disruption of the neural networks. 
 
  
Left Hemisphere 
Lesions 
Right Hemisphere 
Lesions 
Intact Recognition 
Disrupted 
Recognition 
PRC PRC OL ON, OiP, TO 
HPC HPC ON OL, OiP, TO 
mPFC mPFC ON, OL OiP, TO 
PRC & HPC 
PRC & mPFC 
HPC & mPFC 
None 
ON, OL 
OiP, TO 
None 
PRC 
PRC 
HPC 
HPC 
mPFC 
mPFC 
ON 
OL 
OiP 
TO 
Table 4.1: The effects of distinct combinations of lesions on performance in 
multiple object recognition tasks. Summary of the studies by Barker and colleagues 
(2008, 2011). PRC (perirhinal cortex); HPC (hippocampus); mPFC (medial prefrontal 
cortex); OL (object location); ON (object novelty); TO (temporal order); OiP (object-
in-place). 
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Figure 4.1: Diagrams depicting the object recognition protocols used in 
this thesis to test different aspects of memory.  
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Object Memory in Rodent Models of Amyloid Pathology 
Transgenic mouse models that overexpress human amyloid precursor protein 
containing mutations found in familial AD have been used to study the cognitive effects of 
amyloid accumulation for over 20 years (Hsiao et al. 1996, Games et al. 1995). These 
models, such as the Tg2576 and PDAPP have consistently exhibited a phenotype involving 
age-dependent spatial memory deficits that coincide with amyloid deposition, often 
discovered in the Morris water maze (Chen et al. 2000, Westerman et al. 2002). Deficits in 
processing of spatial information have also been reported in object recognition protocols, 
with transgenic mice failing to discriminate novel object-place associations in the OiP task, 
while simultaneously demonstrating intact object novelty memory (Hsiao et al. 1996, Hale 
and Good 2005, Good and Hale 2007, Evans et al. 2018). The studies by Hale & Good also 
reported that their aged Tg2576 colony successfully identified when objects were presented 
in previously unoccupied locations (OL task). However, the mice failed to recognise when 
an object had moved to a position previously occupied by a different object (OiP task). 
This is strong evidence that the mice are able to encode a representation of both object and 
spatial information, but not combine the two dimensions into unified (or configural) 
association of a specific object in a specific location (Good and Hale 2007). Analysing this 
pattern of deficit within the context of the previously discussed studies by Barker et al 
would suggest that in aged Tg2576 mice the perirhinal cortex and hippocampus are able to 
carry out some functions associated with object processing, but the accumulation of 
amyloid disrupts the ability of the perirhinal-hippocampal-medial prefrontal cortex circuit 
to integrate information about object spatio-temporal attributes. There is evidence of Aβ42 
accumulation in the mPFC in 6-month-old Tg2576, correlating to an age dependent deficit 
in reversal learning (Zhuo et al. 2008). Pathology in this brain region may contribute to 
impaired performance on the OiP task.  
Pathology within the entorhinal cortex (EC) may also be relevant, as firstly this is 
one of the earliest affected brain regions in AD patients (Harris et al. 2010). Secondly, Aβ 
accumulation has been reported in the EC of both Tg2576 and PDAPP models (Xu, 
Fitzgerald, et al. 2015, Reilly et al. 2003). Thirdly, selective overexpression of APP in the 
EC was shown to induce spatial learning and memory deficits in mice (Harris et al. 2010). 
Fourthly, there is evidence from lesion studies that this structure is required for integration 
of associative recognition memory (object-place, object-context, object-place-context), but 
not non-associative tasks (ON, OL) (Wilson et al. 2013, Bannerman et al. 2001). Thus, the 
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evidence from the transgenic rodent models of amyloid pathology support the suggestion 
that the functional integrity of medial temporal structures and frontal lobe structures are 
sensitive to amyloid accumulation.  
There is currently no substantial literature concerning the APP-NL-F knock-in mouse 
model performing object recognition tasks. A review of the current evidence of a cognitive 
phenotype in this and the APP-NL-G-F knock in models is covered in section 1.5.4 of this 
thesis, but studies relevant to object recognition tests will be highlighted here. It is worth 
noting that these studies often report inconsistent habituation and test protocols, which is 
important because sampling time and delay duration are known to affect performance in 
object recognition tasks (Ennaceur and Delacour 1988, Antunes and Biala 2012). To date, 
there is only one published study in which object recognition is examined in the APP-NL-F 
mouse: Izumi and colleagues reported that while female APP-NL-F mice explored novel 
objects significantly more than familiar at 9 months of age but not at 12 (Izumi et al. 2018). 
Their protocol involved a 24-hour delay between sampling and testing, which suggests that 
long-term memory (LTM) for object familiarity/novelty discriminations is impaired in 12-
month old APP-NL-F mice. The neural systems that support long- (as opposed to short) -term 
object novelty memory remains in dispute with some evidence suggesting LTM may 
require hippocampal NMDA receptors (Baker and Kim 2002). The question as to whether 
APP-NL-F mice display changes in memory for the spatial properties of objects at the same 
or earlier timepoint remains unclear. 
There are two published studies testing object recognition in the APP-NL-G-F mouse, 
in which the knocked-in Aβ sequence also contains the arctic mutation causing increased 
aggregation of peptides and cognitive deficits at an earlier timepoint. Whyte and colleagues 
(2018) reported a non-significant reduction in the discrimination by APP-NL-G-F mice 
compared to controls when tested at 6 months of age. Mehla et al (2019) also described no 
statistical difference at 6 months, however when tested at 9 and 12 months of age, the APP-
NL-G-F mice had developed a deficit in their ability to discriminate novel from familiar 
objects (Mehla et al. 2019). 
Non-Cognitive Phenotypes of Amyloid models 
Differences in non-cognitive behaviours such as anxiety or locomotive activity may 
confound analysis of performance if they alter the engagement of one group with the task. 
While the cognitive symptoms of Alzheimer Disease are well known, the majority of 
patients also suffer from emotional changes that include depression, aggression and anxiety 
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(Craig et al. 2005, Shin et al. 2005). Patients can often exhibit seemingly opposite 
symptoms, for example either apathy or agitation, and either increased anxiety or 
disinhibition (Chung and Cummings 2000). This makes predictions of murine phenotypes 
difficult: individual mice may mirror the variability in human patients and become either 
hypo- or hyperactive due to apathy or agitation, even showing opposite behaviour in 
different arenas, with similar potential in anxiety tests. Indeed, tests for locomotor activity 
and anxiety behaviour are highly variable even between studies using the same mouse 
model, making it impossible to draw overarching conclusions concerning the general 
phenotype of AD mice (Lalonde, Fukuchi, and Strazielle 2012). It was important to 
establish any differences in anxiety or locomotive behaviours in this specific cohort of mice 
because they may confound results of cognitive tasks by impacting on the animal’s 
propensity to interact with objects (Middei et al. 2006). If one genotype exhibits increased 
or decreased contact with objects in the sample phase, it may introduce a sampling bias 
whereby one group has had greater opportunity to encode an object. 
Investigation of anxiety and locomotor behaviours are frequently assessed using the 
Elevated Plus Maze and Open Field tests, which are two pieces of apparatus that allow 
rodents to express their natural exploratory activity. The Open Field is a simple square 
arena, while the EPM is a raised platform with four arms arranged in a cross. Two arms 
have high black walls and two are open to their surroundings. Both arenas include darker 
regions (the perimeter of the open field and the “closed” arms of the EPM, and normal 
animals will exhibit a preference to remain here rather than venture out into the open 
regions (Rodgers and Cole 1993). Measuring the amount of time each animal spends in 
these open regions allows a comparison of anxiety-like behaviour between groups. More 
anxious animals will spend less time in the open areas and vice versa for less anxious 
animals. Measurement of the total distance travelled by each animal allows comparison of 
locomotive activity. 
The literature surrounding non-cognitive phenotypes in Alzheimer mouse models 
is controversial. The most regularly tested transgenic model for locomotive activity is the 
Tg2576 mouse, which expresses the Swedish mutation. While there are some studies 
showing no effect, the prevailing result describes a hyperactive phenotype, potentially due 
to increased neuroinflammation evidenced by the increased activity being rescued by 
Ibuprofen treatment (Deacon et al. 2009, Lim et al. 2001). Anxiety results are similarly 
controversial: a review by Lalonde et al counted reports of reduced anxiety in 8 AD mouse 
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models out of the 12 that displayed sensitivity to the test.(Lalonde, Fukuchi, and Strazielle 
2012) The age at testing as well as various other environmental and methodological 
confounds offer potential reasons why comparisons of non-cognitive domains are so 
variable. 
While it is necessary to acknowledge the high level of variability between studies 
of anxiety phenotypes in AD models, it would be remiss not to briefly describe the current 
literature concerning the APP-NL-F and APP-NL-G-F knock-in models. Three studies have 
reported increased exploration of the EPM open arms by the APP-NL-G-F knock-in mouse, 
detected from as young as three months of age (Latif-Hernandez et al. 2019, Sakakibara et 
al. 2018, Pervolaraki et al. 2019). This indicates that reduced anxiety phenotypes reported 
in transgenic mice were not artefacts of APP overexpression. While the phenotype present 
in the APP-NL-G-F mice was not shown to be age dependent, this may have been due to the 
speed at which amyloid accumulates in this model and the lack of testing at younger age 
points. Sakakibara et al reported increased effect sizes when APP-NL-G-F mice were assessed 
at 15-18 months of age, but performance at the two age points were not statistically 
compared. The paradoxical, opposing, arena-dependent effects on anxiety were evident in 
the study by Pervolaraki and colleagues, which reported reduced anxiety of the APP-NL-G-F 
mice in the EPM, but increased anxiety when examined in the Open Field. Currently, there 
are no reports of altered anxiety or locomotor phenotypes in the APP-NL-F mouse, but this 
is potentially due to mice not being tested beyond 12 months of age (Izumi et al. 2018). 
Tests of locomotive activity in the APP-NL-G-F is again varied, with one study showing 
hypoactivity at 6 months; (Whyte et al. 2018) while two others found no difference 
compared to control mice up to 12 months of age (Latif-Hernandez et al. 2019, Mehla et 
al. 2019). 
The aim of this chapter is to first characterise any non-cognitive phenotypes in the 
APP-NL-F mouse model compared to WT littermates and then memory performance through 
a battery of object recognition-based tasks. Individual aims and hypotheses are presented 
during introductions to the relevant experiments. 
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4.3 Experiment 3: Anxiety & Locomotive Assessment 
▪ 4.3.1 – Introduction 
Assessments of anxiety and locomotor behaviour were undertaken at two age points 
with the aim of characterising any phenotype of the APP-NL-F knock-in mutations as well 
as any age dependent effects. Identifying any differences in performance would become 
important during analysis of cognitive test results. The hypothesis for this experiment was 
that the knock-in mice may develop anxiolytic behaviour when aged, spending more time 
exploring the open arms of the EPM. This prediction was derived from evidence that the 
more aggressive pathology in the APP-NL-G-F model generated reduced anxiety as young as 
three months of age. The lack of phenotype currently identified in APP-NL-F literature may 
be due to the fact they have not been tested at >12 months of age. Therefore, we 
hypothesised that at 16 months old, amyloid pathology would have developed to a level 
similar to that found in young APP-NL-G-F mice, and we would observe a decrease in anxiety 
behaviours. We did not expect to see differences in locomotor behaviour because no robust 
phenotype has been described in either the APP-NL-F or APP-NL-G-F. 
▪ 4.3.2 – Experiment 3 Methods 
Subjects 
This experiment involved male APP-NL-F and WT mice who were tested twice: at 
both 6-8 and 16-17 months old. The total number of mice in each group was 32 (WT) and 
38 (APP-NL-F). These mice underwent extensive handling and testing in other behavioural 
paradigms following the first time-point measured in these experiments.  
Apparatus 
 The elevated plus maze consisted of a white floored platform 75 cm above the 
ground with four arms arranged in a cross (figure 4.2). Arms were 40 cm long and 7 cm 
wide, and were symmetrical in that those opposite one another were of the same design. 
Two arms were “open” meaning they had 1cm high walls allowing mice to see over them 
to the room and floor. The other arms were “closed”, they had 15 cm high black walls 
restricting any view. The open field arena and procedure was described in Chapter 2 as it 
is relevant to multiple chapters in this thesis. 
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Procedure 
The maze was thoroughly cleaned with 70% ethanol wipes before testing each 
mouse, to remove any odour cues. Mice were picked up in a cardboard tube from their 
home cage and placed in the centre of the maze, facing the same open arm each time. They 
were allowed to freely explore for 5 minutes, recorded by a camera overhead connected to 
a laptop. Recordings of each mouse’s activity were taken and tracked by EthoVision XT 
13 software. An “arena” was drawn around the maze in the videos, identifying the open & 
closed arms as distinct zones. Entry into the open arms was defined as all three body points 
of nose, centre and tail base being in the open arm zone. An exploration ratio was calculated 
for each mouse as the amount of time spent in the open arms divided by the total time in 
the maze (300s). 
  
Figure 4.2: Photo of the elevated plus maze apparatus. The EPM was a raised 
platform with two open arms and 2 closed arms. Normal mice will spend a greater 
amount of time in the closed arms. 
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▪ 4.3.3 – Experiment 3 Results 
Elevated Plus Maze 
 Performance of APP-NL-F & WT mice in the elevated plus maze (EPM) was 
analysed by calculation of the time spent in the open arms as a ratio of total time in the 
maze. The data is displayed in figure 4.3 A. Visual inspection suggested that there was a 
small increase in open arm exploration by the APP-NL-F mice compared to the WT mice. 
Furthermore, exploration appeared to decrease with age in both groups. However, these 
impressions were not confirmed by statistical analysis. A 2-way mixed ANOVA was 
performed with age as a within subjects’ factor and genotype as the between-subject factor. 
There was no significant main effect of age F(1,68) = 3.65, p=0.06; no main effect of 
genotype F(1,68) = 0.959, p=331 and no age*genotype interaction F(1,68) = 0.002, 
p=0.965. 
 The total distance moved by each mouse was calculated as a measure of general 
locomotive activity in the apparatus, Figure 4.3 B. Data were analysed by a 2-way mixed 
measures ANOVA, which did not reveal significant main effects of age F(1,68) = 0.099, 
p=0.754; or genotype F(1,68) = 0.452, p=0.504; and there was no age*genotype interaction 
F(1,68) = 0.055, p=0.816. 
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Figure 4.3: Elevated plus maze results for APP-NL-F and WT mice.  
(A) The ratio of time spent in the open arms as a ratio of the total time spent in the maze. 
(B) Mean distance travelled by the mice throughout exploration of the EPM. Error bars 
show the standard error of the mean (SEM). WT n=32, APP-NL-F n=38 
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Open Field 
 The Open Field test was used to compare general locomotive activity in the WT 
and APP-NL-F mice, as well as for a secondary assessment of anxiety related behaviour. The 
mean total distance travelled by the mice in each group is presented in figure 4.4 A. The 
Shapiro-Wilke test identified violations of distributional normality. The data was therefore 
transformed by taking the inverse of each score, to remedy the violations. It was then 
analysed by a 2-way mixed measures ANOVA with age and genotype as factors. The 
ANOVA revealed a significant main effect of age F(1,68) = 29.1, p<0.0005, as both WT 
& APP-NL-F mice showed lower locomotive activity at the older time point. There was no 
main effect of genotype F(1,68) = 0.236, p=0.629; and no age*genotype interaction F(1,68) 
= 0.886, p<0.350. 
 The central 30 x 30 cm square of the arena was described as the “inner zone”. The 
amount of time each mouse spent within this zone was recorded and expressed as a ratio 
of total exploration time. The results are displayed in figure 4.4 B. Some of the datasets 
were not normally distributed (S-W p<0.05), so were transformed by square root 
transformation. The data was analysed by a mixed measures ANOVA with age as a within 
subjects’ factor and genotype as the between subjects’ factor. There was a significant main 
effect of age F(1,68) = 4.4, p=0.039, but no main effect of genotype F(1,68) = 0.061, 
p=0.806; or age*genotype interaction F(1,68) = 0.961, p<0.330. 
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Figure 4.4: Open field (OF) results for APP-NL-F and WT mice. (A) Total distance moved 
by each genotype at two age-points. (C) Ratio of time spent in the inner zone out of total 
time in the arena. Error bars show the standard error of the mean. *p<0.05, mixed measures 
ANOVA. WT n=32, APP-NL-F n=38. 
 
* 
* 
[104] 
▪ 4.3.4 – Experiment 3 Discussion 
 The aim of this experiment was to determine if APP-NL-F mice show 
anxiety/locomotor changes that may interact with age and thus amyloid pathology. The 
knock-in mice were tested in the Elevated Plus Maze and Open Field and compared to 
Wild-Type littermates at two age points. This was the first study to assess these behaviours 
in the APP-NL-F model at >12 months of age. The results revealed no effect of genotype at 
either 7-8 or 16-17 months on preference for the closed vs open arms of the plus maze or 
locomotive activity.  Comparisons with other APP-NL-F studies are limited, because they 
did not test the mice any older than 12 months. However, it is worth noting that Pervolaraki 
et al (2019) observed no effects in the EPM or Open Field at 8 months, and that their results 
correspond with those reported here. Izumi et al (2018) similarly reported no locomotor 
phenotype in the Open Field. The hypothesis that anxiolytic behaviour may develop with 
age did not come to fruition indicating that even at 17 months old, the amyloid pathology 
in the APP-NL-F model was not great enough to induce changes in this behaviour. This 
presents further evidence that this model has a milder phenotype than the triple knock-in 
APP-NL-G-F  mouse, which has had anxiolytic behaviour reported from as young as 3 months 
of age.(Latif-Hernandez et al. 2017, Sakakibara et al. 2018, Pervolaraki et al. 2019) As this 
mouse has a more aggressive pathology and phenotype, it remains to be seen whether the 
APP-NL-F mice would ever go on to develop a measurably reduced anxiety with more severe 
amyloidosis, or whether the reported phenotype is specific to the APP-NL-G-F mice.  
Effects of age were more apparent in these experiments, and highlighted an 
interesting dichotomy for the effect of age on exploration of the two anxiogenic zones in 
the separate apparatus. Aged mice in the EPM showed a trend for lower exploration of 
open arms, but were significantly more likely to enter the inner zone of the open field. This 
phenomenon of seemingly opposite effects is not uncommon, in fact has recently been 
described by one study of the APP-NL-G-F mice.(Pervolaraki et al. 2019) There are several 
potential explanations for the difference in results in this study, particularly the fact that 
the mice receive greater exposure to the open field arena. Following the open field test at 
8 months, the mice undertook extensive cognitive tests in the same arena. However, the 
EPM is only encountered in a single trial. The extra habituation to the open field arena 
while at 8-10 months could explain the lowered anxiety exhibited by the mice independent 
of genotype when tested at 16 months. Furthermore, exploration in the EPM has been 
shown to fall during repeated exposure.(Bertoglio and Carobrez 2000, Carobrez and 
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Bertoglio 2005) Similarly, there was a significant drop in locomotor activity in the Open 
Field due to age, across both genotypes. This was to be expected, as C57Bl/6 mice are 
known to exhibit reduced activity over the course of their lifespan (Dean et al. 1981). 
In summary, these experiments did not reveal any differences between the 
genotypes in terms of their anxiety or locomotive behaviours and there also were no 
changes in their responses to age. There was a general decrease in activity when the mice 
were tested at the aged timepoint which is common, especially after factoring in the effect 
of repeated testing. The lack of genotype effects will ensure that any differences in 
cognitive performance cannot be attributed to variations in the behaviours tested in this 
experiment. 
4.4 Experiment 4: Object Novelty Memory in APP-NL-F Mice 
▪ 4.4.1 – Introduction 
The dearth of studies of object recognition in the APP-NL-F knock-in mouse 
highlights the need for a further systematic investigation. The current study used different 
object memory tasks to assess the age-of-onset and nature of cognitive changes in APP-NL-
F mice. The aim of experiments 5 to 9 was to test the APP-NL-F mice on a battery of object 
memory tasks designed to interrogate different attributes of object memory, in order to 
identify which phenotypes and thus putative neural systems were sensitive to beta-amyloid 
aggregation in APP-NL-F mice. Four object arrays were used for both the ON and OiP tasks, 
to ensure that they were of comparable complexity. This information will provide 
assessment of changes in medial temporal lobe-frontal networks. Due to the admittedly 
limited evidence, the hypothesis was that the APP-NL-F mice would exhibit an age-related 
decline in memory for object identity. The aim of these experiments was to broaden the 
understanding of recognition processes in this model by assessing whether hippocampal 
dependent associative memory shows a similar pattern of decline. 
▪ 4.4.2 – Methods 
Subjects & Design 
Male APP-NL-F (N=16) mice were tested and compared to male WT (N=16) cage mates 
at 8-10 and 16-17 months of age in experiments 5 and 6. The apparatus, habituation 
protocol and scoring method for the object recognition tasks is described in Chapter 2. 
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The experiments were designed to reduce impact of variables such as task order, 
time of day, object set and the identity/location of the novel object, by counterbalancing 
between and within the two periods of testing. For example, the mice were split into two 
groups which received object sets 1 & 2 at 8-10 months and sets 3 & 4 at 16-17 months, or 
vice versa. The order of ON and OiP tests performed, as well as the object sets, were 
counterbalanced within both groups. Figure 4.5 is a schematic depicting a representative 
protocol for two non-paired mice within the same group. 
Procedure 
The ON and OiP protocols were described in Chapter 2 of this thesis, with a note 
that the object array varies between experiments. Both tasks used a four-object array here. 
Briefly, the protocols involved 3 sample phases of 10-minutes duration each with a 5-
minute delay interval. Another 5-minute delay preceded the test phase, in which two 
objects either had their location switched (OiP) or were replaced with two novel objects 
(ON). A cartoon depicting the OiP and 2-object ON protocols is shown in figure 4.1. The 
object novelty test in this experiment uses 4 different objects in the acquisition phase and 
two new different objects are added for the test phase (figure 4.6). 
Figure 4.5: Experimental design of the counterbalanced object novelty (ON) and 
object-in-place (OiP) tests. Each vertical line represents a new day. The truncated lines 
are rest days. Each mouse performed this protocol at 8-9 and 16-17 months-of-age. 
Object 
Novelty 
Sample Phase Test Phase 
Figure 4.6: Cartoon depicting the object-novelty protocol using four-object array. 
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Statistical Analysis 
 Discrimination Ratios (DRs) were calculated via the equation below. All statistical 
testing was performed with SPSS and is described in Chapter 2. 
Total time spent exploring “Novel” object 
Total time spent exploring all (Novel + Familiar) objects 
 
▪ 4.4.3 – Experiment 4 Results 
Sample Phase Contact Times 
The total interaction time with all four objects throughout the sample phases at 8-9 
and 16-17 months is shown in table 4.2. The Shapiro-Wilke test revealed that all datasets 
were normally distributed, while Levene’s test confirmed that there was homogeneity of 
variances (p>0.05). Mauchley’s test of sphericity reported that the assumption of sphericity 
was met for the sample phase factor (p>0.05). The data were analysed by three-way 
repeated measures ANOVA, with age, sample phase and genotype as factors. 
The ANOVA revealed a significant main effect of age F(1,30) = 8.9, p=0.006, and 
a main effect of phase F(2,60) = 18.1, p<0.0005. There was no main effect of genotype 
F(1,30) = 0.092, p=0.763. There was a significant age*phase interaction F(2,60) = 4.927, 
p=0.01. No other interactions or main effects were significant: age*genotype F(1,30) = 
0.24, p=0.629; phase*genotype F(2,60) = 0.522, p=0.596; age*phase*genotype F(2,60) = 
0.34, p=0.710. 
Tests for simple main effects within the significant age*phase interaction revealed 
that there was increased contact time for all mice in sample phases 1 & 2 at the older 
timepoint (phase 1 p<0.0005; phase 2 p=0.016), but not sample phase 3 (p=0.548). There 
was also a significant simple main effect of phase on contact time at 8-10 months between 
phases 1 & 3, but not between 1 & 2 or 2 & 3 (1 vs 2 p=1; 1 vs 3 p=0.049; 2 vs 3 p=0.07). 
At 16-17 months, while there was no difference in contact time between phases 1 & 2, 
there was a significant drop in exploration between phases 2 & 3 and 1 & 3 (1 vs 2 p=0.493, 
1 vs 3 p<0.0005; 1 vs 2 p<0.0005). 
Collectively, analysis of this data revealed that all mice spent more time interacting 
with objects at the older time point during sample phases 1 & 2, when collapsed over 
= DR 
[108] 
genotype. There was also a general reduction in exploration over the course of the three 
sample phases, as mice habituated to the objects in the arena and provides evidence 
consistent with the view that WT and APP-NL-F mice across all ages were able to process 
information about the objects. 
 
Test Phase Contact Times 
Figure 4.7 shows contact times with novel or familiar objects in the test phase for WT 
and APP-NL-F mice at 8-10 and 16-17 months old. The figure shows that, at both ages, both 
the WT and APP-NL-F mice spent more time interacting with the novel object compared to 
the familiar. High variability of contact times resulted in the Shapiro-Wilke test revealing 
violations of normality of the distributions (p<0.05). A Square Root transformation of the 
data removed the violations (p>0.05) and it was analysed by a repeat measures ANOVA 
with age, object type and genotype as factors. 
The ANOVA revealed a significant main effect of object type F(1,30) = 408, p<0.0005. 
There was no main effect of age F(1,30) = 0.26, p=0.616; or genotype F(1,30) = 0.414, 
p=0.525. There was no significant interactions: age*genotype*object, F(1,30) = 0.19, 
p=0.666; age*genotype F(1,30) = 2.54, p=0.121; age*object F(1,30) = 0.45, p=0.507;  
object*genotype F(1,30) = 0.55, p=0.463. 
 
ON Sample Phase Contact Times 
 WT APP-NL-F 
Age/ Months 8 - 10 16 - 17 8 - 10 16 - 17 
Sample 
Phase 1 
Mean 58.7 78.6 60.1 72.9 
SD 19.7 20.5 15.0 18.8 
Sample 
Phase 2 
Mean 55.1 69.2 58.5 68.9 
SD 22.6 25.8 21.0 25.3 
Sample 
Phase 3 
Mean 52.6 54.9 48.5 51.3 
SD 18.1 19.0 19.6 15.6 
Table 4.2: Mean contact times (seconds) for WT and APP-NL-F mice in the object 
novelty (ON) task across two age-points. SD (standard deviation of the mean). n=16 
for both groups. 
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Discrimination Ratios 
The interaction with the familiar or novel objects was converted into a discrimination 
ratio to take into account the individual variation in contact times between mice. These 
ratios are shown in figure 4.8. None of the datasets violated the assumptions of normal 
distributions (Shapiro-Wilke test p>0.05), or homogeneity of variances (Levene’s test 
p>0.05). A mixed measures ANOVA was performed on the data with age and genotype as 
factors. There was no interaction between age*genotype F(1,30) = 0.018, p=0.895. There 
was no main effect of genotype F(1,30) = 0.155, p=.697; and no main effect of age F(1,30) 
= 0.218, p=0.895. 
One sample t-tests performed on all four groups showed that they were all significantly 
above 0.5. WT at 9 months and 17 months t(15)=12.3 and 13.9, p<.0005 and APP-NL-F at 9 
and 17 months t(15)=11.8 and 17.1, p<0.0005, respectively. These data show that the WT 
and APP-NL-F mice both maintain intact ability to recognise novel objects at a comparable 
efficiency up to 17 months of age. 
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Figure 4.7: Mean contact times of WT and APP-NL-F mice for familiar or novel 
objects in the test phase of the object novelty task. WT and APP-NL-F contact time 
at two age points with error bars showing SEM. N=16 for all groups. 
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4.5 Experiment 5: Object-in-Place Memory in APP-NL-F Mice 
▪ 4.5.1 – Experiment 5 Results 
Sample Phase Contact Times 
Table 4.3 shows the average contact time with all objects through the OiP sample 
phases for both WT and APP-NL-F mice at 8-10 & 16-17 months of age. Inspection of the 
data suggests there was increased interaction with objects at the older timepoint, while in 
all groups, contact times decreased through the sample phases. All datasets were normally 
distributed (S-W test p>0.05), so the data were analysed by a three-way repeated measures 
ANOVA with age, sample phase and genotype as factors. 
The ANOVA displayed a significant main effect of age F(1,30) = 16.3, p<0.0005, 
and a main effect of phase F(2,60) = 46.4, p<0.0005. There was also a significant age*phase 
interaction F(2,60) = 10.1, p<0.0005. There was no main effect of genotype F(1,30) = 0.23, 
p=0.633. There were no further significant interactions: sample phase*genotype F(2,60) = 
0.20, p=0.816; age*genotype F(1,30) = 2.14, p=0.154; age*phase*genotype F(2,60) = 0.75, 
p=0.479. 
0.4
0.5
0.6
0.7
0.8
8 - 10 Months 16 - 17 Months
M
ea
n
 D
is
cr
im
in
at
io
n
 R
at
io
ON Discrimination Ratio
WT
NLF
Figure 4.8: APP-NL-F mice display intact object novelty recognition up to 17 
months of age. Discrimination ratios (DR) for WT and APP-NL-F mice in the object 
novelty (ON) task at two age-points. The black bar represents 0.5 or no object 
preference. Error bars show SEM. N=16 for all groups. 
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The significant age*phase interaction revealed a simple main effect of age: when 
collapsed over genotype, the amount of object exploration increased with age in sample 
phases 1 (p<0.0005) and 2 (p=0.024), but not 3 (p=0.053). There were also simple main 
effects of sample phase within each timepoint independent of genotype. At 8-10 months, 
object contact time significantly decreased between phases 1 & 3 (p<0.0005), but not 
between phases 1 & 2 (p=0.56) or phases 2 & 3 (p=0.08). At 16-17 months, there was a 
significant difference between exploration between all phases: 1 vs 2 p<0.0005; 1 vs 3 
p<0.0005; 2 vs 3 p=0.003. 
Altogether, the analysis of object interaction through the three sample phases of the 
OiP task demonstrated a significant drop in contact time from the 1st and 3rd phases when 
collapsed over genotype. There were no effects of genotype on contact times through the 
sample phases. 
Test Phase Contact Times 
The exploration of objects in either the same or different spatial locations was 
averaged for each group and these means are shown in figure 4.9. The table reveals that at 
8-10 months, both genotypes spent more time with the objects that had switched locations. 
In contrast, at 17 months of age, only the WT exhibited this preference. All of the groups 
were normally distributed (Shapiro-Wilke test p>0.05), and there was homogeneity of 
variance (Levene’s test p>0.05).  
 
OiP Sample Phase Contact Times 
 WT APP-NL-F 
Age/ Months 8 - 10 16 - 17 8 - 10 16 - 17 
Sample 
Phase 1 
Mean 60.5 90.9 61.9 85.0 
SD 18.5 24.3 16.0 24.2 
Sample 
Phase 2 
Mean 55.7 76.6 60.5 64.0 
SD 23.0 23.4 26.2 20.3 
Sample 
Phase 3 
Mean 49.1 61.4 52.2 55.7 
SD 12.9 19.0 21.9 13.8 
Table 4.3 Mean contact times (seconds) for both WT & APP-NL-F in the object in 
place task at the two age points. Standard deviation of the means is also shown. 
N=16 for all groups. 
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The data were analysed by a repeated measures ANOVA with age, genotype and object 
type (novel vs familiar object-place association) as factors. There was a significant 
age*genotype*object interaction F(1,30) = 6.4, p=0.017. There were also significant 
object*genotype F(1,30) = 32.1, p<0.0005, and age*object interactions F(1,30) = 11.8, 
p=0.002. There was no significant age*genotype interaction F(1,30) = 2.2, p=0.150. There 
was a significant main effect of object type F(1,30) = 139.3, p<0.0005 and no other 
significant main effects were reported: age F(1,20) = 0.21, p=0.649; genotype F(1,30) = 
2.82, p=0.103. 
Tests for simple main effects following the significant age*genotype*object type 
interaction revealed that both genotypes exhibited a significant preference for interaction 
with objects in novel locations at 9 months of age (p<0.0005). However, at 17 months, only 
the WT mice showed this difference (p<0.0005; APP-NL-F : p=.496). Furthermore, aged 
APP-NL-F mice interacted with the objects in novel spatial locations less than the aged WT 
mice (p<0.0005). The two genotypes displayed no differential exploration of objects in the 
familiar arrangement at this aged timepoint (p>0.5) and there was no effect of genotype on 
the amount of exploration of either pair of objects at 9 months (p<0.5). APP-NL-F mice had 
significantly less interaction with objects in a novel object-place association at 17 versus 9 
months (p=0.026). There was no significant simple main effect of age for the APP-NL-F 
exploring familiar object-place associations (p=0.060), and no effect on either object 
category for the WT (p=0.473 for novel, 0.062 for familiar). 
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Discrimination Ratios 
Discrimination ratios (DRs) were calculated from each mouse’s exploration of objects 
observed in either novel or familiar arrangements, these were then averaged for each 
genotype at each timepoint and are shown in figure 4.10. All four datasets had normal 
distributions (S-W p>0.05), and were analysed by repeated measures ANOVA. There was 
a significant age*genotype interaction, F(1,30)=14.0 p=0.001, a significant main effect of 
age F(1,30) = 21.4, p<0.0005 and a significant main effect of genotype F(1,30) = 37.3, 
p<0.0005. 
Analysis of simple main effects revealed that, at 9 months old, there was no difference 
in performance of the two genotypes (p=0.267). However, at 17 months, WT mice showed 
a significantly higher preference for objects in a novel location compared to the APP-NL-F  
group (p<0.0005). In addition, there was no simple main effect of age on the WT group’s 
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Figure 4.9: Mean contact times (seconds) of aged WT and APP-NL-F mice in the 
object-in-place (OiP) test phase at two age-points. Contact with objects that had 
either remained in the same or had been switched into different positions is shown. Error 
bars show SEM. N=16 for all groups. ***p<0.001, mixed measured ANOVA. 
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discrimination ratios (p=0.534), while the performance of APP-NL-F mice significantly 
deteriorated with age (p<0.0005). 
One-sample t-tests confirmed that at 9 months of age, both groups discriminated 
significantly above chance (WT: t(15)=9.6, APP-NL-F : t(15)=7.6, both p<0.0005). But at 17 
months old, only the WT mice discriminated above chance t(15) = 9.3, p<0.0005, APP-NL-
F mice failed to discriminate t(15) = -1.381, p=0.188. 
Analysis of these data shows that, at 9 months old, both genotypes exhibited preference 
for exploring objects in  new locations compared to those objects which were presented in 
the same place as during the sample phases. WT mice maintained this ability at 17 months. 
However, the APP-NL-F mice developed an age-dependent deficit in the ability to 
discriminate object-place associations.  
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Figure 4.10: APP-NL-F mice display an age-dependent deficit in object-in-place 
memory. Mean discrimination ratios (DR) calculated from the contact times of WT and 
APP-NL-F mice with objects that had either switched spatial locations or remained in the 
same place during the test phase of the object-in-place (OiP) task. While there was 
comparable performance at 8-10 months-of-age, APP-NL-F mice showed significantly 
worse discrimination at 16-17 months-of-age compared to WT controls. Error bars 
represent SEM. N=16 for all groups. ***p<0.001, Mixed measures ANOVA. 
*** 
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4.6 Experiment 6: Object Location Memory in APP-NL-F Mice 
▪ 4.6.1 – Introduction  
Experiments 5 and 6 revealed an age-dependent deficit in memory for object place 
associations, while recognition of object identity remained intact. In order to characterise 
the specific nature of the deficit, the mice underwent further tests of associative and non-
associative recognition. Considering the failure to recognise novel object-place 
associations, it was hypothesised that the APP-NL-F mice were demonstrating hippocampal 
dysfunction. Therefore, they were tested on two further hippocampal dependent tasks 
investigating Object Location and Temporal Order memory with the prediction that their 
performance in both tasks would be significantly worse than WT controls. Since the 
Temporal Order (TO) task required the capacity to encode object identities over a single 
sample session and Izumi et al reported an age-dependent deficit using a similar protocol, 
a second object novelty experiment was performed (Izumi et al. 2018). Successful 
performance in this task was a prerequisite before conclusions could be drawn concerning 
the TO results. In order to ensure that any changes detected in performance of the aged 
APP-NL-F mice were due to age and not genotype, a separate cohort of young mice were 
also assessed on these three tasks. 
▪ 4.6.2 – Methods  
Subjects & Design 
Experiments 7a, 8a and 9a tested the same cohort of male APP-NL-F and WT cage 
mates as described in experiments 5 & 6. However, one WT mouse died before performing 
these tasks and so the group sizes were 16 (APP-NL-F) and 15 (WT). Experiments 7b, 8b 
and 9b involved a separate cohort of APP-NL-F (n=9) and WT (n=9) mice that were 4 months 
of age. These mice were tested alongside the aged cohort to provide evidence of 
performance in these tasks at a younger time-point. All mice performed the novel location 
task then the object novelty with 4-hour delay and finally the temporal order task, having 
a rest day between the tests. 
  
[116] 
Procedure 
Object Location 
 Object Location recognition was assessed via the same 3x 10-minute sample phase 
protocol as the ON & OiP tasks. However, this protocol used 2 identical objects positioned 
in adjacent corners, 25 cm apart. During the 5-minute delay before the 10-minute test 
phase, one object was moved to the corner diagonally opposite the familiar positioned 
object, as shown in figure 4.1. The novel spatial location was counterbalanced for all 
corners. 
ON with 4-Hour Delay 
 The temporal order (TO) procedure relied upon information about objects after only 
one sample phase and after a 4-hour delay. Given published evidence that APP-NL-F mice 
may be sensitive to object memory deficits at long delays, the same mice were tested on an 
object recognitions paradigm with the same parameters. Mice were placed in the arena to 
explore two identical objects for 10 minutes. After a delay of 4 hours spent in their home 
cages, the mice were returned to the arena which contained one object from the sample 
phase and a novel object.  
Temporal Order 
 The ability of mice to discriminate the temporal order of objects involved a two-
stage sampling procedure, as shown in figure 4.1. Mice were presented with two identical 
objects for 10 minutes in sample phase A. They were then returned to their home cage for 
an interval of 1 hour after which they were returned to the arena and were presented with 
two new identical objects in sample phase B (which lasted 10 minutes). The animals were 
then returned to their home cage for an interval of 3 hours, after which the mice returned 
to the arena for a 10-minute test phase. In the test phase, the mice were presented with one 
object from each sample phase. WT mice were expected to show a preference for exploring 
the object seen least recently, i.e., the object seen in sample phase A. Two object sets (two 
pairs of identical objects) were counterbalanced between the ON and TO tasks, as well as 
the identity and spatial location of the novel / less recently encountered object 
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▪ 4.6.3 – Experiment 6a Results  
Sample Phase Contact Times 
 Table 4.4 shows the average contact time with both identical objects through the three 
sample phases for the aged cohort during the object novel location task. The data was 
analysed by a repeated measures ANOVA with sample phase as a within subjects factor 
and genotype as the between subjects factor. There was a significant main effect of phase 
F(2,58) = 3.76, p<0.029 but no effect of genotype F(1,29) = 0.16, p=0.693 and no 
significant phase*genotype interaction F(2.58) = 0.29 p=0.75. The main effect of phase 
revealed a significant drop in contact time between phases 1 & 2 (p=0.045), but not 
between phases 1 & 3 (p=0.096) and 2 & 3 (p=1), when both genotypes were combined.  
 
 
 
 
 
Test Phase Contact Times 
Inspection of Figure 4.11 suggests that, while both genotypes preferentially 
interacted with the object in a novel location, APP-NL-F mice showed lower overall contact 
with the objects than WT mice. The Shapiro-Wilke test revealed that not all datasets were 
normally distributed (p<0.05). This was remedied by log10 transformation of both groups. 
A repeated measures ANOVA with object location (within subjects) and genotype 
(between subjects) as factors revealed a significant main effect of object location (novel vs 
familiar): F(1,29) = 65.0, p<0.0005. There was no effect of genotype F(1,29) = 1.2, p=0.28 
or significant interaction F(1,29) = 0.01, p=0.92. Together this analysis shows that both 
groups showed a strong preference for exploration of the object that had been moved to a 
novel spatial location. 
 OL Sample Phase Contact Times 
  Aged WT Aged  APP-NL-F 
Sample Phase 
1 
Mean 37 36 
SD 11 12 
Sample Phase 
2 
Mean 32 28 
SD 20 13 
Sample Phase 
3 
Mean 30 30 
SD 20 13 
Table 4.4: Mean contact times (seconds) for aged mice through the sample phases 
in the object location task. Standard deviation of the mean (SD) is also shown. 
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Discrimination Ratios 
Figure 4.12 shows the average discrimination ratios calculated from the preference 
of aged mice to explore the object in a novel location. The distribution of all groups was 
normal and an independent t-test was carried out to compare them. There were no 
significant differences t(29) = 0.06, p=0.953. One sample t-tests showed that both 
genotypes interacted significantly more with the object in a novel location: aged WT 
t(14)=7.1; aged APP-NL-F t(15)=5.6; both p<0.0005. Collectively, these analyses show that 
aged APP-NL-F and WT mice successfully and equally discriminated between the objects 
that had or had not moved to a new spatial location and there was no effect of genotype.   
Figure 4.11: Mean contact times of aged mice in the test phase of the object location 
(OL) task. Contact (seconds) with the object in either a novel or familiar location in the 
test phase is depicted alongside the SEM. WT n=16, APP-NL-F n=15. N=9 for both groups. 
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▪ 4.6.4 – Experiment 6b Results  
Sample Phase Contact Times 
Table 4.5 shows the average contact time with both identical objects through the three 
sample phases for 4-month-old mice in the object novel location task. Some of the datasets 
violated the assumption of normal distribution (S-W p<0.05), and this violation was 
repaired by log10 transformation of both groups for all phases. The data was analysed by 
a repeat measures ANOVA with sample phase as a within subjects factor. There was a 
significant main effect of phase F(2,32) = 17.0, p<0.0005. There was no significant main 
effect of genotype F(1,32) = 0.001, p=0.977 or significant phase*group interaction F(1,32) 
= 0.35 p=0.704. The main effect of phase revealed a significant drop in contact time 
between phases 1 & 2 and 2 & 3 (p<0.0005), but no difference between phases 2 & 3 
(p=0.45). 
 
 
 
 
 
  
 OL Sample Phase Contact Times 
 WT APP-NL-F 
Sample 
Phase 1 
Mean 62 57 
SD 30 7 
Sample 
Phase 2 
Mean 51 43 
SD 32 15 
Sample 
Phase 3 
Mean 42 39 
SD 23 8 
Figure 4.12: Aged APP-NL-F mice show intact object location memory. Mean 
discrimination ratios (DR) of aged WT (n=16) and APP-NL-F (n=15) mice in the object 
location (OL) task. Error bars show SEM. 
Table 4.5: Mean contact times (seconds) by 4-month-old mice with both objects 
through the sample phases in the object location task. Standard deviation of the 
mean (SD) is also shown. n=9 for both groups. 
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Test Phase Contact Times 
Figure 4.13 depicts how 4-month-old APP-NL-F and WT mice explored objects that 
had either moved to a novel position or remained in the same spatial location they inhabited 
during the sample phases. The Shapiro-Wilke test revealed that not all datasets were 
normally distributed. This was remedied by log10 transformation (p<0.05). A repeated 
measures ANOVA with object location (within subjects) and genotype (between subjects) 
as factors revealed significant main effects of object location F(1,16) = 73, p<0.0005 but 
not genotype F(1,16) = 0.233, p=0.636. There was no significant interaction F(1,29) = 
0.139, p=0.715. Together this analysis shows that both genotypes showed a strong 
preference for exploration of the object that had been moved to a novel spatial location. 
 
Discrimination Ratios 
Figure 4.14 shows the average discrimination ratios calculated from the preference of 
4-month-old mice to explore the object in a novel location. The distribution of groups was 
normal and an independent t-test was carried out to compare them. There were no 
significant differences t(16) = -0.482,p=0.759. One sample t-tests showed that both 
genotypes interacted significantly more with the object in a novel location: young WT t(8) 
= 7.6; young APP-NL-F  t(8) = 6.9; both p<0.0005. Collectively, these analyses show that at 
4 months of age APP-NL-F mice successfully discriminated object that had moved to a new 
spatial location to an equal level as WT controls. 
Figure 4.13: Mean contact times for 4-month-old WT and APP-NL-F mice in the 
object location (OL) task. Contact (seconds) with the object in either a novel or 
familiar location is depicted alongside the SEM. N=9 for both groups. 
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4.7 Experiment 7: Object Novelty with 4-Hour Delay  
▪ 4.7.1 – Experiment 7a Results 
Sample Phase Contact Times 
The temporal order task required recognition of an object after a single sample phase 
and 4-hour delay. The mean contact time of the aged APP-NL-F & WT mice in the sample 
phase (table 4.6) were analysed by an independent t-test comparing the two genotypes. The 
t-test returned no significant difference t(29) = 0.171, p=0.866. 
 
 
 
4Hr ON Sample Phase Contact Times 
  Aged WT Aged APP-NL-F 
Sample 
Phase 1 
Mean 47 45 
SD 21 15 
Table 4.6: Mean contact time (seconds) of aged WT and APP-NL-F mice in the sample 
phase of the 4-hour object novelty task, alongside the standard deviation (SD). n=16 (WT), 
n=15 (APP-NL-F). 
Figure 4.14: 4-month-old APP-NL-F mice display comparable performance in the 
object location task to WT controls. Mean discrimination ratios (DR) for 4-month-old 
WT and APP-NL-F in the object location task. Error bars show SEM, n=9 for both groups. 
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Test Phase Contact Times 
Contact with the novel or familiar object was averaged in each group and is 
presented in figure 4.15. The data were transformed by square root in order to restore any 
violations of normality (S-W p>0.05), and analysed by repeat measures ANOVA with 
mouse group and object type as factors. The analysis revealed a significant main effect of 
object type F(1,29) = 48.9, p<0.0005. There was no effect of group F(1,29) = 0.003, 
p=0.958 and no interaction F(1,29) = 0.024, p=0.878. 
 
Discrimination Ratios 
The contact times were converted to a discrimination ratio to take into account the 
differences between groups. These are shown in figure 4.16. The two groups were 
compared by an independent t-test which found no significant difference t(29) = -0.59, 
p=0.561. One-sample t-tests revealed that both genotypes discriminated the novel object 
significantly greater than at chance level (0.5). WT t(14) = 5.1 p<0.0005; APP-NL-F t(15) = 
7.4, p<0.0005. Collectively, these analyses show that at 17 months of age, APP-NL-F mice 
maintained the ability to discriminate a novel from familiar object 4 hours after one sample 
phase and did so at a comparable level to WT controls.  
Figure 4.15: Mean contact times (seconds) of aged WT and APP-NL-F mice in the 
object novelty (ON) task with 4-hour delay test phase. WT n=16, APP-NL-F n=15. 
Error bars represent SEM. 
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▪ 4.7.2 – Experiment 7b Results  
Sample Phase Contact Times 
A separate cohort of 4-month-old APP-NL-F and WT were assessed on the object novelty 
task with 4-hour delay. Table 4.7 shows the mean contact time in the sample phase. Both 
groups were transformed by square root to ensure normal distributions. The two groups 
were compared by independent t-test, which revealed no significant difference                   
t(16) = -0.24, p=0.811.  
 
 
 
 
4Hr ON Sample Phase Contact Times 
  Young WT Young APP-NL-F 
Sample 
Phase 1 
Mean 61 67 
SD 20 40 
Table 4.7: Mean contact time (seconds) for 4-month-old mice in the sample phase 
of the 4-hour object novelty task, alongside the standard deviation (SD) . n=9 for both 
groups. 
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Figure 4.16: Aged APP-NL-F mice display comparable performance in the 4-hour 
object novelty task to WT controls. Mean discrimination ratios (DR) for aged WT 
and APP-NL-F mice in an object novelty (ON) task following a 4-hour delay. Ratios were 
calculated from the contact time when investigating a novel or familiar object. WT 
n=16, APP-NL-F n=15. Error bars represent SEM. 
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Test Phase Contact Times 
Contact with the novel or familiar object in the test phase was averaged in each 
group and is presented in figure 4.17. The data were analysed by repeat measures ANOVA 
with mouse group and object type as factors. The analysis revealed a significant main effect 
of object type F(1,16) = 24.5, p<0.0005. There was no effect of group F(1,16) = 0.019, 
p=0.891 and no interaction F(1,16) = 0.053, p=0.821. This analysis shows that both 
genotypes preferentially explored the novel object. 
 
Discrimination Ratios 
The contact times for 4-month-old mice were converted to discrimination ratios. These 
are shown in figure 4.18. Data were analysed by independent t-test t(16) = 0.241 p=0.812. 
One-sample t-tests revealed that all four groups discriminated the novel object significantly 
greater than at chance level (0.5). WT t(8) = 5.1, p=0.001; APP-NL-F t(8) = 5.3, p=0.001. 
These analyses show all that young APP-NL-F and WT mice displayed the ability to 
significantly discriminate between novel and familiar objects after a single sample phase 
and 4-hour delay.  
 
Figure 4.17: Mean test phase contact times (seconds) of 4-month-old WT and APP-
NL-F mice in an object novelty (ON) task following a 4-hour delay. Contact with 
either the familiar or novel object is shown. N=9 for both groups. Error bars represent 
SEM. 
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4.8 Experiment 8: Temporal Order Memory in APP-NL-F Mice 
▪ 4.8.1 – Experiment 8a Results  
Sample Phase Contact Times 
The temporal order task consisted of two samples phases, with object pair A in sample 
phase A and pair B in phase B. The order in which the pairs of objects appeared was 
counterbalanced. The average exploration of both objects was calculated for the aged WT 
and APP-NL-F mice during each sample phase and is presented in table 4.8. The datasets 
were not all normally distributed, so were transformed by square rooting in order that this 
assumption was no longer violated (S-W p>0.05). 
The data was analysed by a repeat measures ANOVA with genotype as the between 
subjects factor and sample phase as a within subjects factor. There were no main effects of 
phase F(1,29) = 1.20, p=0.282, or genotype F(1,29) = 0.86, p=0.360, and no 
phase*genotype interaction F(1,29) = 0, p=0.991.  
 
Figure 4.18: 4-month-old APP-NL-F show comparable performance in the 4-hour 
object novelty task to WT controls. Mean discrimination ratios (DR) for 4-month-old 
WT and APP-NL-F investigating a novel or familiar object following a 4-hour delay. N=9 
for both groups. Error bars represent SEM. 
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Test Phase Contact Times 
In the temporal order test phase, mice explored one object that had previously been 
observed in sample phase A (object A) and one from phase B (object B). The exploration 
of each object is shown in figure 4.19. The data suggested that the aged WT preferentially 
contacted the object they had seen first (in sample phase A), however this was not the case 
for the aged APP-NL-F group. The Shapiro-Wilke test revealed that not all datasets were 
normally distributed. This was remedied by square root transformation (p<0.05). 
A repeated measures ANOVA with object (within subjects) and genotype (between 
subjects) as factors revealed a significant main effects of object F(1,29) = 6.29, p=0.018; 
but not group F(1.29) = 1.79, p=0.191. There was a significant object*genotype interaction 
F(1,29) = 8.93, p=0.006. Tests for simple main effects following the object*genotype 
interaction reported that WT mice exhibited significantly greater contact with object A 
compared to object B (p=0.001), while the APP-NL-F group failed to do so 
(p=0.728).Furthermore, the APP-NL-F group had significantly reduced exploration of object 
A compared to the WT (p=0.001) but there was no difference in contact with object B 
(p=0.644).  
TO Sample Phase Contact Times 
  Aged WT Aged  APP-NL-F 
Sample 
Phase A 
Mean 47 41 
SD 22 23 
Sample 
Phase B 
Mean 43 36 
SD 25 14 
Table 4.8 Mean contact times (seconds) of aged WT and APP-NL-F mice in the 
sample phases of the temporal order (TO) task. Standard deviation of the mean 
(SD) is also shown. WT n=16, APP-NL-F n=15 
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Discrimination Ratios 
Discrimination ratios (DR) were calculated to determine the preference of each group 
to interact with the object from sample phase A. Figure 4.20 shows the average DRs 
calculated from the preference of each group to explore the object observed first (object 
A). The groups were analysed by an independent t-test which revealed a significant 
difference between the groups t(29) = 2.86 p=0.008. One sample t-tests showed that the 
aged WT mice discriminated object A from object B at a rate significantly above chance 
(DR = 0.5): t(14)=- -3.7, p=0.002. However, the aged APP-NL-F group did not discriminate 
t(15)= -0.16, p=0.872. Collectively, these analyses suggest the aged APP-NL-F mice failed 
to recognise the sequential order in which the objects had originally been presented. 
Figure 4.19 Mean contact time (seconds) aged WT and APP-NL-F mice for objects A 
or B in the temporal order (TO) test phase. Objects A and B were presented in sample 
phases A and B respectively. Error bars represent SEM. WT n=16, APP-NL-F n=15. 
***p<0.001 mixed measured ANOVA. 
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▪ 4.8.2 – Experiment 8b Results 
Sample Phase Contact Times 
A separate cohort of APP-NL-F and WT mice were tested on the TO task at 4 months of 
age. The mean contact time in the sample phases is presented in table 4.9. The datasets 
were not all normally distributed, so were transformed by square rooting in order that this 
assumption was no longer violated (S-W p>0.05). The data was analysed by a repeat 
measures ANOVA with sample phase and genotype as factors. There was no main effect 
of sample phase F(1,16) = 0.339, p=0.568, no main effect of genotype F(1,16) =  1.37, 
p=0.259 and no phase*genotype interaction F(1,16) = 1.37, p=0.259.  
 TO Sample Phase Contact Times 
  Young WT Young APP-NL-F 
Sample 
Phase A 
Mean 72 58 
SD 25 31 
Sample 
Phase B 
Mean 70 67 
SD 32 27 
Figure 4.20: Aged APP-NL-F mice exhibit a deficit in temporal order memory. Mean 
discrimination ratios (DR) for aged WT and APP-NL-F mice. Greater than 0.5 indicates 
preference for the object presented less recently. Error bars show SEM. WT n=16, APP-
NL-F n=15. **p<0.01, independent samples t-test. 
Table 4.9: Contact time (seconds) by 4-month-old WT and APP-NL-F mice in the 
sample phases of the temporal order task. Standard deviation of the mean (SD) is 
also shown. n=9 for both groups. 
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Test Phase Contact Times 
Figure 4.21 shows the average contact times with both objects in the test phase. 
Both groups were normally distributed as shown by the Shapiro-Wilke test (p<0.05). A 
repeated measures ANOVA with object (within subjects) and genotype (between subjects) 
as factors revealed a significant main effect of object F(1,16) = 39.4, p<0.0005; but no 
main effect of group F(1,16) = 0, p=0.985. There was no a object*group interaction F(1,16) 
= 0.27, p=0.613. 
Discrimination Ratios 
Figure 4.22 shows the average Discrimination ratios for the 4-month-old mice in 
the temporal order task. The scores of both groups were transformed by a reflect and log10 
calculation in order to satisfy the assumption of normal distributions. The data were 
analysed by an independent t-test which found no difference between the groups: t(16) = 
0.008, p=0.994. One sample t-tests showed that both genotypes discriminated between 
objects at greater than the chance level of 0.5 (WT: t(8) = 4.9, p=0.001; APP-NL-F: t(8) = 
6.0, p<0.0005).  
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Figure 4.21: Mean contact time (seconds) for 4-month-old WT and APP-NL-F mice 
in the temporal order (TO) test phase. Objects A and B were previously presented in 
either sample phase A or B, respectively. N=9 for both groups. Error bars represent 
standard error. 
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4.9 Chapter Discussion 
The aim of this chapter was to present the first study investigating how the knocked-
in Swedish and Iberian mutations affect multiple object recognition tests in the APP-NL-F 
mouse model. Experiment 3 revealed no differences in anxiety or locomotive behaviours, 
which then permitted analysis of cognitive domains without potential confounding 
behaviours. Experiments 4 and 5 demonstrated that, while aged APP-NL-F mice have intact 
memory for object identity, they failed to discriminate novel object-place associations: a 
novel phenotype in this model. The results suggest that while successful processing of 
object information was maintained up to 17 months of age, the mice exhibited age-related 
cognitive dysfunction specific to the hippocampus. Following this result, experiment 6 
assessed non-associative, hippocampal dependent recognition in the object location task 
and discovered intact memory performance. This result was particularly intriguing in 
comparison to the object-in-place data as it helps to describe the specific nature of 
hippocampal pathology in the APP-NL-F mice. Finally, experiments 7 and 8 revealed a 
deficit in another hippocampal dependent aspect of associative recognition memory, 
temporal order, in the knock-in mice. Memory for the sequential order in which objects are 
presented is another facet of episodic memory and the failure of the APP-NL-F mice in this 
task recapitulates a well-characterised symptom of AD patients. 
Figure 4.22: APP-NL-F display comparable temporal order memory to WT controls 
at 4-months of age. Mean discrimination ratios (DR) for WT and APP-NL-F. The 
predicted score of random chance (0.5) is highlighted by the black line. N=9 for both 
groups. Error bars show SEM. 
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The only previous study assessing object recognition memory in the APP-NL-F  
model reported a deficit in object novelty performance in 12 month old mice (Izumi et al. 
2018). The current study did not replicate this result and in fact reported intact novelty 
discrimination up to 17 months of age. The protocol used in experiment 4 contains many 
discrepancies compared to that used by Izumi and colleagues, particularly the delay 
involved (5 minutes vs 24 hours), the sampling procedure (3- vs 1 10-minute sessions) and 
the object array (4 different objects vs 2 identical). Furthermore, the group tested female 
mice which were not habituated to the arena and objects as in this study. The protocol in 
experiment 7 is more comparable to the published work, involving the one sample phase 
with two identical objects. Although the 4-hour delay in experiment 7 represents a long-
term memory retrieval, the extended duration described by Izumi et al may be the 
determining factor in the reported deficit. We did not test memory at 24-hour interval but 
it would be interesting to determine if this could be replicated in our laboratory. It is also 
worth mentioning that Izumi et al’s results involved APP-NL-F mice which had been 
subjected to daily oral administration of distilled water between 9 & 12 months, as the 
vehicle control group in their experiment. The increased stress induced by this treatment 
may have affected performance (Baker and Kim 2002). 
A study in the APP-NL-G-F mouse also reported an ON deficit. The triple mutation in 
the APP gene of this mouse induces a more aggressive phenotype, which may result in 
significant amyloid pathology in the cortex and thus impact on perirhinal cortex function 
(Mehla et al. 2019). In fact, a common feature of reports of ON deficits in AD mouse 
models is multiple combined mutations or transgenes, such as in the 3xTg, 5xFAD, 
APP/PS1 and J20 models (Oddo et al. 2003, Joyashiki, Matsuya, and Tohda 2011, Webster, 
Bachstetter, and Van Eldik 2013, Mucke et al. 2000, Citron et al. 1997). Therefore, the 
greater number of mutations and/or increased expression of APP and thus more aggressive 
pathology may cause perirhinal cortex dysfunction and ON deficits in these models. 
However, this was clearly not the case in the APP-NL-F mice, as the current study reports 
intact object recognition using two different protocols. 
This chapter reports a novel phenotype: an age-related deficit in the APP-NL-F mice’s 
ability to recognise object-place associations. The concurrent and comparable ON 
recognition test is vital for dissociating the detail of the deficit. Successful detection of 
novelty demonstrates intact memory processes for object identity and validates the deficit 
in the OiP task being caused by a specific deficit in associative memory integrating spatial 
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information with object identity. The lack of a deficit in the object location (OL) task in 
aged APP-NL-F mice is thus intriguing. The latter finding suggest that APP-NL-F have encoded 
some property(ies) of the topography of the object array; ie. they were able to detect when 
the spatial organisation had changed.  While this task is known to be sensitive to 
hippocampal cell loss, APP-NL-F undoubtedly have a more subtle impact on hippocampal 
function, which is further evidenced by the available literature. While the original paper by 
Saito et al described spatial working memory deficits measured by reduced spontaneous 
alternation in the y-maze, it reported no effects in the MWM, further suggesting a subtle 
effect on hippocampal function (Saito et al. 2014). Subsequent literature has failed to 
replicate the original deficit in alternation (Masuda et al. 2016, Whyte et al. 2018).  
Effects of genotype were not observed on basal locomotive or exploratory activity, 
as has been seen in other models of AD (Evans et al. 2019). This meant that there were no 
potential confounding effects of one genotype getting more contact with objects in the 
sample phases thus receiving greater potential for encoding information. This strengthens 
the conclusion that differences observed in exploration by the aged APP-NL-F group were 
due to deficits in memory processing. 
A similar pattern of visuo-spatial recognition memory deficits has been described 
in Tg2576 mice that also express the Swedish mutation. Aged Tg2576 mice exhibited intact 
recognition of object identity and for when familiar objects were moved to a previously 
unoccupied location, but not for when two objects switched spatial location (Good & Hale 
2007). They also display place cell activity- although the quality of information encoded 
by place cell is considerably compromised (Cacucci et al., 2008). This may also explain 
the slower learning in the water maze, and the loss of recognition of more subtle aspects of 
spatial memory (Zhao et al. 2014). While place cell activity has not been examined in APP-
NL-F mice, the current data suggest that these mice are able to encode at least some spatial 
properties of the landmark array.  In this way, the 17-month-old mice exhibited intact 
memory for the individual components of object identity and place. However, they lacked 
the ability to combine these dimensions into configural memories in the OiP task. As the 
APP-NL-F mice show a similar pattern of deficits as the Tg2576 and the models share the 
Swedish mutation, the effect on place cells may be common between them.  
This study also presents the first evidence of a deficit in the APP-NL-F mouse’s 
processing the temporal order of objects. Before discussing this observation, it is important 
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to first acknowledge the APP-NL-F mice were able to carry out a simple object novelty 
discrimination over the 4-hour delay. The data presented here indicate that APP-NL-F mice 
are able to discriminate familiar/novel objects with either a short delay (5-min) or a 
relatively long delay of 4 hours. Therefore, one can assume that in the temporal order task, 
the APP-NL-F mice had encoded both objects sets during the sample phases. Importantly, 
the aged APP-NL-F group failed to show any discrimination between early and recently 
presented objects. This is the first time that such a deficit has been reported in APP mice. 
Hale & Good (2005) reported that Tg2576 mice demonstrated intact recency discrimination 
using a protocol involving a 2-minute delay for both inter-phase intervals. Bonardi et al 
(2016) also reported intact recency in 5-month old APPswe/PS1dE9 mice alongside a 
deficit in OiP performance. Their protocol comprised a 24-hour delay between sample 
phases A and B, and then a 5-minute delay between the second sample and test phases. In 
contrast, the 1- and 3- hour inter-phase intervals used in the current study involved a larger 
separation between exposure and test, thereby reducing relative differences in memory 
strengths of the two object pairs. In this way, while the previous protocols tested a recency 
effect, the current study assessed memory for temporal order. The fact that the APP-NL-F 
mice exhibited decreased exploration through the 3 sample phases of the ON and OiP tasks 
at 16-17 months arguably shows that they also have intact recency memory. 
The pattern of deficits in different recognition paradigms described above provides 
the basis for considering how the APP-NL-F mutation impacts the neural circuitry 
underpinning object memory (c.f., Barker & Warburton – 2011). Barker & Warburton 
showed that deficits in associative recognition memory tasks were caused by lesions of 
either the medial prefrontal cortex (mPFC) or HPC, or alternatively by disconnection of 
the PRC-HPC-mPFC circuit in both hemispheres. As already discussed, the fact that APP-
NL-F mice maintain recognition of objects moving to previously unoccupied locations 
indicates that hippocampal function remains intact to some extent. Furthermore, successful 
discrimination of object novelty after a 4-hour delay suggests hippocampal NMDA 
receptor function was unimpaired considering evidence that long term (>3 hour) object 
recognition memory depends on these receptors (Baker and Kim 2002). There is currently 
no specific data concerning amyloid accumulation in the mPFC in APP-NL-F mice. 
However, altered connectivity involving the hippocampus and prefrontal regions has been 
detected as young as 3 months of age in both the APP-NL-G-F and APP-NL-F knock-in models 
(Latif-Hernandez et al. 2017, Shah et al. 2018). Shah et al., 2018 reported that APP-NL-F 
mice showed impaired reversal learning in the MWM at 3 and 7 months of age, alongside 
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BOLD analyses revealing hypersynchronous functional connectivity between the 
hippocampus and frontal cortex at 3 months, but hyposynchrony at 7 months of age. The 
same group has already reported this age-dependent switch from hyper- to 
hyposynchronous functional connectivity in transgenic models (Shah et al. 2016, Shah et 
al. 2013). The effects in APP-NL-F mice appeared far earlier than the cognitive deficits in 
the current study and were not examined beyond 7 months of age. However, detection of 
aberrant functional connectivity prior to overt cognitive symptoms mirrors what is seen 
children with a FAD mutation and this effect may actually be a compensatory 
neurobiological reaction for Aβ-induced dysfunction (Quiroz et al. 2015). Relating this 
fMRI evidence to mechanisms of cognitive effects is difficult, although cortical 
hyperconnectivity has also been correlated to a decline in reversal learning in mPFC-
lesioned mice (Latif-Hernandez et al. 2016). Deficits in reversal learning are the only APP-
NL-F phenotype that has currently been replicated in more than one study (Masuda et al. 
2016, Shah et al. 2018). There is evidence that this cognitive flexibility is dependent on 
network level communication within the mPFC-hippocampal circuit (de Bruin et al. 1994, 
Latif-Hernandez et al. 2016). Intriguingly, a similar mechanism has been shown to be vital 
to the associative recognition tasks failed by the APP-NL-F mice in the current chapter 
(Barker and Warburton 2011). Multiple studies revealing two phenotypes that are be 
underpinned by the same mechanism provides strong evidence for any putative 
neurobiological pathology in this mouse model. Further analysis concerning amyloidosis 
or synaptic plasticity within the medial prefrontal cortex would be vital in determining to 
what extent this region is affected in the APP-NL-F model.  
 Individual and combinatorial lesions of distinct brain regions have been shown to 
impact performance of specific object recognition paradigms and this is summarised in 
table 4.1. However, recent evidence has presented the entorhinal cortex (EC) as vital for 
associative recognition memory. Despite the speculative proposition of EC dysfunction as 
being causative of the results described in the current study, it is worth discussion. The EC 
integrates multiple aspects of recognition memory required for associative recognition 
tasks and is also one of the most vulnerable regions of the cortex to  early AD pathology 
(Witter et al. 2017, Gomez-Isla et al. 1996). Evidence for the involvement of the EC in 
recognition memory is present across species. Manual segmentation within the EC of 
humans revealed that its volume significantly predicted object-in-place performance 
(Yeung et al. 2019). In vivo electrophysiological recordings in rats revealed distinct cell 
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types in the lateral EC that responded to either objects or spatial locations in which objects 
were previously present (Tsao, Moser, and Moser 2013). These studies present evidence 
that function of the EC may underpin associative recognition memory performance. Recent 
reports have shown that APP-KI mice do exhibit aberrant synaptic and oscillatory 
mechanisms in that brain region, supporting this hypothesis. Nakazono et al (2017) 
published results showing that gamma oscillations are impaired in APP-KI mice due to 
reduced gamma to theta cross frequency coupling. This cross frequency coupling has been 
shown to predict working memory performance (Axmacher et al. 2010) and is a 
hypothesised mechanism for information transfer in the EC-hippocampal circuit during 
associative learning (Lisman 2005, Igarashi et al. 2014). Another recent study identified 
hyperexcitability in the EC of APP-NL-F  mice, along with a reduced expression of 
parvalbumin expressing interneurons (Petrache et al. 2019). This excitatory-inhibitory 
imbalance can lead to excitotoxicity and neurodegeneration, as evidenced by the measured 
reduction of EC pyramidal cell density compared to age matched controls. A similar 
finding was identified recently in transgenic Tg2576 mice which demonstrated degenerated 
pyramidal EC neurons that usually innervate the CA1 of the hippocampus (Yang et al. 
2018). Optogenetic reactivation of these synapses was enough to rescue the spatial memory 
decline in these animals. Neurodegeneration within the EC of APP-NL-F mice could 
certainly provide a mechanism for their failure of associative recognition memory 
following a study by Wilson and colleagues (2013). They reported that lesions of the lateral 
entorhinal cortex in rats impaired recognition of object-place, place-context and object-
place-context associations, while object novelty and object location performance remained 
intact (Wilson et al. 2013).   
In conclusion, these experiments describe a novel cognitive phenotype in the APP-
NL-F mouse model. This study has revealed an intriguing pattern of deficits across a battery 
of object recognition tests. The APP-NL-F mice display intact memory for object identity 
and novel location, but fail the tasks involving encoding associations of specific objects 
with location or time. These associative tasks are related to episodic memory, the decline 
of which is a hallmark of the early stages of Alzheimer’s Disease. The cause of specific 
associative memory failure remains unclear but may be due to disruption of the mPFC-
perirhinal-hippocampus or hippocampus-entorhinal circuits, as both of these mechanisms 
are critical for associative memory performance. 
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Chapter 5 –  
Working Memory Assessment in 
APP-NL-F Mice 
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5.1 Chapter Overview 
A hallmark of Alzheimer Disease symptoms is a decline in spatial working memory 
capabilities. Therefore, investigations into the pathology exhibited by genetically 
engineered rodent models of the disease have predominantly involved assessment of this 
aspect of memory. This chapter introduces navigational strategies underpinning spatial 
memory as well as the various methods used to test it in rodents. While there is extensive 
literature concerning age-related decline in spatial working memory in transgenic mouse 
models, there is limited evidence of the effect in knock-in mice. Experiments in this chapter 
assessed spatial working memory in a task was based on foraging behaviour and permitted 
spatial and non-spatial versions, depending on the availability of extra or intra-maze cues. 
The spatial version is sensitive to hippocampal cell loss and amyloid pathology in a 
transgenic mouse model. 
APP-NL-F mice were tested on the foraging task at two age points in a longitudinal 
design. They exhibited a significant decline in spatial working memory performance with 
age. There were no effects in the non-spatial task, which was run alongside the spatial 
version in a counterbalanced manner. This result augments the results of chapter 4, showing 
that the deficit in processing of spatial information extends to a working memory format in 
these mice. This result is consistent with published data of a deficit in APP-NL-F mice in 
spontaneous alternation measured in a Y-maze. 
 
5.2 Chapter Introduction  
Chapter 4 analysed performance of the APP-NL-F mice in a battery of object 
recognition tasks relevant to Alzheimer’s Disease. The mice exhibited an age-dependent 
deficit in associative recognition memory, failing to discriminate novel object-place 
associations. In order to investigate whether such cognitive deficits translated across 
multiple tests with different sensory, motivational and motor requirements, the mice were 
tested in a foraging based working memory task. This task was used to assess the use of 
both spatial and non-spatial (cue-related) information on foraging behaviour. The spatial 
version of this task has previously been shown to be sensitive to hippocampal lesions, and 
amyloid pathology in the PDAPP transgenic mouse model (Evans et al. 2018).  
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 Working memory has previously been defined as a memory for aspects of object, 
stimulus or location, held within the short term period of a single trial and not recalled in 
subsequent trials (Olton, Becker, and Handelmann 1979, Honig 1978). David Olton 
described this form of memory after having designed the Radial Arm Maze (RAM) to 
assess spatial working memory (SWM) performance. The RAM has a central platform with 
eight arms extending outwards, each baited with a reward. The original paper described 
how rats would learn to visit each arm once, to collect all rewards as efficiently as possible. 
The authors established that the rodents were navigating independent of intra-maze cues 
(e.g. odour) or any specific order (Olton, Becker, and Handelmann 1979). The rats were 
apparently utilising “working memory” to avoid arms they had already visited and 
exploring the others to find unclaimed rewards during that session (Dudchenko 2004). 
Animals are able to perform spatial working memory tasks in the same way they 
naturally navigate through their environment: by generating a “cognitive map” of their 
surroundings (Collett and Graham 2004, Bjerknes et al. 2018). The cognitive map can be 
accessed in distinct navigational strategies. For example, allocentric navigation involves 
integration of distinct visual landmarks to encode their locations relative to one another. 
Alternatively, an animal might model the position of objects or environmental cues relative 
to itself, described as egocentric processing. This contributes to the animal’s conscious 
awareness of its own movement relative to a previously known position, which is another 
navigational strategy known as Path Integration. The memory required to use these 
strategies is believed to be incorporated in the hippocampal and entorhinal networks, 
specifically by hippocampal place cells and grid cells in the medial entorhinal cortex 
(McNaughton et al. 2006, O'Keefe et al. 1998, Morris, Hagan, and Rawlins 1986, Wills et 
al. 2010). The medial temporal lobe is well characterised to be susceptible to early AD 
pathology and it follows that deficits in navigation are a consistent hallmark of patients’ 
symptoms (Graham 2017, Hort et al. 2007). More specific assessments revealed patients 
have a deteriorating ability to use path integration or allocentric navigational strategies as 
an early stage indicator of cognitive decline (Vlček and Laczó 2014, Mokrisova et al. 
2016). 
Spatial working memory tasks such as the radial arm maze described above have 
revealed that transgenic models of Alzheimer Disease pathology perform worse than 
control animals (Hsiao et al. 1996, Morgan et al. 2000). In fact, models exhibit similar 
deficits to patients in tests designed to be analogous between the two species (Laczo et al. 
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2010, Lee et al. 2015). A review of 10 mouse models by Webster et al (2014) identified 
that dysfunction of spatial working memory manifests earlier than other cognitive 
phenotypes, mirroring the pattern of symptom onset in patients (Webster et al. 2014). This 
accumulation of evidence demonstrates that tests of spatial working memory are relevant 
to investigate to what extent models of amyloid pathology recapitulate the cognitive 
symptoms of the disease. Various other tasks have been used to test Spatial Working 
Memory (SWM) in rodents. These include the Morris Water Maze (MWM), Barnes Maze 
and alternation in a T or Y maze. They all require the subject to encode spatial information 
about the environment and express natural and efficient navigation performance. The 
MWM involves a rodent swimming in a circular pool to find a camouflaged platform, 
navigating via extra-maze cues (Morris 1981). Versions of this task have been used 
extensively to test spatial learning and memory in rodents, and are known to be dependent 
on hippocampal function (Morris, Hagan, and Rawlins 1986). 
We have used a recently published foraging-based task which was adapted from 
one used to test pigeons (Pearce et al. 2005). It has been shown to be sensitive to excitotoxic 
hippocampal lesions and amyloid pathology in the transgenic PDAPP mouse model (Evans 
et al. 2018). The task uses 6 pots arranged in a circular pattern similar to a radial arm maze, 
within an arena that was surrounded by extra-maze stimuli to enable spatial navigation. 
Each pot was baited with liquid reward and the mouse allowed to freely explore, foraging 
in the pots until every reward had been consumed, or the time limit was passed. Any return 
visit to a previously foraged pot was scored as an error, meaning the animal must utilise 
spatial working memory to distinguish which pots had been visited from their spatial 
location. A major advantage of this task was that animals did not have to undergo specific 
training more than simply associating the pots with liquid reward, which took place within 
its home cage. The task also does not involve aversive stimuli, relying on the rodent’s 
natural exploratory and foraging behaviour. By drawing a curtain around the arena to 
obstruct view of the extra-maze cues and using individually patterned pots, one can 
manipulate this task to assess non-spatial working memory. Evans et al reported that 
performance of hippocampal lesioned mice was unaffected compared to sham surgery 
control mice in this version of the task (Evans et al. 2018). 
  Currently there are a limited number of studies demonstrating a robust spatial 
working memory in the APP knock-in mice developed by Takaomi Saido and colleagues. 
In fact, only their original paper has examined aged APP-NL-F mice. They reported reduced 
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spontaneous alternation in the Y maze, which manifested at 18 months (Saito et al. 2014). 
While other groups have performed SWM tests with the APP-NL-F model, none aged mice 
beyond 12 months (Izumi et al. 2018, Shah et al. 2016). A summary of the current literature 
in which SWM tests have been used to assess performance of the APP-NL-F knock-in mice 
is presented in figure 1.3. Therefore, this study aimed to be the first to measure SWM 
proficiency in aged APP-NL-F mice since their original publication. In this experiment, APP-
NL-F mice were tested alongside WT at 9-10 months and 16-17 months of age in spatial and 
non-spatial versions of the foraging task to characterise any age dependent or independent 
effects on performance. 
5.3 Experiment 9: Spatial Working Memory in APP-NL-F Mice 
▪ 5.3.1 – Introduction 
Experiments 10 & 11 present assessment of working memory performance in the 
APP-NL-F mouse model was carried out by using a foraging-based task, following a protocol 
adapted from that published by Evans et al (2018). APP-NL-F and wild-type mice were split 
into two groups and each performed both spatial and non-spatial versions of the task in a 
counterbalanced order. The aim of this experiment was to investigate the performance of 
APP-NL-F mice on this spatial working memory task, in order to see whether the deficit in 
visuospatial associative memory could be measured across multiple tasks. Results of this 
experiment will be compared to those from the non-spatial version of the task in order to 
dissociate spatial and non-spatial components. We hypothesised that the performance of 
APP-NL-F mice on the spatial task would deteriorate with age and they would demonstrate 
an increased number of errors compared to wild-type mice, due to published studies 
identifying an age dependent deficit in SWM. Non-spatial performance was not expected 
to be sensitive to differences in genotype, consistent with results observed in novel object 
recognition. 
▪ 5.3.2 – Methods 
Subjects 
The mice tested in this experiment were the same as those described in experiments 
5 to 9. They were male APP-NL-F (n=16) and WT (n=16) mice, tested at both 9-10 and 16-
17 months of age. 
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Apparatus 
White ceramic pots (9 cm diameter, 4.5 cm height, ProCook Ltd, UK) were used to 
contain the liquid reward (figure 5.2, A). Wooden platforms (3x4 cm) were used to raise 
the pots off the floor. Initial training was undertaken in the animal’s home cage (48 x 15 x 
13 cm, (L x W x H)), before the rest of the training and testing took place using the same 
arena and test room described in Chapter 2, including the same extra-maze cues. However, 
a 1 cm deep layer of wood chipping was spread over the floor throughout the foraging 
trials, matching the appearance of the home cage. All test trials were recorded using a USB 
camera connected to a laptop.  
Design 
Mice underwent the same testing protocol at two age points: 9-10 months & 16-17 
months old. This protocol was 17 days long and is detailed in figure 5.1. Mice were water 
deprived to approximately 90% of their pre-experiment weight throughout the whole 
protocol. Water was made available for 2 hours after their training trials each day. 
Procedure 
Home Cage Training: Initial training involved the mice forming an association of 
the pots with a liquid reward. Once water deprived, the pots were filled with water and 
placed in the home cage for 4 hours (figure 5.2 A). On day 1, pots were placed on the floor 
of the cage, but were raised on the wooden platforms for days 2-4, in which the provided 
water level decreased. This ensured the mice learned to climb onto the pot and drink from 
the bottom, as they would in the test trials. 
Test Arena Training: During days 5-7, mice were habituated to the arena and 
trained to find liquid rewards of 1:3 sweetened condensed milk (Nestle) solution prepared 
in water. Two pots were placed in the arena opposite each other, 40 cm apart, with locations 
varying each day to prevent development of any spatial bias during testing (figure 5.2, B). 
Figure 5.1: Experimental design for the foraging tasks. Each vertical line represents 
a separate day of training, testing or resting. Note that while training and rest days were 
consistent between groups, the order of test received was counterbalanced. 
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On day 5, 120 μL of the solution was placed in the centre of the bottom of the pots and the 
mice were placed in the arena and allowed to explore until they had consumed the reward 
from both pots. After this, the mouse was removed and put back in the home cage, before 
the pots were cleaned with 70% ethanol. The same procedure was repeated for each mouse 
on days 6 and 7, however a 30 μL reward was used. By day 7 all mice were successfully 
consuming both rewards within 3 minutes. 
Spatial Foraging Test: Mice received one test trial on each of day of test phase 1 
or 2 (either days 8 to 11 or days 14-17). They performed either the spatial or non-spatial 
foraging tasks in a counterbalanced design, with no testing on days 12 and 13. The spatial 
task continued to use the same white pots and extra-maze cue layout, but involved 6 pots 
arranged in a circular shape, each 20 cm apart and containing 30 μL of the milk solution 
(figure 5.2, C). Mice were placed in the arena, always facing the same direction, and 
allowed to explore until the reward had been foraged from all six pots. Mice were replaced 
in their home cage; the pots were cleaned and fresh rewards placed in each of them. All 
test trials were recorded via a USB camera and saved onto an external hard drive. 
Non-Spatial Foraging Task: A second group of mice performed the non-spatial 
task concurrently to the first group performing the spatial version. In this task, a black 
curtain was drawn around the arena to hide the extra-maze. The six pots were identical size 
and shape but each had a unique pattern on the external wall (figure 5.2, D). They were 
arranged in a circular pattern, and their individual locations changed throughout the four 
days of testing. Mice were transferred into the arena via the cardboard tubes so that they 
were always in the centre of the pots, facing the same wall. They were removed after the 
reward had been consumed from all six pots or 10 minutes has passed. The pots were wiped 
with 70% ethanol wipes and the reward was replenished. All trials were recorded as above. 
Scoring: Foraging behaviour was described as when the mouse climbed upon the 
sides of the pot and directed its head down to find and consume any reward there. The order 
in which pots were foraged was recorded, and an error was counted when a mouse returned 
to a pot which it had already visited in that trial. The number of errors was averaged for 
each mouse across their four trials of each test, before a mean number of errors was 
calculated for each group in each version of the task. These group means were statistically 
analysed as described in chapter 2. 
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Table 5.1: Definitions of the different measurements used to assess performance in 
the foraging-based working memory task. 
Measurement Definition 
Error 
A mouse returning to a pot in which the reward 
has already been consumed. 
Neighbouring Error 
A mouse making an error by visiting the pot 
adjacent to the one it has just foraged in. 
Distal Error 
A mouse making an error by visiting a pot one 
or more pots away from the one it has just 
foraged in. 
Perseverative Error 
A mouse immediately returning to the pot it 
has just foraged in. 
Chaining Response 
A mouse visiting three or more consecutive 
pots that are immediately adjacent to one 
another in one direction. 
Initiation 
The time taken for the mouse to forage in the 
first pot of a session. 
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Figure 5.2: Photographs of the ceramic pots used throughout the foraging experiment.  
 
(A)  Position of the pots in the initial home cage training phase. (B) In the arena training 
phase, two pots were placed opposite each other. (C) Arrangement of the six pots in the 
foraging task test phase. (D) Distinctly patterned pots used in the non-spatial foraging task 
experiment, arranged in their test positions with the curtain drawn around the arena. 
A B 
C 
D 
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▪ 5.3.3 – Experiment 9 Results 
Spatial Foraging Task 
 The number of errors scored by the WT and APP-NL-F mice was recorded at two 
age-points and is presented in Figure 5.3. Visual inspection of figure 5.3 suggested that 
WT performance improved with age, while the opposite occurred for the APP-NL-F. All 
datasets were normally distributed (Shapiro-Wilke test p>0.05), and therefore were eligible 
for a repeated measures ANOVA, with age as a within subjects’ factor and genotype as the 
between subjects’ factor. The ANOVA revealed no main effects of age or genotype, but a 
significant age*genotype interaction F(1,30) = 7.15, p=0.012. 
Tests for simple main effects following the significant interaction revealed that the 
APP-NL-F mice made significantly more errors at the 16-17-month aged timepoint relative 
to their test at a younger age (p=0.039). There were no other significant simple main 
effects: age on WT (9-10 vs 16-17 months) p=0.116; genotype at 9-10 months (WT vs 
APP-NL-F) p=0.122; genotype at 16-17 months (WT vs APP-NL-F ) p=0.109. 
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Figure 5.3: APP-NL-F mice have an age-dependent decline in the spatial foraging 
task. Total errors by WT and APP-NL-F mice at both 9-10 and 16-17 months of age. 
Error bars represent standard error of the mean. N=16 for all groups. * = p<0.05 
* 
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While the number of basic errors gives an indication of spatial working memory 
performance of the mice at both age-points, other parameters were recorded in order to 
assess other aspects of behaviour such as engagement, compulsivity and foraging strategy. 
Table 5.2 presents the data for the initiation time, chaining responses and perseverative 
errors that are defined in table 5.1. The datasets for the initiation times were transformed 
by log10 transformation to render them all normally distributed. They were analysed by a 
repeated measures ANOVA with age as a within subjects’ factor and genotype as a between 
subjects’ factor. The ANOVA revealed no main effect of age F(1,30) = 0.83, p=0.370; no 
main effect of genotype F(1,30) = 0.22, p=0.638 and no significant interaction F(1,30) = 
0.618, p=0.438. 
The datasets for the number of chaining responses were all normally distributed and 
analysed in by the same ANOVA test. Similarly, there was no main effect of age F(1,30) 
= 1.3, p=0.257; no main effect of genotype F(1,30) = 0.34, p=0.566 and no significant 
interaction F(1,30) = 0.057, p=0.812. 
The number of perseverative errors were analysed by non-parametric tests due to 
the large presence of zeros in the data. The Mann-Whitney U test was used to compare the 
two genotypes at each age-point and revealed no significant effect at 9-10 months (U = 
138, z = 0.39, p=0.724); or 16-17 months of age (U = 107, z = -0.841, p=0.445). The effect 
of the within subjects’ factor (age) was analysed by exact sign tests which revealed no 
significant median difference (0.0) in the number of perseverative errors for either the WT 
(z = -0.40, p=0.690) or the APP-NL-F mice (z = -0.289, p=0.774). 
Foraging strategy was assessed by comparison of whether the mice were more 
likely to make errors in pots that were either neighbouring or distal to the pot that had just 
been foraged in. The data was expressed as a ratio of error location : total errors so as to 
negate the effect of differences in the total number of errors made, and this is presented in 
figure 5.4. All data groups exhibited normal distributions, so they were analysed by a 
repeated measures ANOVA with error location and age as within-subjects’ factors, while 
genotype was a between subjects factor. The ANOVA reported no significant main effects: 
error location F(1,30) = 3.16, p=0.086; age F(1,30) = 0.97, p=0.333; genotype F(1,30) = 
1.1, p=0.300. There were also no significant interactions: age*error location F(1,30) = 2.2, 
p=0.147; age*genotype F(1,30) = 0.0, p=1.0; error location*genotype F(1,30) = 0.297, 
p=0.590; age*error location*genotype F(1,30) = 0.014, p=0.906.  
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Measurement Genotype 
9-10 Months 16-17 Months 
Mean SD Mean SD 
Initiation /s 
WT 20 18 19 22 
APP-NL-F 15 10 22 22 
Chaining 
Responses 
WT 0.88 0.51 1.04 0.48 
APP-NL-F 0.98 0.50 1.09 0.58 
Perseverative 
Errors 
WT 0.27 0.25 0.38 0.43 
APP-NL-F 0.33 0.27 0.30 0.48 
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Table 5.2: Comparison of the mean initiation time, number of chaining responses 
and perseverative errors recorded in the spatial foraging task. Results are presented 
of both genotypes at 9-10 and 16-17 months of age. Standard deviation is also shown. 
n=16 for all groups. 
Figure 5.4: Comparison of the locations of errors made by APP-NL-F and WT mice 
in the spatial foraging task. The proportion of both neighbouring and distal errors is 
presented at 9-10 and 16-17 months of age. Error bars represent SEM. 
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5.4 Experiment 10: Non-Spatial WM in APP-NL-F Mice 
▪ 5.4.1 – Experiment 10 Results 
Non-Spatial Foraging Task 
 The non-spatial foraging task assessed hippocampal independent working memory 
performance, as each pot was individually patterned. Inspection of the data in figure 5.5 
indicated that both groups maintained a consistent number of total errors throughout the 
two timepoints. The data were normally distributed as checked by the Shapiro-Wilke test 
(p>0.05), and were analysed by a repeated measures ANOVA with age as the within 
subjects’ factor and genotype as the between subjects’ factor. Results of the test revealed 
no significant main effect of age F(1,30) = 0.089, p=0.767; or genotype F(1,30) = 0.01, 
p=0.921; and no significant interaction F(1,30) = 0.001, p=0.973. 
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Figure 5.5: APP-NL-F mice displayed comparable performance to WT controls in 
the non-spatial foraging task. Total errors scored in the non-spatial foraging task by 
WT and APP-NL-F mice at 9-10 and 16-17 months of age. Error bars represent standard 
error of the mean. N=16 for all groups. 
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Table 5.3 presents the data for the time required to initiate engagement with the 
task as well as the number of chaining responses and perseverative errors. The distribution 
of the initiation times was not normal in all groups, and so the data was transformed by 
log10 transformation to ensure that p>0.05 in the SW test. The data were analysed by a 
repeated measures ANOVA with age as a within subjects’ factor and genotype as a between 
subjects’ factor. The ANOVA revealed no main effect of age F(1,30) = 0.38, p=0.540; no 
main effect of genotype F(1,30) = 0.32, p=0.579 and no significant interaction F(1,30) = 
0.13, p=0.717. 
The presence of zeros in the number of chaining responses resulted in the data being 
analysed by non-parametric tests. The two genotypes were compared by Mann-Whitney U 
tests which revealed no significant differences at 9-10 months (U = 92, z = -1.38, p=0.184); 
or 16-17 months of age (U = 139, z = 0.407, p=0.696). The within subjects’ effect of age 
was assessed by exact sign tests. There was no significant difference in the median number 
of chaining responses in 9-10 and 16-17-month-old WT mice (0.0), z = 0.0, p=1.0. There 
was also no significant median difference between the two ages for APP-NL-F chaining 
responses (0.25), z = 1.1, p=0.267. 
The number of perseverative errors were also analysed by non-parametric tests. The 
Mann-Whitney U test revealed no significant differences between the two genotypes at 9-
10 months (U = 143, z = 0.57, p=0.590); or 16-17 months of age (U = 146, z = 0.681, 
p=0.515). An exact sign test revealed no statistically significant median difference (0.125) 
in the total number of perseverative errors made by the WT mice at the two age-points (z 
= 0.87, p=0.388). There was also no significant median difference (0) between the two ages 
for the APP-NL-F mice (z = 0.0, p=1.0). 
The proportions of neighbouring and distal errors are presented in figure 5.6. All 
datasets were normally distributed and were analysed by a repeated measures ANOVA 
with error location and age as within-subjects’ factors, while genotype was a between 
subjects factor. The ANOVA reported a significant main effect of error location F(1,30) = 
4.6, p=0.04. There was no significant effect of age F(1,30) = 0.0, p=1.0 or genotype F(1,30) 
= 2.1, p=0.154. There were also no significant interactions: age*error location F(1,30) = 
0.001, p=0.971; age*genotype F(1,30) = 0.0, p=1.0; error location*genotype F(1,30) = 
0.004, p=0.953; age*error location*genotype F(1,30) = 0.028, p=0.868.  
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Measurement Genotype 
9-10 Months 16-17 Months 
Mean SD Mean SD 
Initiation (s) 
WT 14 9 17 14 
APP-NL-F 17 11 18 12 
Chaining 
Responses 
WT 1.0 0.14 0.95 0.10 
APP-NL-F 0.75 0.09 0.97 0.08 
Perseverative 
Errors 
WT 0.27 0.27 0.34 0.39 
APP-NL-F 0.39 0.49 0.46 0.46 
Table 5.3: Comparison of the mean initiation time, number of chaining responses 
and perseverative errors recorded in the non-spatial foraging task. Results are 
presented of both genotypes at 9-10 and 16-17 months of age. Standard deviation is 
also shown. 
Figure 5.6: Comparison of the locations of errors made by APP-NL-F and WT mice 
in the non-spatial foraging task. The proportion of both neighbouring and distal errors 
is presented at 9-10 and 16-17 months of age. Error bars represent SEM. 
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5.4 Chapter Discussion 
Experiments within this chapter assessed working memory in the APP-NL-F knock-
in mouse model via a foraging-based paradigm. By manipulating the existence of intra and 
extra maze cues, spatial and non-spatial working memory was examined. The results 
revealed an age-dependent deterioration in the APP-NL-Fs in the spatial version of the task 
in the absence of significant genotypic differences. There were no effects of age or 
genotype in the non-spatial task. This result is consistent with the age-related decline in 
SWM performance of transgenic PDAPP mice in this task, while a previous study has also 
reported a decline in APP-NL-F mice (Saito et al. 2014, Evans et al. 2018, Evans et al. 2019). 
While the original paper by Saito et al presented deficits in Y-maze spontaneous alternation 
at 18 months, subsequent reports have not assessed mice aged beyond 12 months (Izumi et 
al. 2018, Shah et al. 2018). Consistent with these studies, we observed that APP-NL-F mice 
exhibited performance comparable to WT at 9-10 months of age. To our knowledge this is 
the first experiment to replicate the deficit in spatial working memory presented by Saito 
and colleagues. 
Although there is a very limited literature with which to compare the results of the 
APP-NL-F mice, the APP-NL-G-F knock-in model has garnered greater interest. However, 
results of SWM assessment have proved controversial. The spontaneous alternation deficit 
identified at 6 months of age by Saito et al (2014) was not replicated by Whyte et al (2018), 
who suggested the phenotype may not be robust to changes in environmental factors. One 
group used the Barnes maze to assess SWM in the APP-NL-G-F. This is a circular platform 
with numerous holes around the perimeter, one of which leads to the “target box”, a dark 
pocket that becomes the animal’s refuge to escape from the open platform, due to their 
natural preference for a dark environment (Barnes 1979). Male APP-NL-G-F were tested at 
4, 6 and 8 months and exhibited similar performance to WT at 4 & 6, but developed subtle 
deficits in learning the spatial location of the target box at 8 months (Sakakibara et al. 
2018). Testing was not carried out at older age points, potentially because performance of 
WT deteriorates with age (Barnes and McNaughton 1985). The Morris water maze has 
been a more popular tool for examining SWM, with four groups using it to tested APP-NL-
G-F mice. Two of these groups observed no effect of genotype with mice aged 6 and 11 
months respectively (Whyte et al. 2018, Latif-Hernandez et al. 2017). However, two groups 
published data showing reduced learning and memory efficiency. Mehla et al measured 
this at 6 and 12 months of age, while the Sakakibara group only tested 24 month old APP-
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NL-G-F mice (Mehla et al. 2019, Sakakibara et al. 2019). The pattern of discrepant results is 
potentially due to the use of different protocols or environmental factors, but a more 
compelling argument could be made for disparity in sex, age and the nature of control 
groups used. For example, while most groups tested male mice against C57Bl/6 controls, 
the Latif-Hernandez group measured female APP-NL-G-F  mice versus APP-NL mice as 
controls, which express the Swedish mutation and do not develop amyloid pathology 
despite increased soluble beta-amyloid (Salas et al. 2018, Sakakibara et al. 2019). The use 
of this control line may have limited the ability to detect a deficit related in amyloid 
production.  
While the current experiment presents an age-related deficit, it is important to note 
the comparison of errors made by the APP-NL-F and WT groups was non-significant. The 
significant age*genotype interaction was driven by the significant within-subjects 
comparison of the APP-NL-F group at the two ages. The current literature does not include 
experimental designs where this comparison is reported, which may suggest the 
explanation for the apparent lack of cognitive effects in the APP-NL-G-F studies. The 
interaction included a non-significant tendency for the WT to have more errors than the 
APP-NL-F mice at 9-10 months, and for this to reduce with age. Their numerical 
improvement with age can be rationalised simply as an effect of repeated testing, as prior 
experience in the radial arm maze can improve performance (Hall and Berman 1995). 
Furthermore, the WT mice tested by the Evans group seemed to make fewer errors at 14-
16 months than 10-12, although this was not part of their formal analysis (Evans et al. 
2018). As for the non-significant trend for increased errors by WT mice at 9-10 months it 
is tempting to speculate, considering the context of this thesis,  that this is an effect of 
marginally increase levels of beta-amyloid, which has been shown to allow improved 
spatial memory performance in the water maze (Puzzo et al. 2008). The APP-NL-F mice 
express the Swedish mutation at endogenous levels, which would lead to a gradual increase 
in beta-amyloid generation. There will be a point where the APP-NL-F hippocampi contain 
a concentration that is increased by a picomolar magnitude, as was applied in the 
experiment by Puzzo and colleagues, and it is possible that this experiment occurred within 
that window. Further evidence for this theory comes from the original paper by Saito et al, 
in which spontaneous alternation was compared between APP-NL-F, APP-NL=G-F and WT at 
6 months of age. The APP-NL-F performance appears superior to that of the WT, however 
this apparent effect was either not analysed nor discussed (Saito et al. 2014). APP-NL-F 
performance also exceeded that of WT controls in place preference reversal learning during 
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Intellicage experiments (Masuda et al. 2016). This comparison is purely speculative, but 
provides a hypothesis to account for the disparity between the genotypes at 9-10 months 
and strengthens the result of the mixed measures ANOVA. Further assessment of the APP-
NL-F  model at this age would be interesting in order to evaluate whether the trend observed 
in the current study was real. Collectively, the interaction of age and genotype in the spatial 
version of this foraging task represents an age-dependent decline in spatial working 
memory for the APP-NL-F. 
One drawback with using an appetitive reward is that water deprivation must be 
used to ensure engagement and motivation to complete the task. This allows performance 
to become susceptible to individual variations in body weight or hunger (Vorhees and 
Williams 2014). In this way this foraging task is similar to the RAM, in that ideally all 
subjects would need to be equally motivated to consume the food reward. No variations in 
body weight have been reported for the knock-in mice, but there is evidence that motivation 
decreases with amyloidosis, especially in the striatum (Hamaguchi et al. 2019). In these 
experiments, we measured no differences in engagement (time until the first pot was 
foraged) between the genotypes, indicating that motivation to complete the task was 
consistent between them. It is worth mentioning that the foraging-based tasks used in this 
chapter may be a more reliable measure of working memory in mice than other tasks such 
as the MWM, in which forced swimming induces a high stress response, as measured by 
release of glucocorticoids (Aguilar-Valles et al. 2005). Elevated stress levels may confound 
results by affecting cognitive performance independent of baseline hippocampal function 
(Francis et al. 1995, Lupien and McEwen 1997). Furthermore, chronic stress exacerbates 
amyloid pathology and expedites the age of onset of cognitive deficits (Green et al. 2006, 
Jeong et al. 2006, Srivareerat et al. 2009). The potential of these effects to confound results 
has theoretically been limited in this study due to the avoidance of the MWM task; although 
in absence of a specific comparison of stress response induced by both tasks, this cannot 
be concluded for certain. 
The design of this working memory task allows analysis of foraging strategies, as 
well as the dissociation of performance when using extra or intra maze cues. Meanwhile, 
the publication of transgenic PDAPP performance on this task by Evans et al (2018) 
permits direct comparison of second-generation AD model performance to that of a first-
generation model, as well as hippocampal lesioned animals. PDAPP mice scored a similar 
number of errors as WT littermates at 6-8 & 10-12 months, but significantly increased 
[154] 
errors at 14-16 months old. Unlike the study by Evans and colleagues, this experiment did 
not reveal any age-dependent and independent differences in strategy used by the AD 
model compared to WT controls. PDAPP mice exhibited significantly more chaining 
behaviour, and a greater likelihood of going from one pot to neighbouring pots rather than 
distal ones from 6 months old (Evans et al. 2018). This effect is not uncommon and has 
been reported in animals with hippocampal lesions or transgenic models of amyloid 
pathology in the radial arm maze and Morris water maze (Olton and Werz 1978, Huitron-
Resendiz et al. 2002). Considering the APP-NL-F mice did not demonstrate altered foraging 
strategy, and the PDAPP effect was age-independent, it suggests that it was caused by APP 
overexpression, rather than the accumulation of amyloid pathology. Recent studies using 
the APP-NL-F have highlighted such mechanisms, for example chronically elevated 
activation of the calpain-calpastatin pathway (Saito et al. 2016). Calpains are known to 
play an important role in synaptic activity and aberrant manipulation could influence 
working memory processes (Briz and Baudry 2017). In fact, inhibition of calpains in the 
APP/PS1 transgenic mouse model rescued spatial working memory performance, giving 
further evidence that deficits in transgenic mice may be due to artefacts induced by the 
genetic methodology employed to generate them (Trinchese et al. 2008). This further 
validates the APP-NL-F model which was generated to eradicate artefacts of overexpression 
and therefore be a more reliable tool to model mechanisms and pathology of Alzheimer’s 
Disease.  
The current study also identified no differences in perseverative behaviour 
(repeated responses without reward) in this experiment, which defined it as a mouse 
immediately returning to a pot it has just left. Meanwhile, 14-16-month old PDAPP mice 
accumulated a significantly greater number of these errors than their WT counterparts 
(Evans et al. 2018). The authors corrected for perseverative errors when reporting the total 
errors made by both genotypes in their study, in order to eradicate any potential 
confounding effects of this behaviour. However, as the APP-NL-F did not demonstrate this 
difference to controls, there was no need to apply this correction to the data in this chapter. 
It is worth noting that the measurement of perseverative behaviour in this study is similar 
to the compulsivity tests performed by Masuda et al in the IntelliCage characterisation of 
the knock-in AD strains. That paper reported significantly increased compulsivity from 
8months (Masuda et al. 2016). Increased returns to the same pot / arm / location have been 
associated with hippocampal lesions previously, as well as transgenic models of 
Alzheimer’s (Jarrard 1983, Daumas et al. 2008, Honey et al. 2007, Evans et al. 2018). 
[155] 
Therefore, perseverative behaviour may reflect the degree of dysfunction; while APP-NL-F 
mice have a comparatively mild pathology manifesting in compulsivity not being 
consistently observed across multiple test paradigms. 
In conclusion, this chapter presents the first replication of a spatial working memory 
deficit in the APP-NL-F mouse model. While there were no effects of age or genotype on the 
non-spatial version of the foraging task, experiment 9 revealed a significant decline in 
performance between 9-10 and 16-17 months of age in APP-NL-F mice. Furthermore, the 
lack of genotypic differences in engagement, foraging strategy or perseverative behaviour 
further validates knock-in models of amyloid pathology as more reliable reconstructions of 
familial Alzheimer’s Disease than transgenic lines. 
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Chapter 6 –  
Biochemical Characterisation of Aged 
APP-NL-F Mice 
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6.1 Chapter Overview 
Following behavioural characterisation of the APP-NL-F mice, biochemical 
analyses were undertaken to investigate potential changes in hippocampal receptor 
expression that may underpin the cognitive impairment reported in chapter 4. APP-NL-F 
mice accumulated soluble and insoluble Aβ42 with age. This was specifically due to the 
Swedish and Iberian mutations present in their endogenous APP gene, and not due to 
increased expression of APP, validating the rationale of using these mice as second-
generation, non-transgenic models. APP-NL-F mice also demonstrated an age-dependent 
increase in the inflammatory cytokine IL-1β which indicates an increased immune response 
with age.  
6.2 Chapter Introduction 
 The genetic techniques involved in engineering the APP-NL-F knock-in mice 
provides an opportunity to characterise the biochemical progression of amyloid pathology 
in the absence of abnormal APP overexpression seen in first-generation APP transgenic 
mice. The current literature concerning the impact of the Swedish and Iberian knock-in 
mutations on neuronal function is limited. However, the age-related accumulation of 
amyloid species, as well as deposition of amyloid plaques, was reported in the initial study 
by Saito et al (2014). They observed plaques detectable in the cortex and the hippocampus 
from 15 months of age. The proportion of the cortical and hippocampal area that displayed 
plaque deposition was 10% and 7% respectively in 24-month-old mice. Meanwhile, Saito 
et al also reported augmented inflammatory responses around plaques in aged APP-NL-F 
mice, as reactive gliosis was detectable by immunofluorescence analysis due to increased 
reactivity of antibodies to GFAP (glial fibrillary acidic protein) and IbaI, which are markers 
of astrocytosis and microgliosis. Excessive engagement of inflammatory pathways is a 
common feature of transgenic APP mouse models as well as human patients and is thought 
to be a downstream effect of amyloid pathology (see section 1.3). Although amyloid 
accumulation in humans leads to tau pathology, this is not usually observed in murine 
models of FAD expressing mutations in APP alone. Saito et al (ibid.) reported no tau 
hyperphosphorylation but did not publish the data. Due to the dearth of studies involving 
aged cohorts of APP-NL-F mice, it would be interesting to investigate any presentation of 
the biochemical hallmarks of both human AD and transgenic mouse models for comparison 
with the results of the Saito group. 
[158] 
 The decrease in immunoreactivity of the synaptic marker PSD95 that is common to 
APP transgenic models and has been recapitulated in aged APP-NL-F mice, indicating 
reduced density of synaptic connections (Saito et al. 2014, Zhang, Song, et al. 2015). 
However, little is known about the impact of the APP-KI on glutamate receptor dynamics 
that may underpin the cognitive decline of APP-NL-F mice reported in chapters 4 and 5. 
Increased production of Aβ has been linked to changes in synaptic plasticity in the 
hippocampus related to increased removal of glutamate receptors from the synapse, and 
despite electrophysiological techniques not being performed in the current study, an 
impairment in hippocampal LTP induction was previously observed in 6-month-old APP-
NL-F mice (Zhang et al. 2016). Dephosphorylation of GluA1 results in internalisation of 
AMPA receptors, and a reduction in pGluA1 has been reported in the APP-NL-G-F knock-in 
model alongside a hippocampal LTP impairment (Moriguchi et al. 2018). Therefore, one 
may hypothesise that the aged APP-NL-F mice would exhibit similar alterations in AMPA 
receptor dynamics. 
The aim of this experiment was to characterise biochemical features in the 
hippocampi of aged APP-NL-F mice that may relate to any underlying pathology of the 
model and offer a mechanism for the behavioural changes reported in chapters 4 and 5. The 
proposed analysis included age-related changes in the concentration of soluble and 
insoluble Aβ species, as well as inflammatory markers. The hypothesis of this experiment 
was that APP-NL-F mice would demonstrate increased Aβ accumulation with age in the 
absence of APP overexpression, as well as augmented detection of inflammatory markers 
compared to WT controls. Decreased activation of NMDA and/or AMPA receptors in the 
hippocampus, which are known to impact visuospatial memory, were also expected to 
elucidate putative mechanisms by which the accumulation of Aβ may have led to the 
observed decline in cognitive performance.  
[159] 
6.3 Experiment 11: APP Processing in APP-NL-F Mice 
▪ 6.3.1 – Introduction 
The aim of this experiment was to characterise the expression levels of proteins 
involved in APP metabolism and assess any accumulation of Aβ species with age in APP-
NL-F mice. Due to the specific nature of the knock-in method leading to expression of the 
Swedish and Iberian APP mutations, it was hypothesised that Aβ (particularly Aβ42) would 
accumulate and aggregate into insoluble plaques with age, in the absence of changes to 
APP expression.  
▪ 6.3.2 – Methods 
Subjects, Design 
 The samples analysed in this experiment were hippocampi isolated from the same 
cohort of WT and APP-NL-F mice reported in chapters 4 and 5. However, the eldest five 
APP-NL-F mice were not included in this ex vivo analysis as they were involved in a surgical 
pilot study. Four APP-NL-F mice from another cohort that had undergone identical 
behavioural testing were culled at 16 months of age and included in this experiment 
resulting in an n of 15 for the aged APP-NL-F group. Aged WT mice (n=16), 4-month old 
WT (n=9) and 4-month old APP-NL-F (n=9) were compared to the aged APP-NL-F group. 
Animals were culled between 72 and 96 hours following their final behavioural test and 
the hippocampus removed and flash-frozen in liquid nitrogen. Biochemical procedures 
including protein extraction, ELISA and Western blots were carried out by Chiara Favero 
under my supervision, and analysis of all data was carried out by myself. Protein was 
extracted from these hippocampi as described in chapter 2. The left hemisphere was utilised 
to produce tissue homogenate, while synaptosome preparations were obtained from the 
right hemispheres. ELISA and Western blot protocols have been described in chapter 2 
unless otherwise stated. 
Il-1β and TNFα ELISA 
 ELISA kits quantifying the concentration of inflammatory markers IL-1β 
(#DY401) and TNFα (#DY410) were obtained along with the ancillary reagent kit 2 
(#DY008) from R&D Systems (Minnesota, USA). Reagents and protocols were consistent 
for the identification of both markers, unless specified. The capture antibodies were 
reconstituted in 0.5 mL sterile PBS and diluted to the working concentration (8 μg/mL for 
[160] 
anti-IL-1β and 1.33 μg/mL for anti-TNFα). 100 μL of the diluted capture antibody was 
loaded onto 96-well plates and left at RT overnight. The next morning, wells were aspirated 
and washed 3 times with diluted wash buffer before being filled with 300 μL diluted reagent 
diluent and incubated for a minimum of 90 minutes. Following another plate wash cycle, 
100 μL of either serially diluted protein standards or samples of hippocampal homogenate 
were loaded onto the plate before a 2-hour incubation. The plate was then washed and 100 
μL detection antibody was loaded for another 2-hour incubation (200 ng/mL anti-IL-1β or 
75 ng/mL anti-TNFα). The detection antibody was then washed off before 100 μL diluted 
streptavidin-HRP solution (1:40) was loaded into the wells for 20 minutes. Colour reagents 
A and B were mixed in a 1:1 ratio and 100 μL was pipetted into each well after the 
streptavidin HRP had been washed out. After 30 minutes the reaction was halted by the 
addition of 50 μL stop solution. Absorbance was read at 450 nm and the concentrations 
were calculated by inputting the standard curve into GraphPad software. 
▪ 6.3.3 – Experiment 11 Results 
APP Metabolism 
ELISA kits were utilised in order to measure the accumulation of Aβ species in 
aged versus young APP-NL-F mice and the results are presented in figure 6.1. The figure 
shows Aβ40 (A) and Aβ42 (B) concentrations in the soluble fraction of the hippocampal 
homogenate. Both the young and aged groups exhibited normal distributions (Shapiro-
Wilke test p>0.05) and were compared by independent samples t-tests. There was a 
significant increase in Aβ40 quantity t(22) = 2.67; p=0.014; as well as Aβ42 t(22) = -13, 
p<0.0005. The insoluble fraction (6.1 C) was assessed for Aβ42 concentration only, due to 
only 20% of APP-NL-F mice exhibiting a detectable signal in the soluble Aβ40 ELISA (6.1 
A). The distributions of young and aged insoluble Aβ42 demonstrated opposite skewness 
and so were compared by the non-parametric Mann-Whitney U test which revealed a 
significant increase in the aged mice U = 122, z = 3.25, p=0.001. 
Western blot analysis was used to determine the expression levels of APP and 
BACE1 in young and aged WT mice (figure 6.2). A one-way ANOVA revealed significant 
differences between the groups F(3,48) = 5.61, p=0.002. Bonferroni post-hoc tests 
demonstrated that the aged WT mice had significantly greater expression of APP than both 
the young and aged APP-NL-F groups (p=0.034 and p=0.003 respectively, figure 6.2 B). 
[161] 
Meanwhile, assessment of BACE1 expression by one-way ANOVA revealed no significant 
differences between groups F(3,48) = 0.95, p=0.426 (figure 6.2 C). 
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Figure 6.1: Concentration of Aβ species increases with age in the hippocampus of 
APP-NL-F mice. ELISA results comparing the soluble levels of Aβ40 (A) and Aβ42 (B) 
as well as the insoluble Aβ42 (C) in hippocampi of 4-month old (n=9) or 16-17-month 
old (n-15) APP-NL-F mice. Error bars represent SEM. *p<0.05, ***p<0.005 
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Figure 6.2: Expression levels of APP and BACE1 in the hippocampus of APP-NL-F 
mice. (A) Representative Western blot images of the expression of APP and BACE1 in 
the hippocampus of young (4-month) and aged (16-17-month) WT and APP-NL-F mice. 
(B) Quantification of APP expression revealed significant differences between the aged 
WT group and both young and aged APP-NL-F groups (one-way ANOVA, *p<0.05). (C) 
Quantification of BACE1 protein expression. Young WT (n=9), young APP-NL-F (n=9), 
aged WT (n=16), aged APP-NL-F (n=15). Error bars represent SEM. 
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Tau Pathology 
Western blot analysis was performed to characterise the expression and 
phosphorylation of tau protein in young and aged APP-NL-F mice compared to WT 
littermates (figure 6.3). Two anti-phospho-tau antibodies were used which target epitopes 
that are associated with the hyperphosphorylation seen in AD patients, alongside an 
antibody that recognises total tau. PHF1 is a monoclonal antibody which binds tau that is 
phosphorylated at Ser396 and/or Ser404 (Otvos et al. 1994), while CP13 recognises 
phosphorylation of Ser202 (Petry et al. 2014). A one-way ANOVA revealed no differences 
in tau expression between the four different groups F(3,48) = 2.53, p=0.069. Inspection of 
the data from the PHF1 analysis revealed that the assumption of homogeneity of variance 
was violated, as reported by Levene’s test (p=0.009). Therefore, a Welch ANOVA was 
utilised to statistically compare the groups and this revealed a significant difference in the 
total amount of pSer396 and pSer404 tau protein: Welch’s F(3,24.15) = 8.093, p=0.001 
(figure 6.3 B). Games-Howell post-hoc analysis revealed a significantly greater expression 
in aged WT mice compared to young WT (p=0.001) and young APP-NL-F (p=0.013) mice. 
There was also a significant difference between the young WT and aged APP-NL-F groups 
(p=0.010). Finally, the quantification of PHF1 densities were normalised to total tau 
expression to examine relative phosphorylation, and analysed by a one-way ANOVA 
which revealed significant differences between groups F(3,48) = 4.90, p=0.005. Bonferroni 
post-hoc analysis demonstrated significantly greater PHF1-specific phosphorylation of tau 
in aged WT mice compared to young WT (p=0.012) and young APP-NL-F (p=0.035) samples 
(figure 6.3 B). 
Quantification of the pSer202-tau expression (CP13) followed a similar pattern. 
There was no homogeneity of variances (Levene’s test p=0.036) and a Welch ANOVA 
reported significant group differences: Welch’s F(3,23.07) = 7.18, p=0.001. There was 
significantly greater expression of pSer202-tau in the aged WT group compared to young 
WT and young APP-NL-F (p=0.001 and 0.032, Games-Howell post-hoc analysis, (figure 6.3 
C). There was also a significant increase in the relative phosphorylation of tau in the aged 
WT group compared to young APP-NL-F (p=0.013), as revealed by a significant one-way 
ANOVA, F(3,48) = 4.40, p=0.009 and Bonferroni post hoc test (figure 6.3 C). 
[164] 
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Inflammatory Markers 
 Analysis of the inflammatory markers IL-1β and TNF-α was performed using 
ELISA kits to determine any changes in concentration between young and aged WT and 
APP-NL-F mice (figure 6.4). A one-way ANOVA reported significant differences among the 
four groups F(3,48) = 3.43, p=0.025. Post hoc Bonferroni tests showed that aged APP-NL-F 
mice exhibited significantly increased levels of IL-1β compared to young (4-month-old) 
APP-NL-F animals (p=0.034, figure 6.4 A). Although this analysis indicated a specific effect 
for the NLF genotype, this cannot conclusion cannot be supported by the null hypothesis 
significance tests used. Furthermore, observation of the data suggested that there was a 
general increase in IL-1β expression with age across both genotypes.  
Assessment of TNF-α revealed no significant differences between groups: one-way 
ANOVA F(3,48) = 0.615, p=0.609 (figure 6.4 B). 
Figure 6.3: Expression and phosphorylation of tau protein in APP-NL-F mice. 
Western blot analysis of overall tau expression, as well as the phosphorylation at 
multiple serine residues. (A) Representative Western blot images in young (4 month) 
and aged (16-17 month) WT and APP-NL-F mice. (B) Quantification of tau protein, 
pSer396-tau and pSer404-tau expression using the PHF-1 antibody revealed significant 
differences between the groups. Analysis of relative phosphorylation normalised to tau 
levels (PHF-1 / Tau) showed a significant increase in the aged WT mice compared to 
young WT and APP-NL-F (one-way ANOVA). (C) Quantification of pSer202-tau protein 
expression and relative phosphorylation showed similar effects. Young WT (n=9), 
young APP-NL-F (n=9), aged WT (n=16), aged APP-NL-F (n=15). Error bars represent 
SEM. *p<0.05 
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Synaptic Markers 
 Synaptosome extractions were performed to analyse synaptic proteins in young and 
aged WT and APP-NL-F mice by Western blot (figure 6.5). The distributions of all datasets 
were assessed by the Shapiro-Wilke test and transformations were performed in order to 
ensure normal distributions. Differences in protein expression were analysed by one-way 
ANOVAs with Bonferroni post hoc tests where applicable, unless otherwise stated. There 
were no significant differences in PSD95 density F(3,45) = 0.84, p=0.477, indicating that 
there was no difference in the number of synapses between the groups (figure 6.5 B). The 
assumption of homogeneity of variance was violated for the expression of α7-NAChR 
(Levene’s test p<0.05), and so the groups were compared by Welch’s ANOVA. Although 
the ANOVA test was significant: Welch’s F(3,20.3) = 4.25, p=0.018, Games-Howell post-
hoc tests did not show significant differences between groups (largest effects: young WT 
vs aged APP-NL-F p=0.060, young APP-NL-F vs aged APP-NL-F p=0.053, (figure 6.5 B). 
 Expression of NMDA receptors (NR1) was significantly different between the 
groups F(3,45) = 27.1, p<0.0005, with Bonferroni post hoc tests revealing expression was 
lower in the young WT group than all three other groups (p<0.0005 for all, (figure 6.5 B). 
There was also a significant difference between the groups in expression of the NR2B 
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Figure 6.4: Quantification of inflammatory markers in APP-NL-F mice. ELISA analysis 
of the concentrations of IL-1β (A) and TNF-α (B) in the hippocampi of young WT (n=9), 
young APP-NL-F (n=9), aged WT (n=16), aged APP-NL-F (n=15) mice. Error bars represent 
SEM. *p<0.05 
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subunit F(3,45) = 10.9, p<0.0005, with the young WT group showing significantly more 
expression than the young APP-NL-F (p=0.044) and both aged groups (p<0.0005 for both, 
(figure 6.5 C). The one-way ANOVA comparing expression of the phosphorylated form of 
NR2B (pY1472) did not show significant effects F(3,45) = 1.9, p=0.133; however, when 
the relative phosphorylation was calculated by normalising to the amount of NR2B, there 
was a significant group effect F(3,45) = 10.2, p<0.0005. Post hoc tests showed that the 
young WT group had significantly less phosphorylation of NR2B than the other three 
groups (p<0.001 for all, (figure 6.5 C). 
 The expression of the AMPA subunit GluA1 was also assessed by one-way 
ANOVA, revealing no significant differences in expression of the protein F(3,45) = 1.9, 
p=0.142 (figure 6.5 D). There was also no significant result when comparing the amount 
of phosphorylated GluA1 F(3,45) = 1.3, p=0.274. However, there were significant 
differences between the groups when comparing the relative phosphorylation F(3,45) = 
3.2, p=0.031. The young WT group had significantly less phosphorylation than the aged 
APP-NL-F group, as shown by Bonferroni post hoc tests (p=0.023, figure 6.5 D). 
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6.3 Chapter Discussion 
 The main aim of this experiment was to validate the APP-NL-F mouse model as a 
non-transgenic model of FAD. The results confirmed that aged APP-NL-F mice 
demonstrated an age-dependent accumulation of both soluble and insoluble Aβ42 in the 
hippocampus, in the absence of increased APP expression. The ELISA data were consistent 
with the reports of Saito et al as the concentration of Aβ42 in aged APP-NL-F was over an 
order of magnititude greater than that of Aβ40. In fact, the original publication describing 
the APP-NL-F mice showed no age-dependent increase in soluble Aβ40, which may underpin 
why, in the current experiments, only three mice exhibited strong accumulation. The 
accumulation of Aβ42 was not simply due to increased amount of APP or BACE1, as aged 
APP-NL-F mice did not show increased expression of these proteins. In fact, aged WT mice 
mice actually showed significantly higher APP expression than both young and aged APP-
NL-F mice. However, this seems to be driven by the non-significant increase in expression 
between young and aged WT mice. To my knowledge, an age-related increase in APP 
expression is not a phenomenon that has been reported in C57Bl/6 mice and the potential 
cause is unclear. However, most studies investigating APP expression examine FAD 
models rather than WT mice, thus it may not have been thoroughly scrutinised. Replicating 
this result using an ELISA to quantify APP expression levels in each group would increase 
the reliability of this result.  
In addition to the numerical increase in APP expression, the aged WT mice also 
displayed significantly increased phosphorylation of tau compared to young WT and APP-
NL-F, consistent across two antibodies specific to separate phosphorylation epitopes. While 
the lack of genotypic difference was expected, due to previous data on these mice, the effect 
of age in WT mice was not. Similar to APP,  the number of studies investigating the 
Figure 6.5: Western blot analysis of hippocampal synaptosomes in APP-NL-F mice. 
Representative Western blot images of various synaptic markers. (A) Representative 
Western blot images in young (4 month) and aged (16-17 month) WT and APP-NL-F 
mice. (B) Quantification of protein expression for PSD95, α7 nicotinic acetylcholine 
receptor (α7-NAChR) and total NMDA receptor (NR1). (C) Quantification of the 
expression of NR2B and phosphorylated NR2B (pY1472), as well as the relative 
phosphorylation of the receptor. (D) Quantification of the expression of GluA1 and 
phosphorylated GluA1, as well as the relative phosphorylation of the receptor. Young 
WT n=9, young APP-NL-F n=9, aged WT n=16, aged APP-NL-F n=15. Error bars represent 
SEM. *p<0.05, ***p<0.001 
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phosphorylation of tau in WT mice is limited, however, one study has reported an increased 
expression of phosphorylated tau from 10 to 22 month old C57Bl/6 mice (Bu et al. 2018). 
The lack of a significant age-related increase in APP-NL-F mice is therefore interesting; it 
potentially demonstrates some protective mechanism offered by the amyloid accumulation 
in these mice, however, it more likely reveals a lack of sensitivity combined with the 
conservative ANOVA test, particularly in the results of the PHF-1 antibody.  
Inflammatory markers were also analysed to investigate any changes in immune 
activation between the groups. While there were no changes in TNF-α, the IL-1β ELISA 
was inconclusive. Other groups have shown effects of both genotype and age on immune 
activation in these knock-in mice, reporting that microglial and astroglial activation 
increases from 6 to 18 months in APP-NL-F mice, while also being significantly greater than 
WT levels (Saito et al. 2014, Masuda et al. 2016). The explanation for the lack of effects 
observed here may be the difference in techniques used. The current experiment used 
ELISA analysis to quantify inflammatory markers in hippocampal homogenate. While this 
provides information of the general state of immune system activation, the other studies 
used histological techniques which permitted selective, in situ examination of the 
environment surrounding plaques. They observed an increased number of activated 
microglia and astroglia in close proximity to these plaques. The precision enabled by 
histochemical techniques is lost during the homogenisation required for ELISA analysis. 
Alternative studies using ELISA analysis of transgenic APP models have identified an 
increase in inflammatory cytokines that correlates with amyloid burden (Patel et al. 2005). 
It is possible that the lack of significant effects in the current experiment represents the fact 
that these knock-in model exhibit more subtle pathology compared to transgenic mice. 
Synaptic markers and glutamate receptors were analysed with the aim of providing 
a mechanism for the cognitive deficits observed in the aged APP-NL-F group described in 
chapters 4 and 5. There was no difference in synapse density between the groups, which 
was inconsistent to previous studies which have reported a reduction in aged APP-NL-F mice 
(Saito et al. 2014, Zhang, Wu, et al. 2015). An explanation for this discrepancy may be the 
alternative techniques used by other studies. Zhang and colleagues showed a 26% reduction 
in PSD95 immunoreactivity in lysates of neuronal cultures derived from APP-NL-F mice. 
Saido et al examined brain sections, observing decreased immunoreactivity of both PSD95 
and synaptophysin in close proximity to Aβ plaques. The sensitivity provided by analysing 
synaptic density around plaques in situ is lost during the preparation of synaptosomes. The 
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consistency of synaptic density here indicated by PSD95 immunostaining suggested that 
any changes in the density of other receptors were not simply due to alterations in the 
number of synapses. There was a significant effect of group when analysing the α7-NAChR 
but, although the aged APP-NL-F group showed numerically increased expression, this did 
not reach significance during post hoc analysis. Increased expression of this receptor has 
been observed in the brains of AD patients and aged Tg2576 mice (Chu et al. 2005, Dineley 
et al. 2001). However, further discussion of the role of this receptor in both the 
physiological and pathological roles of Aβ will be presented in chapter 8. 
Analysis of glutamate receptors produced an interesting result in the young WT 
group which showed significantly lower overall expression of NMDA receptors, yet a 
significantly higher amount of the NR2B subunit. Although this result seems contradictory, 
the decrease in total NMDA receptors may be conveyed by expression of other subunits 
such as the NR2A. The young WT group also exhibited significantly lower relative 
phosphorylation of NR2B than all groups which was correlated with a numerical reduction 
in GluA1 phosphorylation. The genotypic difference in 4-month old mice is not present at 
17 months and the expression of both aged groups is statistically unchanged from that of 
young APP-NL-F mice, potentially suggesting that this group displays an effect of premature 
aging. The changes in receptor dynamics of young WT mice did not result in differences 
in cognitive performance compared to APP-NL-F mice of the same age in the tests described 
in chapters 4 and 5. However, there is some evidence of functional differences in APP-NL-F 
mice at 3 months of age. Shah et al (2018) demonstrated that 3-month-old APP-NL-F mice 
exhibited a deficit in spatial reversal learning in the MWM compared to APP-NL control 
mice. This was correlated with hypersynchronous functional connectivity within the 
hippocampal network, revealed by resting-state functional MRI, that did not exist when 
mice were reassessed at 7 months of age. While further analysis is required to investigate 
the potential relevance of that study to the observed changes in NMDA receptor expression 
in the current experiment, these results indicate that abnormal APP processing may lead to 
changes in neuronal function even at a young age, prior to Aβ accumulation.  
In summary, this chapter has investigated the biochemical changes associated with 
the Swedish and Iberian mutations expressed in the APP-NL-F model, as well as how these 
change with age. The age-dependent accumulation of Aβ40 and Aβ42 in absence of APP 
hyperexpression validates the model as being non-transgenic. The lack of tau pathology or 
extensive inflammation further present this mouse as a model of preclinical AD. 
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Chapter 7 –  
2B3-Treatment Causes Dissociated 
Effects on Cognition in Aged APP-NL-F 
and WT mice.  
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7.1 Chapter Overview 
Anti-amyloid therapies have been the current primary focus of research into treating 
AD patients. However, the results of Chapter 3 suggest that this approach may have 
detrimental effects on cognition in patients who lack severe amyloid accumulation. 
Although many preclinical studies have reported beneficial effects of clearing amyloid, 
these have been against the background of APP overexpression and very few have 
examined the effect of such interventions in healthy WT control mice. Therefore, this 
chapter details the effect of 2B3 administration on memory function in an aged cohort of 
APP-NL-F as well as aged WT controls. Experiment 12 first replicated the OiP deficit 
reported in experiment 5 in un-treated mice, before the two genotypes underwent chronic 
icv infusion of either 2B3 or a control antibody. The results showed that, while the control 
antibody did not alter performance of either genotype in the OiP test relative to baseline, 
2B3 administration produced an intriguing dissociation in associative recognition memory 
in WT and APP-NL-F mice. Although the anti-APP antibody rescued performance in the 
APP-NL-F mice, it induced a deficit in WT mice. In Experiment 13 ex vivo analysis of the 
hippocampal tissue revealed that the 2B3 significantly reduced Aβ40 in the WT mice and 
Aβ42 in the APP-NL-F mice. Western blot analysis also revealed changes in glutamate 
receptor dynamics, with significantly lower relative phosphorylation of AMPA receptor 
subunit GluA1 being associated with the groups that showed intact memory performance 
7.2 Chapter Introduction 
Putative therapeutic treatments for AD have mainly focused on two amyloid-related 
strategies: small molecule inhibitors of the enzymes responsible for APP metabolism and 
immunotherapies that target Aβ to augment its clearance by the immune system. Despite 
promising results in preclinical studies, these strategies have consistently failed in clinical 
trials due to lack of beneficial effect on cognitive outcomes. In fact, various trials have 
actually reported significant worsening of cognitive decline in the groups of patients 
receiving higher doses of the treatments. Despite these alarming results, the development 
of anti-amyloid therapies has continued. The rationale, mechanisms and preclinical success 
of both β-secretase inhibitors and immunotherapies are summarised in section 1.4.5, and 
this section will evaluate the development and clinical performance of these therapies. 
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▪ 7.2.1 – Anti-Amyloid Immunotherapy 
The concept of immunotherapy has been introduced in section 1.4.5 along with the 
putative mechanisms underpinning this therapeutic strategy. Briefly, immunotherapy in the 
context of AD involves the use of anti-Aβ antibodies to clear plaques and relieve other 
symptoms of amyloid pathology. The antibodies can either be exogenous (passive 
immunotherapy) or raised by the patient’s own immune system (active immunotherapy). 
Active Immunotherapy 
The first in vivo studies of active immunotherapy involved injection of Aβ42 as an 
immunogen. While (Schenk et al. 1999) reported significant inhibition of amyloid 
pathology development following immunisation of both young and old transgenic mice, 
(Das et al. 2001) observed an effect only after treating young transgenic mice. Other studies 
have used fibrillar Aβ as the immunogen. Oddo et al (2006) reported that, although 
vaccination of 18-month-old 3xTg-AD mice did not reduce plaque number, the amount of 
insoluble Aβ or insoluble tau was reduced and cognitive performance significantly 
improved. This evidence gave further credence to the contemporary view that soluble, 
oligomeric Aβ is responsible for the synaptotoxicity in AD. Moreover, while a similar 
vaccine reduced the plaque burden of aged beagles, the absence of a change in oligomer 
concentration was accompanied by a lack of cognitive improvement (Head et al. 2008). 
Active immunotherapy has also been trialled in the clinic. AN1792 (Janssen, 
Pfizer), which used the full-length Aβ42 peptide as the immunogen, was enrolled in a phase 
II trial that was interrupted following reports of meningoencephalitis in 6% of the 300 
patients (Gilman et al. 2005). Long-term follow-up investigations reported significantly 
reduced functional decline in 25 “antibody responders” (patients in whom anti-AN1792 
antibodies had been detected) compared to patients in the placebo group (Vellas et al. 
2009). Meanwhile neuropathological assessment of 8 patients receiving the vaccine 
showed significantly increased plaque clearance in the cerebral cortex that was not 
associated with cognitive improvement, even in the brains with virtually complete plaque 
removal (Holmes et al. 2008). A further follow-up study was recently published which 
analysed neuropathology in 22 patients 15 years after the initial vaccination (Nicoll et al. 
2019). They reported evidence of plaque clearance that had a significant inverse correlation 
with post-vaccination anti-AN1792 antibody production, indicating that the treatment 
exerted a persistent response. However, despite the beneficial effect on plaque reduction, 
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most patients had still progressed to severe stages of dementia, including those with 
extensive plaque reduction. The fact that clearance of amyloid plaques did not arrest 
cognitive decline indicated that plaques are not the appropriate target in patients with AD. 
Approaches to remove plaque burden are not suitable for late stage AD patients where there 
is established tau pathology and neurodegeneration.  
Analysis of the AN1792 clinical trial provoked interest in the development of 
second-generation immunogens with shorter N-terminal fragments of the peptide. These 
reduced brain amyloid accumulation and enhanced memory acquisition in transgenic APP 
mice (Wiessner et al. 2011, Maier et al. 2006, Seabrook et al. 2007). An initial phase I trial 
of CAD106 (Novartis) reported a favourable safety profile and 74% of people responded 
to the vaccine by generating anti-Aβ antibodies (Winblad et al. 2012). In a 90-week phase 
IIb study enrolling 121 patients with mild AD, strong antibody responses were observed in 
55% and 81% of those receiving the 150 and 450 μg dose regimes, respectively 
(Vandenberghe et al. 2017). There was an inverse correlation between antibody response 
and amyloid PET uptake but there was no difference in cognitive decline. Another vaccine, 
ACC-001 (Janssen/Pfizer) has demonstrated a similar safety profile and capability of 
provoking an antibody response, but a beneficial effect on plaque load or cognitive function 
has not been reported (van Dyck et al. 2016, Hull et al. 2017). Although active 
immunotherapy has resulted in no clinical benefit in patients diagnosed with dementia it 
remains a possible intervention in pre-symptomatic stages of the disease. 
Passive Immunotherapy 
Passive immunotherapy with anti-Aβ antibodies does not rely on stimulation of the 
host’s immune system but results in a similar clearance of amyloid following systemic 
injection in PDAPP mice (Bard et al. 2000). Another study observed a rapid 1000-fold 
increase in plasma Aβ along with its clearance from the brain following peripheral injection 
of the m266 mAb (DeMattos et al. 2001). Administration of this antibody was also 
associated with a rapid rescue of object recognition and spatial working memory deficits 
(Dodart et al. 2002). Kotilinek et al (2002) published similar results with BAM-10, an Aβ 
N-terminal region-targeted antibody, which reduced amyloid pathology (significant 
reductions in both soluble and insoluble Aβ) and improved cognitive function in Tg2576 
mice. Passive anti-Aβ immunotherapy has also demonstrated the potential to influence 
other symptoms of amyloid pathology in multiple FAD models, such as synaptic plasticity 
impairment, dendritic spine loss and reactive gliosis (Chauhan and Siegel 2002, 2003, 
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Klyubin et al. 2005, Spires-Jones et al. 2009). Antibody treatment also reduced the rate of 
early aggregation of hyperphosphorylated tau in 12-month-old 3xTg-AD mice (Oddo et al. 
2004). However, this effect did not extend to more advanced stages of NFT pathology in 
older mice; further hinting at a therapeutic window that is restricted to early stage AD. 
Consistent with other mechanisms of anti-AD treatments, clinical trials of passive 
immunotherapies have not been successful (Wisniewski and Goñi 2015). Bapineuzemab 
(Pfizer) was the first antibody to progress to a phase III trial, but was terminated in 2012 
due to the lack of clinical benefit (Vandenberghe et al. 2016). A meta-analysis of six 
randomised controlled trials revealed that, although the treatment provoked no safety 
concerns, significantly reduced the concentration of phosphorylated tau in the CSF and 
reduced brain Aβ burden compared to placebo, no beneficial effect was observed in the 
ADAS-Cog and MMSE cognitive assessments (Abushouk et al. 2017). An alternative 
immunotherapy, Solanezumab (Eli Lilly), is the humanised m266 antibody targeting an 
epitope on the mid-region of Aβ that is only accessible in monomers. It failed its primary 
endpoint, which was a reduction in cognitive decline measured on the 14-item cognitive 
subscale of the Alzheimer Disease Assessment Scale (ADAS-cog). Consequently its 
development was terminated in 2017 due to insufficient evidence that it could demonstrate 
a meaningful benefit to patients with prodromal AD from multiple phase III trials (Siemers 
et al. 2016, Honig et al. 2018). 
 One consequence of these failed clinical trials is that it has led to a refinement of 
patient inclusion criteria, specifically the selection of earlier stage patients with confirmed 
amyloid pathology (Schilling et al. 2018). Crenezumab (Genentech/AC Immune), 
gantenerumab (Hoffman - La Roche) and aducanumab (Biogen/Neurimmune) are 
antibodies that recognise fibrillar Aβ and have all demonstrated the potential to reduce 
amyloid burden in AD patients in early stage clinical trials (Bohrmann et al. 2012, 
Adolfsson et al. 2012). A phase Ib trial of aducanumab in 166 individuals with prodromal 
or mild AD even reported slowing of cognitive decline (Sevigny et al. 2016). However, the 
termination of the phase III trials involving crenezumab and aducanumab was announced 
in January and March 2019 following interim analyses that the treatments would not 
achieve their primary endpoints (ALZFORUM 2019). While the results from the 
aducanumab trials have yet to be disclosed; Roche revealed that in the 13% of 813 enrolees 
for whom data was available, crenezumab treatment had been ineffectual (International 
Conference on Alzheimer’s and Parkinson’s Diseases 2019). 
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▪ 7.2.2 – Small Molecule β-Secretase Inhibitors 
While interest in γ-secretase inhibitors has diminished due to off-target effects 
caused by their impact on alternative substrates, BACE1 has remained the premier anti-
AD target since its discovery. The concept of BACE1 inhibition as a therapeutic method 
was strengthened by reports of genetic KO of the enzyme alleviating the neuropathology 
and cognitive deficits exhibited by aged transgenic models (Ohno et al. 2004). However, it 
is important to note that BACE1 deficiency alone caused sensorimotor impairments, spatial 
memory deficits and hypersensitivity to seizure, indicating that the enzyme plays an 
important physiological role either due to its interaction with APP or its numerous other 
substrates (Laird et al. 2005, Kobayashi et al. 2008). The alternative pathways in which 
BACE 1 has been implicated include neuron myelination, axon guidance and neurogenesis 
(Hu et al. 2006, Hu et al. 2013, Hitt et al. 2012). Heterozygous deletion of BACE1 resulted 
in the rescue of synaptic function and memory performance in 5xFAD mice (Kimura, Devi, 
and Ohno 2010), indicating that partial inhibition but not total eradication of BACE1 
activity may reduce Aβ burden without inducing a detrimental effect on neuronal function. 
Another study replicated some of the phenotype observed in BACE1 KO mice 
following chronic administration of two separate BACE1 inhibitors in WT mice, further 
demonstrating the physiological importance of the enzyme (Filser et al. 2015). Aβ levels 
were reduced in both the cortex and CSF to below 50% of that measured in vehicle-treated 
mice. LTP was reduced in hippocampal slices and dendritic spine formation was disrupted 
in layer V pyramidal neurons, while they also reported cognitive deficits in the Y-maze 
and novel object recognition. This is the only study to date that has investigated the effect 
of pharmacological inhibition of BACE1 on synaptic function and cognition in WT mice 
and it again raised the question of whether the detrimental effects were caused by the 
reduction of interaction with APP or its alternative substrates. Experiments in Chapter 3 
sought to answer this and hinted at the former explanation. Considering the BACE1 
inhibitors LY2811376, LY2886721 (both Eli Lilly) and verubecestat (Merck) have exerted 
beneficial effects on amyloid pathology in aged transgenic models of AD (May et al. 2011, 
May et al. 2015, Kennedy et al. 2016), it is possible that the impact of treatment depends 
on the initial severity of amyloid pathology. In fact, when Verubecestat was administered 
to prodromal AD patients in a clinical trial of 1454 patients, those receiving the highest 
dose (40 mg/day) demonstrated a significantly larger cognitive decline and were more 
likely to progress to AD than patients who had received placebo (Egan et al. 2019). 
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Several BACE1 inhibitors have progressed to clinical trials of AD patients and all 
failed to reduce cognitive decline. LY2811376 (Eli Lilly) was the first oral non-peptidic 
BACE1 inhibitor to demonstrate reduced Aβ levels in both animals and humans (May et 
al. 2011). LY2811376 was not progressed beyond phase I clinical trials, as chronic 
exposure toxicology studies revealed off-target pathology. A second-generation compound 
from Eli Lilly showed similar preclinical data, and progressed to a phase II trial. However, 
the drug was discontinued after 15 months due to potential liver toxicity (May et al. 2015). 
Another drug that showed promising results in rats and phase I trials was MK-3931 
(Verubecestat, Merck) (Kennedy et al. 2016). This drug entered a phase 2/3 trial of 1958 
patients with a diagnosis of mild-to-moderate AD. However, the trial was discontinued 
following a mid-term review that indicated a positive clinical effect was unlikely to be 
achieved (Egan et al. 2018). Moreover, verubecestat treatment was associated with adverse 
events such as rash, sleep disturbance, suicidal ideation, weight loss and hair colour change.  
In order to selectively reduce BACE1 cleavage of APP, the present study used the 
antibody 2B3, which prevents A cleavage by steric hindrance (Thomas et al, 2011). In 
transgenic mice overexpressing human mutant APP, icv infusion of 2B3 into the lateral 
ventricle significantly reduced the concentration of soluble Aβ40 and rescued an OiP 
associative recognition memory deficit (Evans et al. 2019). However, APP overexpression 
causes a number of brain changes that are not specific to A, with one estimate suggesting 
that up to 60% of the phenotypes expressed by transgenic mice, such as increased tau 
phosphorylation and somatodendritic atrophy, are artefactual (Saito et al., 2014). Assessing 
the behavioural and biochemical impact of 2B3 in knock-in mice provides a critical test of 
the hypothesis that excess A deposition is a driving force in cognitive decline.  
In summary, while targeting amyloid remains an active area of clinical 
investigation, the fact that disruption of Aβ processing (even using the most clinically 
effective drugs) does not halt cognitive decline suggests that other factors contribute to 
neurodegeneration and that treatment of those with symptomatic AD will require a multi-
target approach. The fact that the verubecestat trial with prodromal patients returned an 
even more severe outcome suggests that modulation of APP may need to be finely balanced  
in individuals with mild or non-existent amyloid pathology. The results of Chapter 3 
support this hypothesis, and, as 2B3 has previously been shown to rescue cognitive deficits 
in a transgenic hAPP model of AD, the present chapter sought to concurrently examine the 
impact of the antibody in APP-NL-F and WT mice. 
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7.3 Experiment 12: Effect of 2B3 Treatment on OiP Task 
▪ 7.3.1 – Introduction 
The aim of this experiment was to investigate the effects of anti-APP antibody 2B3 
on cognition performance depending in both WT and APP-NL-F  mice. The hypothesis was 
that 2B3 would rescue the OiP deficit exhibited by aged APP-NL-F mice, while inducing an 
impairment of memory in aged WT littermates.  
▪ 7.3.2 – Methods 
Subjects, Design 
 The subjects were a cohort of 16-17 months old male APP-NL-F and WT mice. There 
were 24 mice of each genotype that had been housed in cages of four since weaning (two 
APP-NL-F, two WT in each; littermates where possible). The OiP test protocol was the same 
as that described in Chapter 2, with the exception that animals underwent two trials of the 
OiP task both before and during 2B3 treatment. The control treatment was the same IgG 
described in Chapter 3. The concentration of 2B3 used in this experiment was 2.71 mg/mL. 
Baseline OiP performance was measured for all mice, before the mice in each cage 
were split into the four distinct treatment groups (APP-NL-F 2B3; APP-NL-F IgG; WT 2B3; 
WT IgG), ensuring that DR scores within each genotype were matched as closely as 
possible. Object sets, and the objects that switched positions were counterbalanced both 
between groups and across the two surgery timepoints (pre vs post). The surgical procedure 
was described in Chapter 2. Briefly, osmotic minipumps (Alzet) were filled with antibody 
solution and attached to a cannula inserted into the lateral ventricle. Nine days following 
the surgery, mice underwent habituation to the empty arena before habituation to objects 
on days 10 and 11, which consisted of three 5-minute sessions with four different objects. 
OiP testing took place on days 12 and 14 and mice were culled and brain tissue collected 
immediately following the final test session. 
▪ 7.3.3 – Experiment 12 Results 
Sample Phase Contact Times 
Table 7.1 shows the mean total contact time throughout the sample phases of the 
experiment. Visual inspection of the data indicates a decrease in exploration from sample 
phase 1 to 3. All the data were transformed by log10 in order to ensure that all groups 
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exhibited normal distributions (Shapiro-Wilke test p>0.05). The sample phase contact 
times were analysed by a repeated measures ANOVA with sample phase and surgery 
timepoint (pre- vs post-) as within-subject factors and genotype and antibody treatment as 
the between subjects’ factors. 
 The ANOVA revealed significant main effects of sample phase F(2,88) = 61, 
p<0.0005 and genotype F(1,44) = 5.9, p=0.02. There was no main effect of surgery stage 
F(1,44) = 0.55, p=0.461 or antibody treatment F(1,44) = 0.41, p=0.524. There were no 
significant interactions: surgery*phase F(2,88) = 0.43, p=0.653; surgery*treatment F(1,44) 
= 0.072, p=0.789; surgery*genotype F(1,44) = 0.089, p=0.767; phase*treatment F(2,88) = 
0.33, p=0.720, phase*genotype F(2,88) = 0.098, p=0.907; genotype*treatment F(1,44) = 
0.49, p=0.486; phase*surgery*treatment F(2,88) = 0.057, p=0.944; 
phase*genotype*treatment F(2,88) = 0.27, p=0.767; surgery*genotype*treatment F(1,44) 
= 0.22, p=0.640; phase*surgery*genotype*treatment F(2,88) = 2.05, p=0.135.  
Pairwise comparisons on the main effect of sample phase showed that there was 
significantly greater contact time in sample phase 1 than in both phases 2 and 3 (p<0.0005 
for both). Sample phase 3 also showed significantly less exploration than in phase 2 
(p=0.008). Therefore, all mice demonstrated habituation to the objects across the three 
sample phases. The main effect of genotype revealed that the overall APP-NL-F mice 
explored objects significantly less than their WT counterparts and this was consistent over 
both surgical timepoints. 
 
Sample Phase Contact Times 
Pre-Surgery Post-Surgery 
WT APP-NL-F WT APP-NL-F 
IgG 2B3 IgG 2B3 IgG 2B3 IgG 2B3 
Sample 
Phase 1 
Mean 67 78 67 55 78 75 63 67 
SD 20 25 20 15 30 31 14 27 
Sample 
Phase 2 
Mean 56 55 46 43 53 53 48 47 
SD 22 20 16 11 26 27 18 16 
Sample 
Phase 3 
Mean 47 42 42 36 51 52 43 37 
SD 13 9 16 5 21 21 15 8 
 
 
Table 7.1: Mean contact times across the OiP sample phases pre- and post-infusion 
of 2B3 or control IgG in WT and APP-NL-F mice. Contact time is measured in seconds, 
SD = standard deviation. 
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Test Phase Contact Times 
 The contact times for objects both in familiar or novel locations in the test phase of 
the object in place task are recorded in figure 7.1. The Shapiro-Wilke test reported non-
normal distributions in specific datasets (p<0.05). Log10 transformations of all groups 
generated normal distributions and the data were analysed by a 2x2x2x2 repeated measures 
ANOVA which analysed the main effects of object-place (novel or familiar), surgery stage, 
genotype and treatment. 
 The ANOVA revealed a significant main effect of object-place F(1,44) = 124, 
p<0.0005. Pairwise interactions showed that overall, there was greater exploration of 
objects that had been switched to novel spatial locations. There were no significant main 
effects of surgery F(1,44) = 0.16,  p=0.690; treatment F(1,44) = 0.008, p=0.930 or genotype 
F(1,44) = 0.70, p=0.408. There was a significant four-way surgery*object-
place*genotype*treatment interactions: F(1,44) = 18, p<0.0005. There were also other 
significant interactions: object-place*genotype F(1,44) = 46, p<0.0005; object-
place*genotype*treatment F(1,44) = 25, p<0.0005; object-place*genotype*surgery 
F(1,44) = 20, p<0.0005. F values were <1 for all remaining interactions: surgery*genotype; 
surgery*treatment; surgery*genotype*treatment; object-place*treatment; object-
place*surgery; object-place*surgery*treatment. 
  Simple main effects analysis on the four-way interaction revealed that WT mice 
preferentially explored different over same object-place pairings before surgical 
treatment (both p<0.0005). However, after surgery, only WT mice treated with IgG but not 
2B3 demonstrated this preference (p<0.0005 and p=0.813, respectively). In contrast, APP-
NL-F mice exhibited the opposite pattern: there was no significant difference in contact time 
with the objects in novel locations before 2B3 or control IgG treatment in APP-NL-F mice  
(p=0.553 and p=0.808 respectively) or during infusion of the IgG (p=0.750). However, 
APP-NL-F mice receiving 2B3 did explore the different object-place pairings significantly 
more than familiar ones (p<0.0005). Furthermore, there were no simple main effects of 
treatment prior to the surgery (all p>0.4). In contrast, following the surgery, there was a 
significant simple main effect of treatment in both genotypes on the contact with objects 
that had remained in familiar locations during the test phase. WT mice receiving 2B3 
explored these objects significantly more than those receiving 2B3 (p=0.013); meanwhile 
APP-NL-F mice showed a reduction in exploration (p=0.009). There were no significant 
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effects of treatment in either genotypes contact with objects in novel locations following 
surgery (WT p=0.085; APP-NL-F p=0.855). 
 There was also a significant simple main effect of surgery stage on contact time 
with both object types for the WT 2B3 group. These mice explored the novel object-place 
associations significantly less after the surgery (p=0.007) while spending more time with 
the familiar pairings (p=0.029). APP-NL-F mice treated with 2B3 spent less time exploring 
objects that had remained in the same location during treatment compared to before the 
surgery (p=0.004), whereas contact time with objects that had switched positions did not 
change (p=0.344). There were no significant simple main effects of surgery state on contact 
times in the IgG treated group with either object type (p>0.5). Moreover, prior to the 
surgery there were significant main effects of genotype on contact time with the objects in 
novel locations in both treatment groups, as WT mice showed greater contact times (IgG 
p=0.025; 2B3 p=0.004). There was no difference on the contact times with objects in 
familiar locations (IgG p=0.051; 2B3 p=0.130). Following surgery, the significant effects 
of genotype were evident on contact times with the familiar object-place pairings. WT IgG 
mice showed reduced contact compared to APP-NL-F IgG mice (p=0.023), while the 
opposite (increased contact) was observed in WT 2B3 versus APP-NL-F 2B3 mice 
(p=0.005). There was no significant differences in exploration of objects in novel locations 
in the WT IgG vs APP-NL-F IgG and WT 2B3 vs APP-NL-F 2B3 comparisons (p=0.051 and 
0.768 respectively). 
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Test Phase Discrimination Ratio 
 Figure 7.2 shows the contact preferences during the test phase expressed as 
discrimination ratios for each group, which negates potential confounding effects of 
differences the decreased contact exhibited by APP-NL-F mice. These DRs are displayed in 
figure 7.2. The datasets were all normally distributed and were analysed by a 2x2x2 mixed 
measures ANOVA in which surgery (pre- vs post-) was a within subjects’ factor, and 
antibody treatment and genotype were between subjects’ factors. The ANOVA revealed a 
significant main effect of genotype F(1,44) = 38, p<0.0005), but no main effects of surgery 
F(1,44) = 0.044, p=0.835; or treatment F(1,44) = 1.4, p=0.240. There was no 
surgery*treatment interaction F(1,44) = 0.66, p=0.422, However the surgery*genotype 
Figure 7.1: Mean contact times of WT and APP-NL-F mice in the test phase of the 
object-in-place task pre- and post-infusion of 2B3 or control antibody. 
Measurement in seconds of exploration of objects in either novel or familiar locations. 
Error bars represent SEM, n=12 for all groups. 
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F(1.44) = 24, p<0.0005; genotype*treatment F(1,44) = 23, p<0.0005; and 
surgery*genotype*treatment F(1.44) = 23, p<0.0005 interactions were significant. 
 The simple main effects analysis of the three-way interaction revealed that WT 
mice achieved significantly higher DRs than APP-NL-F mice prior to the surgery, as did the 
WT mice in the IgG group after surgery (all p<0.0005). However, the opposite pattern 
occurred in the 2B3 infused groups, as the APP-NL-F mice demonstrated better 
discrimination than WT mice (p<0.0005). Meanwhile, while there were no simple main 
effects of antibody treatment before surgery, for both WT (p=0.982) and APP-NL-F 
(p=0.745), WT mice treated with 2B3 showed worse discrimination than those receiving 
the control IgG (p<0.0005). In contrast, 2B3 infusion significantly improved performance 
in APP-NL-F mice compared to IgG treatment (p=0.001). The within subjects’ factor of 
surgery state was only significant for the 2B3 treatment in both genotypes, as WT mice 
developed an impairment and APP-NL-F mice improved their DR score (p<0.0005 for both). 
There was no effect of surgery when either genotype received the control IgG (WT 
p=0.798; APP-NL-F p=0.733). 
 The significant treatment*genotype interaction revealed that in the control IgG 
condition, WT mice showed significantly greater discrimination than APP-NL-F mice 
(p<0.0005), there was no difference in the 2B3 condition (p=0.354). Furthermore, the WT 
IgG group had higher DR scores than the WT 2B3 group (p<0.0005) while the APP-NL-F 
IgG group achieved significantly lower scores than the APP-NL-F 2B3 group. Pairwise 
comparisons within the genotype*surgery interaction revealed a significant simple main 
effect of genotype before surgery as WT mice demonstrated higher DRs (p<0.0005), but 
no difference between the WT and APP-NL-F groups after treatment (p=0.549). There were 
significant effects of surgery in both the WT and APP-NL-F groups (p=0.001 and 0.002 
respectively), as the WT mice’s ability to discriminate declined while the APP-NL-F mice 
significantly improved.  
 One-sample t-tests were used to compare the group DR scores to the predicted 
chance score of 0.5. In the pre surgery condition, both WT groups significantly 
discriminated at above chance levels (IgG t(1,11) = 8.3, p<0.0005; 2b3 t(1,11) = 8.7, 
p<0.0005). In contrast, neither APP-NL-F group showed better than chance discrimination 
(IgG t(1,11) = 0.051, p=0.961; 2b3 t(1,11) = -0.38, p=0.715). However following surgery, 
the WT group that had been treated with 2B3 failed to discriminate same and different 
object-location pairings (IgG t(1,11) = 7.2, p<0.0005; 2b3 t(1,11) = -0.17, p=0.865). The 
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opposite pattern occurred in the APP-NL-F mice, as those treated with 2B3 were able to 
discriminate above chance while those receiving control IgG antibody did not perform 
above chance (IgG t(1,11) = 0.574, p=0.578; 2b3 t(1,11) = 6.1, p<0.0005). These results 
were supported by live-tracking data obtained using EthoVision software. The settings 
used for tracking are detailed in section 2.3.3 and data is available on request. 
 Collectively this analysis demonstrates that icv infusion of 2B3 induced contrasting 
effects APP-NL-F and WT mice. It caused a significant object-in-place memory deficit in 
WT mice, while rescuing age-dependent deficit in APP-NL-F mice. 
 
  
Figure 7.2: 2B3 Infusion causes dissociated effects on object-in-place (OiP) memory 
in WT and APP-NL-F mice. Discrimination ratios calculated from contact with objects 
that have either switched or remained in the same spatial location. The score predicted 
by random performance (0.5) is highlighted by the black bar. Error bars represent SEM. 
N=12 for all groups. *** p<0.0005, 2x2x2 mixed measures ANOVA. 
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▪ 7.3.4 – Experiment 12 Discussion 
The results of this experiment present an intriguing dissociation of impact of icv 
infusion of 2B3 on OiP recognition memory performance. While 2B3 significantly 
improved the performance of aged APP-NL-F mice, alleviating their deficit so that they were 
able to discriminate between objects that had or had not switched locations, the opposite 
effect occurred in WT littermates, as 2B3 disrupted visuospatial memory until the group 
were unable to discriminate. This is the first time that this dissociation of effect has been 
reported within one experiment. Furthermore, to our knowledge this is the first rescue of 
cognitive deficits by an anti-amyloid therapy reported in APP-NL-F mice. The effect of 2B3 
in these knock-in mice is consistent with that observed by the Evans group, who saw OiP 
performance improve in aged PDAPP mice following a similar administration and test 
protocol (Evans et al. 2019). Moreover, the deficit in visuospatial memory observed in the 
pre-treatment performance of WT and APP-NL-F mice replicates the result of experiment 5 
in a separate cohort of mice. This replication of the OiP deficit increases the reliability of 
the result and presents a protocol that is sensitive to the age-related changes in neuronal 
function exhibited by the APP-NL-F model. Therefore this protocol may be used by future 
studies in order to assess the efficacy of putative AD therapies. 
There was no impact of 2B3 or control IgG on overall contact time with objects in 
the sample or test phases in any treatment group, demonstrating that neither treatment nor 
the surgery itself impacted the motivation to interact with objects. However, a significant 
main effect of genotype revealed that APP-NL-F mice were less likely to engage with objects 
in the sample phase. The reduction in contact time may present an explanation as to why 
these mice did not discriminate between objects in familiar or novel locations. However, 
this is unlikely because the different cohort of APP-NL-F mice in experiment 5 also showed 
a deficit in discrimination without reduced sampling. However, the reduced object contact 
may suggest why the DR of the 2B3 treated APP-NL-F group is numerically reduced 
compared to the pre-surgery WT groups. 
In summary, these data reveal that 2B3 treament elicited opposite effects in APP-
NL-F and WT mice, indicating that the putatitive therapeutic strategy of inhibiting BACE-
dependent APP cleavage may be advantageous to patients with amyloid accumulation but 
detrimental to those without. 
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7.4 Experiment 13: Ex Vivo Analysis of 2B3 Treatment 
▪ 7.4.1 – Introduction 
The aim of this experiment was to investigate the impact of 2B3 treatment on APP 
metabolism and neuronal receptor dynamics in APP-NL-F and WT mice. The proposed 
mechanism of action of  2B3 on APP metabolism involves binding to the BACE1 cleavage 
site and sterically inhibiting production of Aβ by the endogenous enzyme (Thomas, 
Liddell, and Kidd 2011). On the basis of this, one would expect that the levels of A would 
be lower in the hippocampus of WT and APP-NL-F mice administered 2B3. 
▪ 7.4.2 – Methods 
All of the protocols used in this chapter have been detailed in Chapter 2. The 
samples used in this experiment were isolated from the mice in experiment 12. There were 
four groups (WT control IgG; WT 2B3; APP-NL-F control IgG; APP-NL-F 2B3), all of which 
had an n of 12 mice. Mice were culled immediately following the final OiP trial and the 
brains were dissected and flash-frozen in liquid nitrogen. Hippocampi from the left 
hemispheres were processed to produce homogenate samples, while the right hippocampi 
underwent synaptosome extractions. Homogenate samples were used in ELISA analysis 
with WT mice analysed using the Mouse Aβ40 kit and APP-NL-F groups compared on the 
human Aβ42 kit. The concentration of Aβ42 in WT mice was below detectable levels, 
while a similar issue with APP-NL-F Aβ40 levels has been described in Chapter 6. 
Biochemical procedures including protein extraction, ELISA and Western blots were 
carried out by Chiara Favero under my supervision, and analysis of all data was carried out 
by myself. 
▪ 7.4.3 – Experiment 13 Results 
APP Processing 
The effect of 2B3 on APP processing in APP-NL-F mice was measured by ELISA 
analysis of Aβ42 concentration. There was a significant reduction in hippocampal Aβ42 in 
APP-NL-F mice treated with 2B3 compared to those from APP-NL-F mice receiving control 
IgG antibody, t-test t(22) = 2.15; p=0.043; see figure 7.3 A. Figure 7.3 A also shows the 
effect of 2B3 on Aβ42 extracted in the insoluble fraction. An independent t-test reported 
no effect of treatment type t(22) = 0.97, p=0.344.  
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The impact of 2B3 on APP processing in WT mice was assessed by ELISA 
measuring the concentration of Aβ40, which is presented in figure 7.3 B. There was a 
significant reduction in Aβ40 in the 2B3-treated samples, t-test: t(22) = 2.25, p=0.04. 
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Figure 7.3: 2B3 reduced Aβ concentration in both APP-NL-F and WT mice. ELISA 
results comparing the concentrations of Aβ in hippocampi following icv infusion of 
either 2B3 or a control antibody. Data were normalised to the mean concentration of the 
control group and analysed by independent samples t-tests. (A) 2B3 significantly 
reduced the concentration of soluble Aβ42 in aged APP-NL-F mice (* p<0.05). There was 
no significant difference in the amount of Aβ42 in the insoluble fraction. N=12 for both 
groups. (B) 2B3 also significantly reduced the level of soluble Aβ40 in aged WT mice. 
* p<0.05, independent samples t-test. N=12 for both groups. 
* 
* 
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Synaptic Receptor Expression 
The right hippocampi were processed into synaptosome preparations and Western 
blot analysis was performed to compare expression levels of synaptic markers. The 
distributions of all datasets were assessed by the Shapiro-Wilke test and transformed by 
square root if necessary, to ensure normality (p>0.05).  The groups were compared by a 
two-way ANOVA with genotype and treatment as factors. The total expression of PSD95 
did not show significant effects of genotype F(3,44) = 0.018, p=0.893, or treatment F(3,44) 
= 0.073, p=0.789 (figure 7.4 A). There was also no genotype*treatment interaction F(3,44) 
= 1.6, p=0.217. When comparing the expression of α7-NAChR, there were no significant 
main effects of genotype F(3,44) = 0.39, p=0.537, or treatment F(3,44) = 1.2, p=0.27, and 
no interaction F(3,44) = 0, p=0.992. 
Expression of NMDA receptors was analysed (NR1, figure 7.4 B). There were no 
main effects of genotype F(3,44) = 0.006, p=0.938, or treatment F(3,44) = 2.3, p=0.139, 
however there was a significant interaction: genotype*treatment F(3,44) = 4.3, p=0.044. 
Pairwise comparisons on this interaction showed that there was significantly higher 
expression in WT mice that had been infused with 2B3 than control IgG (p=0.015). The 
NR2B subtype was also investigated (figure 7.4 C), and there were no significant effects 
or interactions present: main effect of genotype F(3,44) = 0.84, p=0.363; main effect of 
treatment F(3,44) = 0.35, p=0.557; genotype*treatment F(3,44) = 0.18, p=0.677. There was 
a similar lack of significant effects in the expression of the phosphorylated form of NR2B 
(pY1472, figure 7.4 C). main effect of genotype F(3,44) = 3.2, p=0.079; main effect of 
treatment F(3,44) = 3.0, p=0.088; genotype*treatment F(3,44) = 3.325, p=0.075. However, 
when the amount of pY1472 was normalised to the amount of NR2B (pY1472 : NR2B, 
figure 7.4 C), there were significant main effects of genotype F(3,44) = 8.0, p=0.007; and 
treatment F(3,44) = 5.9, p=0.019. There was also a significant genotype*treatment 
interaction F(3,44) = 5.2, p=0.027. Pairwise comparisons revealed that WT mice treated 
with 2B3 exhibited lower relative phosphorylation of NR2B than WT mice administered 
control IgG (p=0.002) and 2B3-infused APP-NL-F mice (p=0.001). 
AMPA receptor expression was also investigated (GluA1, figure 7.4 D). There was 
no main effect of genotype F(3,44) = 0.67, p=0.417, or treatment F(3,44) = 0.61, p=0.437, 
and no genotype*treatment interaction F(3,44) = 0.27, p=0.605. Analysis of the expression 
of phosphorylated GluA1 did not reveal main effects of genotype F(3,44) = 0.44, p=0.511 
or treatment F(3,44) = 0.26, p=0.613. There was a significant genotype*treatment 
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interaction F(3,44) = 4.7, p=0.036, however no significant differences were observed in the 
pairwise interactions. When expression of phosphorylated GluA1 was normalised to the 
total amount of GluA1 (pGluA1 : GluA1, figure 7.4 D), there were no main effects of 
genotype F(3,44) = 0.075, p=0.786 or treatment F(3,44) = 0.065, p=0.799, and a significant 
genotype*treatment interaction effect F(3,44) = 10.2, p=0.003. Pairwise comparisons 
revealed that 2B3-treated APP-NL-F mice had significantly reduced phosphorylation of 
GluA1 compared to control-treated APP-NL-F mice (p=0.018). On the other hand, 2B3 
infusion was associated with increased GluA1 phosphorylation in WT mice (p=0.043). 
pY1472 
 
NR2B 
 
NR1 
 
pGluA1 
 
GluA1 
 
PSD95 
 
α7-NAChR 
 
β-Actin 
180 kDa 
 
180 kDa 
 
120 kDa  
 
100 kDa 
 
100 kDa 
 
95 kDa 
 
50 kDa 
 
37 kDa 
A 2B3 APP-NL-F  IgG WT IgG APP-NL-F  2B3 WT 
0
0.5
1
1.5
2
2.5
3
PSD95 α7-NAChR NR1
P
ro
te
in
 D
en
si
ty
 R
el
at
iv
e 
to
 C
o
n
tr
o
l
B
NLF IgG NLF 2b3 WT IgG WT 2b3
*
[191] 
             
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
GluA1 pGluA1 pGluA1 : GluA1
P
ro
te
in
 D
en
si
ty
 R
el
at
iv
e 
to
 C
o
n
tr
o
l
D
NLF IgG NLF 2b3 WT IgG WT 2b3
* *
0
0.2
0.4
0.6
0.8
1
1.2
1.4
NR2B pY1472 pY1472 : NR2B
P
ro
te
in
 D
en
si
ty
 R
el
at
iv
e 
to
 C
o
n
tr
o
l
C
NLF IgG NLF 2b3 WT IgG WT 2b3
**
Figure 7.4: Western blot analysis of hippocampal synaptosomes. 
Representative Western blot images of various synaptic markers. (A) Representative 
Western blot images in APP-NL-F and WT mice treated with either 2B3 or control IgG. 
n=12 for all 4 groups. (B) Quantification of protein expression for PSD95, nicotinic 
acetylcholine receptor α7 (α7-NAChR) and total NMDA receptor (NR1). (C) 
Quantification of the expression of NR2B and phosphorylated NR2B (pY1472), as well 
as the relative phosphorylation of the receptor. (D) Quantification of the expression of 
GluA1 and phosphorylated GluA1, as well as the relative phosphorylation of the 
receptor. Error bars represent SEM. *p<0.05, **p<0.01 
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▪ 7.4.4 – Experiment 13 Discussion 
This experiment demonstrated that selective inhibition of BACE-dependent APP 
cleavage significantly inhibited the production of Aβ42 in the hippocampus of aged APP-
NL-F mice. This is the first example of this strategy being used in a knock-in model of AD, 
as Evans and colleagues infused 2B3 into transgenic PDAPP mice. The fact that 2B3 
induced a significant reduction of Aβ42 in the APP-NL-F mice shows that the result of the 
previous study was not dependent on APP overexpression. As the knock-in model exhibits 
increased clinical relevance compared to transgenics, the results of this experiment support 
the evidence that steric hinderance of BACE-dependent APP cleavage is a potential 
therapeutic strategy to reduce amyloid pathology. Infusion of 2B3 in aged WT mice also 
resulted in significant reduction of Aβ40 concentration, consistent with the result of 
Experiment 2, in which the subjects were 5-months-old. 
 This study also investigated the effect of 2B3 on glutamate receptor dynamics in 
aged APP-NL-F and WT mice. Although no changes were identified in the expression or 
phosphorylation of NMDA receptors between APP-NL-F groups infused with either 2B3 or 
control antibody; WT mice administered 2B3 showed significantly increased NMDA 
expression and reduced phosphorylation of NR2B compared to control-treated mice. 
Although Experiment 2 showed only a numerical increase in NMDA expression following 
2B3-treatment, the effect on NR2B phosphorylation was significant in both that and the 
current experiment. However, the impact on phosphorylation of the AMPA receptor 
subunit GluA1 in WT mice was opposite to that reported previously. While the result in 
Chapter 3 showed a significant decrease in phosphorylation, the current experiment showed 
a significant increase in 2B3-infused hippocampi compared to control-IgG. The reason for 
this is unclear and is expanded upon in section 7.5. Meanwhile, 2B3 administration resulted 
in significantly decreased phosphorylation of GluA1 in APP-NL-F mice compared to the 
control group. The fact that the opposite effect is observed in the two genotypes is 
intriguing considering the association with memory performance reported in Experiment 
12, as the two groups that showed intact OiP performance also showed significant 
dephosphorylation of GluA1 compared to mice that did not. 
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7.5: Chapter Discussion 
Anti-amyloid therapies have consistently showed promise in alleviating the 
amyloid burden and cognitive deficits exhibited by transgenic models of AD, yet failed in 
clinical trials. The failure of therapies aimed at reducing amyloid burden to show clinical 
benefit has led to criticism of previous preclinical studies, as well as challenges to the 
amyloid cascade hypothesis. The artificially high levels of amyloid species in the brains of 
transgenic mice may represent an unphysiologically aggressive insult to neuronal function 
and therefore, while many potential treatments have shown beneficial results in these 
models, they may not be clinically relevant. For example, Evans et al (2019) reported that 
icv infusion of 2B3 reduced Aβ40 in the hippocampus and rescued OiP performance in 
aged PDAPP mice. However, the results of the current chapter indicate that this strategy 
can be effective even in absence of APP overexpression, as 2B3 reduced Aβ42 in the 
hippocampus and rescued the deficit in OiP memory performance of aged APP-NL-F mice. 
This represents the first use of this strategy in a knock-in model that expresses APP at 
normal endogenous levels and therefore provides more evidence in support of the amyloid 
cascade hypothesis and the potential for this therapeutic strategy. 
However, these results also raise an inherent problem with anti-amyloid therapies: 
that endogenous Aβ is required for normal cognition. Amyloid-based therapies may have 
differential impacts on synaptic and memory processes that depend on the level of amyloid 
pathology. Therefore, reducing Aβ concentration in low or near normal contexts may be 
detrimental or not effective. Potentially, that could add noise to a clinical trial. Certainly, 
in terms of a treatment in pre-symptomatic individuals it argues strongly that modulating 
amyloid at this stage could be dangerous. 
Aged APP-NL-F mice demonstrated a deficit in OiP memory in the pre-treatment 
assessment of baseline performance, replicating the result of Experiment 5 in a separate 
cohort of mice, supporting its reliability. Experiment 4 revealed that object novelty 
recognition was intact in aged APP-NL-F mice, suggesting that the OiP deficit was not due 
to a failure to identify different objects, but rather impaired spatial processing. A number 
of studies by the Warburton group have produced a model whereby associative recognition 
memory depends on interactions within a network consisting of the hippocampus, 
perirhinal cortex and mPFC (Warburton and Brown 2015). Therefore, the age-related 
deficit in OiP memory is likely due to Aβ-mediated dysfunction of this network.  
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Aβ peptides have been implicated in cognitive dysfunction in numerous studies 
using either direct infusion or transgenic models to investigate their impact (Hsiao et al. 
1996, Flood et al. 1994). The Iberian mutation at the C-terminus of the Aβ sequence ensures 
that Aβ42 is the predominant species in APP-NL-F mice (Saito et al. 2014), and this peptide 
is thought to induce greater neurotoxicity than Aβ40 (Klein, Kowall, and Ferrante 1999). 
Experiment 13 revealed that 2B3 infusion reduced Aβ42 levels in aged APP-NL-F mice by 
20%. Considering 2B3 infusion rescued OiP memory alongside reducing Aβ accumulation 
in these mice, a probable mechanism is rescue of Aβ-mediated hippocampal function 
within this network. This is a similar result to that observed by the Evans group following 
2B3 administration in aged PDAPP mice. Moreover, as the first example of an anti-amyloid 
treatment delivering benefit to a knock-in AD model, the current study indicates that the 
effect in PDAPP mice was not an artefact of APP overexpression. 
The lack of studies investigating the alleviation of pathology in APP-NL-F mice may 
have been caused by the absence of a robust cognitive phenotype currently in the literature. 
The observation of a significant decline in OiP performance by aged APP-NL-F mice in 
Chapter 4 permitted the current experiment. Izumi et al (2018) reported that administration 
of SAK3, a T-type voltage-gated calcium channel enhancer, to APP-NL-F mice between 9 
and 12 months of age impeded the development of object recognition and step-through 
passive avoidance deficits that were present in 12-month-old, vehicle-treated, APP-NL-F 
mice. Although SAK3 treatment also inhibited plaque deposition in these mice, it is not 
specifically targetted to amyloid, and chronic prophylactic treatment is a different strategy 
compared to the attempted reversal of the deficit observed in the pre-surgery condition of 
the current experiment. The Izumi group also reported no impact of treatment in WT mice, 
while the current chapter presents the first significant effect of selective BACE1-APP 
cleavage inhibition in aged WT mice. Although 2B3-treated WT mice did not discriminate 
objects that had switched positions in experiment 2, no group differences were significant. 
This was likely due to lack of statistical power. The current experiment used a larger group 
size and reveled a significant detrimental effect of 2B3 in WT mice on memory. 
Western blot analyses of the impact of 2B3 in WT mice revealed a reduction in 
NR2B phosphorylation that was consistent between Experiments 2 and 13. 
Phosphorylation of the tyrosine 1472 residue inhibits internalisation of NR2B-containing 
NMDA receptors from the synaptic membrane (Snyder et al. 2005). Therefore, the results 
suggest that 2B3-mediated reduction of Aβ led to a decreased amount of NR2B-containing 
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NMDA complexes in the synaptic membrane in WT mice. Hippocampal NMDA receptors 
are critical to OiP associative memory, as shown by Barker & Warburton (2015) who 
observed impaired performance in rats following infusion of AP5, an NMDA-antagonist 
into the hippocampus. Furthermore, the Evans group demonstrated that the specific NR2B 
inhibitor/antagonist Ro25-6981 induced an OiP memory deficit, while also observing that 
reduced phosphorylation of NR2B in aged PDAPP mice was also correlated with OiP 
impairment. However, while aged APP-NL-F mice exhibited a similar cognitive deficit as 
PDAPP mice, the current experiment did not show changes in expression or 
phosphorylation of NMDA receptors. It may be that the reduced amyloid burden exhibited 
by knock-in mice resulted in more subtle changes in NMDA dynamics which were not 
discernible by the same methods. On the other hand, there may be distinct mechanisms 
leading to disruption of visuospatial memory in the PDAPP and APP-NL-F mice. 
One putative mechanism underpinning disrupted OiP memory that was consistent 
across the two genotypes in this experiment is the increased phosphorylation of GluA1 
subunits of AMPA receptors, which was observed in both the 2B3-treated WT and control-
treated APP-NL-F mice. The fact that dephosphorylation of GluA1 correlated with the two 
genotype/treatment groups that demonstrated the ability to discriminate novel object-place 
associations increases the reliability that this represents a mechanism underpinning 
cognitive performance. Dephosphorylation of the serine 845 residue on the GluA1 subunit 
leads to endocytosis of AMPA receptors and is associated with long term depression 
(LTD), a synaptic plasticity mechanism involved in memory formation (He et al. 2009). In 
fact, while it is speculative to associate the changes in AMPA receptor dynamics observed 
in the current experiment to specific synaptic mechanisms in the absence of in vivo 
electrophysiological recordings; LTD has previously been associated with visual 
recognition memory. Blocking endocytosis of AMPA receptors in the perirhinal cortex 
resulted in impairment of object recognition performance and LTD expression in the 
perirhinal cortex during slice electrophysiology (Griffiths et al. 2008). There is also 
evidence specifically relating to the hippocampus and OiP performance. Ro25-6981, which 
inhibits NR2B activation and OiP memory (as mentioned above), has also been shown to 
impair the induction of LTD. Meanwhile, Goh and Manahan-Vaughan (2013) suggested 
LTD as the major cellular substrate underpinning visuospatial learning, as they measured 
the enabling of LTD in the hippocampus of mice during the learning of a novel spatial 
arrangement of objects. They also reported that this effect was dependent on the activation 
of NMDA and mGluR5 receptors (Goh and Manahan-Vaughan 2013). There is evidence 
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of Aβ peptides enhancing LTD in the dentate gyrus through the activation of mGluR5 
(Chen et al. 2013). Meanwhile, Aβ is able to bind to α7-NAChR with high affinity and this 
has been linked to the recycling of synaptic NMDA (Wang et al. 2000, Snyder et al. 2005). 
In fact, the interaction of Aβ with α7-NAChR is intriguing due to the concentration-
dependent switch from a facilitatory to inhibitory effect which mirrors its impact on 
cognition (Mura et al. 2012). Further discussion of this receptor is presented in section 8.3. 
While the observed impact of 2B3 on NR2B phosphorylation and cognition in WT 
mice in the current experiment was consistent with that observed in Experiment 2; the 
significant increase in GluA1-Ser845 phosphorylation is the opposite effect to the decrease 
previously reported. The explanation for this change is not clear. It is unlikely to be related 
to genetic variability, as although the subjects of the current experiment were bred from an 
APP-NL-F colony, this model uses a C57Bl/6l background strain and so genetic differences 
with the C57Bl/6l mice used in Experiment 2 will be minimal. However, Experiment 2 
involved 5-month-old mice while the current experiment used 17-month-old mice, and this 
age difference may be responsible for the observed change in effect on glutamate receptor 
dynamics. While there are no direct studies on AMPA receptor trafficking in models of 
normal ageing, analysis of synaptic plasticity mechanisms in the hippocampus may provide 
the best available evidence of age-related changes in the function of this receptor. During 
normal ageing, there is a decrease in basal synaptic transmission and LTP is impaired, 
requiring stronger stimulation for induction (Barnes, Rao, and Houston 2000), while, LTD 
is facilitated (Norris, Korol, and Foster 1996). It is possible that the age-dependent change 
in synaptic plasticity mechanisms reported in these studies may explain the inconsistency 
in 2B3 impact on GluA1 phosphorylation observed in 5- and 17-month old mice. 
While this is the first example of an anti-amyloid therapy demonstrating cognitive 
benefit in a non-transgenic APP model, many studies using a variety of strategies have 
been effective in APP overexpressors. The first of such studies involved anti-Aβ antibodies 
which alleviated amyloid burden in 16-month-old PDAPP mice (Bard et al. 2000). Another 
study observed a rapid 1000-fold increase in plasma Aβ along with its clearance from the 
brain following peripheral injection of the m266 mAb (DeMattos et al. 2001). 
Administration of this antibody was also associated with a rapid rescue of object 
recognition and spatial working memory deficits (Dodart et al. 2002). Kotilinek et al (2002) 
published similar results with BAM-10, an Aβ N-terminal region-targeted antibody, which 
reduced both soluble and insoluble Aβ levels and improved cognitive function in Tg2576 
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mice. Passive anti-Aβ immunotherapy has also demonstrated the potential to influence 
other symptoms of amyloid pathology in multiple FAD models, such as synaptic plasticity 
impairment, dendritic spine loss and reactive gliosis (Chauhan and Siegel 2002, 2003, 
Klyubin et al. 2005, Spires-Jones et al. 2009). Antibody treatment also reduced the rate of 
early aggregation of hyperphosphorylated tau in 12-month-old 3xTg-AD mice (Oddo et al. 
2004). However, this effect did not extend to more advanced stages of NFT pathology in 
older mice; further hinting at a therapeutic window that is restricted to early stage AD. 
Inhibition of β-secretase has also shown benefit in reducing the pathology and cognitive 
impairments of transgenic mice (Asai et al. 2006, Hussain et al. 2007). However, due to 
concerns regarding potential off-target effects caused by inhibition of other BACE1-
dependent pathways, the alternative strategy of using anti-APP antibodies targeting the β-
secretase cleavage site to sterically inhibit metabolism has been developed. While 
administration of 2B3 reduced amyloid burden and cognitive deficits in aged PDAPP mice, 
another antibody with a similar mechanism, BBS1 ameliorated amyloid pathology and a 
recognition memory deficit in  the Tg2576 and 3xTg transgenic mouse models (Rakover, 
Arbel, and Solomon 2007, Rabinovich-Nikitin et al. 2012).  
Collectively, these studies provide clear evidence of the beneficial effect of 
reducing amyloid in transgenic mice which overexpress mutant hAPP. However, as the 
current experiments used a knock-in mouse line that does not suffer from the artefacts of 
overexpression, they provide increased clinical relevance and suggests that this therapeutic 
strategy may be beneficial even in the absence of overexpression. While anti-amyloid 
therapies have failed to translate to the clinic, this may be due to a lack of understanding 
of what stage of AD is actually recapitulated in these mouse models. Considering the lack 
of neurodegeneration and NFT pathology in APP mutant mice, they most likely represent 
preclinical AD, and so suggest that anti-amyloid treatments would be most effective during 
this stage of the human disease. However, while the evidence of cognitive benefit in APP-
NL-F mice promotes early intervention strategies, the fact that Aβ reduction was detrimental 
to mice which lack amyloid accumulation supports the argument that the synaptic 
impairment associated with small molecule BACE inhibitors was caused by the impact on 
APP cleavage and not alternative substrates (Filser et al, 2016). Therefore, while selective 
amyloid inhibition represents a promising strategy to treat patients who have developed 
amyloid pathology, it may be detrimental to those who do not. This may offer an 
explanation for the failure of so many clinical trials, and greater understanding of the 
precise therapeutic window for anti-amyloid treatments is required. 
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Chapter 8 –  
Thesis Discussion 
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8.1 Thesis Overview 
 The major aims of this thesis were to examine the role of Aβ in normal neuronal 
function and the effect of age-related accumulation of A in a knock-in mouse model of 
amyloid pathology. In order to investigate the first aim, an anti-APP antibody, 2B3, was 
administered to young WT mice to selectively inhibit production of mouse Aβ and assess 
the effect on cognitive function and biochemical markers of synaptic activity. The second 
aim involved the breeding and aging of a cohort of APP-NL-F mice that express a mutated 
human Aβ sequence under the control of the endogenous murine APP promoter. These 
mice were tested on a battery of behavioral tasks in order to characterize any cognitive 
decline and were subsequently used to examine age- and amyloid-related changes in 
synaptic proteins. The final study assessed the effect of 2B3 in both WT and APP-NL-F mice 
and showed a dissociable effect of the antibody on cognition in WT and knock-in mice, 
disrupting memory in the former and improving memory in the latter. 
8.2 Summary of Findings 
 While the widely accepted amyloid cascade hypothesis presents accumulation of 
Aβ as the central event in the pathogenesis of AD, understanding of the peptide’s normal 
physiological function (if any) is limited. This latter point is important because reduction 
of endogenous amyloid production (by anti-amyloid therapies) remains a potential strategy 
for treatment of those at risk of dementia or displaying early stage biomarkers of disease 
onset. However, the consequences of inhibiting/reducing amyloid production at the pre-
symptomatic stage for mental health remains unclear.  The administration of BACE 
inhibitors in both clinical and preclinical studies has resulted in greater cognitive decline 
and synaptic impairment in patients or WT mice (Filser et al. 2015, Egan et al. 2019). 
However, because alternative substrates of BACE may be affected, it is not possible to 
conclude that the detrimental effects of inhibitors were specific to the impact on APP 
cleavage and Aβ production. 
Chapter 3 evaluated the hypothesis that selectively inhibiting BACE cleavage of 
APP would lead to a memory impairment in healthy WT mice. The 2B3 antibody reduced 
Aβ production in primary cortical cultures derived from PDAPP mice, as well as in vivo 
by icv infusion into aged mice of the same strain (Evans et al. 2019, Thomas, Liddell, and 
Kidd 2011). The results of Experiment 2 revealed that icv infusion of 2B3 by osmotic 
minipump over 14 days significantly reduced Aβ40 in the hippocampus, but not the cortex 
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of 5-month-old WT mice. The WT mice given 2B3 lost their ability to detect changes in 
object-place associations, which had been evident prior to the drug treatment. Western blot 
analysis in Experiment 2 revealed significant reductions in hippocampal NMDA and 
AMPA receptor phosphorylation in the 2B3-infused mice, indicating a putative synaptic 
mechanism linking the reduction in Aβ to cognitive dysfunction. Previous research has 
indeed linked these two glutamate receptors to OiP memory (Barker and Warburton 2015). 
These experiments demonstrated a normal physiological role of Aβ in synaptic function 
and memory in WT mice (Morley et al. 2010, Puzzo et al. 2011).  
 While many therapeutic interventions for AD have demonstrated promising results 
in preclinical models, they have all failed to translate into a clinical benefit for patients. 
One explanation that has gained traction is that the overexpression of mutant human APP 
in first generation models can induce phenotypic artefacts that are independent of the 
activity of the protein of interest (Sasaguri et al. 2017). In fact, some estimates suggest that 
approximately 60% of the phenotypes reported in transgenic AD models are artefacts of 
gene overexpression. APP presents particular issues due to the existence of multiple 
fragments, all of which are overexpressed. Therefore, the second main aim of this thesis 
was to characterise the phenotype of a recently developed knock-in model, the APP-NL-F, 
which expresses murine APP with a humanised Aβ sequence containing two FAD 
mutations, all under the endogenous mouse promoter. Given the extensive evidence that 
hippocampal dependent memory is particularly susceptible to Aβ accumulation, the 
cognitive changes in  APP-NL-F mice were assessed on the OiP task, which is exceptionally 
sensitive to disruption of activity within the hippocampus – perirhinal cortex – mPFC 
network (Barker and Warburton 2011, Webster et al. 2014). OiP assessment was 
counterbalanced with object novelty recognition as a control task to confirm the capability 
of recognizing four individual objects. These tests revealed that while APP-NL-F 
performance was intact at 8 months of age, a deficit in OiP memory developed by 17 
months of age. This specificity of the deficit in associative object-in-place memory was 
then assessed further. In contrast to associative recognition memory, object novelty and 
object location memory were intact in the APP-NL-F mice. However, one other attribute of 
object exposure, that of the temporal order in which objects had been encountered, was 
also impaired in APP-NL-F compared to WT littermates. It is argued that the two tasks 
sensitive to APP-NL-F mice mutation required integration of multiple object features, and 
these associative recognition tasks involve a network comprising the hippocampus, 
perirhinal cortex and mPFC. The specific deficit in associative tasks suggests that the Aβ 
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accumulation induced dysfunction at the network level rather than in a selective brain 
region, as disconnection analysis has demonstrated that communication within the 
aforementioned network is vital to associative recognition memory performance (Barker 
and Warburton 2011). In Chapter 5, the APP-NL-F mice were assessed on a foraging-based 
working memory task to examine the generality of their cognitive deficit. They 
demonstrated an age-related decline in performance of the spatial but not the non-spatial 
version of the task, the former is sensitive to hippocampal lesion (Evans et al. 2018). This 
pattern clearly established the sensitivity of aged APP-NL-F to encoding spatial and temporal 
features of objects and reward locations. In summary, the data presented in Chapters 4 and 
5 indicate that the more refined mechanism of Aβ accumulation exhibited by the knock-in 
APP-NL-F model represents a suitable system in which to assess the mechanisms of early 
AD pathogenesis and the consequences of disrupting amyloid production. 
 The above pattern of results suggest that the benefical effects of disrupting A 
production relies on the level of amyloid pathology. This observation could provide a 
possible explanation for the failure of anti-amyloid therapies in clinical trials.  Patients who 
did not have widespread amyloid pathology might have been adversely affteced by A-
related therapies. Therefore, experiments within Chapter 7 tested the hypothesis that 
reduction of Aβ in mice would lead to differential effects on cognition depending on the 
presence or absence of amyloid pathology. Infusion of 2B3 into aged APP-NL-F mice 
rescued memory dysfunction in the knock-in mice but impaired the healthy WT control 
mice. This dissociation of effect has not been reported previously, as most studies only 
examined the impact of treating mice with widespread amyloid pathology. The results of 
this experiment are important for our understanding of the normal role of amyloid in the 
brain and have wider implications for therapeutic stratgeies targetting this peptide in 
psychologically normal individuals at risk of developing AD. 
 
8.3 Does Aβ Play a Role in Neuronal Function? 
Experiments within Chapters 3 and 7 of this thesis have demonstrated that specific 
inhibition of BACE-dependent APP cleavage resulted in significant reduction of the Aβ 
concentration in the hippocampus, along with deficits in the ability to discriminate objects 
that had changed spatial location. These results were consistent with previous studies that 
used alternative methods to inhibit Aβ function and observed cognitive impairment. Filser 
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et al demonstrated that administration of BACE inhibitors to young WT mice resulted in 
deficits in Y-maze spontaneous alternation (Filser et al. 2015). However, the potential 
impact of BACE inhibitors on alternative BACE substrates challenges the conclusion that 
this effect was due specifically to reduction in Aβ concentration. Nevertheless, three groups 
have observed similar detrimental effects following either icv or intrahippocampal infusion 
of anti-Aβ antibodies (Garcia-Osta and Alberini 2009, Morley et al. 2010, Puzzo et al. 
2011). Furthermore, they also demonstrated that the detrimental effect of Aβ-antibodies 
was rescued by concurrent application of exogenous Aβ42 peptide. The Puzzo group 
injected the anti-Aβ antibodies into the hippocampi of 3-4-month-old mice 15-minutes 
prior to assessment in either the MWM or fear conditioning paradigms. They observed 
impairment of spatial reference memory and contextual (but not cue-related) freezing 
response. In a related study, Puzzo et also showed that application of picomolar 
concentrations of exogenous Aβ actually enhanced memory performance in the same tests, 
further indicating that endogenous  concentrations of the peptide are involved in normal 
neuronal function (Puzzo et al. 2008).  
Interestingly, the inhibitory effect of anti-Aβ antibodies only occurred when they 
were injected prior to, not immediately following training, addition of picomolar Aβ 
enhanced memory performance when injected at either time point. This suggests that, while 
the peptide is required for encoding mechanisms, a small excess is also able to enhance 
retention. Puzzo et al (2011) also showed that production of the peptide was increased in 
the hippocampus 1-minute following a foot shock associated with a context. The effect was 
not found following foot shock alone, suggesting that the increase was correlated with 
associative learning. Aβ has previously been shown to be specifically upregulated by 
excitatory synaptic activity (Cirrito et al. 2005, Kamenetz et al. 2003). The effect of both 
picomolar Aβ and antibodies binding to the peptide on memory performance has been 
replicated in vitro, as the treatments either enhanced or impaired LTP in hippocampal 
slices, respectively (Puzzo et al. 2008, Puzzo et al. 2011, Morley et al. 2010). It is possible 
that Aβ is secreted during processes involved in synaptic plasticity, and that 2B3 inhibits 
this activity-driven release, impairing synaptic function and memory formation. 
The molecular mechanism through which physiological Aβ functions in synaptic 
plasticity and memory performance remains unclear. The studies by the Puzzo, Morley and 
Garcia-Osta groups have cited the α7-NAChR as a putative mediator of Aβ’s effect on 
synaptic plasticity. More specifically, Morley and Garcia-Osta showed that administration 
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of Aβ increased acetylcholine (ACh) production, while α7-NAChR antagonists exhibited 
the same pattern of effects as anti-Aβ antibodies (Morley and Farr 2012, Garcia-Osta and 
Alberini 2009). The Puzzo group reported that the facilitatory effect of Aβ on LTP 
induction was blocked by co-administration of α7-NAChR antagonists and it was also 
abolished in hippocampal slices taken from mice with genetic deletion of the receptor 
(Puzzo et al. 2008). Furthermore, anti-Aβ antibodies showed no effect on LTP or memory 
in these knock-out mice (Puzzo et al. 2011). Aβ binds the α7-NAChR with high affinity, 
and is known to activate it (Wang et al. 2000, Dineley, Bell, et al. 2002). At endogenous 
concentrations, the interaction of Aβ with the α7-NAChR is facilitatory and potentiates the 
release of glutamate (Mura et al. 2012, Hascup and Hascup 2016). Importantly in the 
context of the current studies, activation of this receptor has been linked to enhancement 
of NMDA receptor activity in the hippocampus (Bali, Nagy, and Hernádi 2017, Cheng and 
Yakel 2015, Dougherty, Wu, and Nichols 2003). Therefore, while expression of α7-
NAChRs was unchanged following 2B3 administration in Experiments 2 and 13, it is 
tempting to speculate that depletion of Aβ in the hippocampus by 2B3 reduced the 
endogenous Aβ-mediated activation of the receptor and led to the subsequent decrease in 
NR2B phosphorylation. In turn, this reduction in phosphorylation has been linked to 
increased internalisation of NR2B-containing NMDA complexes from the synaptic 
membrane and impaired OiP performance (Evans et al. 2019).  
An alternative possible mechanism is that 2B3 infusion causes dysfunction within 
the hippocampus – mPFC – perirhinal cortex network (Barker and Warburton 2011). 
Nicotinic ACh receptors are responsible for gating synaptic plasticity at hippocampal – 
prefrontal synapses and α7NAChR activation in the mPFC is critical to the encoding of a 
spatial array of objects in the OiP task (Sabec et al. 2018). Reduction of the Aβ 
concentration by 2B3 may reduce the activation of this receptor, thereby impairing 
performance. However, analysis of Aβ levels in the mPFC following icv infusion of 2B3 
would be required to evaluate whether this putative mechanism is viable, particularly as 
there is no direct evidence of the role of hippocampal α7-NAChRs in OiP memory 
performance. In summary, although Aβ clearly performs an important role in neuronal 
function, further investigation is required to elucidate the specific synaptic processes in 
which it is involved. 
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8.4 How Does the role of Aβ Change in AD? 
Despite evidence of a neurotrophic function of Aβ emerging soon after the peptide 
was first identified (Yankner, Duffy, and Kirschner 1990), research has mainly focussed 
on its neurotoxicity due to its role in the pathogenesis of AD. A vast number of studies 
have shown that application or overexpression of the peptide induces synaptic and memory 
impairment. However, a large body of evidence now indicates that the switch in role of the 
peptide from physiological to pathogenic is dependent on its concentration and aggregation 
state. Studies by the Puzzo group mentioned above showed that Aβ exerts a hormetic effect 
on synaptic (and cognitive) function. Hormesis describes a biphasic dose-response 
interaction where the effect reverses with increasing concentration of a chemical (Kendig, 
Le, and Belcher 2010). Specifically, Aβ demonstrated a facilitatory effect on hippocampal 
LTP at concentrations ranging between 20 picomolar and 2 nanomolar, above which it 
exerted an inhibitory effect (Puzzo, Privitera, and Palmeri 2012). The effect was replicated 
in vivo, as 200 pM Aβ enhanced reference memory in the MWM, while 20 μM impaired 
it. The endogenous concentration of the peptide in the healthy brain is estimated to be in 
the picomolar range, which may explain the concentrations at which a facilitatory effect 
was observed (Puzzo et al. 2008, Schmidt, Nixon, and Mathews 2005). This feature of Aβ 
seems to be consistent with the experiments in this thesis (summarised by figure 8.1), as 
reduction of endogenous Aβ levels was detrimental to cognition, while accumulation of 
mutant human Aβ in APP-NL-F mice also resulted in an age-related decline in associative 
memory tests. The specific mechanisms underpinning how increasing concentration and 
aggregation state of the peptide inhibit neuronal function are not yet fully elucidated, but 
may involve interaction with α7-NAChRs, in an opposite way to that described above.  
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The proposal that α7-NAChRs mediate at least some of the physiological effects of 
Aβ is intriguing, as the hormetic effect of the peptide on synaptic plasticity and memory 
enhancement is mirrored by its effect on α7-NAChR activity. At low endogenous 
concentrations, Aβ activates the receptor and potentiates neurotransmitter release; 
however, following increased concentration or oligomerisation of the peptide, its effect 
becomes antagonistic  (Mura et al. 2012, Sadigh-Eteghada et al. 2014, Hascup and Hascup 
2016, Lazarevic et al. 2017). Aβ aggregates over time and with increasing concentration 
(Bharadwaj et al. 2009). Thus, it is possible that the reversal in α7-NAChR activity with 
higher Aβ concentrations may be due to the oligomerisation state of the peptide. 
Considering the specific nature of protein-protein interactions, oligomerisation will likely 
change the binding properties. For example, Mura and colleagues reported Aβ binding to 
α7-NAChR and α4β2-NAChR receptors at high Aβ concentrations but only to α7-NAChR 
when Aβ levels were low (Mura et al. 2012). It is tempting to speculate that the detrimental 
effect of the peptide on cognition detected in the current study following its age-related 
accumulation in APP-NL-F mice is linked to a change in interaction with α7-NAChRs. 
Specific activation of α7-NAChRs rescued both memory performance and synaptic 
plasticity following administration of nanomolar Aβ into the brains of WT mice in a dose-
dependent manner (Chen et al. 2010, Sadigh-Eteghad et al. 2015). In fact, following the 
continued use of anticholinesterase inhibitors as a symptomatic treatment for AD patients, 
nicotinic agonists have been in clinical trials but none have been approved (Florian et al. 
2016). Meanwhile, another study reported that Aβ interaction with α7-NAChRs increased 
the endocytosis of NR2B-NMDA receptors in hippocampal cultures, a mechanism 
previously associated with disruption of associative memory in aged PDAPP mice (Snyder 
et al. 2005, Evans et al. 2019). Furthermore, considering the involvement of mPFC α7-
NAChR activation in associative memory encoding described above, the antagonistic 
effect of Aβ accumulation on this receptor may have contributed to the deficits observed 
Figure 8.1: Diagram summarising how the results presented in this thesis 
demonstrate the hormetic effect of Aβ on cognition. The normal physiological 
concentration of Aβ is represented by the blue box and is present in healthy WT mice. 
Infusion of 2B3 reduces the concentration below this level by selectively inhibiting 
BACE-dependent APP cleavage, resulting in cognitive impairment, as observed in 
experiments 2 and 12. Increased concentration of the peptide following age-related 
accumulation in APP-NL-F mice also results in a cognitive deficit. However, reduction of 
Aβ concentration in these mice rescued cognitive performance, further indicating that 
the role of this peptide is highly concentration-dependent. 
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in Chapter 4. Histochemical analysis to confirm accumulation of the peptide in this brain 
region would be useful to provide evidence for this hypothesis.  
In addition to mediation of the synaptic functions of Aβ, the α7-NAChR has been 
associated with aspects of amyloid-dependent neurotoxicity, as excessive glutamate release 
following  excessive stimulation of this receptor may contribute to excitotoxicity (Rudy et 
al. 2015). Meanwhile, following the observation that Aβ colocalises with the receptor 
within neurons of AD brains, studies have shown that the interaction between the peptide 
and receptor can result in endocytosis of the complex leading to intracellular accumulation 
of Aβ (Nagele et al. 2002). This in turn can lead to cell lysis and plaque formation 
(D'Andrea et al. 2001). α7-NAChRs have been shown to desensitize quickly in the presence 
of Aβ (Dineley, Xia, et al. 2002). Furthermore, loss of the physiological Aβ-α7-NAChR 
interaction may drive the observed upregulation of the receptor in the brains of AD patients 
and aged Tg2576 mice in a compensatory manner (Chu et al. 2005, Dineley et al. 2001). 
In Experiment 11 of this thesis, there was a significant effect of group when analysing 
expression of α7-NAChRs. However, although there was a numerical increase in APP-NL-
F brains, this did not reach significance during post hoc analysis. 
However, evidence concerning the overall impact of α7-NAChRs in AD 
pathogenesis is controversial. One study showed that genetic deletion of the receptor 
exacerbated cognitive impairments and neuropathology in a transgenic APP mouse model 
(Hernandez et al. 2010), while another showed a protective effect (Dziewczapolski et al. 
2009). The difference in age of the mice assessed in the two studies may explain the 
divergent results and offer an insight to the role of the receptor. α7-NAChR-KO was 
detrimental to 5-month-old APP transgenic mice, but advantageous to animals over 13-
months of age, as MWM performance, LTP induction and synaptic marker density was 
preserved compared to APP transgenic expressing the receptor. This reversal of effect 
seems to agree with the general influence of α7-NAChRs, which seem to facilitate both the 
physiological role of Aβ in young, healthy systems but also the pathogenesis associated 
with accumulation of the peptide. Further analysis of the effect of age on APP mice with 
α7-NAChR-KO would be useful to resolve the role of the receptor, particularly considering 
the transgenic model used was inconsistent between the aforementioned studies. 
In reality, the detrimental effects of amyloid accumulation most likely involves a 
variety of mechanisms as the peptide interacts with many different receptors. This section 
[207] 
has focused on the α7-NAChR due to the evidence supporting its role in facilitating both 
physiological and pathological aspects of Aβ function, which appears to mirror the 
concentration-dependent switch in the peptide’s influence on synaptic and memory 
function. The results of Chapters 4-6 demonstrated an age-related decline in cognitive 
function in APP-NL-F mice that was associated with Aβ accumulation. Although this study 
did not observe significant differences in baseline expression of synaptic markers or 
receptors between aged APP-NL-F and WT mice, this may indicate the lower severity of 
pathology in the knock-in model compared to transgenics. Importantly, the Aβ 
accumulation in these mice did not depend on overexpression of mutant hAPP, indicating 
that this more subtle pathology was sufficient to affect cognition. 
  
8.5 Are Knock-In Models More Reliable than Transgenic 
Mouse Models? 
 A major aim of the research conducted within this thesis was to assess how 
cognitive function changed with age in a knock-in mouse model of amyloid pathology. 
Knock-in models have been described as more physiologically relevant, compared to first-
generation, transgenic models of AD, however a robust cognitive phenotype has not yet 
been established. The lack of overexpression provides a distinct benefit in assessing the 
pathological processes responsible for changes in cognition, and has already been useful in 
exposing results in studies of transgenic AD models that may be artefacts of APP 
overexpression. The only age-related cognitive effects published prior to the current study 
were deficits in spontaneous alternation and reversal learning measured in the Y-maze and 
MWM at 18 and 15 months of age respectively. The observation of a significant age-
dependent deficit in visuospatial memory in two different cohorts of APP-NL-F mice in this 
thesis nevertheless raises the potential for further investigation of how natural Aβ 
accumulation leads to memory impairment in the context of an aged brain. The fact that 
cognitive changes are observable in the absence of overexpression removes the possibility 
that cognitive changes were artefacts of overexpression and provides further evidence in 
support of the amyloid cascade hypothesis. However, results of chapter 7 demonstrated 
that inhibition of Aβ production rescued memory deficits even with the subtle pathology 
exhibited by aged APP-NL-F mice, reinforcing the idea that anti-amyloid strategies may be 
beneficial during a precise, preclinical stage of AD.  
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 The current study has also elucidated some potential artefacts of APP 
overexpression reported in studies using transgenic AD mouse models. The foraging task 
used during experiments presented in Chapter 5 replicated the methods used by Evans and 
colleagues (2018), who assessed PDAPP mice. However, while PDAPP mice exhibited 
both age-dependent and age-independent changes in foraging strategy, these were not 
observed in the APP-NL-F mice of the current study, suggesting that these behaviours were 
artefacts of APP overexpression in the transgenic model. This was particularly important 
for the reliability of the age-dependent decline in performance observed in the APP-NL-F 
mice in Chapter 5, as the results were not confounded by these artefacts. Furthermore, the 
current study did not observe significant differences in anxiety-related behavior by APP-
NL-F mice (Experiment 3). This was consistent with previous groups, although none aged 
the mice beyond 12 months of age. Examination of APP-NL-G-F mice has consistently 
returned an anxiolytic phenotype (Latif-Hernandez et al (2017); Sakakibara et al, 
Pervoloraki et al (2018)). However, reports of anxiety phenotypes in AD models are 
controversial as different studies have observed either anxiogenic or anxiolytic behavior 
(for a review see Lalonde et al, 2012). Therefore, further examination of anxiety-related 
behavior in aged APP-NL-F mice would increase the reliability of this result. However, if the 
lack of anxiety phenotype is valid, it increases the reliability of using this model for 
investigating the impact of Aβ accumulation on behaviour, as results will not be 
confounded by altered emotionality, which is possible in alternative models.  
The validity of modelling a human disease within another species will always be 
questioned. For example, clinical assessment of AD patients requires verbal 
communication of episodic memory which is not possible when analysing mice. Therefore, 
due to the differences in tests used, the memory systems being examined in each species 
may diverge substantially. Furthermore, mice do not naturally develop dementia, and 
genetic models rarely display all of the hallmarks of AD (such as tau pathology and cell 
loss), indicating a fundamental physiological difference between the species. However, this 
is not currently understood. Elucidation of the mechanisms protecting mice from the 
progression of NFTs and brain atrophy despite widespread amyloid pathology may enable 
the development of treatments for this later stage of the condition. The 3xTg model, which 
overexpresses mutant human tau protein in addition to APP and PS1, exhibits a 
comprehensive range of human AD pathology and may be crucial for this. In addition, 
novel human MAPT knock-in mice have recently been developed that express human tau 
protein (Saito et al. 2019). These mice will be useful for understanding the progression of 
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tau pathology in AD, particularly when they are crossed with the APP knock-in mice. 
However, the fact that the mutations in the MAPT gene are not associated with human AD 
means that, although these mice may recapitulate a greater breadth of the human AD-like 
pathology, their physiological relevance diminishes potentially along with their predictive 
validity in terms of treatment outcomes. This trade-off between the simulation of pathology 
versus the extent of artificial manipulation is a commonly acknowledged issue with animal 
models. For example, APP-NL-F mice express two FAD mutations in their APP sequence. 
This combination does not occur naturally, but is required because knock-in of the Swedish 
mutation alone did not result in AD pathogenesis. Furthermore, FAD-linked mutations are 
not relevant for late onset AD, but are a necessary compromise. The complex combination 
of genetic and environmental factors that contribute to late onset AD renders exact 
modelling extremely challenging. Expression of genetic variants associated with the 
condition (such as the ApoE4 allele) in mice does not reproduce many features of AD but 
has developed our understanding of pathogenic mechanisms.  
The crucial question that must be addressed is: what stage of human pathology do 
knock-in mouse models of AD represent? Despite demonstrating Aβ accumulation, plaque 
formation and, in some cases, reactive gliosis and hyperphosphorylation of tau; knock-in 
(nor transgenic) models do not develop NFTs or neurodegeneration. This suggests that they 
imitate a preclinical stage of AD, in which underlying amyloid pathology is present in the 
absence of NFTs, neurodegeneration and detectable cognitive symptoms. This may explain 
why so many anti-amyloid therapies reversed cognitive deficits in mouse studies but not 
clinical trials. Brain pathology that has progressed beyond amyloid accumulation may no 
longer be sensitive to treatments related to this peptide. It is possible that the current models 
expressing FAD mutations are only relevant for the <5% of AD patients that develop this 
early onset form, and clinical trials involving these patients are in development 
(www.clinicaltrials.gov). Alternatively, enhanced diagnostic protocols that can quickly, 
cheaply and reliably detect increasing amyloid concentrations or other brain changes may 
allow clinicians to pinpoint the exact timepoint at which pathology mimics that seen in 
preclinical models and is therefore potentially sensitive to treatment. 
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8.6 Are Anti-Amyloid Therapies Still Viable? 
The widely held conclusion following the failure of so many anti-amyloid therapies 
in clinical trials is that, while these strategies are efficacious in preclinical models of AD, 
their administration provides no beneficial effect in patients with late-stage AD pathology 
such as NFTs and neurodegeneration. Therefore, trials have aimed to recruit patients at 
earlier stages of the disease, prior to the end of the putative therapeutic window. However, 
the results presented in Chapters 3 and 7 of this thesis indicate that reducing Aβ below 
physiological levels may be detrimental. This raises the concern that administration of anti-
amyloid drugs to patients who do not have widespread amyloid pathology may be 
detrimental, further narrowing the period in which these drugs may be beneficial. However, 
although this information presents further complications, Chapter 7 also revealed that 
selective inhibition of Aβ production rescued the memory impairment in a knock-in model. 
This is the first evidence of this strategy demonstrating beneficial effects in a non-
transgenic model, reinforcing the amyloid cascade hypothesis. Therefore, the data 
presented in this thesis indicate that, while the restricted therapeutic window must be 
acknowledged, targeting amyloid is still a viable therapeutic strategy. 
The fact that treatment of AD may only be possible within a specific stage of 
pathology necessitates the development of quick and reliable diagnostic tests. While PET 
scans remain the gold standard, they are not feasible for widespread use due to their 
expense and low throughput. Recently, multiple studies have published blood tests that can 
predict AD pathology with strong reliability. A 2017 study reported that measurement of 
BACE1 activity in the plasma was able to discriminate individuals exhibiting normal 
cognition, MCI or AD with 88% specificity (Shen et al. 2018). Intriguingly, follow up tests 
revealed that MCI patients who converted to AD had shown significantly greater BACE1 
activity in the original test than those who did not convert, suggesting that this assay may 
also predict progression from prodromal to probable AD dementia. Another promising test 
identified novel serum microRNA markers that enabled discrimination between MCI / AD 
and vascular dementia (Dong et al. 2015). Furthermore, analysis of the plasma Aβ42/Aβ40 
ratio by immunoprecipitation and liquid-chromatography mass spectrometry has been able 
to predict current and developing amyloid pathology in multiple different studies, with a 
success rate up to 94% when comparing to the current gold standard: PET neuroimaging 
(Schindler et al. 2019, Nakamura et al. 2018, Perez-Grijalba et al. 2019, Ashton et al. 2019). 
These non-invasive diagnostic tests will reduce cost and increase the scalability of such 
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diagnostics. Their introduction should enable identification of more patients in the 
prodromal stages of AD with the potential for more successful clinical trials. 
Is There Existing Hope for Amyloid Therapies? 
Some of the lessons learned from clinical studies using anti-amyloid treatments 
have been applied to trials of the passive immunotherapy BAN2401 (Biogen / Eisai). This 
antibody is targeted to Aβ protofibrils, theoretically only binding intermediate peptide 
aggregates and therefore does not impair the physiological synaptic function of Aβ 
monomers. Following a favourable safety profile reported in a phase I trial (Logovinsky et 
al. 2016), a phase II trial involving 856 participants was designed. Importantly, this trial 
only recruited patients with significant amyloid pathology observed during PET scans, 
thereby decreasing the likelihood of detrimental effects caused by the anti-amyloid 
treatment. Furthermore, the trial used an innovative Bayesian “adaptive randomisation” 
enrolment design in which, new patients were allocated into one of five different dose 
regimes that had been deemed most likely to be effective by interim analyses (Satlin et al. 
2016). The 18-month treatment phase results were presented at the 2018 Alzheimer’s 
Association International Conference (AAIC) and, strikingly, represented the largest ever 
trial reporting a significant beneficial effect on cognitive decline. While brain amyloid was 
reduced by up to 93% in the maximum dose group (10 mg/kg biweekly), cognitive decline 
was slowed by 47% and 30% as measured on the ADAS-Cog and ADCOMS, respectively. 
However, following a ruling by the European Medicines Agency (EMA) one year into the 
trial, APOE ε4 carriers were no longer permitted to be allocated the highest dose of 
BAN2401, due to Amyloid-related imaging abnormalities (ARIA). This is a phenomenon 
whereby MRI signals detect vasogenic oedema or microhaemorrhages, typically within the 
first three months of Aβ immunotherapy (Penninkilampi, Brothers, and Eslick 2017). It is 
thought to be linked to the increased inflammatory reaction following clearance of 
perivascular Aβ and increased BBB permeability, both of which increases with APOE ε4 
status (Sperling et al. 2012). The effect of the EMA’s ruling was that allocation was no 
longer randomised. However, despite this confound, the potential of BAN2401 is 
promising for patients and researchers. Moreover, the rationale behind the treatment and 
trial strategy seems to be consistent with the data within this thesis, as the antibody targets 
aggregated, not monomeric Aβ, while only patients with Aβ pathology (as diagnosed by 
PET scans) were included in the trial. Results following the continuation of Ban2401 into 
larger scale trials may potentially validate the amyloid cascade hypothesis. 
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8.7 Future Directions 
 While the experiments within Chapters 4 and 5 demonstrate that APP-NL-F mice 
have developed a deficit in associative recognition memory and spatial working memory 
by 16-17 months of age, more frequent testing would elucidate the precise age-point at 
which performance becomes impaired. Correlation with ELISA analysis of Aβ 
accumulation at all of these age-points would provide information regarding the exact 
concentration at which the peptide starts to impair cognitive processes. Furthermore, the 
impact of 2B3 on young APP-NL-F mice was not assessed in the current study. 
Hypothetically, young APP-NL-F mice would respond to 2B3 infusion in a similar way to 
young WT mice, as they do not exhibit amyloid pathology at this age. Investigating the 
effect of 2B3 at multiple age-points in the APP-NL-F mice could pinpoint the amyloid burden 
required to switch the impact of Aβ inhibition from being detrimental to restorative. When 
combined with the ELISA analysis described above, this experiment may elucidate vital 
information regarding the influence of Aβ accumulation and the therapeutic window of 
anti-amyloid treatment. 
Furthermore, repeating the experiments in Chapter 7 using peripheral 
administration would increase the clinical relevance of the study and permit an increased 
duration of 2B3 administration, as the minipump-dependent infusion techniques have time 
limits imposed by the size of the capsule. The increased duration would enable use of the 
alternative cognitive tests described above and investigation into whether 2B3 rescues the 
SWM deficit reported in Chapter 5. Finally, intraperitoneal administration of 2B3 would 
also permit analysis of long-term 2B3 treatment in order to examine any chronic effects of 
BACE-dependent cleavage of APP, as well as whether the impact is reversible after 
treatment has stopped. 
Following evidence of altered glutamate receptor phosphorylation in 2B3-treated 
WT animals, it would be worthwhile to investigate the effect of reduced Aβ on synaptic 
function by using techniques such as slice electrophysiology or in vivo 2-photon imaging. 
Previous studies have used BACE inhibitors, anti-Aβ antibodies or APP-siRNA to show 
impairment of synaptic plasticity (Morley et al. 2010, Puzzo et al. 2011, Filser et al. 2015), 
and it would be interesting to see the effect of selective inhibition of APP-BACE1 cleavage 
by 2B3. Furthermore, considering the involvement of hippocampal glutamate receptor 
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activation in OiP memory, in vivo electrophysiological measurements during the test could 
elucidate the plasticity mechanisms involved in recognition of object-place associations. 
Considering the evidence of the putative influence of the α7-NAChR in facilitating 
both the physiological and pathogenic effects of Aβ, further investigation of the role of this 
receptor would be informative. Previous studies have suggested specific agonism of this 
receptor rescued the cognitive deficit associated with either Aβ infusion or APP 
overexpression (Chen et al. 2010, Sadigh-Eteghad et al. 2015, Medeiros et al. 2014). 
Therefore, it would be interesting to assess whether α7-NAChR agonism rescues the 
cognitive deficits associated with the infusion of 2B3 in WT mice, as well as in aged APP-
NL-F mice. However, it must be acknowledged that these drugs are nootropic and so 
appropriate controls would be required to assess whether any cognitive enhancement was 
a specific response to Aβ manipulation (Thomsen et al. 2010). Section 8.4 describes two 
studies that reported opposite effects of α7-NAChR deletion in APP transgenic mice, 
depending on the age at which testing occurred. However, the models examined were not 
consistent. Crossing KO APP-NL-F with α7-NAChR-KO mice would permit longitudinal 
analysis of the impact of the receptor at multiple stages of amyloid accumulation. 
The plethora of behavioural tasks available for cognitive testing, permits the use of 
alternative tests which would help refine the understanding of the exact memory processes 
that are impaired in aged APP-NL-F mice. The deficits in recognition of object-in-place and 
object-time associations represent some of the core elements that ultimately contribute to 
episodic memory, which is severely impaired in human AD patients (Bellassen et al. 2012). 
However, the combination of these aspects into a single task permits examination of a 
rodent’s ability to form an integrated memory of “what happened”, “where” and “when”, 
in paradigms of object recognition or fear conditioning (Good, Hale, and Staal 2007, 
Iordanova, Good, and Honey 2008). These tasks are comparable to tests that are diagnostic 
of the human condition and have been previously used to demonstrate episodic-like 
memory deficits in transgenic mouse models. Repeating these methods with the knock-in 
APP-NL-F mice would support the view that Aβ pathology is sufficient to drive changes in 
episodic-like memory. 
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 8.8 Thesis Summary and Conclusions 
 This thesis provides evidence of the role of Aβ in cognition in both normal 
physiological and abnormal, pathological states. The age-related deficit in associative 
recognition memory reported in the APP-NL-F model is a novel phenotype and, along with 
the Aβ accumulation in absence of APP overexpression, validates this knock-in strain as a 
physiological representation of AD pathology. The robust OiP deficit measured across 
multiple cohorts can be used by future studies aiming to assess novel treatments for AD. 
Meanwhile, the restoration of memory performance by selectively inhibiting BACE1 
cleavage of APP provides further evidence supporting the amyloid cascade hypothesis. 
This is the first report of an anti-amyloid treatment showing a beneficial effect in the 
absence of APP overexpression, which reinforces confidence in the potential for that 
strategy to yield clinical success. 
 However, the data presented in this thesis also demonstrated the first evidence that 
administration of anti-amyloid therapies induces dissociable effects depending on the 
existence of amyloid pathology. Cognition was impaired in both young and aged WT mice 
following inhibition of BACE1-dependent APP cleavage. This highlights the fact that Aβ 
plays an important and dynamic role in normal cognition and highlights an issue for 
amyloid-based prevention strategies in human clinical trials. Therefore, the results of this 
thesis will be important in determining how we treat AD in the future.  
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